Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non- accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares of Common Stock, par value $0.01, of the Registrant outstanding as of October 31, 2015 was 73,336,871.

Note 3 — Collaborative and Other Research and Development Contracts

U.S. Department of Health and Human Services (“BARDA/HHS”). In January 2007, BARDA/HHS awarded the Company a $102,661, four-year contract for the advanced development of peramivir for the treatment of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a September 2009 contract modification was awarded to extend the i.v. peramivir program and to increase funding by $77,191. On February 24, 2011, the Company announced that BARDA/HHS had awarded it a $55,000 contract modification, intended to fund completion of the Phase 3 development of i.v. peramivir for the treatment of patients hospitalized with influenza. That contract modification brought the total contract award from BARDA/HHS to $234,852 and provided funding to support the filing of an NDA to seek regulatory approval for i.v. peramivir in the U.S. In December 2013, BioCryst submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December 2014. The BARDA/HHS contract expired on June 30, 2014 according to its terms.

On March 31, 2015, the Company announced that the Biomedical Research and Development Authority within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This BARDA/HHS contract includes a base contract of $13,314 to support BCX4430 drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $36,169. As of September 30, 2015, a total of $16,300 has been awarded under exercised options within this contract.

National Institute of Allergy and Infectious Diseases (“NIAID/HHS”). In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The total funding under this contract as of September 30, 2015 could be up to $34,002, if all contract options are exercised by NIAID/HHS, over a five year period. The goals of this contract, including amendments, are to file IND applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase 1 human clinical trial. As of September 30, 2015, a total of $29,875 has been awarded under exercised options within this contract. BCX4430 is the lead compound in the Company’s BSAV research program.

The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions that are related to the development of peramivir and BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company’s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.

Seqirus UK Limited (“SUL”). On June 16, 2015, the Company and Seqirus UK Limited ("SUL"), a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the "SUL Agreement") granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the "Territory"). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment in the world and was approved by the U.S. Food and Drug Administration in December 2014 for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. The Company retains all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S.

Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion. The Company will exercise sole decision-making authority with regard to the development and commercialization of RAPIVAB outside of the Territory and is responsible for all associated costs.

In December 2013, the Company submitted a New Drug Application ("NDA") for RAPIVAB to the FDA. Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory filings and interactions with the Health Canada and the European Medicines Agency ("EMA") until marketing approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.

Under the terms of the SUL Agreement, the Company received an upfront payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from the date of the SUL Agreement (the "Royalty Term"). The Company developed RAPIVAB under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.

The term of the SUL Agreement shall continue on a country-by-country basis until the expiration of the last-to-expire Royalty Term in any such country in the Territory. Either party may terminate the SUL Agreement in its entirety if the other party breaches a payment obligation, otherwise materially breaches the SUL Agreement, subject to applicable cure periods, or if the other party suffers an insolvency event. The Company may also terminate the SUL Agreement if SUL or any of its affiliates seek to challenge the validity of the Company's patents. Termination does not affect a party's rights which have accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations exercised by the Company, the SUL Agreement provides for the termination of any sublicenses granted by SUL to third parties, and in the case of termination by the Company for cause, the ceasing of SUL's activities with respect to RAPIVAB, the discontinued use of all Company intellectual property and the termination of licenses and rights previously granted to SUL. If requested by the Company, SUL shall also promptly sell to the Company all licensed product it then holds in stock, otherwise, SUL may continue to sell such licensed product for designated periods.

Shionogi & Co., Ltd. (“Shionogi”). In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan and to provide rights for Shionogi to perform a Phase 3 clinical trial in Hong Kong. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan. Shionogi submitted an NDA to the Taiwan FDA in late 2013.

Green Cross Corporation (“Green Cross”). In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.

Mundipharma International Holdings Limited (“Mundipharma”). In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (“PNP”) inhibitor, for use in oncology. Under the terms of the license agreement, as amended, Mundipharma obtained worldwide rights to forodesine.

Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (“AECOM” and “IRL” respectively). In June 2000, the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the “Licensors”). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000 per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement may be terminated by the Company at any time by giving 60 days advance notice or in the event of material uncured breach by the Licensors.

In May 2010, the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i) any milestone payments the Company may receive in the future under its license agreement dated February 1, 2006 with Mundipharma and (ii) royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.

In consideration for these modifications in 2010, the Company issued to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally, at the Company’s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination of cash and shares.

On November 17, 2011, the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.

On June 19, 2012, the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.

At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash, in shares of the Company’s common stock, or in a combination of cash and shares.

On January 6, 2014, the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (“VUW”) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties, the terms and conditions of the contracts are substantially the same.

The University of Alabama at Birmingham (“UAB”). The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company upon three months’ notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties’ proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.

Note 4 — Royalty Monetization

Overview

On March 9, 2011, the Company completed a $30,000 financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of $22,691 from the transaction after transaction costs of $4,309 and the establishment of a $3,000 interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.

As part of the transaction, the Company entered into a purchase and sale agreement dated as of March 9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii) the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the “Currency Hedge Agreement”) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company’s collaboration with Shionogi was not impacted as a result of this transaction.

Non-Recourse Notes Payable

On March 9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the “PhaRMA Notes”). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March 9, 2011 (the “Indenture”), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14% per annum, payable annually in arrears on September 1st of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.

Royalty Sub’s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company’s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.

On September 1, 2014, Royalty Sub was unable to pay the full amount of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the Consolidated Balance Sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company’s future results of operations or cash flows.

The Indenture does not contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.

The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.

Foreign Currency Hedge

In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2016 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $1,950 will be required if, on May 18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.

The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company’s Consolidated Statement of Comprehensive Loss. Cumulative mark-to-market adjustments resulted in a loss of $460 and a gain of $4,082 for the three months ended September 30, 2015 and 2014, respectively and a loss of $793 and a gain of $732 for the nine months ended September 30, 2015 and 2014, respectively. During the nine months ended September 30, 2015, the Company realized a currency exchange gain of $1,654 associated with the exercise of a U.S. Dollar/Japanese yen currency option. The Company is also required to post collateral in connection with the mark-to-market adjustments based on defined thresholds. As of September 30, 2015 and December 31, 2014, no collateral was posted under the Currency Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of September 30, 2015, the maximum amount of hedge collateral the Company may be required to post is $9,750.

Note 5 — Stockholders’ Equity

On March 3, 2015, the Company filed a $150,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective upon filing and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale.

On November 6, 2013, the Company filed a $125,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. The Company has $10,000 remaining under this shelf registration statement.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q contains statements of a forward-looking nature relating to future events or the future financial performance of BioCryst. Such statements are only predictions and the actual events or results may differ materially from the results discussed in the forward-looking statements. Factors that could cause or contribute to such differences include those discussed below and elsewhere in this report, as well as those discussed in other filings made by the Company with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. See “Information Regarding Forward-Looking Statements.”

Cautionary Statement

The discussion herein contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created in Section 21E. Forward looking statements regarding our financial condition and our results of operations that are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted within the United States (“U.S. GAAP”), as well as projections for the future. The preparation of these financial statements requires our management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. Our estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The results of our estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

We operate in a highly competitive environment that involves a number of risks, some of which are beyond our control. We are subject to risks common to biotechnology and biopharmaceutical companies, including risks inherent in our drug discovery, drug development and commercialization efforts, clinical trials, uncertainty of regulatory actions and marketing approvals, reliance on collaborative partners, enforcement of patent and proprietary rights, the need for future capital, competition associated with products, potential competition associated with our products and product candidates and retention of key employees. In order for any of our product candidates to be commercialized, it will be necessary for us, or our collaborative partners, to conduct clinical trials, demonstrate efficacy and safety of the product candidate to the satisfaction of regulatory authorities, obtain marketing approval, enter into manufacturing, distribution and marketing arrangements, and obtain market acceptance and adequate reimbursement from government and private insurers. We cannot provide assurance that we will generate significant revenues or achieve and sustain profitability in the future. In addition, we can provide no assurance that we will have sufficient funding to meet our future capital requirements. Statements contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report which are not historical facts are, or may constitute, forward-looking statements. Forward-looking statements involve known and unknown risks that could cause our actual results to differ materially from expected results. The most significant known risks are discussed in the section entitled “Risk Factors.” Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We caution you not to place undue reliance on any forward-looking statements.

Our revenues are difficult to predict and depend on numerous factors, including the prevalence and severity of influenza in regions for which peramivir has received regulatory approval, seasonality of influenza, ongoing discussions with government agencies regarding future RAPIVAB and/or BCX4430 development and stockpiling procurement, as well as entering into, or modifying, licensing agreements for our product candidates. Furthermore, revenues related to our collaborative development activities are dependent upon the progress toward and the achievement of developmental milestones by us or our collaborative partners.

Our operating expenses are also difficult to predict and depend on several factors, including research and development expenses (and whether these expenses are reimbursable under government contracts), drug manufacturing, clinical research activities, the ongoing requirements of our development programs, the anticipated regulatory approval of our drug candidates, expenses related to building a commercial organization, and the availability of capital and direction from regulatory agencies, which are difficult to predict. Management may be able to control the timing and level of research and development and selling, general and administrative expenses, but many of these expenditures will occur irrespective of our actions due to contractually committed activities and/or payments.

As a result of these factors, we believe that period to period comparisons are not necessarily meaningful and you should not rely on them as an indication of future performance. Due to all of the foregoing factors, it is possible that our operating results will be below the expectations of market analysts and investors. In such event, the prevailing market price of our common stock could be materially adversely affected.

Overview

We are a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. We focus on the treatment of rare diseases in which significant unmet medical needs exist and align with our capabilities and expertise. We integrate the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design.

Critical Accounting Policies and Estimates

The accompanying discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements and the related disclosures, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. We evaluate our estimates, judgments and the policies underlying these estimates on a periodic basis, as situations change, and regularly discuss financial events, policies, and issues with members of our audit committee and our independent registered public accounting firm. We routinely evaluate our estimates and policies regarding revenue recognition, administration, inventory and manufacturing, taxes, stock-based compensation, research and development, consulting and other expenses and any associated liabilities.

Recent Corporate Highlights

RAPIVAB (peramivir injection)

RAPIVAB was approved by the FDA on December 19, 2014 for the treatment of acute uncomplicated influenza in adult patients who have been symptomatic for no more than two days. We have elected the “Sell-Through” revenue recognition methodology and recognized approximately $0.6 million of RAPIVAB product sales in the first nine months of 2015. With the approval, commercial availability and out-licensing collaboration of RAPIVAB, we have moved our focus to obtaining a stockpiling procurement contract with the U.S. Government.

On June 16, 2015, we and Seqirus UK Limited, a limited company organized under the laws of the UK ("SUL") and a subsidiary of CSL, entered into a License Agreement (the "SUL Agreement") granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the "Territory"). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment in the world. We retain all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. government, while SUL has the right to pursue government stockpiling outside the U.S.

Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion. We will exercise sole decision-making authority with regard to the development and commercialization of RAPIVAB outside of the Territory and are responsible for all associated costs.

Under the terms of the SUL Agreement, we are responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment we will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the European Union (“EU”), we are also responsible for regulatory filings and interactions with the Health Products and Food Branch of Health Canada ("Health Canada") and the European Medicines Agency ("EMA") until marketing approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, we and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.

Under the terms of the SUL Agreement, we received an upfront payment of $33.7 million, and we may receive up to $12.0 million in additional milestone payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication in Canada. We are also entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, we receive tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as July 1 – June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Contract Year, each subject to certain downward adjustments for circumstance or events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from the date of the SUL Agreement (the "Royalty Term").

The term of the SUL Agreement shall continue on a country-by-country basis until the expiration of the last-to-expire Royalty Term in any such country in the Territory. Either party may terminate the SUL Agreement in its entirety if the other party breaches a payment obligation, otherwise materially breaches the SUL Agreement, subject to applicable cure periods, or if the other party suffers an insolvency event. We may also terminate the SUL Agreement if SUL or any of its affiliates seek to challenge the validity of our patents. Termination does not affect a party's rights which have accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations exercised by us, the SUL Agreement provides for the termination of any sublicenses granted by SUL to third parties, and in the case of termination by us for cause, the ceasing of SUL's activities with respect to RAPIVAB, the discontinued use of all of our intellectual property and the termination of licenses and rights previously granted to SUL. If requested by us, SUL shall also promptly sell to us all licensed product it then holds in stock, otherwise, SUL may continue to sell such licensed product for designated periods.

HAE Program

Avoralstat, formerly known as BCX4161

On December 18, 2014, we announced the dosing of the first patient in OPuS-2 (Oral ProphylaxiS-2), a blinded, randomized, placebo-controlled clinical trial of orally-administered avoralstat in patients with HAE. OPuS-2 is a 12-week, three-arm, parallel cohort design trial to evaluate the efficacy and safety of two doses of avoralstat, 300 mg and 500 mg, administered three-times daily compared with placebo. This trial is being conducted in the U.S., Canada and Europe and approximately 100 HAE patients have been enrolled. The primary efficacy endpoint for the trial is the mean angioedema attack rate for each avoralstat dose group compared to placebo. Avoralstat has Orphan Drug designation in the U.S. and Europe and has Fast Track designation for the treatment of HAE in the U.S.

On October 8, 2015, we announced that the OPuS-2 trial completed enrollment, and we anticipate the final OPuS-2 patient visits will occur in January 2016. Accordingly, we expect to report results in early 2016. The results of this trial will then be provided for regulatory discussions intended to determine the scope of any additional information that may be required for completion of avoralstat registration. We have been corresponding with regulatory agencies regarding a deferral of a two-year rat carcinogenicity study for avoralstat. The results from this type of study are normally required to be available at the time of submission for approval. Currently, we have reached agreement with the EMA to defer submission of these results as a post-filing commitment. Agreement has not been reached with the FDA regarding a deferral at this time and the most recent (September 2015) communication from the FDA indicated that we would be required to complete the two year rat carcinogenicity at the time of filing for avoralstat. At the end-of-Phase 2 meeting following the completion of OPuS-2, we plan to engage in further dialogue with the FDA to discuss deferral, in the context of all available toxicology and clinical data. We plan to initiate a two-year rat carcinogenicity study in early 2016. Without a deferral, we expect our NDA filing to occur in 2018.

BCX7353 and other 2nd generation HAE compounds

In January 2015, we selected BCX7353 to advance into Phase 1 development as a once-daily, oral prophylactic HAE treatment. BXC7353 is structurally different from avoralstat, but has a similar mechanism of action targeting plasma kallikrein. On May 13, 2015, we announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers.

On October 8, 2015, we announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX7353 in healthy volunteers successfully met all of its objectives. Oral BCX7353 was generally safe and well tolerated at all doses up to 500 mg once-daily for 7 days and 350 mg once-daily for 14 days in healthy volunteers, and no dose-limiting toxicity was identified.

BCX7353 plasma levels increased in approximate proportion to dose, and drug exposure was not affected by dosing with food. The half-life of BCX7353 was estimated at 50-60 hours. After daily dosing, blood levels met or exceeded a predicted target therapeutic range throughout the 24 hour dosing interval. Inhibition of the target enzyme, plasma kallikrein, was measured in a sensitive and specific bioassay. Daily dosing with BCX7353 strongly inhibited plasma kallikrein at all four dose levels; the degree of inhibition was dose-related (p < 0.0001) and inhibition was sustained throughout the 24 hour dosing interval. This pharmacodynamic effect correlated strongly to the achieved drug concentration (r = 0.91, p < 0.0001).

There were no serious adverse events (“AEs”) and most AEs observed were mild. Two subjects discontinued the study due to moderate gastrointestinal AEs. One subject developed a delayed-type hypersensitivity rash after completing seven days of study drug; the rash resolved quickly with oral and topical steroids. No clinically significant laboratory abnormalities were seen at any dose or duration tested. The safety, tolerability, drug exposure and on-target plasma kallikrein inhibition results strongly support advancing the development program into a Phase 2 study in HAE patients. A Phase 2, four week dose ranging trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of BCX7353 as a preventative treatment to reduce the frequency of attacks in HAE patients is expected to begin in early 2016.

On October 27, 2015 the Japanese Ministry of Health Labor & Welfare (“MHLW”) announced that BioCryst’s BCX7353 was one of six products designated under MHLW’s new “Sakigake” fast track review system. The Sakigake Designation System promotes R&D in Japan, aiming at early practical application for innovative pharmaceutical products. This designation provides for additional interactions with the regulatory agency in Japan from early development through filing, and prioritized development and review, with the aim of introduction of the product as soon as possible to address a serious unmet medical need.

In addition to BCX7353, we have succeeded in inventing several uniquely different plasma kallikrein inhibitor molecules from distinct structural classes. Accordingly, we have selected additional drug candidates that have suitable pharmacologic properties to advance into preclinical development. The development of these candidates is approximately two years behind BCX7353.

BCX4430

On December 15, 2014, we announced the dosing of the first subject in a randomized, placebo-controlled Phase 1 clinical trial to evaluate i.m. administration of BCX4430 in healthy volunteers. The main goals of this first-in-human study are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of BCX4430 administered via i.m. injection in healthy subjects. This Phase 1 study is expected to continue in 2016.

Results of Operations (three months ended September 30, 2015 compared to the three months ended September 30, 2014)

For the three months ended September 30, 2015, total revenues were $11.0 million as compared to $3.2 million for the three months ended September 30, 2014. The increase in revenue in the third quarter of 2015, as compared to 2014, resulted from higher levels of product and collaboration revenue associated with the sale of RAPIVAB and the SUL out-licensing transaction, as well as increased collaboration revenue associated with the development of BCX4430 under the NIAID/HHS and BARDA/HHS contracts. Revenues in the third quarter of 2015 included $5.7 million of RAPIVAB product revenue and $0.2 million of collaborative revenue related to the SUL out-licensing transaction, $0.1 million of royalty revenue from Shionogi and Green Cross associated with sales of peramivir in Japan and Korea, $4.6 million of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS related to the development of BCX4430 and $0.3 million associated with collaborative revenue amortization from other corporate partnerships. Revenues in the third quarter of 2014 included $2.9 million of reimbursement of collaborative expenses from NIAID/HHS related to the development of BCX4430 and $0.3 million associated with collaborative revenue amortization from other corporate partnerships.

Research and development (“R&D”) expenses increased to $20.1 million for the third quarter of 2015 from $13.0 million in 2014. The increase in 2015 R&D expenses, as compared to 2014, reflect increased spending on our HAE program, and to a lesser extent, higher expenses associated with two discovery-stage rare disease projects. The increase in spending on our HAE program was associated with the clinical advancement of avoralstat and BCX7353.

Selling, general and administrative (“SG&A”) expenses increased to $2.7 million for the third quarter of 2015 as compared to $1.8 million in 2014. The increase of $0.9 million is primarily associated with initiation of activities in preparation for commercialization of our HAE product candidates and to a lesser extent commercial expenses associated with RAPIVAB. With the completion of the SUL transaction, we do not anticipate incurring substantial commercial expenses to promote RAPIVAB in the future. We do expect our SG&A expenses to be higher than in previous quarters due to administrative expenses associated with corporate growth in preparation for future NDA and other regulatory filings and for HAE product commercialization.

Interest expense related to the non-recourse notes issued in conjunction with the non-dilutive peramivir royalty monetization transaction in March 2011 was $1.2 million in the third quarter of 2015 and 2014. In addition, a mark-to-market loss of $0.5 million was recognized in the third quarter of 2015 related to our foreign currency hedge, compared to a mark-to-market gain of $4.1 million in the same quarter of 2014, both resulting from changes in the U.S. dollar/Japanese yen exchange rate in the related time periods. In addition, we realized a currency exchange gain of $0.1 million in the third quarter of 2015 related to the exercise of a U.S. Dollar/Japanese yen currency option under our foreign currency hedge.

Results of Operations (nine months ended September 30, 2015 compared to the nine months ended September 30, 2014)

For the nine months ended September 30, 2015, total revenues were $43.7 million as compared to $8.2 million for the nine months ended September 30, 2014. The increase in 2015 was primarily due to recognizing revenue associated with the SUL out-licensing transaction, RAPIVAB product revenue and increased collaboration revenue associated with BCX4430 development. Revenues in the first nine months of 2015 included $5.7 million of RAPIVAB product revenue and $21.8 million of collaborative revenue related to the SUL Agreement, $1.8 million of royalty revenue from Shionogi and Green Cross associated with sales of peramivir in Japan and Korea, $12.8 million of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS related to the development of BCX4430 and $0.9 million associated with collaborative revenue amortization from other corporate partnerships. In addition, we recorded approximately $0.6 million of RAPIVAB revenue under the “Sell-Through” revenue recognition methodology. Revenues in the first nine months of 2014 included $2.0 million of royalty revenue from Shionogi and Green Cross associated with sales of peramivir in Japan and Korea, $5.3 million of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS related to the development of BCX4430 and i.v. peramivir and $0.9 million associated with collaborative revenue amortization from other corporate partnerships.

R&D expenses increased to $53.7 million for the first nine months of 2015 from $33.3 million in 2014. The increase in 2015 R&D expenses, as compared to 2014, reflect increased spending on our HAE program, and to a lesser extent, our BCX4430 program and two rare disease projects.

The following table summarizes our R&D expenses for the periods indicated (amounts are in thousands).

	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
R&D expenses by program:
Avoralstat	$	7,296	$	4,822	$	19,390	$	13,634
BCX4430		3,394		3,204		9,746		6,877
2nd generation HAE compounds		6,308		3,530		16,415		7,450
Peramivir		647		608		2,685		1,970
Other research, preclinical and development costs		2,422		872		5,475		3,355

Total R&D expenses	$	20,067	$	13,036	$	53,711	$	33,286

SG&A expenses increased to $10.3 million for the first nine months of 2015 as compared to $5.4 million in 2014. The increase of $4.9 million is primarily associated with initiation of commercial organization in preparation for commercialization of our HAE drug candidates, unrestricted grants awarded to the U.S. and international HAE patient advocacy groups, as well as deal-related expenses associated with the SUL out-license transaction.

Interest expense related to the non-recourse notes issued in conjunction with the non-dilutive peramivir royalty monetization transaction in March 2011 was $3.9 million in the first nine months of 2015, compared to $3.7 million in the first nine months of 2014. In addition, a mark-to-market loss of $0.8 million was recognized in the first nine months of 2015 related to our foreign currency hedge, compared to a mark-to-market gain of $0.7 million in the same period in the prior year, both resulting from changes in the U.S. dollar/Japanese yen exchange rate in the related time periods. In addition, a realized currency exchange gain of $1.6 million was recognized in the first nine months of 2015 related to the exercise of a U.S. Dollar/Japanese yen currency option under our foreign currency hedge.

Liquidity and Capital Resources

Cash expenditures have exceeded revenues since our inception and we expect our 2015 operating expenses to exceed our 2015 revenues. Our operations have principally been funded through public offerings and private placements of equity securities; cash from collaborative and other research and development agreements, including U.S. Government contracts for peramivir and BCX4430; and to a lesser extent, the PhaRMA Notes financing. To date, we have been awarded a BARDA/HHS peramivir development contract totaling $234.8 million, which expired on June 30, 2014, a NIAID/HHS BCX4430 development contract totaling $34.0 million, which is ongoing, and a BARDA/HHS BCX4430 development contract totaling $36.2 million, which is also ongoing. The total amount of NIAID/HHS and BARDA/HHS funding obligated under awarded options in the active contracts is $29.9 million and $16.3 million, respectively. Most recently, we completed a successful public offering in June 2014 of 11.5 million shares of common stock at a price of $10.00 per share following the release of our OPuS-1 clinical trial results, which provided net proceeds to us of approximately $107.8 million. This financing and the recently completed SUL out-licensing transaction provides us liquidity into 2017. We retain the ability to offer for sale approximately $160.0 million of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants, and units from effective shelf registration statements, which we filed with the Securities and Exchange Commission. In addition to the above, we have received funding from other sources, including other collaborative and other research and development agreements; government grants; equipment lease financing; facility leases; research grants; and interest income on our investments.

As of September 30, 2015, we had net working capital of $20.1 million, a decrease of approximately $12.0 million from $32.1 million at December 31, 2014. The decrease in working capital was principally due to our normal operating expenses associated with the development of our product candidates. Our principal sources of liquidity at September 30, 2015 were approximately $46.6 million in cash and cash equivalents; approximately $71.5 million in investments considered available-for-sale; and approximately $7.5 million in receivables from collaborations. We anticipate our cash and investments will fund our operations into 2017.

We intend to contain costs and cash flow requirements by closely managing our third party costs and headcount, leasing scientific equipment and facilities, contracting with other parties to conduct certain research and development projects and using consultants. We expect to incur additional expenses, potentially resulting in significant losses, as we continue to pursue our research and development activities and begin to build a commercial infrastructure. We may incur additional expenses related to the filing, prosecution, maintenance, defense and enforcement of patent and other intellectual property claims and additional regulatory costs as our clinical programs advance through later stages of development. The objective of our investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. We place our excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of our credit exposure. We have not realized any significant losses on our investments.

We extended or executed additional lease obligations in 2015 for our Birmingham, Alabama operations, which increases the obligation by $5.6 million and extends these new obligations through 2026. These operating lease obligations encompass future rental obligations of our Birmingham operating facilities.

We plan to finance our needs principally from the following:

	•	lease or loan financing and future public or private equity financing;
	•	our existing capital resources and interest earned on that capital;
	•	payments under existing and executing new contracts with the U.S. Government; and
	•	payments under collaborative and licensing agreements with corporate partners.

As our programs continue to advance, our costs will increase. Our current and planned clinical trials, plus the related development, manufacturing, regulatory approval process requirements and additional personnel resources and testing required for the continuing development of our product candidates will consume significant capital resources and will increase our expenses. Our expenses, revenues and cash utilization rate could vary significantly depending on many factors, including our ability to raise additional capital, the development progress of our collaborative agreements for our product candidates, the amount and timing of funding we receive from existing U.S. Government contracts for BCX4430, the amount of funding or assistance, if any, we receive from new U.S. Government contracts or other new partnerships with third parties for the development and or commercialization of our product candidates, the progress and results of our current and proposed clinical trials for our most advanced product candidates, the progress made in the manufacturing of our lead product candidates and the progression of our other programs.

With the funds available at September 30, 2015, we believe these resources will be sufficient to fund our operations into 2017. Our future liquidity needs, and ability to address those needs, will largely be determined by the success of our product candidates and key development and regulatory events in the future. In order to continue our operations substantially beyond 2017, we will need to: (1) successfully secure or increase U.S. Government funding of our programs, including procurement contracts; (2) out-license rights to certain of our products or product candidates, pursuant to which we would receive cash milestones; (3) raise additional capital through equity or debt financings or from other sources; (4) obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5) reduce spending on one or more research and development programs; and/or (6) restructure operations. We retain the ability to offer for sale approximately $160.0 million of securities, including common stock, preferred stock, depositary shares stock purchase contracts, warrants, and units from our effective shelf S-3 registration statements.

Our long-term capital requirements and the adequacy of our available funds will depend upon many factors, including:

	•	our ability to perform under our government contracts and receive reimbursement, and receive stockpiling procurement contracts;
	•	the magnitude of work under our government contracts;
	•	the progress and magnitude of our research, drug discovery and development programs;
	•	the timing, progress and magnitude of building out our commercial capabilities;
	•	changes in existing collaborative relationships or government contracts;
	•	our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies and governmental agencies or other third parties;
	•	the extent to which our partners, including governmental agencies, will share in the costs associated with the development of our programs or run the development programs themselves;
	•	our ability to negotiate favorable development and marketing strategic alliances for certain product candidates;
	•	successful commercialization of marketed products by either us or our partners;
	•	the scope and results of preclinical studies and clinical trials to identify and develop product candidates;
	•	our ability to engage sites and enroll subjects in our clinical trials;
	•	the scope of manufacturing of our product candidates to support our preclinical research and clinical trials;
	•	increases in personnel and related costs to support the development and commercialization of our product candidates;
	•	the scope of manufacturing of our drug substance and product candidates required for future NDA filings;
	•	competitive and technological advances;
	•	the time and costs involved in obtaining regulatory approvals as well as the success or failure of obtaining regulatory approvals both in the United States and in other major markets;
	•	post-approval commitments for RAPIVAB and other products that receive regulatory approval; and
	•	the costs involved in all aspects of intellectual property strategy and protection including the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims.

We expect that we will be required to raise additional capital to complete the development and commercialization of our current product candidates and we may seek to raise capital in the near future. Additional funding, whether through additional sales of equity or debt securities, collaborative or other arrangements with corporate partners or from other sources, including governmental agencies in general and existing government contracts specifically, may not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable than those of the currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or rights of our existing stockholders. In addition, collaborative arrangements may require us to transfer certain material rights to such corporate partners. Insufficient funds may require us to delay, scale back or eliminate certain of our research and development programs. Our future working capital requirements, including the need for additional working capital, will be largely determined by the advancement of our portfolio of product candidates as well as rate of reimbursement by U.S. Government agencies of our BCX4430 expenses and any future decisions regarding the future of the RAPIVAB and BCX4430 programs, including those relating to stockpiling procurement. More specifically, our working capital requirements will be dependent on the number, magnitude, scope and timing of our development programs; regulatory approval of our product candidates; obtaining funding from collaborative partners; the cost, timing and outcome of regulatory reviews, regulatory investigations, and changes in regulatory requirements; the costs of obtaining patent protection for our product candidates; the timing and terms of business development activities; the rate of technological advances relevant to our operations; the efficiency of manufacturing processes developed on our behalf by third parties; and the level of required administrative support for our daily operations.

Financial Outlook for 2015

Based upon our development plans, expected operations and our awarded government contracts, we expect 2015 operating cash usage to be in the range of $8 to $18 million upon adjusting our previously predicted range for the first nine months of operations including the SUL transaction, and expect our total 2015 operating expenses to continue to be in the range of $75 to $95 million. Our operating expense range excludes equity-based compensation expense due to the difficulty in accurately projecting this expense as it is significantly impacted by the volatility and price of our stock, as well as vesting of our outstanding performance-based stock options. Our operating cash forecast excludes any impact of our royalty monetization, and hedge collateral posted or returned, but includes the impact of the $33.7 million payment received associated with the SUL transaction. Our ability to remain within our operating expense and operating cash target ranges is subject to multiple factors, including unanticipated or additional general development and administrative costs and other factors described under the Risk Factors located elsewhere in this report.

Off-Balance Sheet Arrangements

As of September 30, 2015, we do not have any unconsolidated entities or off-balance sheet arrangements.

Critical Accounting Policies

We have established various accounting policies that govern the application of U.S. GAAP, which were utilized in the preparation of our consolidated financial statements. Certain accounting policies involve significant judgments and assumptions by management that have a material impact on the carrying value of certain assets and liabilities. Management considers such accounting policies to be critical accounting policies. The judgments and assumptions used by management are based on historical experience and other factors, which are believed to be reasonable under the circumstances. Because of the nature of the judgments and assumptions made by management, actual results could differ from these judgments and estimates, which could have a material impact on the carrying values of assets and liabilities and the results of operations.

While our significant accounting policies are more fully described in Note 1 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2014, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our financial statements.

Inventory

Our inventories consist of RAPIVAB finished goods and work in process, which are valued at the lower of cost or market using the first-in, first-out (i.e., FIFO) method. Cost includes materials, labor, overhead, shipping and handling costs. Our inventories are subject to expiration dating. We regularly evaluate the carrying value of our inventories and provide valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, we may experience spoilage of our raw materials and supplies. Our determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires us to utilize significant judgment. In connection with the FDA approval of RAPIVAB in December 2014, we began capitalizing costs associated with the production of RAPIVAB commercial inventories. In connection with the June 2015 SUL collaboration, we sold all of our available RAPIVAB finished goods inventory to SUL in accordance with terms stipulated in the licensing agreement.

Accrued Expenses

We enter into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. We record liabilities under these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed and estimating the level of service performed and the associated cost when we have not yet been invoiced or otherwise notified of actual cost. The majority of our service providers invoice us monthly in arrears for services performed. We make estimates of our accrued expenses as of each balance sheet date based on the facts and circumstances known to us. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued expenses include:

	•	fees paid to Clinical Research Organizations (“CROs”) in connection with preclinical and toxicology studies and clinical trials;
	•	fees paid to investigative sites in connection with clinical trials;
	•	fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and product candidates; and
	•	professional fees.

We base our expenses related to clinical trials on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we will adjust the accrual accordingly. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of these costs, our actual expenses could differ from our estimates.

Revenue Recognition

We recognize revenues from collaborative and other research and development arrangements and product sales. Revenue is realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the seller’s price to the buyer is fixed or determinable; and (iv) collectability is reasonably assured.

Collaborative and Other Research and Development Arrangements and Royalties

Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and we have no further continuing performance obligations or we have completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. In the event a license agreement contains multiple deliverables, we evaluate whether the deliverables are separate or combined units of accounting. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.

Under certain of our license agreements, we receive royalty payments based upon our licensees’ net sales of covered products. We recognize royalty revenues when we can reliably estimate such amounts and collectability is reasonably assured. Royalty revenue paid by Shionogi on their product sales is subject to returns.

For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has “stand-alone value” to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (“TPE”) and (iii) best estimate of selling price (“BESP”). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis. In most cases we expect to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.

In June 2015, we entered into a License Agreement (the "SUL Agreement") granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and EU marketing approvals. We received an upfront payment of $33.7 million from SUL of which $7.0 million was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21.8 million of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3.7 million of the upfront payment was allocated to the sale of inventory and was recognized in the third quarter when the inventory transfer was completed. Approximately $1.2 million of the revenue from the SUL Agreement will be recognized ratably over the expected period of involvement in these regulatory support activities.

Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the SUL Agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.

Under the terms of the SUL Agreement, we may receive up to $12.0 million in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication in Canada. We evaluated each event based payment under the provisions of ASU 2010-17, Milestone Method of Revenue Recognition, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.

Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the income statement rather than as a reduction in expenses. Under our contracts with BARDA/HHS and NIAID/HHS, revenue is recognized as reimbursable direct and indirect costs are incurred.

Product Sales

We recognize revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price was fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, we sell RAPIVAB to specialty distributors, who, in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.

Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions to revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.

We utilize data from external sources to help estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. External sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and sell-through to customers, and information from third-party suppliers of market research data to the pharmaceutical industry.

We have categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which we consider to be critical accounting estimates, and requires us to use information from external sources.

Rebates and Chargebacks

Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB’s selling price. As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, we maintain reserves for amounts payable under these programs relating to RAPIVAB sales.

Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.

The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of our product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. We acquire prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. We update our estimates and assumptions each period and record any necessary adjustments to reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from our estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.

Discounts and Sales Incentives

Discounts and other sales incentives primarily consist of Inventory Management Agreement (“IMA”) Fees. Per contractual agreements with our specialty distributors, we provide an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in our individual contracts. We track sales to our specialty distributors each period and accrue a liability relating to the unpaid portion of these fees by applying contractual rates to such sales.

Product Returns

We do not record a product return allowance as we do not offer the ability to return goods once a bona fide shipment has been accepted by a specialty distributor.

Research and Development Expenses

Our research and development costs are charged to expense when incurred. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of our manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by us over the service periods specified in the contracts and estimates are adjusted, if required, based upon our on-going review of the level of services actually performed.

Additionally, we have license agreements with third parties, such as AECOM, IRL, and UAB, which require fees related to sublicense agreements or maintenance fees. We expense sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. We expense maintenance payments as incurred.

Deferred collaboration expenses represent sub-license payments paid to our academic partners upon receipt of consideration from various commercial partners, and other consideration to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from our commercial partners and are being expensed in proportion to the related revenue being recognized. We believe that this accounting treatment appropriately matches expenses with the associated revenue.

We group our R&D expenses into two major categories: direct external expenses and indirect expenses. Direct expenses consist of compensation for R&D personnel and costs of outside parties to conduct laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials, as well as other costs related to our clinical and preclinical studies. These costs are accumulated and tracked by program. Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our research and development efforts. These costs apply to work on our clinical and preclinical candidates as well as our discovery research efforts.

Stock-Based Compensation

All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in our Consolidated Statements of Comprehensive Loss based on their fair values. Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related assumptions for the model requires judgment, including estimating the life of an award, the stock price volatility, and the expected term. We utilize the Black-Scholes option-pricing model to value our awards and recognize compensation expense on a straight-line basis over the vesting periods. The estimation of share-based payment awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until “performance” has occurred. Significant management judgment is also required in determining estimates of future stock price volatility and forfeitures to be used in the valuation of the options. Actual results, and future changes in estimates, may differ substantially from our current estimates.

Foreign Currency Hedge

In connection with our issuance of the PhaRMA Notes, we entered into a foreign Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, we have the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which we may be required to pay a premium in each year from 2016 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $2.0 million will be required if, on May 18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement. In conjunction with establishing the Currency Hedge Agreement, we will be required to post collateral to the counterparty, which may cause us to experience additional quarterly volatility in our financial results. We will not be required at any time to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. In establishing the hedge, we provided initial funds of approximately $2.0 million to support our potential hedge obligations. As of September 30, 2015, the maximum amount of hedge collateral we may be required to post is $9.8 million.

The Currency Hedge Agreement does not qualify for hedge accounting treatment and therefore mark-to-market adjustments will be recognized in our Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the nine months ended September 30, 2015 resulted in a $0.8 million loss. Mark-to-market adjustments are determined by quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing the Level 2 in the fair value hierarchy as defined by generally accepted accounting principles. We are also required to post collateral in connection with the mark-to-market adjustments based on defined thresholds. As of September 30, 2015, no collateral was posted under the agreement.

Tax

We account for uncertain tax positions in accordance with accounting principles generally accepted in the U.S. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. We have recorded a valuation allowance against all potential tax assets, due to uncertainties in our ability to utilize deferred tax assets, primarily consisting of certain net operating losses carried forward, before they expire. The valuation allowance is based on estimates of taxable income in each of the jurisdictions in which we operate and the period over which our deferred tax assets will be recoverable.

Information Regarding Forward-Looking Statements

This filing contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created in Section 21E. All statements other than statements of historical facts contained in this filing are forward-looking statements. These forward-looking statements can generally be identified by the use of words such as “may,” “will,” “intends,” “plans,” “believes,” “anticipates,” “expects,” “estimates,” “predicts,” “potential,” the negative of these words or similar expressions. Statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions containing these forward-looking statements are principally contained in “Business,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as any amendments we make to those sections in filings with the SEC. These forward-looking statements include, but are not limited to, statements about:

	•	the initiation, timing, progress and results of our preclinical testing, clinical trials, and to the extent applicable, post-marketing commitments, for our HAE product candidates, RAPIVAB, BCX4430, and our other research and development efforts;
	•	the further preclinical development, clinical development, commercialization, or post marketing studies by either us or partners of our product candidates and products, including our HAE program, RAPIVAB, BCX4430, and early stage discovery programs;
	•	the potential funding from our contracts with NIAID/HHS and BARDA/HHS for the development of BCX4430;
	•	the potential for government stockpiling orders of RAPIVAB, additional regulatory approvals of RAPIVAB or milestones royalties or profit from commercial sales of RAPIVAB by us or our partners;
	•	the potential use of RAPIVAB as a treatment for H1N1, H5N1, and H7N9 or other strains of influenza;
	•	the implementation of our business model, strategic plans for our business, products, product candidates and technology;
	•	our ability to establish and maintain collaborations or out-license rights to our drug candidates;
	•	plans, programs, progress and potential success of our collaborations, including Seqirus UK Limited (“SUL”) for RAPIVAB, Mundipharma for forodesine and Shionogi and Green Cross for peramivir in their territories;
	•	Royalty Sub’s ability to service its payment obligations in respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub;
	•	the foreign currency hedge agreement entered into by us in connection with the issuance by Royalty Sub of the PhaRMA Notes;
	•	the scope of protection we are able to establish and maintain for intellectual property rights covering our products, product candidates and technology;
	•	our ability to operate our business without infringing the intellectual property rights of others;
	•	estimates of our expenses, revenues, capital requirements, annual cash utilization and our needs for additional financing;
	•	the timing or likelihood of regulatory filings or regulatory agreements, deferrals, and approvals;
	•	our ability to raise additional capital to fund our operations;
	•	our financial performance; and
	•	competitive companies, technologies and our industry.

These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Risk Factors.” Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Risk

We are subject to interest rate risk on our investment portfolio and borrowings under our PhaRMA Notes.

We invest in marketable securities in accordance with our investment policy. The primary objectives of our investment policy are to preserve capital, maintain proper liquidity to meet operating needs and maximize yields. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. We place our excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of credit exposure. Some of the securities we invest in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate.

Our investment exposure to market risk for changes in interest rates relates to the increase or decrease in the amount of interest income we can earn on our portfolio, changes in the market value due to changes in interest rates and other market factors as well as the increase or decrease in any realized gains and losses. Our investment portfolio includes only marketable securities and instruments with active secondary or resale markets to help ensure portfolio liquidity. A hypothetical 100 basis point drop in interest rates along the entire interest rate yield curve would not significantly affect the fair value of our interest sensitive financial instruments. We generally have the ability to hold our fixed-income investments to maturity and therefore do not expect that our operating results, financial position or cash flows will be materially impacted due to a sudden change in interest rates. However, our future investment income may fall short of expectations due to changes in interest rates, or we may suffer losses in principal if forced to sell securities which have declined in market value due to changes in interest rates or other factors, such as changes in credit risk related to the securities’ issuers. To minimize this risk, we schedule our investments to have maturities that coincide with our expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, we do not believe that we have material exposure to interest rate risk arising from our investments. Generally, our investments are not collateralized. We have not realized any significant losses from our investments.

We do not use interest rate derivative instruments to manage exposure to interest rate changes. We ensure the safety and preservation of invested principal funds by limiting default risk, market risk and reinvestment risk. We reduce default risk by investing in investment grade securities.

Foreign Currency Risk

The majority of our transactions occur in U.S. dollars and we do not have operating subsidiaries or investments in foreign countries. Therefore, we are not subject to significant foreign currency exchange risk in our normal operations.

In connection with the issuance by Royalty Sub of the PhaRMA Notes, we entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, we are required to post collateral based on our potential obligations under the Currency Hedge Agreement as determined by periodic mark-to-market adjustments. Provided the Currency Hedge Agreement remains in effect, we may be required to pay an annual premium in the amount of $2.0 million from May 2016 through May 2020. Such payment will be required if, in May of the relevant year, the spot rate of exchange for Japanese yen-U.S. dollars (determined in accordance with the Currency Hedge Agreement) is such that the U.S. dollar is worth 100 yen or less.

Item 4. Controls and Procedures

We maintain a set of disclosure controls and procedures that are designed to ensure that information relating to BioCryst Pharmaceuticals, Inc. required to be disclosed in our periodic filings under the Exchange Act is recorded, processed, summarized and reported in a timely manner under the Exchange Act. We carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2015, the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports filed or submitted by it under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and include controls and procedures designed to ensure that information required to be disclosed by the Company in such reports is accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer of the Company, as appropriate to allow timely decisions regarding required disclosure.

There have been no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2015 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1A. RISK FACTORS

An investment in our common stock involves risks. You should consider carefully all of the information that is included or incorporated by reference in this report before investing in our common stock. In particular, you should evaluate the uncertainties and risks referred to or described below, which may adversely affect our business, financial condition, liquidity or results of operations.

Risks Relating to Our Business

We have incurred losses since our inception, expect to continue to incur such losses, and may never be profitable.

Since our inception, we have not achieved sustained profitability. We expect to incur additional losses for the foreseeable future, and our losses could increase as our research and development efforts progress. We expect that such losses will fluctuate from quarter to quarter and losses and fluctuations may be substantial.

To become profitable, we, or our collaborative partners, must successfully manufacture and develop product candidates, receive regulatory approval, and successfully commercialize and/or enter into profitable agreements with other parties. It could be several years, if ever, before we receive significant revenue from any current or future license agreements or revenues directly from product sales.

Because of the numerous risks and uncertainties associated with developing our product candidates and their potential for commercialization, we are unable to predict the extent of any future losses. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are unable to achieve and sustain profitability, the market value of our common stock will likely decline.

Our success depends upon our ability to advance our products through the various stages of development, especially through the clinical trial process.

To receive the regulatory approvals necessary for the sale of our product candidates, we or our partners must demonstrate through preclinical studies and clinical trials that each product candidate is safe and effective. The development process and related regulatory process are complex and uncertain. Because of the cost and duration of clinical trials, we may decide to discontinue development of product candidates that are unlikely to show good results in the clinical trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to have reasonable commercial potential. We may suffer significant setbacks in pivotal pre-clinical studies and clinical trials (e.g. BCX4430, avoralstat, BCX7353 and our other rare disease product candidates), even after earlier clinical trials show promising results. The development of our product candidates, including our clinical trials, may not be adequately designed or executed, which could affect the potential outcome and analysis of study results. Any of our product candidates may produce undesirable side effects in humans. The pre-clinical and clinical data from our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials of a product candidate. Undesirable data or side effects in humans could also result in the FDA or foreign regulatory authorities refusing to approve the product candidate for any targeted indications. In addition, the FDA or other regulatory agencies may determine that study data from our product candidates necessitates additional studies or study designs which differ from our planned development strategy, and regulatory agencies may also require patient monitoring and testing or may implement restrictions or other conditions on our development activities, any of which could materially impact the cost and timing of our planned development strategy. We, our partners, the FDA or foreign regulatory authorities may suspend or terminate clinical trials at any time if we or they believe the trial participants face unacceptable health risks. Clinical trials may fail to demonstrate that our product candidates are safe or effective and have acceptable commercial viability. Regulatory authorities may interrupt, delay or halt clinical trials for a product candidate for any number of reasons.

Our ability to successfully complete clinical trials is dependent upon many factors, including but not limited to:

	•	our ability to find suitable clinical sites and investigators to enroll patients;
	•	the ability to maintain contact with patients to provide complete data after treatment;
	•	our product candidates may not prove to be either safe or effective;
	•	clinical protocols or study procedures may not be adequately designed or followed by the investigators;
	•	formulation improvements may not work as expected, which could negatively impact commercial demand for our product candidates;
	•	manufacturing or quality control problems could affect the supply of product candidates for our trials; and
	•	delays or changes in our planned development strategy, the regulations or guidelines, or other unexpected conditions or requirements by governmental agencies.

Clinical trials are lengthy and expensive. We or our partners incur substantial expense for, and devote significant time to, preclinical testing and clinical trials, yet we cannot be certain that the tests and trials will ever result in the commercial sale of a product. For example, clinical trials require adequate supplies of drug and sufficient patient enrollment. Lack of adequate drug supply or delays in patient enrollment, including in our planned clinical trials for HAE, can result in increased costs and longer development times. Even if we or our partners successfully complete clinical trials for our product candidates, we or our partners might not file the required regulatory submissions in a timely manner and may not receive regulatory approval for the product candidates.

We focus on rare diseases, which may create additional risks and challenges.

Because the focus of our Company is developing drugs for rare diseases, we may seek orphan drug, breakthrough therapy or fast track designations for our product candidates in the United States or the equivalent designations elsewhere in the world. Often, regulatory agencies have broad discretion in determining whether or not to grant such designations. We cannot guarantee that we will be able to receive orphan drug status from the FDA or equivalent regulatory designations elsewhere. We also cannot guarantee that we will obtain breakthrough therapy or fast track designation, which may provide certain potential benefits such as more frequent meetings with the FDA to discuss the development plan and intensive guidance on an efficient drug development program as well as potential eligibility for rolling review or priority review. Even if we are successful in obtaining any such designation by the FDA or other regulatory agency for our product candidates, such designations may not lead to faster development or regulatory review or approval, and it does not increase the likelihood that our product candidates will receive marketing approval. Additionally, we may not be able to maintain such designations for our product candidates, and our competitors may obtain these designations for their product candidates, which could impact our ability to develop and commercialize our product candidates and may adversely impact our business, financial condition or results of operations.

We have received orphan and fast track designations for avoralstat in the United States. Despite this designation; we may not experience a faster development, review or approval process compared to the conventional FDA procedures. The FDA may withdraw fast track designation if it believes the designation is no longer supported by data from our clinical development program. Although we have also received Sakigake designation for BCX7353 in Japan; we may not experience a faster development, review or approval process compared to the conventional process.

Our clinical trials may not adequately show that our product candidates are safe or effective.

Progression of our product candidates through the clinical development process is dependent upon our trials indicating our product candidates have adequate safety and efficacy in the patients being treated by achieving pre-determined safety and efficacy endpoints according to the clinical trial protocols. Failure to achieve either of these in any of our programs, including avoralstat, BCX7353 and our other rare disease product candidates, could result in delays in our trials or require the performance of additional unplanned trials. This could result in delays in the development of our product candidates and could result in significant unexpected costs or the termination of programs.

If we fail to reach milestones or to make annual minimum payments or otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional remedies.

If we are unable or fail to meet payment obligations, performance milestones relating to the timing of regulatory filings, product supply obligations, post approval commitments for RAPIVAB, or development and commercial diligence obligations, are unable or fail to make milestone payments or material data use payments in accordance with applicable provisions, or fail to pay the minimum annual payments under our respective licenses, our licensors may terminate the applicable license or seek other available remedies. As a result, our development of the respective product candidate or commercialization of the product would cease.

If we fail to obtain additional financing or acceptable partnership arrangements, we may be unable to complete the development and commercialization of our product candidates or continue operations.

As our programs advance, our costs are likely to increase. Our current and planned discovery, pre-clinical and clinical trials plus the related development, manufacturing, regulatory approval process requirements, and additional personnel resources and testing required for supporting the development of our product candidates will consume significant capital resources. Our expenses, revenues and cash utilization rate could vary significantly depending on many factors, including: our ability to raise additional capital; the development progress of our collaborative agreements for our product candidates; the amount of funding we receive from NIAID/HHS and BARDA/HHS for BCX4430 or from other new partnerships with third parties for the development of our product candidates, including avoralstat, BCX7353 and our other rare disease product candidates; the commercial success of peramivir by our partners; the amount or profitability of any orders for RAPIVAB or BCX4430 by any government agency or other party; the progress and results of our current and proposed clinical trials for our most advanced product candidates, including avoralstat, BCX7353 and our other rare disease product candidates; the progress made in the manufacture of our lead products and the progression of our other programs.

In order to continue future operations and continue our drug development programs, we will be required to raise additional capital. In addition to seeking strategic partnerships, transactions and government funding, we may decide to access the equity or debt markets or seek other sources to meet liquidity needs. Our ability to raise additional capital may be limited and may greatly depend upon the success of ongoing development related to our current drug development programs, including post approval studies for RAPIVAB, the progress, timeline and ultimate outcome of the avoralstat development program (including, but not limited to, the OPuS-2 clinical trial, long-term human safety studies, and the timing of carcinogenicity studies), progress of BCX7353 and our other rare disease product candidates, funding for and continued successful development of BCX4430, and progress of our early discovery programs. In addition, constriction and volatility in the equity and debt markets may restrict our future flexibility to raise capital when such needs arise. Furthermore, we have exposure to many different industries, financing partners and counterparties, including commercial banks, investment banks and partners (which include investors, licensing partners, and the U.S. Government) which may be unstable or may become unstable in the current economic and political environment. Any such instability may impact these parties’ ability to fulfill contractual obligations to us or they might limit or place burdensome conditions upon future transactions with us. Also, it is possible that suppliers may be negatively impacted. Any such unfavorable outcomes in our current programs or unfavorable economic conditions could place severe downward pressure on the stock and credit markets, which could reduce the return available on invested corporate cash, which if severe and sustained could have a material and adverse impact on our results of operations and cash flows and limit our ability to continue development of our product candidates.

If BARDA/HHS or NIAID/HHS were to eliminate, reduce or delay funding from our contracts, this would have a significant negative impact on our revenues and cash flows.

Our projections of revenues and incoming cash flows are substantially dependent upon BARDA/HHS and NIAID/HHS reimbursement for the costs related to our BCX4430 program. If BARDA/HHS or NIAID/HHS were to eliminate, reduce or delay the funding for these programs or disallow some of our incurred costs, we would have to obtain additional funding for continued development or regulatory registration for these product candidates or significantly reduce or stop the development effort.

In contracting with BARDA/HHS and NIAID/HHS, we are subject to various U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which may limit our reimbursement or if we are found to be in violation could result in contract termination. U.S. Government contracts typically contain extraordinary provisions that would not typically be found in commercial contracts. For instance, government contracts permit unilateral modification by the government, interpretation of relevant regulations (i.e., federal acquisition regulation clauses), and the ability to terminate without cause. In addition, U.S. Government contracts are subject to an in-process review, where the U.S. Government will review the project and its options under the contract. As such, we may be at a disadvantage as compared to other commercial contracts. U.S. Government contracts are subject to audit and modification by the government at its sole discretion. If the U.S. Government terminates any of its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract schedule and terms, significant negative impact on our cash flows and operations could result.

Our government contracts with BARDA/HHS and NIAID/HHS have special contracting requirements, which create additional risks of reduction or loss of funding.

We have recently completed work under a contract with BARDA/HHS for the development of our neuraminidase inhibitor, peramivir. We also have entered into contracts with BARDA/HHS and NIAID/HHS for the development of BCX4430 as a treatment for diseases caused by RNA pathogens, including Marburg virus disease and Ebola virus disease. In contracting with these government agencies, we are subject to various U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which may limit our reimbursement or, if we are found to be in violation, could result in contract termination. U.S. Government contracts typically contain extraordinary provisions that would not typically be found in commercial contracts. For instance, government contracts permit unilateral modification by the government, interpretation of relevant regulations (i.e., federal acquisition regulation clauses), and the ability to terminate without cause. In addition, U.S. Government contracts are subject to the in-process review described above. As such, we may be at a disadvantage as compared to competitors that do not rely on U.S. Government contracts.

U.S. Government contracts typically contain unfavorable termination provisions and are subject to audit and modification by the government at its sole discretion, each of which subjects us to additional risks. These risks include the ability of the U.S. Government to unilaterally:

	•	terminate or reduce the scope of our contract; and
	•	audit and object to our contract-related costs and fees, including allocated indirect costs.

The U.S. Government may terminate its contracts with us either for its convenience or if we default by failing to perform in accordance with the contract schedule and terms. Termination for convenience provisions generally enable us to recover only our costs incurred or committed, and settlement expenses and profit on the work completed prior to termination. Termination does not permit these recoveries under default provisions. In the event of termination or upon expiration of a contract, the U.S. Government may dispute wind-down and termination costs and may question prior expenses under the contract and deny payment of those expenses. Should we choose to challenge the U.S. Government for denying certain payments under a contract, such a challenge could subject us to substantial additional expenses which we may or may not recover. Further, if the U.S. Government terminates its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract schedule and terms, significant negative impact on our cash flows and operations could result. As a U.S. Government contractor, we are required to comply with applicable laws, regulations and standards relating to our accounting practices and are subject to periodic audits and reviews. As part of any such audit or review, the U.S. Government may review the adequacy of, and our compliance with, our internal control systems and policies, including those relating to our purchasing, property, estimating, compensation and management information systems. Audits conducted by the U.S. Government for the completed BARDA/HHS contract have been performed and concluded through fiscal 2009; all subsequent fiscal years are still open and auditable. Audits under the active BARDA/HHS and NIAID/HHS contracts may occur at the election of the U.S. Government. Based on the results of its audits, the U.S. Government may adjust our contract-related costs and fees, including allocated indirect costs. This adjustment could impact the amount of revenues reported on a historic basis and could impact our cash flows under the contracts prospectively. In addition, in the event BARDA/HHS or NIAID/HHS determines that certain costs and fees were unallowable or determines that the allocated indirect cost rate was higher than the actual indirect cost rate, BARDA/HHS or NIAID/HHS would be entitled to recoup any overpayment from us as a result. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject to civil and criminal penalties and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension of payments, fines and suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm to our reputation if allegations of impropriety were made against us. In addition, under U.S. Government purchasing regulations, some of our costs may not be reimbursable or allowed under our contracts. Further, as a U.S. Government contractor, we are subject to an increased risk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared to private sector commercial companies.

If we fail to successfully commercialize or establish collaborative relationships to commercialize certain of our product candidates or if any partner terminates or fails to perform its obligations under agreements with us, potential revenues from commercialization of our product candidates could be reduced, delayed or eliminated.

Our business strategy is to increase the asset value of our product candidate portfolio. We believe this is best achieved by retaining full product rights or through collaborative arrangements with third parties as appropriate. As needed, potential third-party alliances could include preclinical development, clinical development, regulatory approval, marketing, sales and distribution of our product candidates.

Currently, we have established collaborative relationships with Mundipharma for the development and commercialization of forodesine and with each of Shionogi and Green Cross for the development and commercialization of peramivir, in Japan, Taiwan and South Korea. Most recently we have established a collaborative relationship with Seqirus UK Limited for RAPIVAB in the United States and countries other than Israel, Japan, Korea and Taiwan. The process of establishing and implementing collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:

	•	our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, including post approval clinical commitments, a change in business strategy, a change of control or other reasons;
	•	our contracts for collaborative arrangements may expire;
	•	our partners may choose to pursue alternative technologies, including those of our competitors;
	•	we may have disputes with a partner that could lead to litigation or arbitration;
	•	we do not have day to day control over the activities of our partners and have limited control over their decisions;
	•	our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and efficacy of our product candidates, obtain regulatory approvals and achieve market acceptance of products developed from our product candidates;
	•	we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;
	•	we or our partners may not devote sufficient capital or resources towards our product candidates; and
	•	we or our partners may not comply with applicable government regulatory requirements.

If we or our partners fail to fulfill our responsibilities in a timely manner, or at all, our commercialization efforts related to that collaboration could be reduced, delayed or terminated, or it may be necessary for us to assume responsibility for activities that would otherwise have been the responsibility of our partner. In the case of our collaboration with SUL, we continue to have certain promotional regulatory and government pricing risks because we hold the RAPIVAB NDA and our partner is conducting the marketing and commercialization efforts.

If we are unable to establish and maintain collaborative relationships on acceptable terms, we may have to delay or discontinue further development of one or more of our product candidates, undertake commercialization activities at our own expense or find alternative sources of funding. Any delay in the development or commercialization of our product candidates would severely affect our business, because if our product candidates do not progress through the development process or reach the market in a timely manner, or at all, we may not receive additional future event payments and may never receive milestone, product sales or royalty payments.

We do not have a great deal of experience in commercializing our products or technologies, and our future revenue generation is uncertain.

We do not have a great deal of experience in commercializing our products or technologies. We currently have limited marketing capability, no direct or third-party sales force and limited distribution capabilities. We may be unable to establish or sufficiently increase these capabilities for products we currently, or plan to, commercialize. In addition, our revenue from collaborative agreements may be dependent upon the status of our preclinical and clinical programs. If we fail to advance these programs to the point of being able to enter into successful collaborations, we will not receive any potential future event or other collaborative payments.

Our ability to receive revenue from products we commercialize presents several risks, including:

	•	we or our collaborators may fail to successfully complete clinical trials, or satisfy post-marketing commitments, sufficient to obtain and keep FDA marketing approval;
	•	many competitors are more experienced and have significantly more resources, and their products could reach the market faster, be more cost effective or have a better efficacy or tolerability profile than our product candidates;
	•	we may fail to employ a comprehensive and effective intellectual property strategy, which could result in decreased commercial value of our Company and our products;
	•	we may fail to employ a comprehensive and effective regulatory strategy, which could result in a delay or failure in commercialization of our products;
	•	our ability to successfully commercialize our products is affected by the competitive landscape, which cannot be fully known at this time;
	•	reimbursement is constantly changing, which could greatly affect usage of our products; and
	•	future revenue from product sales would depend on our ability to successfully complete clinical studies, obtain regulatory approvals, and manufacture, market and commercialize our approved drugs.

If our development collaborations with third parties, such as our development partners and contract research organizations, fail, the development of our product candidates will be delayed or stopped.

We rely heavily upon other parties for many important stages of our product candidate development, including but not limited to:

	•	discovery of compounds that cause or enable biological reactions necessary for the progression of the disease or disorder, called enzyme targets;
	•	licensing or designing of enzyme inhibitors for development as product candidates;
	•	execution of some preclinical studies and late-stage development for our compounds and product candidates;
	•	management of our clinical trials, including medical monitoring and data management;
	•	execution of additional toxicology studies that may be required to obtain approval for our product candidates; and
	•	formulation improvement strategies and methods, including those for avoralstat; and
	•	manufacturing the starting materials and drug substance required to formulate our products and the product candidates to be used in our clinical trials, toxicology studies and any potential commercial product.

Our failure to engage in successful collaborations at any one of these stages would greatly impact our business. If we do not license enzyme targets or inhibitors from academic institutions or from other biotechnology companies on acceptable terms, our drug development efforts would suffer. Similarly, if the contract research organizations that conduct our initial or late-stage clinical trials, conduct our toxicology studies, manufacture our starting materials, drug substance and product candidates or manage our regulatory function breached their obligations to us or perform their services inconsistent with industry standards and not in accordance with the required regulations, this would delay or prevent both the development of our product candidates and the availability of any potential commercial product.

If we lose our relationship with any one or more of these parties, we could experience a significant delay in both identifying another comparable provider and then contracting for its services. We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service as the original provider. In addition, any provider that we retain will be subject to applicable FDA current Good Laboratory Practices (“cGLP”), current Good Manufacturing Practices (“cGMP”) and current Good Clinical Practices (“cGCP”), and comparable foreign standards. We do not have control over compliance with these regulations by these providers. Consequently, if these practices and standards are not adhered to by these providers, the development and commercialization of our product candidates could be delayed, and our business, financial condition and results of operations could be materially adversely affected.

Commercialization of RAPIVAB by our partners is subject to the potential commercialization risks described herein and numerous additional risks. Any potential revenue benefits to us in the form of milestones, royalties or other consideration are highly speculative.

Commercialization success of RAPIVAB is uncertain and is subject to all the risks and uncertainties disclosed in our other risk factors relating to drug development and commercialization. In addition, commercialization of RAPIVAB is subject to further risks and commercialization may be negatively impacted by a number of factors, including, but not limited to, the following:

	•	RAPIVAB may not prove to be adequately safe and effective for market approval in markets other than the United States;
	•	necessary funding for post marketing commitments and further development of RAPIVAB may not be available timely, at all, or in sufficient amounts;
	•	flu prevention or pandemic treatment concerns may not materialize at all, or in the near future;
	•	advances in flu vaccines or other antivirals, including competitive i.v. antivirals, could substantially replace potential demand for RAPIVAB;
	•	a limited number of governmental entities are expected to be the primary potential stockpiling customers for RAPIVAB and if we are not successful at marketing RAPIVAB to these entities for any reason, we will not receive substantial revenues from stockpiling orders;
	•	government and third party payors may not provide sufficient coverage or reimbursement which would negatively impact the demand for RAPIVAB;
	•	we may not be able to supply commercial material to our partners and our partners may not be able to maintain or establish sufficient and acceptable commercial manufacturing, either directly or through third-party manufacturers;
	•	the commercial demand and acceptance for RAPIVAB by healthcare providers and by patients may not be sufficient to result in substantial revenues of RAPIVAB to our partners and may result in little to no milestones or royalties to us;
	•	effectiveness of marketing efforts for RAPIVAB by our partners;
	•	market satisfaction with existing alternative therapies;
	•	perceived efficacy relative to other available therapies;
	•	disease prevalence;
	•	cost of treatment;
	•	pricing and availability of alternative products;
	•	marketing and sales activities of competitors;
	•	shifts in the medical community to new treatment paradigms or standards of care; and
	•	relative convenience and ease of administration.

If any or all of these and other risk factors occur, we will not attain significant revenues or gross margins from RAPIVAB and our stock price and or cash flows may be adversely affected.

We are subject to various federal and state laws regulating the marketing of RAPIVAB and, if we do not comply with these regulations, we could face substantial penalties.

Our sales, promotion and other activities related to RAPIVAB, or any of our other products under development following their regulatory approval, are subject to regulatory and law enforcement authorities in addition to the FDA, including the Federal Trade Commission, the Department of Justice, and state and local governments. We are subject to various federal and state laws pertaining to health care “fraud and abuse,” including both federal and state anti-kickback laws. Although we seek to comply with these statutes, it is possible that our practices, or those of our distributors, might be challenged under anti-kickback or similar laws. Violations of fraud and abuse laws may be punishable by civil or criminal sanctions, including fines and civil monetary penalties, and future exclusion from participation in government healthcare programs.

Because we continue to hold the NDA for RAPIVAB in the United States, we may be held responsible for any and all sales, promotion and other activities related to RAPIVAB, as well as any of our other products under development following their regulatory approval. We are subject to regulatory and law enforcement authorities in addition to the FDA, including the Federal Trade Commission, the Department of Justice, and state and local governments. We are subject to various federal and state laws pertaining to health care “fraud and abuse,” including both federal and state anti-kickback laws. Although we seek to comply with these statutes, it is possible that our practices, or those of our partners, might be challenged under anti-kickback or similar laws. Violations of fraud and abuse laws may be punishable by civil or criminal sanctions, including fines and civil monetary penalties, and future exclusion from participation in government healthcare programs.

We have a number of outstanding post-marketing commitments to the FDA that we retain despite our partnership, which we may not complete successfully or on time for any number of reasons, including but not limited to lack of funds to complete the studies or insufficient interest by appropriate sites, investigators or study subjects. For example, as a condition of the approval of RAPIVAB, we are required to complete a pediatric patient study of RAPIVAB and to submit the final results of this clinical trial to the FDA. Depending on the outcome of this clinical trial, we may be unable to expand the indication for RAPIVAB or we may be required to include specific warnings or limitations on dosing this product, which could negatively impact sales of RAPIVAB and negatively impact our relationship with our partner. We may be subject to penalties if we fail to comply with post-approval legal and regulatory requirements and our products could be subject to continual recordkeeping and reporting requirements, review and periodic inspections by the FDA and other regulatory bodies. Regulatory approval of a product may be subject to limitations on the indicated uses for which the product may be marketed or to the other restrictive conditions of approval that limit our ability to promote, sell or distribute a product. Furthermore, RAPIVAB, and any other future product candidates’ approval, may contain requirements for costly post-marketing testing and surveillance to monitor its safety or efficacy.

Advertising and promotion are subject to stringent FDA rules and oversight and as the holder of the NDA we may be held responsible for any advertising and promotion conducted by our partner that is not in compliance with the rules and regulations. In particular, the claims in all promotional materials and activities must be consistent with the FDA approvals for approved products, and must be appropriately substantiated and fairly balanced with information on the safety risks and limitations of the products. Adverse event information concerning approved products must be reviewed as well and as the NDA holder of RAPIVAB we are required to make expedited and periodic adverse event reports to the FDA and other regulatory authorities.

In addition, the research, manufacturing, distribution, sale and promotion of products are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments. Until we can successfully transfer the pricing responsibilities to our partner, we remain responsible for pricing and rebate programs. Pricing and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990, as amended, and the Veterans Health Care Act of 1992, as amended. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially subject to federal and state consumer protection and unfair competition laws.

If our operations with respect to RAPIVAB or our other products which are subject to healthcare laws and regulations are found to be in violation of any of the healthcare fraud and abuse laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. Moreover, achieving and sustaining compliance with all applicable federal and state fraud and abuse laws may be costly.

We and our partners may be subject to new legislation, regulatory proposals and healthcare payor initiatives that may increase our costs of compliance and adversely affect our ability to market our products, including RAPIVAB, obtain collaborators and raise capital.

In March 2010, the President signed the Patient Protection and Affordable Care Act, or PPACA, which makes extensive changes to the delivery of health care in the U.S. The PPACA includes numerous provisions that affect pharmaceutical companies, some of which became effective immediately and others of which will be taking effect over the next several years. For example, the PPACA seeks to expand health care coverage to the uninsured through private health insurance reforms and an expansion of Medicaid. The PPACA will also impose substantial costs on pharmaceutical manufacturers, such as an increase in liability for rebates paid to Medicaid, new drug discounts that must be offered to certain enrollees in the Medicare prescription drug benefit, an annual fee imposed on all manufacturers of brand prescription drugs in the U.S., and an expansion of an existing program requiring pharmaceutical discounts to certain types of hospitals and federally subsidized clinics. The PPACA also contains cost containment measures that could reduce reimbursement levels for health care items and services generally, including pharmaceuticals. It also will require reporting and public disclosure of payments and other transfers of value provided by pharmaceutical companies to physicians and teaching hospitals. We cannot predict what effect the PPACA or other healthcare reform initiatives that may be adopted in the future will have on our business. Further, it remains unclear whether there will be any changes made to provisions of the PPACA or other health care laws through acts of Congress in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of health care services to contain or reduce costs of health care could result in decreased net revenues from our pharmaceutical products and decrease potential returns from our development efforts. In addition, pharmaceutical and device manufacturers will also be required to report and disclose investment interests held by physicians and their immediate family members during the preceding calendar year. Failure to submit required information may result in civil monetary penalties for payments, transfers of value or ownership or investment interests not reported in an annual submission. Compliance with the PPACA and state laws with similar provisions is difficult and time consuming, and companies that do not comply with these state laws face civil penalties. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business, financial condition, results of operations and growth prospects.

In addition, there have been a number of other legislative and regulatory proposals aimed at changing the pharmaceutical industry. In particular, legislation has been enacted in certain states and proposed at a federal level that requires development of an electronic pedigree to track and trace each prescription drug at the saleable unit level through the distribution system. Compliance with these electronic pedigree requirements may increase our operational expenses and impose significant administrative burdens. In addition, our compliance may be deemed insufficient and we could fact a material adverse effect on our business, financial condition, results of operations and growth prospects. As a result of these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change our contract arrangements, any of which could have a material adverse effect on our business, financial condition and results of operations.

Managed care organizations are increasingly challenging the prices charged for medical products and services and, in some cases, imposing restrictions on the coverage of particular drugs. Many managed care organizations negotiate the price of medical services and products and develop formularies which establish pricing and reimbursement levels. Exclusion of a product from a formulary can lead to its sharply reduced usage in the managed care organization’s patient population. The process for obtaining coverage can be lengthy and costly, and we expect that it could take several months before a particular payor initially reviews our product and makes a decision with respect to coverage. For example, third-party payors may require cost-benefit analysis data from us in order to demonstrate the cost-effectiveness of RAPIVAB or any other product we might bring to market. For any individual third-party payor, we may not be able to provide data sufficient to gain reimbursement on a similar or preferred basis to competitive products, or at all which may have a material adverse effect on our business, financial condition and results of operations.

There are risks related to the potential government use or sale of RAPIVAB.

Government use or sale of RAPIVAB in emergency situations, or otherwise, may result in the use of RAPIVAB which is outside of its approved use. To the extent that RAPIVAB is used as a treatment for influenza by any government entity, there can be no assurance that it will prove to be generally safe, well-tolerated and effective. Such government use of RAPIVAB may create certain liabilities for us. There is no assurance that we or our manufacturers will be able to fully meet the demand for RAPIVAB in the event of additional orders. Further, we may not achieve a favorable price for additional orders of RAPIVAB in the United States or in any other country. Our competitors may develop products that could compete with or replace peramivir. We may face competition in markets where we have no existing intellectual property protection or are unable to successfully enforce our intellectual property rights.

There is no assurance that the non-U.S. partnerships that we have entered into for peramivir will result in any order for peramivir in those countries. There is no assurance that RAPIVAB will be approved for any use or will achieve market approval in additional countries. In the event that any emergency use or market approval is granted, there is no assurance that any order by any non-U.S. partnership or commercialization of RAPIVAB in other countries will be substantial or will be profitable to us. The sale of peramivir, emergency use or other use of peramivir in any country may create certain liabilities for us.

Because we have limited manufacturing experience, we depend on third-party manufacturers to manufacture our product, product candidates and the materials for our product candidates. Often, especially early in the development and commercialization process, we have only one source for manufacturing. If we cannot rely on existing third-party manufacturers, we will be required to incur significant costs and potential delays in finding new third-party manufacturers.

We have limited manufacturing experience and only a small scale manufacturing facility. We currently rely upon third-party manufacturers to manufacture the materials required for our product, product candidates and most of the preclinical and clinical quantities of our product candidates. We depend on these third-party manufacturers to perform their obligations in a timely manner and in accordance with applicable governmental regulations. Our third-party manufacturers, which may be the only manufacturer we have engaged, may encounter difficulties with meeting our requirements including but not limited to problems involving:

	•	inconsistent production yields;
	•	product liability claims or recalls of commercial product;
	•	difficulties in scaling production to commercial and validation sizes;
	•	interruption of the delivery of materials required for the manufacturing process;
	•	scheduling of plant time with other vendors or unexpected equipment failure;
	•	potential catastrophes that could strike their facilities or have an effect on infrastructure;
	•	potential impurities in our drug substance or products that could affect availability of product for our clinical trials or future commercialization;
	•	poor quality control and assurance or inadequate process controls; and
	•	lack of compliance or cooperation with regulations and specifications or requests set forth by the FDA or other foreign regulatory agencies, particularly associated with RAPIVAB and planned studies for avoralstat, BCX7353 and BCX4430.

These contract manufacturers may not be able to manufacture the materials required for our product candidates at a cost or in quantities necessary to make them commercially viable. We also have no control over whether third-party manufacturers breach their agreements with us or whether they may terminate or decline to renew agreements with us. To date, our third-party manufacturers have met our manufacturing requirements, but they may not continue to do so. Furthermore, changes in the manufacturing process or procedure, including a change in the location where the drug is manufactured or a change of a third-party manufacturer, may require prior review and approval in accordance with the FDA’s cGMP and comparable foreign requirements. This review may be costly and time-consuming and could delay or prevent the launch of a product. The FDA or similar foreign regulatory agencies at any time may also implement new standards, or change their interpretation and enforcement of existing standards for manufacture, packaging or testing of products. If we or our contract manufacturers are unable to comply, we or they may be subject to regulatory action, civil actions or penalties.

If we are unable to maintain current manufacturing or other contract relationships, or enter into new agreements with additional manufacturers on commercially reasonable terms, or if there is poor manufacturing performance or failure to comply with any regulatory agency on the part of any of our third-party manufacturers, we may not be able to complete development of, seek timely approval of, or market, our product candidates.

Our raw materials, drug substances, and product candidates are manufactured by a limited group of suppliers and some at a single facility. If any of these suppliers were unable to produce these items, this could significantly impact our supply of product candidate material for further preclinical testing and clinical trials.

Royalties and milestone payments from Shionogi under our license agreement with Shionogi (the “Shionogi Agreement”) will be required to be used by Royalty Sub to service its obligations under its PhaRMA Notes, and generally will not be available to us for other purposes until Royalty Sub has repaid in full its obligations under the PhaRMA Notes.

In March 2011, our wholly-owned subsidiary Royalty Sub issued $30.0 million in aggregate principal amount of PhaRMA Notes. The PhaRMA Notes are secured principally by (i) certain royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from us the rights to market peramivir in Japan and, if approved for commercial sale, Taiwan, (ii) rights to certain payments under a Japanese yen/U.S. dollar foreign currency hedge arrangement put into place by us in connection with the issuance of the PhaRMA Notes and (iii) the pledge by us of our equity interest in Royalty Sub. Payments from Shionogi to us under the Shionogi Agreement will generally not be available to us for other purposes until Royalty Sub has repaid in full its obligations under the PhaRMA Notes. Accordingly, these funds will be required to be dedicated to Royalty Sub’s debt service and not available to us for product development or other purposes. As of September 1, 2014, the payments from Shionogi were insufficient for Royalty Sub to service its obligations under the PhaRMA Notes, resulting in an event of default with respect to the PhaRMA Notes. As a result of this event of default, the holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may exercise other remedies available to them under the indenture or other documents related to the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs and we might otherwise be adversely affected.

Because an event of default has occurred under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub, in which case we may not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be adversely affected.

Royalty Sub’s ability to service its payment obligations in respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub, is subject to numerous risks. Royalty Sub’s ability to service the PhaRMA Notes may be adversely affected by, among other things, changes in or any termination of our relationship with Shionogi, reimbursement, regulatory, manufacturing and/or intellectual property issues, product returns, product recalls, product liability claims and allegations of safety issues, as well as other factors. As Royalty Sub has been unable to service its obligations under the PhaRMA Notes and an event of default has occurred under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may exercise other remedies available to them under the indenture or other documents related to the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs and we might otherwise be adversely affected.

We may be required to pay significant premiums under the foreign currency hedge arrangement entered into by us in connection with the issuance of the PhaRMA Notes. In addition, because our potential obligations under the foreign currency hedge are marked to market, we may experience additional quarterly volatility in our operating results and cash flows attributable to the foreign currency hedge arrangement.

In connection with the issuance by Royalty Sub of the PhaRMA Notes, we entered into a foreign currency hedge arrangement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the foreign currency hedge agreement, we may be required to pay an annual premium in the amount of $2.0 million in each May, provided the foreign currency hedge arrangement remains in effect, continuing through May 2020. Such payment will be required if, in May of the relevant year, the spot rate of exchange for Japanese yen-U.S. dollars (determined in accordance with the foreign currency hedge arrangement) is such that the U.S. dollar is worth 100 yen or less. We will be required to mark-to-market our potential obligations under the currency hedge and post cash collateral, which may cause us to experience additional quarterly volatility in our operating results and cash flows as a result. Additionally, we may be required to pay significant premiums or a termination fee under the foreign currency hedge agreement entered into by us in connection with the issuance of the PhaRMA Notes. We are required to maintain a foreign currency hedge at 100 yen per dollar under the agreements governing the PhaRMA Notes.

If we or our partners do not obtain and maintain governmental approvals for our product candidates under development, we or our partners will not be able to sell these potential products, which would significantly harm our business because we will receive no revenue.

We or our partners must obtain regulatory approval before marketing or selling our future product candidates. If we or our partners are unable to receive regulatory approval and do not market or sell our future product candidates, we will never receive any revenue from such product sales. In the United States, we or our partners must obtain FDA approval for product candidates that we intend to commercialize. The process of preparing for and obtaining FDA approval may be lengthy and expensive, and approval is never certain. Products distributed abroad are also subject to foreign government regulation and export laws of the United States. Because of the risks and uncertainties in biopharmaceutical development, our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval. If the FDA delays regulatory approval of our product candidates, our management’s credibility, our value and our operating results may suffer. Even if the FDA or foreign regulatory agencies approve a product candidate, the approval may limit the indicated uses for a product candidate and/or may require post-approval studies.

The FDA regulates, among other things, the record keeping and storage of data pertaining to potential pharmaceutical products. We currently store most of our preclinical research data, our clinical data and our manufacturing data at our facility. While we do store duplicate copies of most of our clinical data offsite and a significant portion of our data is included in regular backups of our systems, we could lose important data if our facility incurs damage, or if our vendor data systems fail, suffer damage or are destroyed. If we receive approval to market our potential products, whether in the United States or internationally, we will continue to be subject to extensive regulatory requirements. These requirements are wide ranging and govern, among other things:

	•	adverse drug experience reporting regulations;
	•	product promotion;
	•	product manufacturing, including good manufacturing practice requirements; and
	•	product changes or modifications.

Our failure to comply with existing or future regulatory requirements, or our loss of, or changes to, previously obtained approvals, could have a material adverse effect on our business because we will not receive product or royalty revenues if we or our partners do not receive approval of our products for marketing.

We face intense competition, and if we are unable to compete effectively, the demand for our products, if any, may be reduced.

The biotechnology and pharmaceutical industries are highly competitive and subject to rapid and substantial technological change. There are many companies seeking to develop products for the same indications that we are working on. Our competitors in the United States and elsewhere are numerous and include, among others, major multinational pharmaceutical and chemical companies and specialized biotechnology firms. Most of these competitors have greater resources than we do, including greater financial resources, larger research and development staffs and more experienced marketing and manufacturing organizations. In addition, most of our competitors have greater experience than we do in conducting clinical trials and obtaining FDA and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals of product candidates more rapidly than we do. Companies that complete clinical trials, obtain required regulatory approvals, and commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including patent and FDA exclusivity rights that would delay our ability to market products. We face, and will continue to face, competition in the licensing of desirable disease targets, licensing of desirable product candidates, and development and marketing of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. Competition may also arise from, among other things:

	•	other drug development technologies;
	•	methods of preventing or reducing the incidence of disease, including vaccines; and
	•	new small molecule or other classes of therapeutic agents.

Developments by others may render our product candidates or technologies obsolete or noncompetitive.

We and our partners are performing research on or developing products for the treatment of several disorders including HAE, recurrent/refractory peripheral T-cell lymphoma and broad spectrum antivirals which may be developed as medical countermeasures. We expect to encounter significant competition for any of the pharmaceutical products we plan to develop. Companies that complete clinical trials, obtain required funding or government support, obtain required regulatory approvals and commence commercial sales or stockpiling orders of their products before their competitors may achieve a significant competitive advantage. Such is the case with Eisai Co. Ltd.’s TARGRETIN® for cutaneous T-cell lymphoma and the current neuraminidase inhibitors marketed by GSK and Roche for influenza and CINRYZE® and FIRAZYR® for HAE, marketed by Shire Pharmaceuticals, Inc., and KALBITOR® for HAE, marketed by Dyax Corporation. Therapeutic products with potentially promising data to treat Ebola include Mapp Biopharmaceutical, Inc.’s ZMapp (antibody-based) and Gilead Sciences, Inc.’s (small molecule), both of which have been used in Ebola infected patients. Further, several pharmaceutical and biotechnology firms, including major pharmaceutical companies and specialized structure-based drug design companies, have announced efforts in the field of structure-based drug design and molecules in development in the fields of HAE and in other therapeutic areas where we have discovery and development efforts ongoing. If one or more of our competitors’ products or programs are successful, the market for our products may be reduced or eliminated.

Compared to us, many of our competitors and potential competitors have substantially greater:

	•	capital resources;
	•	research and development resources, including personnel and technology;
	•	regulatory experience;
	•	preclinical study and clinical testing experience;
	•	manufacturing and marketing experience; and
	•	production facilities.

Any of these competitive factors could impede our funding efforts, render technology and product candidates noncompetitive or eliminate or reduce demand for our product candidates.

If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of those rights would diminish.

Our success will depend in part on our ability and the abilities of our partners to obtain, protect and enforce viable intellectual property rights including but not limited to trade name, trademark and patent protection for our Company and its products, methods, processes and other technologies we may license or develop, to preserve our trade secrets, and to operate without infringing the proprietary rights of third parties both domestically and abroad. The patent position of biotechnology and pharmaceutical companies is generally highly uncertain, involves complex legal and factual questions and has recently been the subject of much litigation. Neither the United States Patent and Trademark Office (“USPTO”), the Patent Cooperation Treaty offices, nor the courts of the United States and other jurisdictions have consistent policies nor predictable rulings regarding the breadth of claims allowed or the degree of protection afforded under many biotechnology and pharmaceutical patents. Further, we may not have worldwide patent protection for all of our product candidates and our intellectual property rights may not be legally protected or enforceable in all countries throughout the world. In some jurisdictions, some of our product candidates in certain programs, including our HAE program, may have short or no composition of matter patent life and we may therefore rely on orphan drug exclusivity or data exclusivity. There can be no assurance that we will obtain orphan drug exclusivity or data exclusivity in every jurisdiction. Further, in some jurisdictions, we may rely on formulation patents or method of use patents. Both the ability to achieve issuance and the enforcement of formulation and method of use patents can be highly uncertain and can vary from jurisdiction to jurisdiction, and such patents may therefore not adequately prevent competitors and potential infringers in some jurisdictions. The validity, scope, enforceability and commercial value of the rights protected by such patents, therefore, is highly uncertain.

We also rely on trade secrets to protect technology in cases when we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborators and advisors, our ability to receive patent protection or protect our proprietary information may be imperiled.

We may be involved in lawsuits to protect or enforce our patents, the patents of our partners or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.

Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming and unsuccessful. An adverse result in any litigation or defense proceeding could put one or more of our patents at risk. Our success depends in part on avoiding the infringement of other parties’ patents and other intellectual property rights as well as avoiding the breach of any licenses relating to our technologies and products. In the United States, patent applications filed in recent years are confidential for 18 months, while older applications are not published until the patent issues. As a result, avoiding patent infringement may be difficult and we may inadvertently infringe third-party patents or proprietary rights. These third parties could bring claims against us, our partners or our licensors that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, our partners or our licensors, we or they could be forced to stop or delay research, development, manufacturing or sales of any infringing product in the country or countries covered by the patent we infringe, unless we can obtain a license from the patent holder. Such a license may not be available on acceptable terms, or at all, particularly if the third party is developing or marketing a product competitive with the infringing product. Even if we, our partners or our licensors were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property.

If we or our partners are unable or fail to adequately initiate, protect, defend or enforce our intellectual property rights in any area of commercial interest or in any part of the world where we wish to seek regulatory approval for our products, methods, processes and other technologies, the value of the product candidates to produce revenue would diminish. Additionally, if our products, methods, processes, and other technologies or our commercial use of such products, processes, and other technologies, including but not limited to any trade name, trademark or commercial strategy infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO and the patent offices of other jurisdictions have issued to us a number of patents for our various inventions and we have in-licensed several patents from various institutions. We have filed additional patent applications and provisional patent applications with the USPTO. We have filed a number of corresponding foreign patent applications and intend to file additional foreign and U.S. patent applications, as appropriate. We have also filed certain trademark and trade name applications worldwide. We cannot assure you as to:

	•	the degree and range of protection any patents will afford against competitors with similar products;
	•	if and when patents will issue;
	•	if patents do issue we cannot be sure that we will be able to adequately defend such patents and whether or not we will be able to adequately enforce such patents; or
	•	whether or not others will obtain patents claiming aspects similar to those covered by our patent applications.

If the USPTO or other foreign patent office upholds patents issued to others or if the USPTO grants patent applications filed by others, we may have to:

	•	obtain licenses or redesign our products or processes to avoid infringement;
	•	stop using the subject matter claimed in those patents; or
	•	pay damages.

We may initiate, or others may bring against us, litigation or administrative proceedings related to intellectual property rights, including proceedings before the USPTO or other foreign patent office. Any judgment adverse to us in any litigation or other proceeding arising in connection with a patent or patent application could materially and adversely affect our business, financial condition and results of operations. In addition, the costs of any such proceeding may be substantial whether or not we are successful.

Our success is also dependent upon the skills, knowledge and experience, none of which is patentable, of our scientific and technical personnel. To help protect our rights, we require all employees, consultants, advisors and partners to enter into confidentiality agreements that prohibit the disclosure of confidential information to anyone outside of our company and require disclosure and assignment to us of their ideas, developments, discoveries and inventions. These agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information, and if any of our proprietary information is disclosed, our business will suffer because our revenues depend upon our ability to license or commercialize our product candidates and any such events would significantly impair the value of such product candidates.

We face an inherent risk of liability in the event that the use or misuse of our products results in personal injury or death and our product liability insurance coverage may be insufficient.

If the use or misuse of peramivir or any other regulatory body-approved products we or a partner may sell in the future harms people, we may be subject to costly and damaging product liability claims brought against us by consumers, healthcare providers, pharmaceutical companies, third-party payors or others. The use of our product candidates in clinical trials, including post marketing clinical studies, could also expose us to product liability claims. We cannot predict all of the possible harms or side effects that may result from the use of our products or the testing of product candidates and, therefore, the amount of insurance coverage we currently may not be adequate to cover all liabilities or defense costs we might incur. A product liability claim or series of claims brought against us could give rise to a substantial liability that could exceed our resources. Even if claims are not successful, the costs of defending such claims and potential adverse publicity could be harmful to our business.

We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face even greater risks upon any commercialization by us of our product candidates. We have product liability insurance covering our commercial sale of RAPIVAB and our clinical trials. Clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance or increase our existing coverage at a reasonable cost to protect us against losses that could have a material adverse effect on our business. An individual may bring a product liability claim against us if one of our products or product candidates causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought against us, with or without merit, could result in:

	•	liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;
	•	an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;
	•	withdrawal of clinical trial volunteers or patients;
	•	damage to our reputation and the reputation of our products, resulting in lower sales;
	•	regulatory investigations that could require costly recalls or product modifications;
	•	litigation costs; and
	•	the diversion of management’s attention from managing our business.

Insurance coverage is increasingly more costly and difficult to obtain or maintain.

While we currently have insurance for our business, property, directors and officers, and our products insurance is increasingly more costly and narrower in scope, and we may be required to assume more risk in the future. If we are subject to claims or suffer a loss or damage in excess of our insurance coverage, we will be required to bear any loss in excess of our insurance limits. If we are subject to claims or suffer a loss or damage that is outside of our insurance coverage, we may incur significant uninsured costs associated with loss or damage that could have an adverse effect on our operations and financial position. Furthermore, any claims made on our insurance policies may impact our ability to obtain or maintain insurance coverage at reasonable costs or at all.

If our facility incurs damage or power is lost for a significant length of time, or if we incur significant cost overruns or delays in the construction of our new discovery facilities in Birmingham, Alabama, our business will suffer.

We store clinical and stability samples at our facility that could be damaged if our facility incurs physical damage or in the event of an extended power failure. We have backup power systems in addition to backup generators to maintain power to all critical functions, but any loss of these samples could result in significant delays in our drug development process.

In addition, we store most of our preclinical and clinical data at our facilities. Duplicate copies of most critical data are secured off-site. Any significant degradation or failure of our computer systems could cause us to inaccurately calculate or lose our data. Loss of data could result in significant delays in our drug development process and any system failure could harm our business and operations.

We also face the risk that the costs and time required in connection with the construction of our new discovery facilities in Birmingham, Alabama could exceed our current expectations. If there is a significant cost overrun or significant delay in the completion of the construction, our business, financial condition, and results of operations could be adversely affected.

A significant disruption in our information technology systems or a cyber-security breach could adversely affect our business.

We are increasingly dependent on information technology systems to operate our business. Like other companies in our industry, our networks and infrastructure may be vulnerable to cyber-attacks or intrusions, including by computer hackers, foreign governments, foreign companies or competitors, or may be breached by employee error, malfeasance or other disruption. A breakdown, invasion, corruption, destruction or interruption of critical information technology systems could negatively impact operations. If our systems are damaged, fail to function properly or otherwise become unavailable, we may incur substantial costs to repair or replace them, and we may experience loss of critical data and interruptions or delays in our ability to perform critical functions, which could adversely affect our business, financial condition or results of operations. Any compromise of our data security could also result in a violation of applicable privacy and other laws, significant legal and financial exposure, damage to our reputation, loss or misuse of the information and a loss of confidence in our data security measures, which could harm our business. There can be no assurance that our efforts to protect our data and information technology systems will prevent breakdowns or breaches in our systems, or those of third parties with which we do business, and any such events could adversely affect our business.

If we fail to retain our existing key personnel or fail to attract and retain additional key personnel, the development of our product candidates and commercialization of our products and the related expansion of our business will be delayed or stopped.

We are highly dependent upon our senior management and scientific team, the unexpected loss of whose services might impede the achievement of our development and commercial objectives. Competition for key personnel with the experience that we require is intense and is expected to continue to increase. Our inability to attract and retain the required number of skilled and experienced management, commercial, operational and scientific personnel will harm our business because we rely upon these personnel for many critical functions of our business.

If because of our use of hazardous materials, we violate any environmental controls or regulations that apply to such materials, we may incur substantial costs and expenses in our remediation efforts.

Our research and development involves the controlled use of hazardous materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and some waste products. Accidental contamination or injury from these materials could occur. In the event of an accident, we could be liable for any damages that result and any liabilities could exceed our resources. Compliance with environmental laws and regulations or a violation of such environmental laws and regulations could require us to incur substantial unexpected costs, which would materially and adversely affect our results of operations.

Risks relating to investing in our common stock

Our existing principal stockholders hold a substantial amount of our common stock and may be able to influence significant corporate decisions, which may conflict with the interest of other stockholders.

Several of our stockholders own greater than 5% of our outstanding common stock. Our top ten stockholders own more than 50% of BioCryst and can individually, and as a group, influence our operations based upon their concentrated ownership. These stockholders, if they act together, may be able to influence the outcome of matters requiring approval of the stockholders, including the election of our directors and other corporate actions.

Our stock price has been, and is likely to continue to be, highly volatile, which could result in the value of an investment in our common stock to decline significantly.

The market prices for securities of biotechnology companies in general have been highly volatile and may continue to be highly volatile in the future. Moreover, our stock price has fluctuated frequently, and these fluctuations are often not related to our financial results. For the twelve months ended September 30, 2015, the 52-week range of the market price of our stock was from $7.85 to $16.83 per share. The following factors, in addition to other risk factors described in this section, may have a significant impact on the market price of our common stock:

	•	announcements of technological innovations or new products by us or our competitors;
	•	developments or disputes concerning patents or proprietary rights;
	•	additional dilution through sales of our common stock or other derivative securities;
	•	status of new or existing licensing or collaborative agreements and government contracts;
	•	announcements relating to the status of our programs;
	•	developments and announcements regarding new and virulent strains of influenza;
	•	we or our partners achieving or failing to achieve development milestones;
	•	publicity regarding actual or potential medical results relating to products under development by us or our competitors;
	•	publicity regarding certain public health concerns for which we are or may be developing treatments;
	•	regulatory developments in both the United States and foreign countries;
	•	public concern as to the safety of pharmaceutical products;
	•	actual or anticipated fluctuations in our operating results;
	•	changes in financial estimates or recommendations by securities analysts;
	•	changes in the structure of healthcare payment systems, including developments in price control legislation;
	•	announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;
	•	additions or departures of key personnel or members of our board of directors;
	•	purchases or sales of substantial amounts of our stock by existing stockholders, including officers or directors;
	•	economic and other external factors or other disasters or crises; and
	•	period-to-period fluctuations in our financial results.

Future sales and issuances of securities may dilute the ownership interests of our current stockholders and cause our stock price to decline.

Future sales of our common stock by current stockholders into the public market could cause the market price of our stock to fall. As of October 31, 2015, there were 73,336,871 shares of our common stock outstanding. We may from time to time issue securities in relation to a license arrangement, collaboration, merger or acquisition. We may also sell, for our own account, shares of common stock or other equity securities, from time to time at prices and on terms to be determined at the time of sale.

As of October 31, 2015, there were 9,820,203 stock options and restricted stock units outstanding, 890,262 shares available for issuance under our Amended and Restated Stock Incentive Plan, and 497,204 shares available for issuance under our Employee Stock Purchase Plan. In addition, we could also make equity compensation grants outside of our Stock Incentive Plan. The shares underlying existing stock options, restricted stock units and possible future stock options, stock appreciation rights and stock awards have been registered pursuant to registration statements on Form S-8.

If some or all of such shares are sold or otherwise issued into the public market over a short period of time, our current stockholders’ ownership interests may be diluted and the value of all publicly traded shares is likely to decline, as the market may not be able to absorb those shares at then-current market prices. Additionally, such sales and issuances may make it more difficult for us to sell equity securities or equity-related securities in the future at a time and price that our management deems acceptable, or at all.

We have anti-takeover provisions in our corporate charter documents that may result in outcomes with which you do not agree.

Our board of directors has the authority to issue up to 4,800,000 shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions of those shares without further vote or action by our stockholders. The rights of the holders of any preferred stock that may be issued in the future may adversely affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third parties to acquire a majority of our outstanding voting stock.

In addition, our certificate of incorporation provides for staggered terms for the members of the board of directors and supermajority approval of the removal of any member of the board of directors and prevents our stockholders from acting by written consent. Our certificate also requires supermajority approval of any amendment of these provisions. These provisions and other provisions of our by-laws and of Delaware law applicable to us could delay or make more difficult a merger, tender offer or proxy contest involving us.

We have never paid dividends on our common stock and do not anticipate doing so in the foreseeable future.

We have never paid cash dividends on our stock. We currently intend to retain all future earnings, if any, for use in the operation of our business. Accordingly, we do not anticipate paying cash dividends on our common stock in the foreseeable future.

Item 6. Exhibits

See the Exhibit Index attached to this quarterly report and incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 6th day of November, 2015.

	BIOCRYST PHARMACEUTICALS, INC.

	/s/ Jon P. Stonehouse
	Jon P. Stonehouse
	President and Chief Executive Officer
	(Principal Executive Officer)

	/s/ Thomas R. Staab, II
	Thomas R. Staab, II
	Senior Vice President, Chief Financial Officer
	and Treasurer
	(Principal Financial and Principal Accounting Officer)

INDEX TO EXHIBITS

Number		Description
	3.1	Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed December 22, 2006.
	3.2	Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed July 24, 2007.
	3.3	Certificate of Increase of Authorized Number of Shares of Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed November 4, 2008.
	3.4	Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed May 7, 2014.
	3.5	Certificate of Increase of Authorized Number of Shares of Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit 3.2 to the Company’s Form 8-K filed May 7, 2014.
	3.6	Amended and Restated Bylaws of Registrant effective October 29, 2008. Incorporated by reference to Exhibit 3.2 to the Company’s Form 8-K filed November 4, 2008.
	(10.1)†	Amendment #2 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, dated July 8, 2015. (Portions omitted pursuant to request for confidential treatment.)
	(10.2)†	Amendment #3 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, dated August 25, 2015. (Portions omitted pursuant to request for confidential treatment).
	(10.3)†	Amendment #14 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated September 16, 2015. (Portions omitted pursuant to request for confidential treatment.)
	(31.1)	Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
	(31.2)	Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
	(32.1)	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
	(32.2)	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
	(101)	Financial statements from the Quarterly Report on Form 10-Q of BioCryst Pharmaceuticals, Inc. for the three months ended September 30, 2015, formatted in XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements.

______________

( )	Filed or furnished herewith.
†	Confidential treatment requested.

EX-10.1 2 exh_101.htm EXHIBIT 10.1

EXHIBIT 10.1

EX-10.2 3 exh_102.htm EXHIBIT 10.2

EXHIBIT 10.2

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

ATTACHMENT 1

Statement of Work

HHSO100201500007C

BCX4430 NDA Enabling CMC and Non-Clinical Toxicology Studies

August 19, 2015

PREAMBLE

Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to perform the Statement of Work submitted in response to the BARDA Broad Agency Announcement (BAA) CBRN-BAA-10-100-SOL-00013.

The Government reserves the right to modify the milestones, progress, schedule, budget, or deliverables to add or delete deliverables, process, or schedules if the need arises. Because of the nature of this research and development (R&D) contract and the complexities inherent in this and prior programs, at designated milestones the Government will evaluate whether work should be redirected, removed, or whether schedule or budget adjustments should be made.

Overall Objectives and Scope

The overall objective of this contract is to advance the development of BCX4430, a novel small molecule nucleoside with broad spectrum antiviral activity being developed for diseases caused by RNA pathogens. BCX4430, an inhibitor of viral RNA – dependent RNA polymerase (RdRp), is the lead compound in our broad-spectrum antiviral program to meet the need for a parenteral, direct-acting antiviral medical countermeasure (MCM) having efficacy across multiple viruses. The scope of work for this contract includes preclinical and manufacturing development activities that fall into the following areas: manufacturing of clinical trial material, manufacturing process improvements and development, non-clinical toxicology studies; and all associated regulatory, quality assurance, management, and administrative activities. The proposed activities take into account the Ebola virus disease (EVD) outbreak in West Africa. The R&D effort will contribute toward an NDA filing for BCX4430. Overall, this Statement of Work (SOW) focuses on:

Drug substance (DS) and drug product (DP) manufacturing process development activities that will be conducted at US based facilities, which will result in the ability to consistently produce high quality, cGMP compliant material and deliver drug supply that could be available for deployment as a medical countermeasure during the Ebola crisis and support future clinical and non-clinical studies

Nonclinical development activities to advance the intramuscular (IM) and intravenous (IV) formulation through NDA-enabling toxicology including *** and *** studies in the ***

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

BASE: Manufacture of Clinical Trial Material

Duration: 18 months

Drug Substance and Drug Product cGMP manufacturing by US suppliers to support non-clinical and clinical activities. Drug Substance will be produced following an *** starting with ***, which will be used as the GMP starting material to produce BCX4430.

The primary objectives will be to

Produce *** batches of BCX4430 drug substance following ***.

Conduct drug product process improvements that will be focused on validation of analytical methods, stress testing, stability studies, and process design space optimization

1.1. Procurement of Starting Materials

The contractor shall procure the starting materials to produce *** of the current manufacturing process of BCX4430. The key starting materials to be procured are *** and ***.

1.1.1. Procurement of Starting Materials to produce two 35 kg batches of BCX1777

The contractor shall procure *** and *** for the manufacture of *** of *** to support a *** campaign (WBS 1.4.1 and 1.4.2) and a *** batch of BCX4430 (Clinical Trial Material Batch *** WBS1.7.1)

1.2. Further Process Improvements of ***

The contractor shall conduct further process improvements that may be identified focused on improving the existing plant-scale processes following generally the same ***.

1.2.1 Conduct Process Improvements

The contractor shall conduct the process improvements with existing plant-scale processes.

1.2.2 Determination that Process is Sufficient to move to Commercial Scale up

The contractor shall evaluate the processes developed and provide sufficient information through a deliverable that will enable BARDA to determine that the processes are sufficient to move to commercial scale –up activities.

1.3. Manufacture of *** at ***

The contractor shall produce *** of *** will be utilized as the starting material for the manufacture of BCX4430 in accordance with cGMP guidance.

1.3.1. Manufacture of *** of *** (Batch ***)

The contractor shall produce *** of *** using the existing process at ***.

1.3.2. Manufacture of *** of *** (Batch ***)

The contractor shall produce *** of *** using the existing process at ***.

1.4. Manufacturing Campaign of BCX4430

The contractor shall produce *** batches of BCX4430 at *** in compliance with cGMP.

1.4.1. Manufacturing of *** of cGMP BCX4430 (DS Batch ***)

The contractor shall produce and release *** of cGMP BCX4430 ***.

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

1.4.2. Manufacturing of *** of cGMP BCX4430 (DS Batch ***)

The contractor shall produce and release *** of cGMP BCX4430 ***.

1.4.3. Prepare a Campaign Summary Report

The contractor shall prepare a campaign summary report of the manufacture and release of DS Batches ***.

1.4.4. Drug Substance Stability Studies

The contractor shall place samples from DS Batch *** of BCX4430 on a *** stability program at *** and a *** accelerated stability study at ***.

Table 1. BCX4430 Drug Substance Stability Study Sampling Points

Test ID	Months
Test ID	0	1	3	6	9	12	18	24	48	60
A	X	X	X	X	X	X	X	X	X	X
B	X	X	X	X	X	X	X	X	X	X
C	X	X	X	X	X	X	X	X	X	X
D	X	X	X	X	X	X	X	X	X	X
E	X	X	X	X	X	X	X	X	X	X
F	X	X		X		X	X	X	X	X
G	X	X		X		X	X	X	X	X

NOTE: BARDA will only cover stability activities for ***.

Table 2. BCX4430 Drug Substance Stability Tests

Test ID	Test
A	***
B	***
C	***
D	***
E	***
F	***
G	***

1.5. Drug Product Development

The contractor shall conduct drug product process improvements that will be focused on validation of analytical methods, stress testing, stability studies, and process design space optimization.

The contractor shall conduct formulation development activities and produce a sterile, parenteral formulation containing *** of the active compound per unit in compliance with cGMP guidance. Initial development efforts will be focused on delivering *** that tolerates terminal sterilization and provides an acceptable stability profile to support a *** shelf life. Additionally, studies to include: *** will be conducted to evaluate the feasibility of ***.

1.5.1. Stress Conditions Studies

The contractor shall conduct a series of experiments under conditions outlined in ICH guidance to evaluate the stability of the drug product made from available drug substance.

1.5.2. Design Space Studies

The contractor shall conduct studies to evaluate and define the design space of the formulation process.

1.5.3. Analytical Method Validation

The contractor shall conduct analytical methods validation or qualification as listed in the table below.

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

Table 3. BCX4430 Drug Product Methods that will be Validated or Qualified

Test	Method and Objective
***	***
***	***
***	***
***	***
***	***
***	***
***	***
***	***
***	***
***	***
***	***
***	***

1.5.4. Prepare Process Development Report for DP

The contractor shall prepare a process development report summarizing the experiments and results of the studies conducted to define the process and evaluate the formulation.

1.5.5. Pre-formulation and Physicochemical Properties Studies

The contractor shall conduct studies to determine the physicochemical properties of the drug substance and identify potential formulations and primary packaging for an IM injection based on stability and ability to be produced on manufacturing lines.

1.5.6. Feasibility Runs

The contractor shall conduct small-scale, nonGMP manufacturing runs of potential formulations and formats.

1.5.7. Extractable/Leachable Study

The contractor shall conduct studies to determine drug product stability in primary packaging and of syringe types that will be used for delivery.

1.5.8. Excipient Compatibility Studies for IV Formulation from IM

The contractor shall conduct studies to evaluate the compatibility of the IM formulation added to various standard IV fluids.

1.6.

Manufacturing of Drug Product to Support Clinical Trials

The contractor shall produce *** batches of approximately *** of drug product suitable for clinical trial use. The drug product will produced from the *** cGMP DS Batches *** (WBS 1.4.1 and 1.4.2)

1.6.1. Manufacture of Clinical Trial Material (CTM Batch ***)

The contractor shall produce approximately *** per cGMP for use in clinical trials which will include active drug and placebo batches to support the future clinical safety study.

1.6.2. Manufacture of Clinical Trial Material (CTM Batch ***)

The contractor shall produce approximately *** per cGMP for use in clinical trials which will include active drug and placebo batches to support the future clinical safety study.

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

1.6.3. Prepare a Campaign Summary Reports

The contractor shall prepare a campaign summary report of the manufacture and release of CTM Batches ***.

1.6.4. Drug Product Stability Studies - Active

The contractor shall place drug product on stability based on the following conditions:

Table 4. BCX4430 Drug Product Stability Testing Conditions and Sampling

Stability Conditions	Configuration	Test Points
***	***	***
***	***	***
***	***	***

NOTE: BARDA will only cover stability activities for ***

Testing at each interval, unless otherwise specified below, will include:

***

1.6.5. Drug Product Stability Studies - Placebo

The contractor shall place drug product on stability based on the following conditions:

Table 5. BCX4430 Drug Product Stability Testing Conditions and Sampling

Stability Conditions	Configuration	Test Points
***	***	***
***	***	***
***	***	***

Testing at each interval, unless otherwise specified below, will include:

***

NOTE: BARDA will only cover stability activities for ***

1.6.6. Comparability Study

The contractor shall conduct comparability studies evaluating drug substance produced by *** and ***, and the subsequently produced drug product, will be conduct per FDA Guidance. These studies will evaluate: in-process checks, impurity profiles, release testing results, and stability profiles at standard and accelerated conditions to ensure the material produced by both manufacturers is substantially comparable.

1.7. Manufacture of Additional Supply

That contractor shall produce *** of BCX4430 based on *** facility and subsequently produce *** of drug product at *** suitable for clinical trial use.

1.7.1. Manufacturing of *** cGMP BCX4430 (DS Batch ***)

The contractor shall produce *** of cGMP BCX4430 from ***.

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

1.7.2. Prepare a Campaign Summary Report

The contractor shall prepare a campaign summary report of the manufacture and release of ***.

1.7.3. Manufacturing of approximately *** (CTM Batch ***)

The contractor shall produce approximately *** of cGMP BCX4430 drug product using drug substance from the *** cGMP BCX4430 (DS Batch ***, WBS 1.7.1).

1.7.4. Prepare a Campaign Summary Report

The contractor shall prepare a campaign summary report of the manufacture and release of CTM Batches ***

1.7.5. Stability Studies for DS and DP

The contractor shall conduct drug substance and drug product stabilities for the DS and DP manufactured in from the *** of cGMP BCX4430 drug substance based on *** (WBS 1.6).

NOTE: BARDA will only cover stability activities for ***

1.7.6. Comparability Studies

The contractor shall conduct comparability studies evaluating drug substance produced by *** and both process at ***, and the subsequently produced drug product, will be conduct per FDA Guidance. These studies will evaluate: in-process checks, impurity profiles, release testing results, and stability profiles at standard and accelerated conditions to ensure the material produced by both manufacturers and both *** process are substantially comparable.

2 Option 1: Commercial Scale up and NDA Registration Batches

Duration: ***

Go/No Go Criteria to Initiate: WBS 1.2.2 BARDA approval of process developed

Through optimization of manufacturing processes, BARDA will evaluate and determine what process should be sufficient to initiate commercial scale up activities in this Option. This Option will add value to the project through conducting manufacturing regulatory activities that will be needed for future product approval with the FDA.

Decision Criteria:

***

The objective is to produce DS registration batches from the qualified process, ***. This will be determined upon the conclusion of the DS development effort being undertaken by BioCryst and funded by NIAID that is scheduled to conclude in December 2015. Additionally during this stage, the DP manufacturing process would be finalized for the commercial presentation and registration batches produced.

2.1. Procurement

The contractor shall procure the *** starting materials needed to produce BCX4430.

2.1.1. Procurement of ***

The contractor shall qualify a vendor(s) to produce the *** and procure enough material to support the manufacture of *** batches of BCX4430 drug substance.

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

2.1.2. Procurement of ***

The contractor shall qualify a vendor(s) to produce the *** and procure enough material to support the manufacture of *** batches of BCX4430 drug substance.

2.2. Drug Substance Process Scale-up

The contractor shall conduct process development work targeting a *** that can be scaled to plant equipment. This work will include: development of a *** through lab scale studies, process hazard evaluation including RC-1 and digital scanning calorimetry, lab scale qualification runs, pilot plant scale-up technical batches, necessary modifications to analytical methods based on the ***, and plant-scale registration runs.

2.2.1

Further Process Improvements of Final Route

The contractor shall conduct further process improvements that may be identified focused on improving the *** to be scaled up. The *** will be based either ***.

2.2.2

Process Hazard Evaluation

The contractor shall conduct process hazard evaluation studies needed for the scale-up of the optimized process into the plant.

2.2.3 Scale-up Technical Run

The contractor shall conduct a nonGMP manufacturing run at plant-scale to ensure the safety and output of the optimized process.

2.2.4 Analytical Method Development and Qualification

The contractor shall modify, add to, revalidate, or requalify the analytical methods.

2.2.5

Prepare Process Development Report

The contractor shall prepare a process development report describing the experiments and results leading to the selection of the optimized manufacturing process

2.3 Manufacture of cGMP Drug Substance Registration Batches

The contractor shall produce *** cGMP batches of BCX4430 following the *** at a scale comparable to the estimated commercial scale.

2.3.1

Manufacture of DS Batch (DS Batch ***)

The contractor shall manufacture a batch of cGMP BCX4430 at plant scale.

2.3.2 Manufacture of DS Batch (DS Batch ***)

The contractor shall manufacture a batch of cGMP BCX4430 at plant scale.

2.3.3 Manufacture of DS Batch (DS Batch ***)

The contractor shall manufacture a batch of cGMP BCX4430 at plant scale.

2.3.4 Prepare Campaign Summary Report

The contractor shall prepare a report summarizing the conduct, observations, and results of the manufacturing of DS Batches ***.

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

2.4 Drug Product Registration Batches

The contractor shall produce *** drug product lots at *** that will be used as the NDA registration batches.

2.4.1 Manufacture of DP Registration (DPR Batch ***)

The contractor shall manufacture a NDA registration batch of cGMP BCX4430 drug product at a scale at least *** the estimated commercial scale.

2.4.2 Manufacture of DP Registration (DPR Batch ***)

The contractor shall manufacture a NDA registration batch of cGMP BCX4430 drug product at a scale at least *** the estimated commercial scale.

2.4.3 Manufacture of DP Registration (DPR Batch ***)

The contractor shall manufacture a NDA registration batch of cGMP BCX4430 drug product at a scale at least *** the estimated commercial scale.

2.4.4 Prepare campaign summary report

The contractor shall prepare a report summarizing the conduct, observations, and results of the manufacturing of DPR Batches ***.

2.5 Stability studies for DS and DP

The contractor shall conduct drug substance and drug product stabilities as described in Table 2 and Table 3 .

NOTE: BARDA will only cover stability activities for ***

2.6 Comparability study

The contractor shall conduct comparability studies evaluating drug substance produced for clinical trials in the base period versus the NDA registration batches manufactured via *** in Option 1, and the subsequently produced drug product, will be conduct per FDA Guidance. These studies will evaluate: in-process checks, impurity profiles, release testing results, and stability profiles at standard and accelerated conditions to ensure the material produced by both processes is substantially comparable.

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

3 Option 2: Nonclinical NDA-enabling Toxicology

Duration: ***

Go/No Go Criteria to Initiate: Availability of cGMP BCX4430 *** DS batch manufactured under NIAID contract HHSO100201500007C

Through completion of manufacturing of Drug substance there will be material to conduct further regulatory activities such as the IM non-clinical NDA-enabling toxicology studies in this option. This Option will add value to the project through conducting additional non-clinical activities that will support a potential future NDA.

Decision Criterion:

***

The contractor shall perform nonclinical GLP studies of BCX4430 to characterize ***.

3.1. GLP *** Toxicology

The contractor shall for each toxicology study develop the protocol, select and qualify the vendor, conduct in life and recovery phases and analyze study data resulting in a final study report.

Studies include:

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

3.1.1. Conduct GLP *** toxicology study - ***

3.1.2. Conduct GLP *** general toxicology study - ***

3.2. *** toxicology

The contractor shall for each *** study segment develop the protocol, select and qualify the vendor, conduct in life and recovery phases and analyze study data resulting in a final study report.

Studies include:

3.2.1. Conduct *** assessment in ***

3.2.2. Conduct *** Dose Range Finding Studies in the ***

3.2.3. Conduct Definitive *** toxicology in the ***

3.2.4. Conduct *** toxicology ***

3.3. Nonclinical ADME

The contractor shall procure radiolabeled BCX4430. In addition for each ADME study, the contractor shall develop the protocol, select and qualify the vendor, conduct the study and analyze study data resulting in a final study report. Studies include:

3.3.1. Conduct Radiolabeled ADME study - ***

3.3.2. Conduct Radiolabeled ADME – ***

A listing of the proposed studies for the nonclinical NDA-enabling toxicology studies is provided.

Table 6 Nonclinical NDA-enabling Toxicology Studies

Study #	Description	Objective(s)	Species (N)
	GLP *** general toxicology	***	***
	GLP *** general toxicology	***	***
	*** assessment	***	***
	*** Dose Range Finding	***	***
	*** Dose Range Finding	***	***
	Definitive *** toxicology	***	***
	Definitive *** toxicology	***	***
	*** toxicology	***	***
	Radiolabeled ADME	Determine the absorption, distribution, metabolism and excretion of the test article following IM dosing	***
	Radiolabeled ADME	Determine the absorption, metabolism and excretion of the test article following IM dosing	***

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

4 Option 3: In vitro Experiments – IV

Duration: ***

Go/No Go to Initiate: Selection of a preliminary IV formulation (LRI) based on initial studies

Through completion of earlier studies, it will be determined what is an appropriate IV formulation to continue with toxicology studies of the IV formulation under this Option. This Option will add value to determine if there is any identified toxicology in in vitro assays before moving to animal studies in Option 4.

Decision Criterion:

***

4.1.

*** – IV

The contractor shall develop the protocol, select and qualify the vendor, conduct the experiments and analyze the data resulting in a study report.

4.2.

Conduct *** Test – IV

The contractor shall develop the protocol, select and qualify the vendor, conduct the experiment and analyze the data resulting in a study report.

A listing of the proposed experiments for the in vitro experiments to be conducted in advance of the nonclinical NDA-enabling toxicology studies for the IV formulation is provided in Table 7 .

Table 7 In vitro Experiments - IV

Study #	Description	Objective(s)	Species (N)
	***	***	***
	***	***	***

4.3 Study Report on all in vitro assays

The contractor shall submit a summarized study report with data and conclusions from all in vitro experiments conducted in table 7 to determine whether there is any toxicology before advancing into non-clinical NDA enabling toxicology studies (Option 5).

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

5 Option 4: Nonclinical NDA-enabling Toxicology - IV

Duration: ***

Go/No Go Criteria to Initiate: WBS 4.3 Study Report on all in vitro assays

Through completion of the IV in vitro toxicology studies with the IV formulation conducted in Option 3 and summarized in WBS 4.3, it will be determined if the IV formulation is safe to move into non-clinical toxicology animal studies in this Option. This Option will add value to the project through conducting additional non-clinical activities that will support a potential future NDA.

Decision Criterion:

***

5.1.

GLP *** Toxicology – IV

The contractor shall for each toxicology study develop the protocol, select and qualify the vendor, conduct in life and recovery phases and analyze study data resulting in a final study report. Studies include:

5.1.1. Conduct GLP *** IV general toxicology study - ***

5.1.2. Conduct GLP *** IV toxicology study - ***

5.2. *** toxicology - IV

The contractor shall for each *** study segment develop the protocol, select and qualify the vendor, conduct in life and recovery phases and analyze study data resulting in a final study report. Studies include:

5.2.1. Conduct *** assessment in ***

5.2.2.

Conduct *** Dose Range Finding Studies in the ***

5.2.3. Conduct Definitive *** toxicology in the ***

5.2.4. Conduct *** toxicology ***

A listing of the proposed studies for the nonclinical NDA-enabling toxicology studies for the IV formulation is provided in Table 8.

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

Table 8. Nonclinical NDA-enabling Toxicology Studies for an IV Formulation

Study #	Description	Objective(s)	Species (N)
	GLP *** IV general toxicology	***	***
	GLP *** IV general toxicology	***	***
	*** assessment	***	***
	*** Dose Range Finding	***	***
	*** Dose Range Finding	***	***
	Definitive *** toxicology	***	***
	Definitive *** toxicology	***	***
	*** toxicology	***	***

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

6 Program Management

The contractor shall provide all expertise needed for the implementation of the activities to be performed under this contract, including: research, manufacturing, regulatory, clinical, statistical analyses, management and administrative activities.

6.1. Technical and Project Management Support

The contractor shall appoint a Principal Investigator (PI) who will be responsible for all aspects of project performance and communication with the BARDA.

The contractor shall provide project management that will ensure day-to-day monitoring and tracking of progress and timelines, the coordination of project activities and costs incurred.

The contractor shall provide all managerial and administrative functions necessary for overall planning, monitoring, and implementing activities for the completion of the strategic product development plan.

The contractor shall provide for all necessary legal affairs required to ensure the timely acquisition of all proprietary rights, including intellectual property rights and all materials needed to perform the project, as well as reporting to the Government all inventions made in the performance of the project.

6.2. Subcontractor Management

The contractor shall provide for tracking, coordination and oversight of subcontractor efforts and manage communications with subcontractors.

6.3. Risk Management

The contractor shall identify project risks, develop risk management strategies and implement mitigation actions.

6.4. Earned Value Management (EVM)

The contractor shall provide EVM information.

6.5. Project Communications

The contractor shall provide for project communications including communications with BARDA and external experts.

The contractor shall provide planning and steps required for the conduct of contract review meetings.

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

7 Regulatory

The contractor shall ensure adherence to FDA regulations and guidance, including requirements for the conduct of animal studies and assays under GLP, the manufacturing of the therapeutic product under cGMP, and the conduct of clinical trials under GCP standards.

7.1. Regulatory Authority Interactions

The contractor shall prepare and submit documentation and correspondence to regulatory authorities as required. The contractor shall request and conduct meetings with regulatory authorities to ensure the development program is conducted in accordance with regulatory guidelines and expectations.

7.2. Quality Assurance

The contractor shall maintain quality assurance documentation. The contractor shall arrange for audits of subcontractor facilities to ensure all planned procedures comply with the FDA regulations and guidance that are required to meet GLP, cGMP and GCP standards. In addition, the contractor shall ensure that all contractor and/or subcontractor records and staff are available for site visits or audits.

7.3. Expert Collaborations

The contractor shall collaborate with experts in the field in the design of experiments and studies that support the advancement of the development program.

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

ATTACHMENT 2

MILESTONE AND DELIVERABLES CHART

August 20, 2015

HHSO100201500007C

WBS	Milestone		Deliverable	Success Criteria	Timing	Go/No-Go for initiation
CLIN 0001 - MANUFACTURE OF CLINICAL TRIAL MATERIAL
1.2.1	Process Improvements Report	Report on Process Development		Process Developed	***
1.2.2	Determination of Sufficient Process for Commercial Scale up	Evaluation report		BARDA approval of developed process	***	N/A
1.3.1	Manufacture * (Batch *)	***		Acceptable quality and yield	***	N/A
1.3.2	Manufacture * (Batch *)	***		Acceptable quality and yield	***	N/A
1.4.1	Manufacture cGMP BCX4430 (* campaign DS Batch *)	BCX4430 DS CofA,		Acceptable quality and yield	***	N/A
1.4.2	Manufacture cGMP BCX4430 (* campaign DS Batch *)	BCX4430 DS CofA,		Acceptable quality and yield	***	N/A
1.4.3	Prepare a Campaign Summary Reports	Campaign Reports (DS Batches ***)		Completion of DS Campaigns	***	N/A
1.4.4	Drug substance stability study	Initial Report on stability activities		Stability data	***
1.5	Drug Product Development	DP Process Development Report (WBS 1.5.4) Pre-formulation and Physicochemical Report (WBS1.5.5) Extractable/Leachable Report (WBS 1.5.7)		Completion of Studies	***	N/A
1.5.8	Excipient Compatibility Report for IV Formulation	Compatibility Report		IV formulation completed	***
1.6.1	Manufacture cGMP DP (CTM Batch ***)	BCX4430 DP CofA,		Acceptable quality and yield	***	Accepted GMP DS

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

1.6.2	Manufacture cGMP DP (CTM Batch ***)	BCX4430 DP CofA,		Acceptable quality and yield	***	Accepted GMP DS
1.6.3	Prepare a Campaign Summary Reports	Campaign Reports (CTM Batches ***)		Completion of DP Campaigns	***	N/A
1.6.4	Drug Product stability study - Active	Initial Report on stability activities		Stability Data	***
1.6.5	Drug Product stability study - Placebo	Initial Report on stability activities		Stability Data	***
1.6.6	Comparability Study	Comparability Protocol and Report		Completion of DS and DP Campaigns	***
1.7.1	Manufacture cGMP BCX4340 (* campaign DS Batch *)	BCX4430 DS CofA		Acceptable DS process	***	N/A
1.7.2	Prepare a Campaign Summary Report	Campaign Reports (DS Batch***)		Completion of DS Campaign	***	N/A
1.7.3	Manufacture cGMP DP (CTM Batch ***)	BCX4430 DP CofA,		Acceptable quality and yield	***	Accepted GMP DS
1.7.4	Prepare a Campaign Summary Report	Campaign Report (CTM Batches ***)		Completion of DS Campaigns	***	N/A
1.7.5	Drug Substance and Drug Product stability study	Initial report on stability activities		Stability Data	***	Manufacture of 1.7.1 drug substance and 1.7.2 drug product
1.7.6	Comparability Study	Comparability Protocol and Report		Comparable DS and DP profiles	***	N/A
CLIN 0002 – COMMERCIAL SCALE UP AND NDA REGISTRATION BATCHES Go/No Go Criteria to Initiate: WBS 1.2.2 BARDA approval of process developed
2.2	Drug Substance Process Scale-up		Process Development Report (WBS 2.2.4)	Selection of the optimized manufacturing process	***	*** process
2.3.1	Manufacture BCX4340 DS (DS Registration Batch ***)		BCX4430 Registration DS CofA	Acceptable quality and yield	***	*** process
2.3.2	Manufacture BCX4340 DS (DS Registration Batch ***)		BCX4430 Registration DS CofA,	Acceptable quality and yield	***	*** process
2.3.3	Manufacture BCX4340 DS (DS Registration Batch ***)		BCX4430 Registration DS CofA,	Acceptable quality and yield	***	*** process

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

2.3.4	Prepare a Campaign Summary Report	Campaign Reports (DS Batches ***)	Completion of DS Campaign	***	N/A
2.4.1	Manufacture BCX4430 DP (DP Registration Batch ***)	BCX4430 DP CofA,	Acceptable quality and yield	***	Accepted GMP DS
2.4.2	Manufacture BCX4430 DP (DP Registration Batch ***)	BCX4430 DP CofA,	Acceptable quality and yield	***	Accepted GMP DS
2.4.3	Manufacture BCX4430 DP (DP Registration Batch ***)	BCX4430 DP CofA,	Acceptable quality and yield	***	Accepted GMP DS
2.4.4	Prepare a Campaign Summary Report	Campaign Report (CTM Registration Batches ***)	Completion of DS Campaigns	***	N/A
2.5	Drug substance and Drug Product stability study	Report on stability activities	Stability Data	***
2.6	Comparability Study	Comparability Protocol and Report	Comparable DS and DP profiles	***	Accepted GMP DS
CLIN 0003 – NONCLINICAL NDA-ENABLING TOXICOLOGY Go/No Go Criteria to Initiate: /availability of * cGMP batch of DS manufactured under NIAID contract HHSO100201500007C**
3.1.1	Complete GLP *Tox Study - *	Study Report	Established NOAEL	***	Drug Substance confirming to release criteria
3.1.2	Complete GLP * Tox Study - *	Study Report	Established NOAEL	***	Drug Substance confirming to release criteria
3.2.1	Conduct * assessment in *	Study Report	No significant findings	***	N/A
3.2.2	Conduct * Dose Range Finding Studies in the *	Study Report	No significant findings	***	N/A
3.2.3	Conduct Definitive * toxicology in the *	Study Report	No significant findings	***	N/A
3.2.4	Conduct * toxicology *	Study Report	No significant findings	***	N/A
3.3.1	Conduct Radiolabeled ADME study - ***	Study Report	Characterize drug disposition	***	Acceptable Radiolabel Material
3.3.2	Conduct Radiolabeled ADME – ***	Study Report	Characterize drug disposition	***	Acceptable Radiolabel Material

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

CLIN 0004 – IN VITRO EXPERIMENTS – IV Go/No Go to Initiate: selection of an appropriate preliminary IV formulation
4.1.	Conduct *** Test – IV	Study Report	No effect on ***	***	IV formulation WBS 1.5.8
4.2.	Conduct *** – IV	Study Report	No effect on mitotic apparatus	***	N/A
4.3	In Vitro IV experiments	Study report on all In Vitro assays with recommendation to proceed CLIN0005	No toxicology in vitro	***
CLIN 0005 – NONCLINICAL NDA-ENABLING TOXICOLOGY – IV Go/No Go to Initiate: WBS 4.3 Completion of * IV toxicology studies**
5.1.1	Complete GLP * IV Tox Study - *	Study Report	Established NOAEL	***	Drug Substance confirming to release criteria
5.1.2	Complete GLP * IV Tox Study - *	Study Report	Established NOAEL	***	Drug Substance confirming to release criteria
5.2.1	Conduct * assessment in *	Study Report	No significant findings	***	N/A
5.2.2	Conduct * Dose Range Finding Studies in the *	Study Report	No significant findings	***	N/A
5.2.3	Conduct Definitive * toxicology in the *	Study Report	No significant findings	***	N/A
5.2.4	Conduct * toxicology *	Study Report	No significant findings	***	N/A

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

ATTACHMENT 3

BCX4430 MANUFACTURING SUMMARY

August 20, 2015

Starting Material	DS Campaign	CMO	DS Process Desc	DS Timing	DP Campaign	DP Timing	Use	Funding
***	***	***	***	***	***	***	***	***
***	***	***	***	***	***		***	***
***	***	***	***	***	***		***	***
***	***	***		***	***		***	***
***	***	***		***	***	***	***	***
***	***	***		***	***	***	***	***
***	***	***		***	***	***	***	***
***	***	***		***	***	***	***	***
***	***	***	***	***	***		***	***
***	***	***	***	***	***	***	***	***
	***	***		***	***	***	***	***
	***	***		***	***	***	***	***
***

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

Attachment 4

HHSO100201500007C

August 20, 2015

***

All activities covered under this BioCryst contract will provide merit and value to the Government by ensuring that funding supported under the Base period results in progress towards several activities to ensure moving the BioCryst BCX4430 compound through the development pipeline for future FDA approval. This activities include manufacturing clinical trial material to be used in clinical trials as an urgent need to the Ebola epidemic in west Africa (Base), commercial scale up and manufacturing of registration batches, a regulatory approval requirement (Option 1), non-clinical toxicology studies to support NDA regulatory requirements (Option 2) and non-clinical toxicology studies of the IV formulation first in vitro (Option 3) and then in animals (Option 4) to support NDA regulatory requirements. BioCryst’s ability to complete three critical GO/NO GO contract milestones in the Base period will determine, whether to exercise any follow-on option phases to continue supporting development of the compound.

There are 4 decision points which will trigger advancement to Options.

Trigger 1 (for start of Option 1): Further optimization processes for manufacturing will be developed under the WBS 1.2 Once these activities are sufficient to warrant a scale up manufacturing process, as will be evaluated in a delivered report, process development (milestone WBS1.2, July 2015), Option 1 can begin. In Option 1, the process developed in WBS 1.2 and other processes being developed to manufacture the BCX4430 compound will be evaluated, such that BioCryst can select a process of most value to the Government to generate *** drug substance registration batches that will then be used to make *** drug product registration batches at a scale at least *** the estimated commercial scale which is a regulatory requirement for qualifying a GMP process for manufacturing.

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked "***" and has been filed separately with the

Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.

Trigger 2 (for start of Option 3): In order to conduct toxicology experiments in animals, the IV formulation of BCX4430 will first need to be assessed in vitro through *** as well as *** (Option 3) before moving into animals. Initially a go/no go milestone was established to evaluate excipient compatibility of the IV formulation before initiating these studies. However, since BioCryst has determined that the BCX4430 drug substance to be used in these studies will be available and released *** as well as having identified a preliminary IV solution (LRI) based on initial results, it was determined that there was sufficient data to support the initiation of these in vitro toxicology studies of this formulation - Option 3 (in Vitro experiments- IV) before moving in to animal toxicology studies (Option 4).

Trigger 3 (for start of Option 2): In order to conduct further regulatory activities to support NDA activities, toxicology experiments will need to be conducted in animals as well as radiolabeled absorption, metabolism and excretion studies. The original go/no go criteria was to generate enough drug substance material WBS 1.4.1 that conformed to release criteria to use in these studies. However additional batches of BCX4430 have been manufactured that will start to be available *** and therefore should provide enough material to conduct these non-clinical animal toxicology studies in Option 2, a NDA regulatory requirement.

Trigger 4 (for start of Option 4): In order to proceed with conducting further regulatory activities to support NDA activities for the IV formulation, toxicology experiments will need to be conducted in animals. However, this can only proceed if the preliminary toxicology studies performed in vitro, as evaluated in the in vitro study report (WBS 4.3, ***) demonstrate that the IV formulation is safe.

EX-10.3 4 exh_103.htm EXHIBIT 10.3

EXHIBIT 10.3

EX-31.1 5 exh_311.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATIONS

I, Jon P. Stonehouse, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 6, 2015	/s/ Jon P. Stonehouse
	Jon P. Stonehouse
	President and Chief Executive Officer

EX-31.2 6 exh_312.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATIONS

I, Thomas R. Staab, II, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 6, 2015	/s/ Thomas R. Staab, II
	Thomas R. Staab, II
	Senior Vice President, Chief Financial Officer and Treasurer

EX-32.1 7 exh_321.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jon P. Stonehouse, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

	(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Jon P. Stonehouse

Jon P. Stonehouse

President and Chief Executive Officer

Date: November 6, 2015

EX-32.2 8 exh_322.htm EXHIBIT 32,2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas R. Staab, II, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

	(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Thomas R. Staab, II

Thomas R. Staab, II

Senior Vice President, Chief Financial Officer and Treasurer

Date: November 6, 2015

EX-101.INS 9 bcrx-20150930.xml XBRL INSTANCE FILE <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accrued Expenses</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </div><table style="; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 700px;" cellpadding="0" cellspacing="0"> <tr> <td style="width: 5%"> </td> <td style="vertical-align: top; width: 2%"><div style="display: inline; font: 10pt Times New Roman, Times, Serif">•</div></td> <td style="vertical-align: top; width: 1%"> </td> <td style="vertical-align: top; width: 92%"><div style="display: inline; font: 10pt Times New Roman, Times, Serif">fees paid to Clinical Research Organizations (“CROs”) in connection with preclinical and toxicology studies and clinical trials;</div></td> </tr> </table><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </div><table style="; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 700px;" cellpadding="0" cellspacing="0"> <tr> <td style="width: 5%"> </td> <td style="vertical-align: top; width: 2%"><div style="display: inline; font: 10pt Times New Roman, Times, Serif">•</div></td> <td style="vertical-align: top; width: 1%"> </td> <td style="vertical-align: top; width: 92%"><div style="display: inline; font: 10pt Times New Roman, Times, Serif">fees paid to investigative sites in connection with clinical trials;</div></td> </tr> </table><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </div><table style="; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 700px;" cellpadding="0" cellspacing="0"> <tr> <td style="width: 5%"> </td> <td style="vertical-align: top; width: 2%"><div style="display: inline; font: 10pt Times New Roman, Times, Serif">•</div></td> <td style="vertical-align: top; width: 1%"> </td> <td style="vertical-align: top; width: 92%"><div style="display: inline; font: 10pt Times New Roman, Times, Serif">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products; and</div></td> </tr> </table><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </div><table style="; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 700px;" cellpadding="0" cellspacing="0"> <tr> <td style="width: 5%"> </td> <td style="vertical-align: top; width: 2%"><div style="display: inline; font: 10pt Times New Roman, Times, Serif">•</div></td> <td style="vertical-align: top; width: 1%"> </td> <td style="vertical-align: top; width: 92%"><div style="display: inline; font: 10pt Times New Roman, Times, Serif">professional fees.</div></td> </tr> </table><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company’s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of September 30, 2015 and December 31, 2014, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div> P60D 500000 150000 42000 141000 28000 211000 22000 151000 6000 179000 27183000 25459000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 65%; font-size: 10pt; text-align: left">Maturing in one year or less</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right">23,700</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right">18,232</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">27,183</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">25,459</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">20,604</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">15,657</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,487</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> </tr> </table></div> 20604000 15657000 P1Y180D P18Y 77191000 55000000 234852000 102661000 P5Y 5162000 3233000 35643000 6211000 4582000 2937000 12788000 5323000 132000 132000 296000 296000 888000 888000 152000 21835000 5162000 3233000 35643000 6211000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Significant Customers and Other Risks</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company relies primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company’s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the CSL transaction as CSL will be responsible for commercial sales on a worldwide basis with the exception of Israel, Japan, Korea and Taiwan.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company’s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB (i.e., peramivir) and BCX4430 development expenses, which was earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company’s collaborative and other research and development revenues. The completion, as with the June 30, 2014 BARDA/HHS peramivir development contract, or termination of the NIAID/HHS and BARDA/HHS BCX4430 programs/collaboration could negatively impact the Company’s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company’s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. The Company’s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company’s ability to complete its drug development activities.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><div style="display: inline; font-style: italic;">Risks from Third Party Manufacturing and Distribution Concentration</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished product manufacturing of RAPIVAB. Additionally, the Company relies upon a single third party to provide warehousing and distribution services for RAPIVAB. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div> P4Y <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Currency Hedge Agreement</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement (defined in Note 4) to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company’s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the nine months ended September 30, 2015 and 2014 resulted in a loss of $792 and a gain of $732, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized a currency exchange gain of $1,653 during the first nine months of 2015 associated with the exercise of a U.S. Dollar/Japanese yen currency option.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of September 30, 2015 and December 31, 2014, no hedge collateral was posted under the agreement.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div> 282000 177000 117000 -45000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">BioCryst Pharmaceuticals, Inc. (the “Company”) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash and investments of $119,736, to continue its planned operations into 2017. The Company’s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond 2017 it will need to: (1) successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2) out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3) raise additional capital through equity or debt financings or from other sources; (4) obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5) reduce spending on one or more research and development programs; and/or (6) restructure operations. The Company retains the ability to offer for sale approximately $150,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants, and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on March 3, 2015.  Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on November 6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div> 1782000 290000 2508000 4627000 5632000 34002000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Interest Expense and Deferred Financing Costs</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Interest expense for the three months ended September 30, 2015 and 2014 was $1,214 and $1,217, respectively, and for the nine months ended September 30, 2015 and 2014 was $3,862 and $3,684, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended September 30, 2015 and 2014, and $329 for each of the nine months ended September 30, 2015 and 2014.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div> 3000000 P12Y P3Y P3Y P12Y 150000000 125000000 9750000 12000000 12000000 4000000 1400000 3 2 90000 0.5 0.85 0.85 0.15 P25Y 30000000 16300000 5000000 29875 10000000 P5Y 100 22691000 30000000 30000000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 4 — Royalty Monetization</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Overview</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 9, 2011, the Company completed a $30,000 financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of $22,691 from the transaction after transaction costs of $4,309 and the establishment of a $3,000 interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As part of the transaction, the Company entered into a purchase and sale agreement dated as of March 9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii) the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the “Currency Hedge Agreement”) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company’s collaboration with Shionogi was not impacted as a result of this transaction.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Non-Recourse Notes Payable</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the “PhaRMA Notes”). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March 9, 2011 (the “Indenture”), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14% per annum, payable annually in arrears on September 1st of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.  </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Royalty Sub’s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company’s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On September 1, 2014, Royalty Sub was unable to pay the full amount of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the Consolidated Balance Sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company’s future results of operations or cash flows.</div>  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   </div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Indenture does not contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Foreign Currency Hedge</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2016 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $1,950 will be required if, on May 18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company’s Consolidated Statement of Comprehensive Loss. Cumulative mark-to-market adjustments resulted in a loss of $460 and a gain of $4,082 for the three months ended September 30, 2015 and 2014, respectively and a loss of $793 and a gain of $732 for the nine months ended September 30, 2015 and 2014, respectively. During the nine months ended September 30, 2015, the Company realized a currency exchange gain of $1,654 associated with the exercise of a U.S. Dollar/Japanese yen currency option. The Company is also required to post collateral in connection with the mark-to-market adjustments based on defined thresholds. As of September 30, 2015 and December 31, 2014, no collateral was posted under the Currency Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of September 30, 2015, the maximum amount of hedge collateral the Company may be required to post is $9,750.</div></div> P10Y <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt"></td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">September 30, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt"></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><div style="display: inline; font-size: 10pt"> </div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"><div style="display: inline; font-size: 10pt">Billed</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><div style="display: inline; font-size: 10pt"> </div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"><div style="display: inline; font-size: 10pt">Unbilled</div></td> <td style="padding-bottom: 1pt"><div style="display: inline; font-size: 10pt"> </div></td> <td colspan="3" style="border-bottom: black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">Total</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">—</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">5,444</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">5,444</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">129</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">—</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">129</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><div style=" margin: 0">Seqirus UK Limited</div> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,922</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">—</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,922</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,051</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,444</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,495</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">December 31, 2014</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">—</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">2,778</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">2,778</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Shionogi & Co. Ltd.</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,071</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">—</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,071</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,071</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,778</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,849</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Three Months</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Nine Months</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; text-align: left">Product sales, net</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,699</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">—</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">6,236</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">—</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Royalty revenue</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">126</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">5</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">1,776</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">1,951</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: -20pt; padding-left: 20pt">Collaborative and other research and development revenues:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 30pt">U.S. Department of Health and Human Services</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">4,582</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">2,937</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">12,788</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">5,323</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Green Cross Corporation</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">132</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">—</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">132</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">—</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Shionogi (Japan)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">296</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">296</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">888</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">888</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt"><div style=" margin: 0">Seqirus UK Limited</div> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">152</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">—</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">21,835</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">—</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total collaborative and other research and development revenues</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">5,162</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">3,233</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">35,643</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">6,211</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,987</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,238</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">43,655</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">8,162</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> </tr> </table></div> 150000000 10000000 25000 P1Y 1319000 0.25 1 28000 5911000 4309000 false --12-31 Q3 2015 2015-09-30 10-Q 0000882796 73336871 Yes Large Accelerated Filer BIOCRYST PHARMACEUTICALS INC No Yes bcrx

3782000

2849000

7495000

3849000

5641000

23027000

11329000

-1000

-130000

556095000

542943000

7773000

7553000

220000

6550000

6388000

162000

110000

329000

110000

329000

3821000

4240000

3673000

3986000

138956000

136874000

84502000

89343000

71487000

59348000

23187000

27402000

20898000

20306000

27261000

11781000

28000

26000

10000

64000

5000

-2000

-14000

-49000

-65000

-23000

-47000

-63000

-133000

23119000

27249000

20909000

71277000

20307000

27152000

11838000

59297000

23700000

18232000

23700000

18232000

47787000

41116000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">September 30, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Estimated<br /> Fair Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">23,119</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">42</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">28</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(2</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">23,187</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">27,249</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">141</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">26</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">(14</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">27,402</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">20,909</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">28</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">10</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(49</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">20,898</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,277</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">211</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(65</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,487</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">December 31, 2014</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Estimated<br /> Fair Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">20,307</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">22</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">—</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(23</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">20,306</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">27,152</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">151</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">5</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">(47</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">27,261</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">11,838</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">6</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">—</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(63</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">11,781</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,297</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">179</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(133</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> </tr> </table></div>

46627000

54540000

21164000

121157000

-7913000

99993000

0.01

200000000

73337000

71955000

73337000

71955000

733000

720000

-14530000

-8732000

-24755000

-33519000

0.9

1346000

1361000

24149000

14848000

65905000

38777000

0.14

88000

76000

345000

394000

3740000

1223000

2102000

1481000

16000

5605000

10122000

3552000

137000

100

732000

1654000

793000

-0.20

-0.12

-0.34

-0.52

14839000

11982000

1654000

-460000

4082000

-793000

732000

-352000

4082000

861000

732000

2731000

1812000

10326000

5413000

13314000

22855000

36169000

12582000

3602000

1602000

-880000

-793000

732000

-512000

957000

-683000

-1331000

29000

-1995000

1123000

1472000

-1000

134000

14000

367000

50000

1241000

1217000

3862000

3684000

5517000

6029000

416000

683000

267000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Investments</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company’s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company’s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company’s investments are not collateralized. The Company has not realized any significant losses from its investments.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At September 30, 2015, the Company believes that the costs of its investments are recoverable in all material respects.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The following tables summarize the fair value of the Company’s investments by type. The estimated fair value of the Company’s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </div><div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="19" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2015</td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Amortized</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Cost</div></div></td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Accrued</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Interest</div></div></td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Gross</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Unrealized</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Gains</div></div></td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Gross</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Unrealized</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Losses</div></div></td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Estimated</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Fair Value</div></div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 45%; text-align: left">Obligations of U.S. Government and its agencies</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">23,119</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">42</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">28</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">(2</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">23,187</td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Corporate debt securities</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,249</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">141</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">26</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(14</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,402</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Certificates of deposit</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">20,909</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">28</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">10</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(49</td> <td style="border-bottom: Black 1pt solid; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">20,898</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">71,277</td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">211</td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">64</td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">(65</td> <td style="border-bottom: Black 2.25pt double; text-align: left">)</td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">71,487</td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> </tr> </table> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </div><div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="19"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="19" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2014</td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Amortized</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Cost</div></div></td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Accrued</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Interest</div></div></td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Gross</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Unrealized</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Gains</div></div></td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Gross</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Unrealized</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Losses</div></div></td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Estimated</div></div><br /> <div style="display: inline; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-weight: bold;">Fair Value</div></div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 45%; text-align: left">Obligations of U.S. Government and its agencies</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">20,307</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">22</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">(23</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">20,306</td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Corporate debt securities</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,152</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">151</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(47</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,261</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Certificates of deposit</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">11,838</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">6</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(63</td> <td style="border-bottom: Black 1pt solid; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">11,781</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">59,297</td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">179</td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">5</td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">(133</td> <td style="border-bottom: Black 2.25pt double; text-align: left">)</td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">59,348</td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> </tr> </table> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The following table summarizes the scheduled maturity for the Company’s investments at September 30, 2015 and December 31, 2014.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </div><div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Maturing in one year or less</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">23,700</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">18,232</td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Maturing after one year through two years</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,183</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">25,459</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Maturing after two years</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">20,604</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">15,657</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">71,487</td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">59,348</td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> </tr> </table> </div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div>

119736000

138956000

136874000

64444000

57293000

30000000

5392000

111546000

-15017000

13108000

1712000

-24661000

-24884000

-33517000

-14621000

-8731000

-13162000

-11610000

-22250000

-30615000

5239000

6031000

91000

-1000

129000

-2000

1950000

48343000

15852000

1076000

41000

0.001

5000000

4970000

6172000

1175000

106600000

33740000

7000000

33740000

250000

35874000

29000000

3861000

4636000

356000

310000

1146000

207000

5444000

129000

1922000

2051000

5444000

7495000

2778000

1071000

2778000

3849000

13000

20067000

13036000

53711000

33286000

1402000

150000

70000

1622000

150000

-492782000

-467898000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the seller’s price to the buyer is fixed or determinable; and (iv) collectability is reasonably assured.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Collaborative and Other Research and Development Arrangements and Royalties</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Under certain of the Company’s license agreements, the Company receives royalty payments based upon its licensees’ net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has “stand-alone value” to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (“TPE”) and (iii) best estimate of selling price (“BESP”). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">In June 2015, the Company entered into a License Agreement (the “Agreement”) granting CSL Limited (“CSL”) and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (“EU”) marketing approvals. The Company received an upfront payment of $33,740 from CSL of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the current quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter when the inventory transfer was completed. Approximately $1,223 of this revenue will be recognized over the expected period of involvement in these regulatory support activities.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Under the terms of the Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the European Union and (iii) by Health Canada for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, <div style="display: inline; font-style: italic;">Milestone Method of Revenue Recognition</div>, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company’s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (”BARDA/HHS”) and the National Institute of Allergy and Infectious Diseases (“NIAID/HHS”), revenue is recognized as reimbursable direct and indirect costs are incurred.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt"><div style="display: inline; font-style: italic;">Product Sales</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, the Company sells RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations. With the completion of the CSL worldwide license of RAPIVAB, CSL will be primarily responsible for sales of RAPIVAB other than U.S. Government stockpiling sales and the Company’s commercial sales will be minimal.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer. </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources. </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Rebates and Chargebacks</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB’s selling price. As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company’s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company’s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue. </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Discounts and Sales Incentives</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Discounts and other sales incentives primarily consist of Inventory Management Agreement (“IMA”) Fees. Per contractual agreements with the Company’s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales. </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Product Returns</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor. </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Advertising</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company recorded the following revenues for the three and nine months ended September 30, 2015 and 2014:</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </div><div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 700px;" cellpadding="0" cellspacing="0"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months</td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Product sales, net</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">5,699</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">6,236</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">-</td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Royalty revenue</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">126</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,776</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,951</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Collaborative and other research and development revenues:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">U.S. Department of Health and Human Services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,581</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,937</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,788</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5,323</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Green Cross Corporation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">132</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">132</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shionogi (Japan)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">296</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">296</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">888</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">888</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">CSL Limited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">153</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">21,835</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total collaborative and other research and development revenues</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">5,162</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">3,233</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">35,643</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">6,211</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt">Total revenues</td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">10,987</td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">3,238</td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">43,655</td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right">8,162</td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> </tr> </table> </div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div>

21777000

10987000

3238000

43655000

8162000

5000

507000

78000

126000

5000

1776000

1951000

5699000

6236000

10987000

3238000

43655000

8162000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Awards<br /> Available</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Options<br /> Outstanding</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Weighted<br /> Average<br /> Exercise<br /> Price</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt">Balance December 31, 2014</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 12%; font-size: 10pt; text-align: right">2,362</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 12%; font-size: 10pt; text-align: right">9,605</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">6.21</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock unit awards granted</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">(155</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">—</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">—</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Restricted stock unit awards cancelled</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">1</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">—</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">—</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards granted</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">(1,319</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">1,319</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">11.99</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock option awards exercised</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">—</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">(1,102</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">4.36</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock option awards cancelled</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">28</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(28</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">9.05</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance September 30, 2015</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">917</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9,794</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">7.19</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"> </td> </tr> </table></div>

7773000

6550000

P4Y

P2Y

1000

155000

0.83

0.87

0.015

0.016

3000

1475000

497000

2362000

917000

7.19

28000

9.05

1319000

1032000

1250000

8.15

8.19

9605000

9794000

6.21

4.36

11.99

0.25

0.5

0.75

P5Y182D

P5Y

P10Y

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 1 — Significant Accounting Policies</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the “Company”) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash and investments of $119,736, to continue its planned operations into 2017. The Company’s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond 2017 it will need to: (1) successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2) out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3) raise additional capital through equity or debt financings or from other sources; (4) obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5) reduce spending on one or more research and development programs; and/or (6) restructure operations. The Company retains the ability to offer for sale approximately $150,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants, and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on March 3, 2015.  Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on November 6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (“Royalty Sub”). Royalty Sub was formed in connection with a $30,000 financing transaction the Company completed on March 9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management’s opinion, necessary to present fairly, in all material respects, the Company’s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These financial statements should be read in conjunction with the financial statements for the year ended December 31, 2014 and the notes thereto included in the Company’s 2014 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December 31, 2014 has been derived from the audited consolidated financial statements included in the Company’s most recent Annual Report on Form 10-K.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Certain balance sheet amounts as of December 31, 2014 have been reclassified to conform to the 2015 presentation.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</div>  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   </div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Cash</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Restricted cash as of September 30, 2015 reflects $150 the Company is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program, $70 in royalty revenue paid by Shionogi & Co., Ltd. (“Shionogi”) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,402 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Investments</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company’s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company’s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company’s investments are not collateralized. The Company has not realized any significant losses from its investments.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At September 30, 2015, the Company believes that the costs of its investments are recoverable in all material respects.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following tables summarize the fair value of the Company’s investments by type. The estimated fair value of the Company’s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">September 30, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Estimated<br /> Fair Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">23,119</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">42</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">28</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(2</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">23,187</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">27,249</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">141</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">26</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">(14</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">27,402</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">20,909</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">28</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">10</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(49</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">20,898</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,277</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">211</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(65</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,487</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> </tr> </table> </div> <div style=" margin-top: 0; margin-bottom: 0"> </div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">December 31, 2014</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Estimated<br /> Fair Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Obligations of U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">20,307</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">22</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">—</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(23</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">20,306</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">27,152</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">151</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">5</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">(47</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">27,261</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">11,838</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">6</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">—</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">(63</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">11,781</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,297</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">179</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(133</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> </tr> </table> </div>  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   </div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes the scheduled maturity for the Company’s investments at September 30, 2015 and December 31, 2014.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 65%; font-size: 10pt; text-align: left">Maturing in one year or less</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right">23,700</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right">18,232</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">27,183</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">25,459</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">20,604</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">15,657</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">71,487</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">59,348</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Collaborations</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, and product sales to Green Cross Corporation (“Green Cross”) and Seqirus UK Limited (“SUL”). These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At September 30, 2015 and December 31, 2014, the Company had the following receivables.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt"></td> <td style="padding-bottom: 1pt"> </td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">September 30, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt"></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><div style="display: inline; font-size: 10pt"> </div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"><div style="display: inline; font-size: 10pt">Billed</div></td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><div style="display: inline; font-size: 10pt"> </div></td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid"><div style="display: inline; font-size: 10pt">Unbilled</div></td> <td style="padding-bottom: 1pt"><div style="display: inline; font-size: 10pt"> </div></td> <td colspan="3" style="border-bottom: black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><div style="display: inline; font-size: 10pt">Total</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">—</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">5,444</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">5,444</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Green Cross Corporation</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">129</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">—</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">129</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><div style=" margin: 0">Seqirus UK Limited</div> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,922</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">—</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,922</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,051</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,444</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,495</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> </tr> </table> </div> <div style=" margin-top: 0; margin-bottom: 0"> </div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">December 31, 2014</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">—</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">2,778</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">2,778</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Shionogi & Co. Ltd.</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,071</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">—</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">1,071</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,071</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,778</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,849</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> </tr> </table> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company’s calculations of its indirect cost rates are subject to audit by the U.S. Government.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Product Sales</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">®</div>. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Inventory</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">At December 31, 2014, the Company’s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (“FIFO”) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories. In connection with the June 2015 SUL collaboration, the Company sold all of its available RAPIVAB finished goods inventory to SUL in accordance with terms stipulated in the licensing agreement.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During 2014, in connection with the Food and Drug Administration (“FDA”) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB commercial inventories.</div>  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   </div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company’s inventory consisted of the following at September 30, 2015 and December 31, 2014:</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 65%; font-size: 10pt; text-align: left">Work in process</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right">—</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 14%; font-size: 10pt; text-align: right">267</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Finished Goods</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">—</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">416</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net inventories</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">—</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">683</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patents and Licenses</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accrued Expenses</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <table border="0" cellpadding="0" cellspacing="5" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"> <tr> <td style="vertical-align: middle; width: 2%"> </td> <td style="vertical-align: top; text-align: left; width: 3%">•</td> <td style="vertical-align: middle; width: 95%">fees paid to Clinical Research Organizations (“CROs”) in connection with preclinical and toxicology studies and clinical trials;</td> </tr> <tr> <td style="vertical-align: middle"> </td> <td style="vertical-align: top; text-align: left">•</td> <td style="vertical-align: middle">fees paid to investigative sites in connection with clinical trials;</td> </tr> <tr> <td style="vertical-align: middle"> </td> <td style="vertical-align: top; text-align: left">•</td> <td style="vertical-align: middle">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products; and</td> </tr> <tr> <td style="vertical-align: middle"> </td> <td style="vertical-align: top; text-align: left">•</td> <td style="vertical-align: middle">professional fees.</td> </tr> </table> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company’s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of September 30, 2015 and December 31, 2014, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The liability method is used in the Company’s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accumulated Other Comprehensive Loss</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders’ equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the nine months ended September 30, 2015, realized gains of $13 were reclassified out of accumulated other comprehensive loss. No reclassifications out of accumulated other comprehensive loss were recorded during the nine months ended September 30, 2014. </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the seller’s price to the buyer is fixed or determinable; and (iv) collectability is reasonably assured.</div>  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   </div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Collaborative and Other Research and Development Arrangements and Royalties</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under certain of the Company’s license agreements, the Company receives royalty payments based upon its licensees’ net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has “stand-alone value” to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (“TPE”) and (iii) best estimate of selling price (“BESP”). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">In June 2015, the Company entered into a License Agreement (the “SUL Agreement”) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (“EU”) marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">Under the terms of the SUL Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (“Health Canada”) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, <div style="display: inline; font-style: italic;">Milestone Method of Revenue Recognition</div>, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company’s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (”BARDA/HHS”) and the National Institute of Allergy and Infectious Diseases (“NIAID/HHS”), revenue is recognized as reimbursable direct and indirect costs are incurred.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 20pt"><div style="display: inline; font-style: italic;">Product Sales</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 20pt"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, the Company sells RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations. With the completion of the SUL worldwide license of RAPIVAB, SUL will be primarily responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales, and the Company’s commercial sales will be minimal.</div>  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   </div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer. </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources. </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Rebates and Chargebacks</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB’s selling price. As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company’s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company’s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue. </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Discounts and Sales Incentives</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory Management Agreement (“IMA”) Fees. Per contractual agreements with the Company’s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales. </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Product Returns</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor. </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Advertising</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB.</div>  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   </div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the three and nine months ended September 30, 2015 and 2014:</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Three Months</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">Nine Months</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: black 1.1pt solid">2014</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; text-align: left">Product sales, net</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,699</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">—</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">6,236</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">—</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Royalty revenue</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">126</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">5</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">1,776</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">1,951</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: -20pt; padding-left: 20pt">Collaborative and other research and development revenues:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 30pt">U.S. Department of Health and Human Services</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">4,582</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">2,937</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">12,788</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">5,323</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Green Cross Corporation</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">132</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">—</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">132</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">—</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Shionogi (Japan)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">296</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">296</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">888</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">888</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt"><div style=" margin: 0">Seqirus UK Limited</div> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">152</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">—</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">21,835</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">—</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total collaborative and other research and development revenues</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">5,162</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">3,233</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">35,643</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: right">6,211</td> <td style="border-bottom: black 1.1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,987</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,238</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">43,655</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">8,162</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development Expenses</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company’s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company’s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company’s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company’s on-going review of the level of services actually performed.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (“AECOM”), Industrial Research, Ltd. (“IRL”), and the University of Alabama at Birmingham (“UAB”), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid to the Company’s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company’s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue. </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-Based Compensation</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company’s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until “performance” has occurred.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Interest Expense and Deferred Financing Costs</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense for the three months ended September 30, 2015 and 2014 was $1,241 and $1,217, respectively, and for the nine months ended September 30, 2015 and 2014 was $3,862 and $3,684, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended September 30, 2015 and 2014, and $329 for each of the nine months ended September 30, 2015 and 2014.</div>  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   </div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Currency Hedge Agreement</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement (defined in Note 4) to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company’s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the nine months ended September 30, 2015 and 2014 resulted in a loss of $793 and a gain of $732, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized a currency exchange gain of $1,654 during the first nine months of 2015 associated with the exercise of a U.S. Dollar/Japanese yen currency option.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of September 30, 2015 and December 31, 2014, no hedge collateral was posted under the agreement.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net Loss Per Share</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company’s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended September 30, 2015 and 2014 does not include 3,821 and 4,240, respectively, of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the nine months ended September 30, 2015 and 2014 does not include 3,673 and 3,986, respectively, of such potential common shares, as their impact would be anti-dilutive.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Significant Customers and Other Risks</div></div></div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">The Company relies primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company’s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company’s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0">The Company’s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company’s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company’s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company’s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company’s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company’s ability to complete its drug development activities.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 27pt"><div style="display: inline; font-style: italic;">Risks from Third Party Manufacturing and Distribution Concentration</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 27pt"> </div> <div style=" font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Credit Risk</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company’s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</div>  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   </div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recent Accounting Pronouncements</div></div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In April 2015, the FASB issued ASU No.2015-03, <div style="display: inline; font-style: italic;">Simplifying the Presentation of Debt Issuance Costs</div>. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company does not expect this ASU will have a material impact on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2014, the FASB issued ASU 2014-09 – <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers</div>, which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements.</div></div>

41000

1102000

64045000

75635000

73262000

71801000

72752000

65057000

iso4217:USD xbrli:pure xbrli:shares iso4217:USD xbrli:shares iso4217:JPY 0000882796 bcrx:GreenCrossCorporationMember 2006-06-01 2006-06-30 0000882796 bcrx:USDepartmentOfHealthAndHumanServicesMember 2007-01-01 2007-01-31 0000882796 bcrx:USDepartmentOfHealthAndHumanServicesMember 2007-01-01 2011-02-24 0000882796 bcrx:USDepartmentOfHealthAndHumanServicesMember 2009-09-01 2009-09-30 0000882796 bcrx:AECOMAndIRLMember 2010-05-01 2010-05-31 0000882796 bcrx:USDepartmentOfHealthAndHumanServicesMember 2011-02-01 2011-02-24 0000882796 bcrx:JPRRoyaltySubLLCMember bcrx:PhaRMANotesMember 2011-03-01 2011-03-09 0000882796 bcrx:JPRRoyaltySubLLCMember bcrx:RoyaltyMonetizationMember 2011-03-01 2011-03-09 0000882796 us-gaap:PerformanceSharesMember bcrx:IncentivePlanMember bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember 2013-08-01 2013-08-31 0000882796 bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember 2013-09-01 2013-09-30 0000882796 2013-11-06 2013-11-06 0000882796 2014-01-01 2014-09-30 0000882796 bcrx:JPRRoyaltySubLLCMember bcrx:PhaRMANotesMember bcrx:CurrencyHedgeAgreementMember 2014-01-01 2014-09-30 0000882796 bcrx:CSLMember 2014-01-01 2014-09-30 0000882796 bcrx:GreenCrossCorporationMember 2014-01-01 2014-09-30 0000882796 bcrx:ShionogiAndCoLtdMember 2014-01-01 2014-09-30 0000882796 bcrx:USDepartmentOfHealthAndHumanServicesMember 2014-01-01 2014-09-30 0000882796 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2014-01-01 2014-09-30 0000882796 bcrx:EmployeeStockPurchasePlanMember 2014-01-01 2014-09-30 0000882796 bcrx:IncentivePlanMember 2014-01-01 2014-09-30 0000882796 us-gaap:PerformanceSharesMember bcrx:IncentivePlanMember bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember 2014-01-01 2014-12-31 0000882796 2014-07-01 2014-09-30 0000882796 bcrx:JPRRoyaltySubLLCMember bcrx:PhaRMANotesMember bcrx:CurrencyHedgeAgreementMember 2014-07-01 2014-09-30 0000882796 bcrx:CSLMember 2014-07-01 2014-09-30 0000882796 bcrx:GreenCrossCorporationMember 2014-07-01 2014-09-30 0000882796 bcrx:ShionogiAndCoLtdMember 2014-07-01 2014-09-30 0000882796 bcrx:USDepartmentOfHealthAndHumanServicesMember 2014-07-01 2014-09-30 0000882796 2015-01-01 2015-09-30 0000882796 bcrx:JPRRoyaltySubLLCMember bcrx:PhaRMANotesMember bcrx:CurrencyHedgeAgreementMember 2015-01-01 2015-09-30 0000882796 bcrx:August2013Member us-gaap:PerformanceSharesMember bcrx:IncentivePlanMember bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember 2015-01-01 2015-09-30 0000882796 bcrx:December2014Member us-gaap:PerformanceSharesMember bcrx:IncentivePlanMember bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember 2015-01-01 2015-09-30 0000882796 us-gaap:EmployeeStockOptionMember bcrx:IncentivePlanMember us-gaap:MaximumMember 2015-01-01 2015-09-30 0000882796 us-gaap:EmployeeStockOptionMember bcrx:IncentivePlanMember us-gaap:MinimumMember 2015-01-01 2015-09-30 0000882796 us-gaap:EmployeeStockOptionMember bcrx:IncentivePlanMember bcrx:NonEmployeeDirectorsMember 2015-01-01 2015-09-30 0000882796 us-gaap:EmployeeStockOptionMember bcrx:IncentivePlanMember bcrx:Vest25PercentEachYearUntilFullyVestedMember 2015-01-01 2015-09-30 0000882796 bcrx:StockOptionsAndRestrictedStockMember 2015-01-01 2015-09-30 0000882796 bcrx:StockOptionsAndRestrictedStockMember bcrx:IncentivePlanMember bcrx:Vest50PercentEachYearUntilFullyVestedMember 2015-01-01 2015-09-30 0000882796 bcrx:UnvestedPerformanceSharesMember bcrx:IncentivePlanMember 2015-01-01 2015-09-30 0000882796 us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember bcrx:RAPIVABMember 2015-01-01 2015-09-30 0000882796 bcrx:CSLMember 2015-01-01 2015-09-30 0000882796 bcrx:GreenCrossCorporationMember 2015-01-01 2015-09-30 0000882796 bcrx:ShionogiAndCoLtdMember 2015-01-01 2015-09-30 0000882796 bcrx:USDepartmentOfHealthAndHumanServicesMember 2015-01-01 2015-09-30 0000882796 bcrx:PhaRMANotesMember bcrx:CurrencyHedgeAgreementMember 2015-01-01 2015-09-30 0000882796 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2015-01-01 2015-09-30 0000882796 bcrx:EmployeeStockPurchasePlanMember 2015-01-01 2015-09-30 0000882796 bcrx:IncentivePlanMember 2015-01-01 2015-09-30 0000882796 us-gaap:MaximumMember 2015-01-01 2015-09-30 0000882796 us-gaap:MinimumMember 2015-01-01 2015-09-30 0000882796 bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember 2015-01-01 2015-09-30 0000882796 bcrx:UABMember 2015-01-01 2015-09-30 0000882796 bcrx:AECOMAndIRLMember 2015-01-01 2015-09-30 0000882796 bcrx:ASPRBARDAContractMember 2015-01-01 2015-09-30 0000882796 2015-03-03 2015-03-03 0000882796 bcrx:CSLMember bcrx:RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember bcrx:RAPIVABMember bcrx:AgreementMember 2015-06-01 2015-06-30 0000882796 bcrx:CSLMember bcrx:RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember bcrx:RAPIVABMember bcrx:AgreementMember 2015-06-01 2015-06-30 0000882796 bcrx:CSLMember bcrx:RAPIVABMember bcrx:ContingentUponEuMarketingApprovalMember bcrx:AgreementMember 2015-06-01 2015-06-30 0000882796 bcrx:CSLMember bcrx:RAPIVABMember bcrx:AgreementMember 2015-06-01 2015-06-30 0000882796 bcrx:CSLLimitedMember 2015-06-16 2015-06-16 0000882796 2015-07-01 2015-09-30 0000882796 bcrx:JPRRoyaltySubLLCMember bcrx:PhaRMANotesMember bcrx:CurrencyHedgeAgreementMember 2015-07-01 2015-09-30 0000882796 bcrx:CSLMember 2015-07-01 2015-09-30 0000882796 bcrx:GreenCrossCorporationMember 2015-07-01 2015-09-30 0000882796 bcrx:ShionogiAndCoLtdMember 2015-07-01 2015-09-30 0000882796 bcrx:USDepartmentOfHealthAndHumanServicesMember 2015-07-01 2015-09-30 0000882796 bcrx:JPRRoyaltySubLLCMember bcrx:PhaRMANotesMember 2011-03-09 0000882796 bcrx:JPRRoyaltySubLLCMember bcrx:RoyaltyMonetizationMember 2011-03-09 0000882796 bcrx:JPRRoyaltySubLLCMember 2011-03-09 0000882796 2013-11-06 0000882796 2013-12-31 0000882796 2014-09-30 0000882796 2014-12-31 0000882796 bcrx:CollaborationReceivablesMember 2014-12-31 0000882796 us-gaap:TradeAccountsReceivableMember 2014-12-31 0000882796 us-gaap:BilledRevenuesMember 2014-12-31 0000882796 us-gaap:BilledRevenuesMember bcrx:ShionogiAndCoLtdMember 2014-12-31 0000882796 us-gaap:BilledRevenuesMember bcrx:USDepartmentOfHealthAndHumanServicesMember 2014-12-31 0000882796 us-gaap:UnbilledRevenuesMember 2014-12-31 0000882796 us-gaap:UnbilledRevenuesMember bcrx:ShionogiAndCoLtdMember 2014-12-31 0000882796 us-gaap:UnbilledRevenuesMember bcrx:USDepartmentOfHealthAndHumanServicesMember 2014-12-31 0000882796 bcrx:JPRRoyaltySubLLCMember bcrx:PhaRMANotesMember bcrx:CurrencyHedgeAgreementMember 2014-12-31 0000882796 bcrx:ShionogiAndCoLtdMember 2014-12-31 0000882796 bcrx:USDepartmentOfHealthAndHumanServicesMember 2014-12-31 0000882796 bcrx:PhaRMANotesMember bcrx:CurrencyHedgeAgreementMember 2014-12-31 0000882796 bcrx:DeferredCollaborativeRevenueMember 2014-12-31 0000882796 bcrx:DeferredProductSalesMember 2014-12-31 0000882796 bcrx:CurrencyHedgeAgreementMember 2014-12-31 0000882796 us-gaap:CertificatesOfDepositMember 2014-12-31 0000882796 us-gaap:CorporateDebtSecuritiesMember 2014-12-31 0000882796 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2014-12-31 0000882796 2015-03-03 0000882796 bcrx:ASPRBARDAContractMember 2015-03-31 0000882796 bcrx:AdditionalDevelopmentOptionsMember 2015-03-31 0000882796 bcrx:BaseContractMember 2015-03-31 0000882796 2015-09-30 0000882796 bcrx:CollaborationReceivablesMember 2015-09-30 0000882796 us-gaap:TradeAccountsReceivableMember 2015-09-30 0000882796 us-gaap:BilledRevenuesMember 2015-09-30 0000882796 us-gaap:BilledRevenuesMember bcrx:CSLLimitedMember 2015-09-30 0000882796 us-gaap:BilledRevenuesMember bcrx:GreenCrossCorporationMember 2015-09-30 0000882796 us-gaap:BilledRevenuesMember bcrx:USDepartmentOfHealthAndHumanServicesMember 2015-09-30 0000882796 us-gaap:UnbilledRevenuesMember 2015-09-30 0000882796 us-gaap:UnbilledRevenuesMember bcrx:CSLLimitedMember 2015-09-30 0000882796 us-gaap:UnbilledRevenuesMember bcrx:GreenCrossCorporationMember 2015-09-30 0000882796 us-gaap:UnbilledRevenuesMember bcrx:USDepartmentOfHealthAndHumanServicesMember 2015-09-30 0000882796 bcrx:CSLLimitedMember 2015-09-30 0000882796 bcrx:GreenCrossCorporationMember 2015-09-30 0000882796 bcrx:JPRRoyaltySubLLCMember bcrx:PhaRMANotesMember bcrx:CurrencyHedgeAgreementMember 2015-09-30 0000882796 bcrx:USDepartmentOfHealthAndHumanServicesMember 2015-09-30 0000882796 us-gaap:PerformanceSharesMember 2015-09-30 0000882796 bcrx:StockOptionsAndRestrictedStockMember 2015-09-30 0000882796 bcrx:JapanYenMember bcrx:PhaRMANotesMember bcrx:CurrencyHedgeAgreementMember 2015-09-30 0000882796 bcrx:PhaRMANotesMember bcrx:JPRRoyaltySubLLCMember 2015-09-30 0000882796 bcrx:DeferredCollaborativeRevenueMember 2015-09-30 0000882796 bcrx:DeferredProductSalesMember 2015-09-30 0000882796 bcrx:CurrencyHedgeAgreementMember 2015-09-30 0000882796 us-gaap:CertificatesOfDepositMember 2015-09-30 0000882796 us-gaap:CorporateDebtSecuritiesMember 2015-09-30 0000882796 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-09-30 0000882796 bcrx:EmployeeStockPurchasePlanMember 2015-09-30 0000882796 us-gaap:CertificatesOfDepositMember 2015-09-30 0000882796 bcrx:CollateralForCreditMember 2015-09-30 0000882796 bcrx:RoyaltyReceivableMember 2015-09-30 0000882796 bcrx:AECOMAndIRLMember 2015-09-30 0000882796 2015-10-31

EX-101.SCH 10 bcrx-20150930.xsd XBRL SCHEMA FILE 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Disclosure - Note 1 - Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 2 - Stock-Based Compensation link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 4 - Royalty Monetization link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 5 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 1 - Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 2 - Stock-Based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 1 - Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 014 - Statement - Note 1 - Fair Value of the Company's Investments by Type (Details) link:calculationLink link:definitionLink link:presentationLink 015 - Statement - Note 1 - Scheduled Maturity for the Company's Investments (Details) link:calculationLink link:definitionLink link:presentationLink 016 - Statement - Note 1 - Summary of Receivables (Details) link:calculationLink link:definitionLink link:presentationLink 017 - Statement - Note 1 - Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 018 - Statement - Note 1 - Summary of Revenues (Details) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 2 - Stock-Based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 020 - Statement - Note 2 - Stock Incentive Plan Activities (Details) link:calculationLink link:definitionLink link:presentationLink 021 - Statement - Note 2 - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts (Details Textual) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 4 - Royalty Monetization (Details Textual) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 5 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 11 bcrx-20150930_cal.xml XBRL CALCULATION FILE EX-101.DEF 12 bcrx-20150930_def.xml XBRL DEFINITION FILE EX-101.LAB 13 bcrx-20150930_lab.xml XBRL LABEL FILE Agreement [Member] Represents a License Agreement (the "Agreement") granting rights to develop, manufacture and commercialize RAPIVAB®. Document And Entity Information Customer Concentration Risk [Member] Employee Stock Option [Member] Note To Financial Statement Details Textual us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Investments statementsignificantaccountingpoliciespolicies statementnote1significantaccountingpoliciestables statementnote2stockbasedcompensationtables Sales Revenue, Product Line [Member] statementnote1fairvalueofthecompanysinvestmentsbytypedetails statementnote1scheduledmaturityforthecompanysinvestmentsdetails bcrx_MaturityperiodOfShortTermInvestment Maturity Period of Short Term Investment Maturity period of short term investment. statementnote1summaryofreceivablesdetails statementnote1inventorydetails bcrx_LongtermInvestmentMaturityMinimum Long-term Investment Maturity, Minimum Represents long term investment maturity minimum. Amendment Flag Concentration Risk Benchmark [Axis] statementnote1summaryofrevenuesdetails statementnote2stockincentiveplanactivitiesdetails Concentration Risk Type [Axis] Vesting [Domain] statementnote2weightedaverageassumptionsforstockoptionawardsgrantedtoemployeesanddirectorsundertheincentiveplandetails Employee stock purchase plan sales Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member] Represents deferred revenue from upfront payment allocated to the regulatory support for the Canadian and EU marketing approvals, portion to be recognized ratably over the expected period of involvement. Concentration Risk Benchmark [Domain] Vesting [Axis] Notes To Financial Statements us-gaap_AllocatedShareBasedCompensationExpense Allocated Share-based Compensation Expense Plan Name [Domain] Notes To Financial Statements [Abstract] us-gaap_IncreaseDecreaseInDeferredRevenue Deferred revenue Concentration Risk Type [Domain] Plan Name [Axis] Revenue from Sale of Inventory to be Recognized When the Inventory Transfer Is Complete [Member] Represents deferred revenue from the sale of inventory to be recognized when the inventory transfer is complete. Minimum [Member] CSL [Member] Represents CSL Limited (“CSL”) and its affiliates. Maximum [Member] Performance Shares [Member] Range [Axis] Range [Domain] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Document Fiscal Year Focus us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Sale of common stock, net Net loss Net loss bcrx_SecuritiesOffered Securities Offered Represents securities offered for sale. Document Fiscal Period Focus Exercise of stock options Document Period End Date us-gaap_IncreaseDecreaseInInterestPayableNet Interest payable Investments bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities Average Maturity Period of High Quality Marketable Securities Average maturity period of high quality marketable securities. Current Fiscal Year End Date Products and Services [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized Revenue Recognition Royalty and Milestone Revenue Recognized Revenue recognition royalty and milestone revenue recognized. Products and Services [Axis] us-gaap_CostsAndExpenses Total operating expenses UAB [Member] UAB Expenses AECOM and IRL [Member] AECOM and IRL Award Type [Axis] bcrx_CollaborativeAgreementAdditionalContractValue Collaborative Agreement Additional Contract Value Collaborative agreement additional contract value during the period. Entity Current Reporting Status Entity Voluntary Filers US Department of Health and Human Services [Member] United States department of health and human services. Entity Filer Category bcrx_MaturityPeriodOfHighQualityMarketablesecurities Maturity Period of High Quality Marketable Securities Represents maturity period of high quality marketable securities. Document Type bcrx_CollaborativeAgreementAdjustedContractValue Collaborative Agreement Adjusted Contract Value Represents collaborative agreement adjusted contract value. bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts Proceeds from awards for Research and Development Contracts Represents proceeds from awards for research and development contracts. Award Date [Axis] Equity Award [Domain] Amortization of debt issuance costs Amortization of Financing Costs Award Date [Domain] Estimated Fair Value Total investments bcrx_AveragematurityForPortfolioInvestments Average Maturity for Portfolio Investments Average maturity for portfolio investments during the period. Cost of products sold Royalty Receivable [Member] Represents royalty receivable. RAPIVABMember Repesents RAPIVAB product. Collateral for Credit [Member] Restricted cash and cash equivalents required to maintain as collateral for a letter of credit. Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Investing activities Entity Well-known Seasoned Issuer Stock option awards exercised (in dollars per share) Prepaid expenses and other current assets Stock option awards granted (in dollars per share) Stock option awards cancelled (in dollars per share) Legal Entity Type of Counterparty [Domain] Legal Entity of Counterparty, Type [Axis] Receivables Trade Accounts Receivable [Member] Statement [Table] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Weighted Average Exercise Price (in dollars per share) Receivable [Domain] Receivable Type [Axis] Billed Revenues [Member] Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Unbilled Revenues [Member] Receivables Billing Status [Domain] bcrx_DeferredCollaborationExpenseAssets Deferred collaboration expense Represents deferred collaboration expense. Billing Status, Type [Axis] Restricted cash Restricted Cash and Cash Equivalents, Current us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Research and development Assets us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (Decrease) Increase in cash and cash equivalents Income Statement [Abstract] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Balance September 30, 2015 (in dollars per share) us-gaap_InterestExpense Interest expense Interest Expense us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Derivative Instrument [Axis] Collaborative and other research and development Collaborative and other research and development during the period. us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net cash provided by financing activities us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net cash (used in) provided by investing activities Derivative Contract [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Awards Available (in shares) Balance September 30, 2015 (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant us-gaap_DeferredRevenueAdditions Deferred Revenue, Additions us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net cash provided by (used in) operating activities us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Stock option awards cancelled (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Options Outstanding (in shares) Balance September 30, 2015 (in shares) us-gaap_StockholdersEquity Total stockholders’ equity Currency [Domain] Deferred Revenue Arrangement Type [Axis] Deferred Revenue [Domain] us-gaap_TableTextBlock Notes Tables bcrx_PaymentsForModificationOfLicenseAgreement Payments for Modification of License Agreement Represents payments for modifications of license agreement. Risk-Free Interest Rate Preferred stock, shares issued (in shares) Deferred collaboration expense Comprehensive Income, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] Preferred stock, shares authorized (in shares) bcrx_ContractTerm Contract Term Period of time between the contract date and its expiration. Expected Volatility Preferred stock par value (in dollars per share) bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement Stock Issued During Period, Value, for Modification of License Agreement Represents stock issued during period value for modification of license agreement. Expected Life in Years bcrx_RoyaltyTerm Royalty Term Period of time between the date of the Agreement and its expiration. Inventory Net inventories bcrx_AdvanceNoticePeriodForTerminationOfAgreement Advance Notice Period for Termination of Agreement Represents advance notice period for termination of agreement. us-gaap_Revenues Revenues Preferred stock, shares outstanding (in shares) Research and Development Expense, Policy [Policy Text Block] Common stock, shares outstanding (in shares) Unrealized gain (loss) on available for sale investments Maturing in one year or less CSL Limited [Member Represents CSL Limited which is a company organized under the laws of Australia. Stockholders' Equity Note Disclosure [Text Block] Relationship to Entity [Domain] Expected Dividend Yield Income Tax, Policy [Policy Text Block] Title of Individual [Axis] Restricted stock unit awards cancelled (in shares) bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four Employee service share based compensation nonvested awards compensation cost expected to be recognized year four. bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Five Employee service share based compensation nonvested awards compensation cost expected to be recognized year five. Restricted Cash and Cash Equivalents [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Restricted stock unit awards granted (in shares) bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate Share-based Compensation Arrangement by Share-based Payment Award, First Vesting Period After Grant Date Share based compensation arrangement by share based payment award first vesting period after grant date. Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Cash and Cash Equivalents [Domain] bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three Employee service share based compensation nonvested awards compensation cost expected to be recognized year three. bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year. us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two Employee service share based compensation nonvested awards compensation cost expected to be recognized year two. Royalty Monetization [Text Block] Royalty monetization. us-gaap_ReceivablesNetCurrent Receivables Additional paid-in capital Liabilities and Stockholders’ Equity us-gaap_Assets Total assets bcrx_PeriodOfAgreement Period of Agreement Represents period of agreement. bcrx_RenewablePeriodOfAgreement Renewable Period of Agreement Represents renewable period of agreement. Stockholders’ equity: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax us-gaap_PaymentsToAcquireProductiveAssets Acquisitions of furniture and equipment Legal Entity [Axis] Corporate Debt Securities [Member] bcrx_MilestonePaymentMaximum Milestone Payment Maximum Represents milestone payment maximum. us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Purchases of investments Furniture and equipment, net Entity Registrant Name Royalty revenue Royalty revenue Entity Central Index Key Entity [Domain] National Institute of Allergy and Infectious Diseases [Member] Represents National Institute of Allergy and Infectious Diseases. Available-for-sale Securities [Table Text Block] us-gaap_SalesRevenueNet Total revenues bcrx_MilestonePaymentMinimum Milestone Payment Minimum Represents milestone payment minimum. Other assets EX-101.PRE 14 bcrx-20150930_pre.xml XBRL PRESENTATION FILE GRAPHIC 15 exh2_1.jpg GRAPHIC begin 644 exh2_1.jpg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�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end GRAPHIC 16 exh2_2.jpg GRAPHIC begin 644 exh2_2.jpg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exh3_1.jpg GRAPHIC begin 644 exh3_1.jpg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end GRAPHIC 18 exh3_2.jpg GRAPHIC begin 644 exh3_2.jpg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end GRAPHIC 19 exh3_3.jpg GRAPHIC begin 644 exh3_3.jpg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end GRAPHIC 20 exh1_1.jpg GRAPHIC begin 644 exh1_1.jpg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end GRAPHIC 21 exh1_2.jpg GRAPHIC begin 644 exh1_2.jpg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exh1_3.jpg GRAPHIC begin 644 exh1_3.jpg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end EXCEL 23 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`#&%9D?6X#P>EP$``+H1```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V874_",!2&_PK9K6&E5?$CP(UXJR3Z!^IVQAK:M6G+@']O.]#H,@TH M2\[-/GA/S_MNIWLNF+SN#+C!5LG*39/2>W-/B,M*4-REVD`5E$);Q7VXM4MB M>+;B2R!L-!J33%<>*C_TL4ZCK4 M12$RR'6V5F%)ZH,U7`0]&2RX]4]/XJ26\A?O`WS[?XVOA;TER/. MM;G^:>B-Z$ASZA$2)^5@2')<(LEQA23'-9(<8R0Y;I#DN$62XPY)#CK"$@0+ M42D6I%(L3*58H$JQ4)5BP2K%PE6*!:P4"UD9%K(R+&1E6,C*L)"582$K^R0K M:?ZRF;T#4$L#!!0````(`#&%9D=(=07NQ0```"L"```+````7W)E;',O+G)E M;'.MDLMNPD`,17\EFGUQ2B46$6'%AAU"_(`[XSR4S'CD,2+]^X[8@,)#K<32 MKWN/KKP.J:P.-*+V'%+7QU1,?@RIROW:=*JQ`DBV(X]IP9%"GC8L'C67TD)$ M.V!+L"S+%4EK0VTPAGEN&;>5ADZ3SXB?078VZ: MWM*6[13@2=&AXD7U(V8#$NTIO8+Z M>@"%,;X[)9J4@B,WHX*[O]C\`E!+`P04````"``QA69'>Q>T)50!``!8$``` M&@```'AL+U]R96QS+W=ORJ.C#HRZ09@,"2^-_PR>+\^"2[(DZ[5LS MN*8=7?3>=X/+IO=YW'@_9DJYHJ%>NXT9:9A6*V-[[:='6ZM1%W==D\(D295= MSHDOYY^SHUN9Q_960AR]:%N3S^,W8^^N(?).S3?83!M,RX^1_K.]J:JVH*LI M7GL:_!\5ZFN#6(6#,!R$(D';<-!6)&@7#MJ)!.W#07N1H#0=1((@861,9)(XK&6T!H9KD/$:&+!!1FQ@R`89LX%!&V34!H9M MD'$;&+A!1FY@Z`89NX'!&V3T1D9OE-$;&;U1Z*S-';9E]$9&;Y31&QF]449O M9/1&&;UQH;=KM*7RV=MVJ-W:-=^<4+O)U_=+1^RCR5;5AH[:>=2,W7U3_W M>>IGB/KU$^'R`5!+`P04````"``QA69'+Z?7KY`"``!K"```$````&1O8U!R M;W!S+V%P<"YX;6R]5DU3VS`0_2L:7YH>P(F!'C+!,R&A4V9*R9`4SHN\MC7( MDBO)'L*O[]HFQH$DU!R:2U:K??OQ=E?)1-GA>&%TCL8)M.PID\J.27GNI<[E M8]^W/,4,[#&9*+J-M9&A:_-H M4T1G)WZKK,6N;5<6IV%P5EN0M&WIMY6%+[1MU5UI5L))M#?Q`HS[3U34-;5$ MG'F=ZC=:*W3B M>7]W:L39)K-4RXCV\`N[_%-0;WO/V>CH#]GH]TS<#C.Z6', M=]HZ=@>RP*K_1/'^N7F-0TL7%9(RNP97/\^,MN$#3)%E8-95D%OD*$IXD!_Q M=J5*&DQ-J,$<'0AIO_8(0MB"?N0&\_Y$!\-_P%!ZG-*KQG-!N\JFAS'W*)*T MVKAIB0829%-KBZS_$@0'AF#?$K!!_S78QKQ[M-\\T?[V7XOP+U!+`P04```` M"``QA69'PBY5/SX!``!I`P``$0```&1O8U!R;W!S+V-O&ULS9--3\,P M#(;_"NJ]2[/!#E'7`R!.3$)B",0M)-X6UGPH\=3UWY-E7,; M(-.BF!,-R"5'3H[`W/7$K"JE8,(#1^L[O!0]WNU]G6!2$*A!@\%`Z(22K'HQ M.V,;4Y)!7Y71<@NJK MFJ:9-+-4%P>FY&WY^)S.)E-!G3!=MAVTC?4R5.E^#='QY<25;:QO3ZD?T<6KJKX`4$L# M!!0````(`#&%9D>97)PC$`8``)PG```3````>&PO=&AE;64O=&AE;64Q+GAM M;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]' M-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D M$4$P&:>O\,`*I4Q>M5II`,,X?+&A`T%116F]?(+3E'S/X% M/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB`@LE]E`6Z2?:C MTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP'`3@4;N>PIWT;+^D M00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG`J-6T_3:W?=TXZ)QJW0>`V^\4^' MPZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@`%AP=M;,T@.67BGZ=90: MV1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9`%#@`WQ-%,4'RO0;:*X,*2TER0 MUL\IM5`:")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CD MGZ>3UTU"SG"\+`GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V& MF&I0'`*D"3&6H8;XM,:L$>`3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F M<]%L^P>E1M'V5;SOX% M^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:CFED)O816:I^JAS0^ MJ!XR"@7QN1X^Y7IX"C>6QKQ0KH)[`?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$ MKYI9+2,6D$N!LT$DN/R+RO`JQ`GH9%LE"0AMNZ5/U2I77Y:^Y M*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9 M!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE`T%&UL MK"0L1K=@N-?Q+!3@9&`MH`>#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2 MX]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\, M$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T M74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT M%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ`$:MB MOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\4 M8JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5`Y3_;U`UH]@TT')$% M7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%`````@`,85F1QP$3&->`@`` MT@H```T```!X;"]S='EL97,N>&ULS5;M:MLP%'T5H8S1PHCM;'6[U3:,0F"P ME4'S8_^*;,N.0!^>+&=.WV;/AP["4W3I.W6_-'5T=6Y1U?7N8IJM:3X M9HZQ`BVCO([A7*GJD^?5V1PS5(]%A;E>*81D2.FI++VZDACEM=G$J#?Q_=!C MB'"81+QA4Z9JD(F&JQA^Z"'@]E^)',?P]N3MST:HRS?`C:-WHY%_>WJYC9_8 MA5,(',>7/(9!>`:]QY..?7\WL5G<(@\/)'^(>XOZ?`_UG]\[LM$OW)N."T/K M=7E/HD+P(?T3Z(`DJN_``E'M'QCW3%`A@=+WJ^-;A".&G<<5HB25Q(`%8H0N M'3PQ@"V)SH\1+J2-[2)LQQG[0R19IC'TN]_CPZ4#NQW,\0BEF\?30!)52"DL M^51/0&?/EI4^'!<<.Y'6;X]W*=$RF)RM;;"#CIL*F6/91P[@"DHBB@NE-TA2 MSLVH1&6D"Z4$TT9.4"DXHH9RM:,S-&V&*;TQ'^"/8H.[+8#S,7?L0V!4K$R= MB,X2W&E_4PB9!K"$8(&E(MDZ\DNB:H9;U56PUQ:[%!Y[Y->N:8BOB^Z0X!:Z M;EB*Y=3^$QTNZ?WY_CS93P)NR?RW5W6$A.>OY_]Y3Z9?OEB6GBHM?+W27J:\ MGT7:Q1.E>5UG6&L_&\VG1T':$*H(7VE`YKEP;733C;XP-![-F;=#S[&K"J7Z M@;D119/EN$`-5=_)0BB[&,/!_FKD!V'O->LI8CC8WW!.&O;1*AA>L&PO=V]R:V)O;VLN>&ULE9;; M4MLP$$!_1>.7T@<:VR0!,H092*!EIEP&&'A6[$V\@RRYDIP`7]^50V`#,2U/ MMGPYTFJ/5CIP@X6Q#Q-C'L1CJ;0;V&%4>%\-.AV7%5!*]\-4H.G=U-A2>FK: M6<=,IYC!V&1U"=IWTCCN=RPHZ=%H5V#EHA>:^Q^:JRS(W!4`OE1+6"E11X<' M;C!%!7=@'8&%K*H+6<(P>E214-+YDQP]Y,.H2TVS@+4'MJZ.:U2AT8M[42?` M5J%>69&9'):PVP+=_-#]1#^[U"8W18[;VH9>3ZY")8=2/"3A'AQ-4Z)^& M47.O($32>1=*,_UO=T(WD[-*L3C2N3C1GBCB3"^31U,3QD`?G^5-QW:`=&// M\F0Y51PT(C&,PISF(A?'4DF=@6C"<6)K5#-0RD#I5T$[#+3#0#O_`-UXNH1` MG3!3,3)EQ4!=!NI^#21=P4`]!NI]!%T8#R(1V^(&9QIIA%N)USN9(/=GX^JRU%< M[V2#WZ^H4XE6W$E50W";\O]^H21<\.13PVDWR&M%X9U+7]M05JBH2JIQM47T=1C!G%&%;Q%=5.<<117/6T3?6` MN@><%:'<'6JIUSUM$WUMMHBMCB*JYZVJ=Y6 M7]917/6T][*COFVB=(Y`#7DX8KBF&]JCLW#NH,NR%G1[P8+0/J>SR#`*!P8Z M&]1*C>C9I?YM9+.M+LFKD\;A7U!+`P04````"``QA69'*I''N(_S/@;;LL?.1_QQX:ZZUU`-!600S[]QTM!<-ZSU.+SM_ MC[9'E&J(0?QLZ$,LVIZ>_(FQ=]WY?M[YH9X#;6DE=0BB7G=ZI&VK(RGEWU/0 M3TU-7+:?T;^:=-7T3T30(VM_-6=9J]F&OG>F%W)KY1M[?*-3#HD.6+%6F*=7 MW81DW9/B>QWY&-]-;]Z/\4N")QI,P!,!SP2\^2\AF@C13$"QR72'Q(%`,R)0L6>6@(C(C:(WB#R'&>; M%%9)0)7$41PP(I*)`Z](TEX")0""MDH$+F\I$E`4`P+)&#$KG+CRP) M`!+#$AM08N/R$TL"@*RLM3Y"(->%;@1[N2',2B)HQ=O(C9!;YILPR[V;15&4 MYMF*RQ%H\SW"KI:]OP`,7ME@"/8Z\+`9RI3$OS:]\$Y,JL)FRL^%,4G55,(7E6JM+AQSIZ47J9N9 M:O.Q!(\=R8;GC6*^UI1_`5!+`P04````"``QA69'I"-BS$H$``!W%@``&``` M`'AL+W=OE9B)C94LKZ3$VV]?27:\#N=130ZQ_KPA'T>:'RFNCDW[O=N& MT"]^UM6^NUUN^_YPDV7=XS;49?>Y.83]<.>I:>NR'T[;YZP[M*'<3$%UE9%2 M+JO+W7ZY7DW7OK;K5?/25[M]^-HNNI>Z+MM_[T+5'&^7>OEVX=ON>=N/%[+U M*KO$;79UV'>[9K]HP]/M\C=]R"_=-]<]NTV\' MMVJYV(2G\J7JOS7'/$Y#'9L\+&INNG_XO&EZYOZ+62YJ,N?I]_=?OH]GNYX M=0[#`70.H$N`-K,!?`[@*"`[.9O&]:7LR_6J;8Z+]O0P#N7XS/4-#YE['"]. MB9KN#2/KAJNO:_*K['5LYRRY.TGH6O)><0\4Q462#?U?3!`T05,\7\6SPO$, MXWF*=]?Q&L<;&&]D_]$0[TZ2?)+L)TEN"JN4BE(A=>Q-<:U[Y\="/U;Z81SO M8+S[<#YR&)__?SZ`Q$2I.$G,52JL,SJ9"@^M>-F/Q?$%C"]D*AR.'ZL=%8B2 M#O*X0I1XZJ05R;?C++S.B38^G1.=*%HM/?E$"[CB-'T\+[CF-'\@+RR'ZT!6 MI,PZ9=-9P56L01D7L2,CNC+.40Y,2:4UUJBT*US+6A:S4;$K"_)$Z/T!0CMC M">-!.VE)QY:RI$5]X#1U*6NZ0?PF@DB49C(S\DB>>- M16Q$RH)-^LD1AB-).(JW^ZQYAX$\]P`#2*FUGLE58HDCUSC&Q:Y(5I(V`)A` M2"I/6\($)TEP\3J11#-Y]/``Z?,91YC@)`ENXCF%`)>)"V!)"IWB]%Q+F-\$ M^!VOD`E@F7UAT:-#4N=SD_:%(4X`XO%L1Q+-G,/')X4TMVPEC'"2>+;Q7$<2 MS\0*S<(H)XER&T]V)!G-2J$I^"/* M]Y]1&.@L@6[C28\EIIT9_J0KH+0Y%6F@,P8Z2Z#;F%,L,:V51DLHH&1KTW,Q M8YZSY+F-YSZ6F&8#OAF1KD@#@1,?P?(KV":6](SQRQ*_-L8O2ZJ*X2"TOH!0O+[*K+<)#^1S^*MOGW;Y;/#1] MW]33GN!3T_1A:%9]'JIH&\K-Y:0*3_UXF`_'[6E?]'32-X>W;=[+7O/Z/U!+ M`P04````"``QA69'(#:2C1L"``!*!P``&````'AL+W=O51K-HUT[B!#0&4]L)T[>O M;0@%VY-,%O'M_\_Y#K;LHJ?LC5<8"^^](2W?^I40W08`?JQP@_B*=KB5*V?* M&B3DD%T`[QA&)VUJ"`@A7(,&U:U?%GKNA94%O0I2M_B%>?S:-(C]W6%"^ZT? M^/>)U_I2"34!R@),OE/=X);7M/48/F_]+\%FGRN%%ORJ<<]G?4^Q'RA]4X,? MIZT/%0(F^"A4!"2;&]YC0E0@F?C/&/-_2F6<]^_1O^EJ)?T!<;RGY'=]$I6$ MA;YWPF=T)>*5]M_Q6$*B`AXIX?K?.UZYH,W=XGL->A_:NM5M/ZQD<+2Y#>%H M""=#$#\T1*,A,@Q@(--U?44"E06CO<>&O>B0VO)@$\DO=U23^D/I-5D9E[.W MJ!4OD9(ELEK7!,DCB698$ZI]!\URWX(F=/+'-DQH\L97')'FD6#`D3H;$ M9L@,AN0IPR/%@F'M9%C;#+G!,$CRY>Z;1^2):$&2.DE2BR0U:MVE5JTAA,XS M\AGE@BES,F4VDU'X+K,RI5$4I3:20QCD2?(A4>XDRFTBX]K8Y9\E<@C=1&!V M[77H@G\B=JE;[AVHD#>HON?.E`HL@\*5/)"5?-BF`<%GH;JI[+/AKA\&@G;W MEVMZ/LM_4$L#!!0````(`#&%9D&PO=V]R:W-H M965T&ULC5A-!+Z(.6X*K:9VCULU=0<=L[$ M5F+7@/$`B6?__0(F#N@UV;W81N[74NOCO4;+2UG]K`_.-<'O(C_5#XM#TYSO MP[#>'5R1U5_*LSNU_SR759$U[6/U$M;GRF7[/JC(0Q%%.BRRXVFQ6O9MWZK5 MLGQM\N/)?:N"^K4HLNJ?M^@&_Q36?[L'O[W<7G> M,;4]_QI(/_KL`L>_W]F_]G+;X3]EM=N4^8_COCFTHXT6P=X]9Z]Y\[V\_.$& M#:HCW)5YW7\&N]>Z*8OWD$509+^OW\=3_WVY_F.C(0P'B"%`W`)N_>``.03( MCX#XTX!X"(C_;P]J"%!>#^%5>S]SVZS)5LNJO`35=;G/6;>KZ%ZU:[/K&ONE MZ/]KYZYN6]]61B[#MXYG@*RO$#&&Q%/(ED/HA@C;_F^#$&@0:\'"Q;2##4<8 MY8WA/TG23TDFPY1PKF0?K\?Q&L?',#[NX^4XWGAS?868'G+J(4HG211%WGQP M*NFO":?20FI&E7Y*-5&EH"K%55E/U142CX9"@H]DH[AX!MH"+F.`+$Y&B:(Q M;J)-0VV::TL\;9J-1Y$67!S'22$EUP=P2L<U$H84*+3NT=B8W)3`^X3/DY95UPF=( MQF!_I?)F"=P4T:78(1`OQM:W"`-FW-<=25AS()3Z?,*T`J@00G%H MBJ`RTJ3FU6+G0-PZ6-\Z$*CW,@92`8[#M@`F04)+`6XZ%5-]V#T0MP_6MP_$ MR_@=M3L7*(1(XH/?(J2T8(.D$*EM/*\4VPCB/B+Q?03QNG\G%=JUP"!$%N58 M#K2H6`*S#8):+SL,*@%2Q`:]N"!H=PP3+C8< M7=04KGKIK\CJ8%>^GII.Y:CU=@WWV-_">>UKNM\0:-_2?7J]9/N@7RW/V8O[ M*ZM>CJ"J;IBSZ2Z#GLFQWZ\O5OU!+`P04````"``QA69'+M8PNA,$```[$P``&````'AL+W=O'L!QS[\?@8ECZQZELP@@SI7.%=(G68M+T_[L#M;VT:^JK+OGV:'O M3T]QW&T.MBJZ+\W)UN[-KFFKHG>/[3[N3JTMMF-05<8B2=*X*H[U;+D8R[ZW MRT5S[LMC;;^W47>NJJ+];V7+YO(\H]E[P8_C_M`/!?%R$=_BML?*UMVQJ:/6 M[IYG+_2TEF*0C(J_C_;2W=U'@_G7IODY//RY?9XE@P=;VDT_5%&XRYM=V[(< M:G(M_SM5^M'F$'A__U[[US%=9_^UZ.RZ*?\Y;ON#>R_]%I*NYS9#X=A1XSN76>=*WY9YNHC? MAGHFR>HJ$7<2NBEB5_FM!8%:6`D6+AX;6'.%T;@%"7.08WQZGX/!\0K&JS%> MWL>3UP=7B1DE]2B9"Y5E*DD2+QF@E%*3N5<^>-+0D^8Y93@^A?$ISRGW[AL;J0(^AD8A["0L/%'B0Q4$2`+L:2DG].D M>1A<>:YY5I/P85H1"1G."\+HA00SI9@IP4=8!GH:U"55P`T&%TGPW95O1X() M*`GXD0!2X9%(&(;$::B8)<4'&1%@!Q`J'7:$44@:])+V+6G>2T)G`GCB2IDF MG\P0#%CBA-4^08BS>+"7(DK`'W)G\*"TU?JS("-'U".]`W;P@`6',!NI?-M(0+K!#$82,DM'UG8%\:P MX%M2HL"60&!F"LY,(G]Q$6##20;L"9`P2=//>AQS4X#M*?D+C.`\E%D*EF$@ M5*E,PZ8P.`4`)_G@%&#SJ1%<@(X^Z2<,30&VJ>0O,()O0+7,$5NXT$T_K<(] M)3&()0`Q^2"6`*\F)\`7H,S=7WBK*3&*)4`Q^2B6'+!::94`6UPIW(!085L8 MQQ+@6/@XGD3F80RG`M`%*,GY0IN7^.Y,HK+M?CRKZ:)-?_7>GM/.AE M/`[RRE?TM+Z>ZGQ4LURCJMMYV?)_4$L#!!0````(`#&%9D?=TVUPH`$` M`+$#```8````>&PO=V]R:W-H965T&UL=5/!;N0@#/T5Q`>4 MA$F[JU$F4J=5U1XJ53WLGIG$25`A3H%,NG^_0"9IVLU>`!N_YV=C\A'-FVT! M'/G0JK,'VCK7[QFS90M:V"OLH?,W-1HMG#=-PVQO0%01I!7C27+#M)`=+?+H M>S%%CH-3LH,70^R@M3!_CJ!P/-"4SHY7V;0N.%B1LP5720V=E=@1`_6!WJ;[ M8Q8B8L`O":-=G4G0?D)\"\93=:!)D``*2A<8A-_.<`=*!2*?^/W"^9DR`-?G MF?TA5NO5GX2%.U2_9>5:+S:AI():#,J]XO@(EQ*N`V&)RL:5E(-UJ&<()5I\ M3+OLXCY.-]D,VP;P"X`O@)])%#XEBC+OA1-%;G`D9FIM+$+IGON&U$&9ZP[ MWGFAUGO/12G)U34GK_\]B**A=./[P9S.-U&0X[.,)6P#88'2QI44G76HKI"$*/X^[$+'O1]N]KL1M@Q@(X!-@-LT"A\219F_ MN.-Y9K`G9FAMR\,+K@[,-Z((SEAWO/-"K?=>\A7;9O02B,:8TQ##YC%3!/7L M4PJVE.+$?L#9,GR]J'`=X;LO"O]#L%DDV$2"]1>"W;<2EV+VWY+064\5F#J. MCB4%=CH.ZLP[3><=BV_R&9YG+:_A+S>UT):G--B&-_S^3 M(:%RX;CW9S.,U&`X;*\?9/JE^0=02P,$%`````@`,85F1V@?7-*C`0``L0,` M`!@```!X;"]W;W)K?(]V2+' MWBMIX,D2UVLM[)\S*!Q.=$-OCF?9M#XZ6)&S&5=)#<9)-,1"?:(/F^-Y%R-2 MP$$@UN<2=1^07R)QO?J1+,H`124/C*(L%WA$92*1"'Q[XGS+64$+L\W]J^I MVJ#^(AP\HOHE*]\&L1DE%=2B5_X9AV\PE7`?"4M4+JVD[)U'?8-0HL7KN$N3 M]F&\V1\FV#J`3P`^`PY9$CXF2C*_""^*W.)`[-C:3L07W!QY:$09G:GN=!>$ MNN"]%AM^R-DU$DTQYS&&+V/F"!;8YQ1\+<69_P/GZ_#MJL)M@N_?*?P/P6Z5 M8)<(MN\(/G\H<25FFWU(PA8]U6";-#J.E-B;-*@+[SR=#SR]R5MXD7>B@1_" M-M(X4M.'_S(:"VL?CIW"VXTB-AL?N]D'F7UK\!5!+ M`P04````"``QA69'_N@+?Z(!``"Q`P``&````'AL+W=OC3*1.J]7V4*GJ8??,)$Z""C@%,NG^ M_0+)I&F;7@`;O^=G8XH1S8OM`!QY4U+;0](YU^\IM54'BMLK[$'[FP:-XLZ; MIJ6V-\#K"%*2LC2]H8H+G91%]#V9LL#!2:'AR1`[*,7-OR-('`])EEP+ZI,(_PFW5V]@W!;I-@%PGR#R6R3R5NQ>2?DM!53Q68-HZ. M)14..@[JRKM,YRV+;_(>7A8];^&1FU9H2T[H_,O&_C>(#KR4].HZ(9W_/XLA MH7'A^,.?S312D^&POWR0Y9>6_P%02P,$%`````@`,85F1V+\[A*B`0``L0,` M`!D```!X;"]W;W)K&UL=5/;;MP@$/T5Q`<$+WMI MM?):RB:JVH=*41[:9]8>VRC`.(#7Z=\7L-=Q4O<%F&'.F3/#D`]H7UP+X,F; M5L:=:.M]=V3,E2UHX>ZP`Q-N:K1:^&#:AKG.@J@22"O&L^S`M)"&%GGR/=DB MQ]XK:>#)$M=K+>R?,R@<3G1#;XYGV;0^.EB1LQE720W&233$0GVB]YOC>1O$^9XR`I?G&_NW M5&U0?Q$.'E#]EI5O@]B,D@IJT2O_C,-WF$K81\(2E4LK*7OG4=\@E&CQ-N[2 MI'T8;_;9!%L'\`G`9\#7!&!CHB3S47A1Y!8'8L?6=B*^X.;(0R/*Z$QUI[L@ MU`7OM=AL=SF[1J(IYCS&\&7,',$"^YR"KZ4X\W_@?!V^756X3?##,CO_#\%N ME6"7"+8?2MQ_*G$MYO`I"5OT5(-MTN@X4F)OTJ`NO/-TWO/T)N_A1=Z)!GX* MVTCCR`5]>-G4_QK10Y"2W>TI:?F6EV$?%='SG7TT;6]6L9'K8?G)%';(^^8>A(#[\V3 MO9`=TV8I#XD:)&<[%]2U"4W3(NE8T\=UY?9>95V)DVZ;GK_*2)VZCLE_:]Z* MRS(F\6WCK3DJ$7TD^7X9K\CSFN86XA"_&WY1#_>1+7XC MQ+M=_-PMX]36P%N^U9:"F?*EPC@EFD&#F"+(O M!`OO%0%FEN(D.4R2`P+B)4&8P*$H29X20E3%("@MQ+@C`%3C*' M2>:`P)<=P@0.?@&3+`"!?_``DP<.WKH;.2@%%/[10U#@[$G`J010^*Q40' M"!32`6X"!#B\F.@`@4(ZP'V``),7$QT@4$@'N!40X/-BH@,$"ND`=P,"K%Y, M=`!`94`'%/<#"JQ>^CJ`H(`.*.X'%%B]]'4`00$=4-P/*+!ZZ>L`@@(ZH+@? M4&#UTM"W%T)S4TOZ9&HYFLG] MOFCY7MO;TMS+<98=%UH,M]'\_O^@_@]02P,$%`````@`,85F1\IAU6?7`0`` M104``!D```!X;"]W;W)K&UL=53-CILP$'X5BP=8 M$Y(`&Q&DS595>ZBTVD-[=F#XT=J8VB9LW[ZV(2Q+IQ=LC[^?LA&#JSP6X',_!+K@'7MNZ,2Y`\XPNO+(5T.E6=D1!=0Z> M=J=+ZA`>\+.%4:_FQ.5^E?+-+;Z7YR!T*0"'PC@%9H<;/`/G3L@:_YXU/RP= M<3V_JW_UI[797YF&9\E_M:5I;+)A0$JHV,#-JQR_P7R$HQ,L)-?^2XI!&RGN ME(`(]CZ-;>?'<=I)XIF&$Z*9$"V$-/2)3T8^S2_,L#Q3N1?('])X'CYH@8)L9-CJC)$1%(-B88)L5-8M0D1@0>-R8(YC'$ M31+4)$$$=AL3#/.?1TU1DQ01V/YV&&;[\'3UGPM0M2]G30HY=+YYK*)+QWB* M?)U\P/.L9S7\8*IN.TVNTMAJ\S5126G`IA(^V*=K;$];%APJXZ:)G:NIS*>% MD?V]:2V=,_\+4$L#!!0````(`#&%9D>VT]C0K`$``!8$```9````>&PO=V]R M:W-H965T0'*([STS1R+#5=K78/*U4] MM&=BCVU48+R`X_;M"]AQO5DN`8;O;PPD'U"_FQ;`D@\IE#DFK;7=@5)3MB"9 MN<,.E-NI44MFW5(WU'0:6!5(4M`L37=4,JZ2(@^U9UWDV%O!%3QK8GHIF?X\ M@<#AF*R2:^&%-ZWU!5KD=.957((R'!714!^3Q]7AM/6(`'CE,)C%G/CL9\1W MO_A='9/41P`!I?4*S`T7>`(AO)`S_CMI?EMZXG)^5?\9NG7IS\S`$XHW7MG6 MA4T34D'->F%?++&9QROZC9W'Z.IIP'>B[I?M^$Q?81`4V06#]3XN[FQ9CF/NX MR39JLHT([&],8IB'&Q.Z.#@)N@GWTY`2>Q5>PZ(Z/X''+!S\-[S(.];`'Z8; MK@PYHW77)QQRC6C!14GO7);6/=)Y(:"V?GKOYGJ\M^/"8G=]A?-?0?$%4$L# M!!0````(`#&%9D>[6"(4<@0``%,8```9````>&PO=V]R:W-H965TTE8::30/;\ M_7!K6NRU$UZ:0-:^>J]E0Q?'HOQ=[8RI9W_R;%]=SW=U?;CRO&J],WE2?2L. M9M_\LBW*/*F;R_+5JPZE23:=49YYTO=#+T_2_7RYZ.[]*)>+XJW.TKWY4PV:6[V55KL9Z797L__$5?/BEI( MA_B5FF/UY?NL3?ZE*'ZW%T^;Z[G?YF`RLZY;%TGS\6YN39:UGIK(_PU./V.V MAE^_?WA_Z,IMTG])*G-;9/^FFWK79.O/9QNS3=ZR^F=Q?#1##4'K<%UD5?=W MMGZKZB+_,)G/\N1/_YGNN\]C_TOD#V;80`X&\F0@U%D#&@QHJH$:#-14@V`P M"*8:A(-!.-5`#P;ZTR`\:Q`-!M'4"/%@$$\U:->\7SG?,O'Z)>\&YBZID^6B M+(ZSLI_R0]*225R)=B;7[=UN!+L?FYFIFKOORX8["^^]]31@;GJ,'&'$&'.+ M,'*,N4,8&F/N`6:,>'`1.AA#5A>=/%YV\@2T_E3^R5NO^P\ MT,A#@#T0]D#`0V@UM6KL(<`>`N`ALNKH M,>I+ECHFWV=2#7&@$`2REGX5.H%$&"C?YLYCZ+1-DV03TC@A[28D&`\1]A`! M#Q:%GR,GU;9S/IMLC$/%()3$'EKU@J+D`Q^.4OCN$@2^LP*KR[AQ3IQ0"I`3 M0W;!L%T`NKMU27>&45F78..,&/400#X$(T""8;8`U!:V!`V@T2HH7X*ZE#.& M-G"<%:,6`LB%8`1',$(@@!((6W(@*&8",007@.'2Z0P""280HP,""(&4=B`$ M(B80HP("R(!4=B`$8J9/,EHA@5;(D/'!<%L";CM=02!NG26WW0,!D-H.A$!, M^R7#:PEX+2/&!\-K"7AM'X'NI$M7?6[3D`Q=):`K<3X8NDK`1!)VPN[.35J= M29BAK`1L)&:?DPP;)2":FW#D*F!@S>YQVX`X[)A^$V`W\H*J`9(:80!END!%81"X@PV04=,1OE!&S150<^4L$U)S)4"A M""CO97<%D5M&H_^MV9[V9ED<[K(S+9N MO^KF>]F_\^XOZN+P\0K_]'^$Y5]02P,$%`````@`,85F1VQ_0#PY`P``J`X` M`!D```!X;"]W;W)K&ULC9?+;MLP$$5_1=`^$8=Z M![:!QD71+@H$7;1KQ:9M(9+H2G*<_GVI1UR;/+;[H#NVJMB.07452"&2 MH"[*QE\MQK:G=K70I[XJ&_74>MVIKHOVSZ.J]'GID__>\*/<'_JA(5@M@DO< MMJQ5TY6Z\5JU6_J?Z&$MHT$R*GZ6ZMQ=W7N#^6>M7X:';]NE+P8/JE*;?DA1 MF,NK6JNJ&C*9-_^>D_Y[YQ!X??^>_C46E>_RFU_,&Z%[VW5KCA5 M_0]]_JKF/L1#PHVNNO'7VYRZ7M?O(;Y7%V_3M6S&ZWGZ)Q-S&`Z0N$AP@A`F"$&"U.K&I$E' M33-I0J+U`C[D1B&S&T$0,;5F\?8V9# M6D[7/$T881L)M)%P&[&P;"3,QIT]&@D;C3L98A\I])$"'V3Y2/EPA)19A;0& M*E,BCGK-H)D,F'%,;@X3Y!\H^)S[3%D)K)&*7&8&)"**B`^4_"RZ?A-%9),$ MB*ZFZ=:,`VGT@<*?13?=3FPO7!,[G&"L$>`:J_U9=%/\%-E6@"AR0(DP(@DP MDBV`671;#9%@O$=`S"$<4>`=WP5<)21L)WP1*X/`&'8$:(=6P89J'`V1QG_ M"B2.KP!A1;R)0BMI\!LC@/(YM\P=69XECLU?>BW9=- MYSWKWAQ/QD/$3NM>F93BWL#T8(Z-EX=*[?KA-C7W[720FAYZ?7P_%UX.IZN_ M4$L#!!0````(`#&%9D=P1?YLW0$``!D%```9````>&PO=V]R:W-H965T"!R^[_#C(!03%V^R(T0%'XP.\A1V2HU'`&3=$8;E`Q_)H&=: M+AA6>B@N0(Z"X,::&`4QA`?`<#^$96%C+Z(L^%71?B`O(I!7QK#X_40HGTYA M%-X#K_VE4R8`R@*LOJ9G9)`]'P)!VE/X)3I6R"BLX&=/)KGI!X;]S/F;&7QO M3B$T"(226ID,6#'1-=N=H$;:'LG-Z9U-%;&:.D M`#>3:-$\S9IXJ_FLJ#R*QU4"-,!*$7LI8NM//E&D#L6LR:QFF#5)!J%#LE=% M>9S$?IC$"Y-X8)`#,VO2+4P6Y4[A*H\*I>@?E4F],*D'YN#`I/MEX`$Z]:OV MJ@@=4.:'05X8Y(')'!BT.X`L2G-'5>U5Z#%)+C_2%:7\/R#U!+`P04```` M"``QA69'('#Y&C,SEZTUU&C,@O$DKANW[X)H$4X M6=D;@7#^DY/(1\+\+*M7=1!">^]%7JJ%?]#Z^!@$:G,0!54!A.@H)GI;^>I4%+SZ^R1R>5[X MS+\TO&3[@[8-P7(>7.NV62%*EUNQXZ=FSO3 ML"W#!=06T+6`Q1\61&U!U"L(FF3UN+YRS9?S2IZ]JODSCMS^Y^PQ,C.WL8WU M1-7WS,B4:7U;4C*=!V_6J-4\-1KJ:FX5*Z"8726!"7!-03`%U?7130J'000- MHH%!U,OX!"1Q;Q@?2FY2Q#!%/!S&),0&"31([@^CD:2UI*PES#77$]C'!(1D MV""%!NG=D*MT&#),'9U,82=3D)*PP0P:S.Y/92.)NREGY.C$O@L0/B'(&3DL M'`2R^TE;33=81(90''B@(!A%MD(&%M-]PE)XKC/(U!1FDX= M:3"3#$&9."PPE6P$EDCCFC;,)4-@3AP6F$PV`DVD<07%:#+$9NJPP'"R$70B MC2,H83@)P>EX>@C#22/@;#5WGF6@_.35/BN5 MMY;:[+#K??!.2BV,8_A@'IJ#^?*Y7N1BI^UI:LZKYEN@N=#R>/FTN7Y?+?\! M4$L#!!0````(`#&%9D=CWNCWO`$``(8$```9````>&PO=V]R:W-H965TN6L4\>@T;H_8*S*!CA5=Z*'SHS4 M0G*J32C/6/42:.5,G.$X#%/,:=L%>>9R3S+/Q$6SMH,GB=2%LCRWX2XL4&OZIC M$%H$8%!J6X&:Y@H%,&8+F8G_C37_3VF-\_ZM^@^W6D-_H@H*P?ZVE6X,;!B@ M"FIZ8?I9##]A7,+.%BP%4^Z+RHO2@M\L`>+TU;=MY]K!CY#[T;9MB$=#/!FB MY$L#&0UD8<">S*WK.]4TSZ08D/3_HJ?VET<'8G:NM$FW46[,K$R9[#6/]R3# M5UMHU#QZ33S7?%04&XK[28(-P$01;U+$SD\^4"0+BK6&+"2%E^R=I/-ETGT8 MAMLH9!.%;*#L%BAKS0K%2Y(92A*EGZ(DFRC)!DJZ0%EK5BC):E?2;V2-@F=' MIJ=G^$WEN>T4.@EM3I\[([40&DS)\&X7H,8\"E/`H-:VNS=]Z>^)#[3H;[=^ M>GKR=U!+`P04````"``QA69'U,T8EQ@#```?#0``&0```'AL+W=O$X9E&5%W6XF-FQYV8QDR=5%K5X M;H+V5%5Y\VARB\#+P4^X,R`]%B%EWCMD4EZK:0=="(W3Q\1`]/*#40 MB_A9B',[N`],\J]2OIF'[]MY&)L<1"DVRE#D^O(N5J(L#9.>^7=/^CFG"1S> M7]B_6KDZ_=>\%2M9_BJVZJ"SC<-@*W;YJ50O\OQ-]!JH(=S(LK6_P>;4*EE= M0L*@RC^Z:U';Z[G[AR5]F#\`]P'X&G"=QQ]`^@#R&7!_AJ0/2*;.0/L`ZLP0 M==JM<^M#*&K"$$71&13N":!?9EL<0@'(\G6$$$ITX._R1YNDLR2I-XS2(VG@QG M8)F?(/$2)):`C=Q._0342T!A!CQSEJO#<(NI+2:AJ>LG!.&,.`N_AB"D\TT= M5R&*$DS\JIA7%?.HBOT$W$O`I_N:>@G2";YVF&3H!G%MA3S$W2H3:)[NTHSD M9%XYF4?.C0UIVJBO+\33+44W6@N:8&H/2D:%R!Q7>Q"_!UI[F%)0JQZF(6@L MR]NK'A&&LM(;U8K\?021_S#7WTE0,L7 MZVKR\'`.-$$BE-%;+<+?=!&?4H(<+A9BH`8A2K]"B"O-@Z(L(:XV"&,8W=+F M?Q\@V(%=#Y<]9N1AG*7&ULC9C;;J-($(9?Q?(#A.ZJYA0YEA([H]F+E49SL7M-[/9!`\8#.)Y] M^P5,'-S]EY4;`^V_#D!_U47/SF7UJ]Y9VTS^%/FA?IKNFN;X&`3U:F>+K'XH MC_;0_K,IJR)KVLMJ&]3'RF;KWJC(`U(J"HIL?YC.9_W8CVH^*T]-OC_8']6D M/A5%5OWW8O/R_#35TX^!G_OMKND&@ODLN-JM]X4]U/OR,*GLYFGZK!]?3=I) M>L4_>WNN1^>3+OFWLOS57?RU?IJJ+@>;VU73N\^5F>O]OA'L+.X:K,Z_YW MLCK535E\F$PG1?;G! MOFL0#@:ADU)PN??^R2VS)IO/JO(\J2ZO^YAULTH_ANV[676#_:OH_VN?7=V. MOL\IT;/@O7,T:%XN&KK1T*UFX6L<+Z_("U\U09OE-55"J;X0<&"<-)`FO-4L MD29RDD6:&"?+\+ER[X!O'"38@8$.#'"0.G=[T<2]YM!K%`X1PA"A'R(5'$30 M000<.*]]@32$@\0P2`PZ](FX50I MX:%W%0XAJT"LV.7Q(C+C8'%"BWS(!HS'(LJ_3D5Q0 M&://@&IRT1]$-RN-B84FWV#V#6"?W&7"^*VW284"87"!,(!]%^90,3""S*XBAA0(-A=KJ!(BB-\-(,JXK81#=S#>A^!I<%0Q8Y?W-AMBOG'$,*B<01F$H?\L8 M7&<,:`G8A7H0W7RB"5%PZ3"H='A$^Z4CU0Z.KT!$'+G9!*.-N<)6VWY+M)ZL MRM.AZ3:<1J/7;==GZC;VG/&%?EQ>-D\_W_P]02P,$%``` M``@`,85F1WVB^ZF2`@``D@D``!D```!X;"]W;W)K&ULC99-;Z,P$(;_"N)>\)BO4!&DIJO5[F&EJH?=LYLX"2K@K.TTW7^_MDDH MQ8/4'()M9N:9,9K7KBY"OJHCYSIX[]I>K<.CUJ?[.%;;(^^8BL2)]^;-7LB. M:3.5AUB=)&<[Y]2U,24DCSO6]&%=N;4G65?BK-NFYT\R4.>N8_+?AK?BL@XA MO"T\-X>CM@MQ7<6CWZ[I>*\:T0>2[]?A`]QO8&5-G,7OAE_49!S8Y%^$>+63 MG[MU2&P.O.5;;4,P\WCCC[QM;21#_GL-^L&TCM/Q+?IW5ZY)_X4I_BC:/\U. M'TVV)`QV?,_.K7X6EQ_\6D-F`VY%J]Q_L#TK+;J;2QAT['UX-KU[7H8W!5S= M<`=Z=:"C0T)SMB=E/"/?4;,36+KJZW3N3J#*K;W62 MY%7\9@-=;3:##9W8P&@1F^@C@F*(#?7 M+7>0+=12H)0"H=`9I?`H"X6L4,0*020SQ`HI)($2QY0HIOP"IO0K6:18(<": MC2"<=-YMQ/O\`%&Y1%IH:T!(V9P$R,X!6>@:0+O[`2A"\A2$>C6ET41G/H-P M%0!$!M)B#D)T8+6`P64`$!WP,;X0W"UR<"$`3`GFJ@:^%)01RD!``";!0``&0```'AL+W=O;&+\0[0`TONDI!='OY5R."`DRA8H%D]L@%[MU(Q3+-62-T@,''!E2)2@ M*`A21''7^WEF8F\\S]@H2=?#&_?$2"GF_PH@;#KZH7\-O'=-*W4`Y1E:>55' MH1<=ZST.]=%_"0^G5",,X'<'D]C,/>W]S-B'7ORLCGZ@+0"!4FH%K(8+G(`0 M+:02_UTT;RDU<3N_JG\WU2KW9RS@Q,B?KI*M,AOX7@4U'HE\9],/6$I(M&#) MB#!?KQR%9/1*\3V*/^>QZ\TXS3O/P4)S$Z*%$*V$<31Z?_\6`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`Z2) MAYI'2".&FB=(DPPU*U=CC<[SB+MZ`30Q.6M\/47G>6+P/+$N`K^LXZ+6000. M1^!.!!Y3:]0`#>5PE@#.$@!9K!%[[#5QIRD[#24LBB@AR)B$<*X0R&6MR[O0 MR16&I/NS%I4KC&.:X#5%<$T14)/%P7/DI&(\$"%#<\5PKAC(%<(1!!Q!`!$L MVI;"'4%H`%>NCB4"JR>!ZTF`>BRR5XF3AP>$X(/7=E6P\Q$@F;#Q!T04X8YB M+98"B;`8"/[4Y9\+>P9`$442(5V"`BU`,#L1U">P.T(:!04ZA4!Z#44:``4Z M@`CLWNN233FG`;Y@$+0IP+9`UC=%D*4`LV[%O2BX1(F)KF\AV1"\*<"WB)`8 M")(48-*M&(`RHE&"5LP0*!D$I=615D8TF-&(#WO2,!M")G/)9.AS&7LP`T]F M9NTBGHQHT!S#*_4B<#((SAB)@7#'7.[TT\<>XS]G1(-DUV8"X9@!'"=V/S8B]]&)Y$(H9@#%";5S02*&)$)0 M9P#JB;6ANF=Z^W>E8FRO[H+N0+HPHD$;9-.V2<;R,N&Y4;#=U/P&3VOT):1& M_$S8N;RY-V3Q[YQ_R(?OVZEIRQI8RC9"4L35Y9,M6)I*IBKS[Y;T7TX9>'M_ M87^NIUN5_QZ7;,'37\E6'*IJ;=/8LEU\2L4;/Z]9.P=/$FYX6M:_QN94"IY= M0DPCB[^::Y+7UW/S3VBW870`M@%X#4"X&^"T`<[8`+<-<,<&>&V`-S;`;P/\ ML0%!&Q",#0C;@%`)L)KEJ!=S&8MX-BGXV2B:-_`8RQ<=GL+J==G(P?KMJ/^K MEK.L1C]G3N1/K$])U&+F#08[F*"+65"8L(M94IBHBUF-X'D>P?.B8US;[F+6 M%`:N&*OJV[5Y2#8/:P*G0X`T@4,2.!H!VDKW%PTFJ#%YC5'FL1I$O-Q#=,IT MR3)=8IZ.4F:#<6]2/+B^;:M-7[I:*:X=HH9;$7Q!Y&BX9YTO<#ITG?EYY/P\ M8GZN4H^GU0.^Y_8F\LE$/I'(4QKI:Q.*`D]OY&H8URDH(`L*B()\FB`D"4*" M0/&&>:A5*M>QO]2(S!01F11GF%.8B$XBOVB4']HZ!?34"3V6"KJJ`51/A?]L M"M`6!(0'ZWD1_0CZD]%V!;I?N8!J,D=+YCIVU)^+]AP@3`<<-9?N$L[= M)M+Z!\(`P.VAH)4-A+1!E78+ZIB(INL!4+<86M5`R!IZ9`VTKH$0-@1JJ;JR M(;KC04`K&PC9@B+M=0N2^ASN"]+B1DK+RA(N"!!&BDY6`Z!N M,3W[#UW\>/,]Z5+0DL8Q6Q`P)2GWMUWX3Z=_S!\?0-T9(`TCLG`ACZH.^<"!RY=;)NSA+'>,]^Q,4^ MR4OCG8OJ6%(?'G:<"U9QVH]5ZP[5&?GZD+*=D+=!=5\TI\;F0?#CY1!\/8G/ M_@)02P,$%`````@`,85F1V*GEM2=`0``U0,``!D```!X;"]W;W)K&UL?5/;;N,@$/T5Q`<4&YI&BAQ+3:JJ?:A4]:%])O8X1N7B M`HG;OR]@QYOU6OMBF.&<,V<84_3&?KH6P*-O);7;XM;[;D.(JUI0W-V8#G0X M:8Q5W(?0'HGK+/`ZD90D-,ONB.)"X[)(N5=;%N;DI=#P:I$[*<7MSPZDZ;G2%U4GYXVZ4#!2_'M8A4YK/YRLZ4A;)M"10"="?OM? M`AL);$8@@[/4UP/WO"RLZ9$=9M'Q./)\P\+-53&9+BJ=AWS_Z>ID5Y5>__4U3_/8WZ]\^KZ:;95ZND[-REKPHU\5ZF[PJ^0E% M52:[27.3U7GSFZ_7O_W-UW@/WW>:O*G*]4T#]\SR6?O7RWRUETSVTV2\/SIL M__ANNH8?1_T_RA#>Y]=%LZXS&-C;;)FWKWKVZMWY^[]ASF9%>9U<;I=7U:+]Z]6T M_M3^[GQ3U[AT+XMF"D_^2Y[5N!S)\VS=&?'N[FB\.QD-#.YEL9_5UGIQ-ISEKJE[3C-;9>M/9P;]T-U6>\*=J`926 MU3*NSF5OJX$;_YPO%KO?E]5=F5SF65.5,-173;,9'FNU7`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`]R'\65=-'@W;/+)\7TZ*S M44P<3>]V]5^[:#&RA]W[A=)EYR+#7V[R=0%"L$%Q\R3Y>D"M;%%3V%G2!&9( MU#6<$E@ZNK\CL3K4V*6'>U2*H;NKAVDD0[<+M=US9TS4CYUT?/>C9MQ[ZV/' M^[A5BL@(5=.6.$4A15EJR>LH"?P;V+BL1: M_S&N!X;W8D`>G5<@BV"95SS$H%]Z"S(^P<.X1)T?=CI-+G.RQP-*[P^FRV+ MD@PWG-C`HO1/!FQ7O`MH9TB<(ATD\[I:ZK5`2(,B-ZQI060T>.&`#B)4=PVV M<@*4#@9Q7ER7(H*G6UB9&A2OOEF^S=>]G/Q9UA137M5BL4'B+^5*.MI3.5)( MT`\\]W^&(=W@@[);6`\P$1]W$#^6=9XMB$/0-'<6-&481':;%0O2LV'>1.6P MBH/JXOEGA=A]1QZUV)>+ZJ[I/^$=7<[())O"ZOS[S8RUF1=):ABE5.P M9,."P[?XF51H.`VW!7"&Y&J;[&P:^%"43QTYAO=T=)_G.4Q\6K".1?2_1)/[ M1_JB5Y_:O3N%,YR=YUOLO(:]RJ99X7* M$+CU$=3+CR".ZI:`U&.:H5,=^E3!(?/@80HVK^%GM.JWC]^X?MOG,T0T!26H M(;W`,;T%]O_UUL0$FF^$JP([EQF\GI6V^V^Q%0JKXM>J M>,#L7Q8ED-G]U^#(<"332!GH$88O/N7UM&CH8E;KJE4O]WZQ7"VJ;9ZK\B=+ ME*Q`UV1A^R!BF#]@\#O/\RFPOR9_BGH&?4I(0E'N@"+`)VD;T$B M7X"X6F;3?,,&0XH;M)?L`!^!9_Y-+O_YI[\_!6Z89,E5`>^;WI35HKK>$F?% MIZUO8!UG>0,#@"<@O2U!TC5>JVG`]H0/2;/,%HMD62WRZ08H>E9OKAN^_PKG MEWR?;V%'?MPNB2W>5HM;.E0)#FB5@9:-&E!3T*F<`9GCH=Z+IC9'CQ\>6[YI M#>1&)Q?OJ%'>ZVWXV+N;`K2OQJW%XX//H].2([L>' MWN39[(=-5H/.A.8!"-&IW;.I;[)EFKP%:74#XKR&O2VS^%T%*%O7^):&Y@^S MG18KN(PY&6P@;EV:3''[82\JN'9U`U_0E`NTK#'`@7KEEL\,/!M>YM>LWM,)GY.*T])>89=1EN,_Q!#AJ:0>`)W0 M5HI-'40:,D(@Y[5;6]Q>U.4+'DFSF:.3@-U$P%5`GX*%-.H@LL$G&:-S<@0W MX\EH=)H>3XY27%+0F^!BT"'P5GPW.O3=\&%?*S2X?D&]W@/N$Q2U:`8=2;N M]VMSA9KU&I@GC7!;P9-Q`7#Y:?0X$WC"-\G.Z*F.=K[!JQL@03A:%5DD+'`^ M[EWN);]#HBUIG/,-*^UA=G`2EK`P<,=B0S\AE<)CZ'(<90TBKODVV1D_1;5_ M%_@J*DU)C98!:BAKG&6YD3>6*[JS8+7$KTPPMA M+T&Q!G$-9QE&,7D*_`PE?1:<8N(,L[/&SB5\/VFT)JQI2'Q`2&5L*A#_]-0# MF-L53<(]MC-XO\/9"O4!$AX\"1XXFZIT*7OZ30#C\80W'<+XX$=T*<`#0$43)T+PK<]`6,A;@2 M3OO2ID!O>/%IREHTNIG`XB$#J$S>T+I/.&Z\EP2_ZV(;L\0O6]%_P(+^8]?S M+3`>##$E1[2DDY9^@-S,^"`L'\DX)XL^(^I0U0LN*OB0X:%)%CFI7$%*P9.; MS0I#U3"FZXJ.G#LIZ#4A=G^!)Z]<\QK@0*?>J3`WG;8)[@7>O)SI0$U->)2G M%=5P[FXJH*-=$/VXI\#F07C!9J;)'R[>)^K-N]Q<):]?GR<[H(>Z[U`7W8LN M0N4*76)H>T#-W=GA_8%'55R'^)&H]`B[LI^VX?SY-ZU6&)\`I5+ M2D<;7I+W^721@1B;TU3Q:)Z+DMN:QY)9_O!\E/?4]D32WG$>>(#Q(PZ2(L$K M)X#V$O/?T(<7SG_CA6C@4+@R!<97NPX?>,D5.1&[A MN#2,`],EB;B0&Y8L-C!P=`6GAQ3#L!-N(TBOP?0C'`$E8ZPI2L82V=PN"5B" M<'1PW69J0J3)D^-]\B#'041*+T"Y<7D#)%A=%\E_S9:K;V'<>VGR>@WB%P6= M_DARCIT5?!I5Y.'81OSE+V#.X@^D%)9],UBJ>TKX]&:4'^^,'K5#? M5$&DH:<&*8&G"N>LPIB)5U@79`[GGX"CF\R\VA2+V2X8M6JZEOE=\JQ`?\#U M3;8,EM@\FXJ_"[EE(/+8`X7?$^'?@&FL8_D!>`Q:!ZVST58_"OI:+P&I!F;V MUM3O1I99%@,$*[H:V:<$.G(A%@C,`E5F/B?5U7>BY MX\)Y:5#Q9&;$G%X)15ZN*$*\%>F MHFUWR[K*5N(6I3"<^#+6US"0W:ML^CU:/&XPL)AHA*'VTG15^BYQ"HF0"Q*5 M2#5XD0AV=??=$KK5$W-HF8$8V"Q)>[DM9CAS$43;((906VG$E2UD:K$_.),80L=S9CR7_=]$*MFF$?[`Q@SNIE$PVP^VR+"B\P6ZD.!V>&G$ M8)`/PUAB"L9B@-EF(4?3<[:VA*=A3RL4JV]V?;.!!;^M"O*& MD)++KD[TF.7YDF5CH(VZJ.B0XB!L2V8TB3,ZB_"8MN-F5N4-J;178%2"T%.G M=A9,$#W4?$#=TM)*@$Y<-#@^X^<.95'6L:\#X=5+%.L@R3)*(N1\."Z^Q M%`I:>A>T$?=(_T#\DTSS;-2";.\;KH!F9.R"5-U%_]5>TLK?D/@\O[8J.S/" M-`@8WH_JDV@G;:3)IF0%KX1/]FC*ER@:4V!YST%A=089Z%;(AFHV&5DL3C.A M\;YGW:"/GQXTY!7EV"=&:1:D`!7Y79>@4$B"F!;U=+-$IS\).S:O><-R6;`&RI1?.0'1&9&*H-@]1 M#I,*Z<9,*<502E4PX1Z8T$<)7"2&ZBBVLVF4I:![`0]0`I16KLW``S:[OJE4 M7_0^*5S7>L;>L0Q8^7J]X-@(101HDV.ED!Y1U<4UA14=,\SD'F?2:(`G,H.8 M9)#"EVR19&LSC5C,C/52,X]CLY1>@TO@;,[,HGT]P\T"`Y41?>D[%B#9R9P" M)KSNL8IB=NQH4ZD=LXYZ650=T?B@YXB)'P0U'$3:=*X8:39+)%_1FN/DI?LX M-48%MRLY4IC4LF1;Y]X'S(M/1-E"P_$DXO5Z3=[JL84*PW-O"I@ID,D6+W.6 MD_GTU!&%EXN7`I]_I0'>ZHJT=M(I09F9KB4:*W\4Y6J#^EXXV#]L*IP;?#%E MZ[P!-6"1U2E82FMV1-*A`9:91H8]&31D:[#^0BPN?AH9AWHW_BS/;C]''Z"N M17HM/]P<;[9&/&&.W*FS".:78V1-5`1R?>,ZT"CX6(%=@*S)K3VNQ%Z?#2\I M6RM6GGR-!FY'Q)!E/TM'H%#X#?HP,'%PM^.[E^LT>$X&1V.DD.8^3&OU?AH-+A6HU%Z M,CE)CNA-.T?X'OCJ^&34NU:'I^GX%`_P;;=,;>CZ9#11V)F^SBA MC,/EV9R<+'J'Y;7<56(WX4*?3)+Q87IP>-J^SUVVGQ[M'\!^I$>'QT/4AQ1F MR^<+_^B(1W6!3??W:?R[2@Z2XN0R$J^MKWH`BM^<;?;Y89%JXR-TJ=^ZTU`W6QI>)_<<4`.+3?U>A2 M/J>#I92/2@QZY]QOY*"C,L+\AZ(&X^KC'Y/7Z-'`T@MTY'U\S8%%YJM^%+AF M.0L67@U3II)BGO!*L?,1UQ-)6U0##7_`?L*3"M`59I1OB+'9$/T2*^WA%!RK M#3<9!T'"H7)C[^7CSXH%'JZ/Y15_8+I[S&X9YP'Z/CBP_P]MQ6A\2M?C_WN6 M?Y2>`C.C"^B3EEN$'8"CF.X?CMP+@<.?'O8PWE]P;N/T^/C$_M_U`K,3>)3N M'X]D\/BI;_#\2WCB)#TYD(I^"B*!F3\5.FLV5[`H0F>//41?>&);V8-H&#?H M_EP7ZX5X666H^M!,':V MF.)M*A59^W4ODL?+>J%KEW+<,"JFF6LM2;K798QQ_6_GYYC/?"';Y)MA"N_/ M+E[]Z>Q9\G_^=V+EOGCD[S_;)N;X>O%YYC/_Q#E6`"%CN:ZJF;^:+*>J_IX= M9)1LN>=>7C0<)YQIA`F8AP0.8(73R&`LR0-,H=JZ6>\6F.I`GS!<@,SSY:N7 M[XC!LN68DL^3E->8MJQ4@4 M,V,:C.=3$*W`L@XUMF:L6W-28H*5*]42[.&KO`0;@RXT%QV[88);1P,2(>A( M<9I%03G$*RH#!II:<=IQ-UEN+_G(%W5^B?D[9P9Q5A\JZI@MD_^P"?+VH:M( MCOEV<@S>\8=-*4%7$(*QPM#R=5:+F?>:A<*ESU(C#`X?WA/M03+K8Q6<6TE: MTS7(%3[%SUF/XI/2D^N#-[Z$5[/@Q`3B,UKOCU+;(K[,R MK#USK894QX+]$5KN-T[+_7/,!8*`.SK&Z@3> ML-_1AN$/!Z.C!`L]_`'46XY`J;V`>6LVW6M.@(VC?TV>?X]%1FM)U%S+#E7L MI2`/%^41ZCDFRYC&)D$539OE'"EYDM*Y;`&>5S[ZS&H_7R`96`4Z(0.'R)K@ M3+'@(3$,NF%&=4CD2=V4DM^[9W:=5G\.)"+D)2?QEY+FC!(/'8Y&TXU24%'/ M=E'*;Q-8]EE54Y*<%MH,LK\44XTVNLGBTDPUW2+"0C M7.)"J)E)\$F/CQ2E-.(GEQ3*TB\:DK!Z-2E^*A%"C"9RAA![&EMJ"("[MEMV%A25JY)+Z\EKQ'J6&XRF^RQ9P+4=C)H+Y>S@2E?%MZEKM7 MTZ@<5R,MRPZ(6M]Z*ZUU;(-P>&:;KW6-:>5FB88,[@H&W6!?'[KM=0L;T1&6 MV7>5!A)MC$S]=:,/C-ZZ-`4:"*XF@YK2C76Q;(8QA2VS[^%'=5\V/)BX"%+R M6,A0Z_'T%KS8O1E7I@*S!U/)(0ILW!-[P52H`@6B9-%N@**V*F_#F$WJ=%>* M:Q=QBCZ?#PQ5RSW<`Z:5+5>BF@8_;F<5)'OL&V#^_RN9YP284A"W/0=>2\Y+ MJU]_5X.LE$Q8S@$]?_^.K>X>.8V%O/H((K_J4S'EDK)F#7J\R`&[9HUN[>;; M[D"DNE(2HIMB+7&DUOL^_R`]O8Z?,MWUZABQL`=^"B;)G?G?X;13\9+4KTRY M\H&^4LE&=0LT"OAFGE.6.&8@Y&WJN.)"M743ML4I?*UY*1N(B-N12:/%)'SH M\SF<#WTR,697CA+8&0>R,I#UGCJZCFFP6H`S5H(!:&A<]0D&DQU,,(%> M8-V(1_)385ASX5O$VV-A*H^EXQ!8/$5'^MX!&UCDSIFH<^DQCIC/*<>L2;T* M.0^@J@TE)=[C7>MF5G9EA$^HA'N*NC^MLJA]8F4(FNXIY,J'[)/HCZKT;#4$ MBSIGTY^^ZY+T.=F0GK7&9V&R`FM,E#/#)OE,2VC@D@&(@7:DV&39K,!BGIR" M\E?Y^@Y%_&`B/SS^2BOMA]XC4>EEGF%VB8])YV7&YC8\IK82PT5VY\)@+9L< MJ9#*>()BX@?*$#?BV:%BYV=R?*])-+XF# M&25M/%;8PCULH&"T':P#RBJ`-P$78!;2CR6UAP&H#51MY6[6 MY/9'/,'>S^LT>]2D#O8,`?$].Y6LULK;0N1L:D)E5SNH\R!`HX0JX+@@Q4(M M>A!C3R<=(5OMJI;/AA<"SR]1H]:QD]/K,U?S0UW!3G!I3$'E1YU)V,'ZFV2G M>$I6T":C=+-`5]_4%)J%=T* M][*&M%CD-7%6BM*K.^UJLT5BUSP&JJ-E!HF39#5NI[A]2GL"/$89.*\+V')P M&68M$)_;2[I05,QY(ARHYV[GSMS.T8_O;?-T"X@DM!29M0`-IHDZ`]]0NI7[ MFS,[!\B%-.-6%EMF1!C8+&XOU1*;;=R$PBK5'F(CT M5[D,2U7'W:(,>"RE&\%2HKK%NHA!GG M)/D083-R[TC<8BOQD4?P8\TS4KVYN/QU940M5X+G4FM8OY>^$0(#;C;G.HG5A]*(_;`V3 M9!DN]0+S0HG!M`RLDQ8Y*&JFN,&,_9&X*IS'0Y_JYD."`,_MSS_]C4#2=K,% M3HITY)]_^KMRV2DH\*!-2'V<)K]F4I^;K0<9,-5JB'01E!0LWFYZ]N+RP1(D$_PJU7>@' MZ3SB3K,9XV?=:7)$,>\0S!W)&HR+U0N).DE85T\PYY\Z@K+<4RYKG)(!$MG" M`MPB1P3FCJ1$XY]+VH:X9EO45PU007Q9E_QZJ*YH6@+5J,\B9EYA89E"KT5O M]4+2)?3(]!X23J2GU^4:AQ1QY6:`@94R6VQ_5'+T:I5W//M[0B$(1?(Y@O#= M9G;-[(G5O1;YHX\%JRTC3SRQ(KK&YIJB'"(65M4F'Y2;28(W196SDC7=?LE/ M!&#AS)8SA$R8&8=B,HU<)6/I:3 M*_*21`\Q\BLQ12:_:)3J_F4'.+I.JDU#N;H-^YE4ZPL`&QF0"N)A8\T3;=5F M!7HDZWYI\#6U-$8A)3,@A(X$-&+=&9:UNT)BME,HXF8DTALFZH12UMU>GYH@XA[2#5B)>\F;SFGK,;Z"=:(# M)E)BK^<-)K,HD8K&@/FSYC)&,;LCIFXXW(7#V+JE_9:Z;PL)QD^.[[X+15DM MC5=SB@QJK6.^J.$L0S*#,V9*R%ZV/1N\ M?VO6ZAH1/*@M^RNBC5C`<#R!L;HV*QS3D]&8>$(+2BM,(DK<<6&"UK([\@D[ MZIEY#S/!S1:EZ>7S,ZD.7^7`([%@7TNK*%9"NR#7OG@CU^*0.32B%RH[`.;E M-,:MIB->J!V*/U(.SC,XC,`80\8B,>F,^''TC8'$#+R5KVJEDIEE0TH'NS=8 MK5?>$[P`)!X;S2<\N_R(^L'^[N@X=6?O#;O<,7FGQR_WWJ<^.@+$84MJ(B+" M5?/=537%LM6^<-UG,J?;5-GBPX^K_`+%T$KUQ,[7D&5A*,B-)_06PHR/_N'/ MSXI*03'/9K>H>/S_[^O>_OS2#!9_W M-I,C]4I"D21-SM"1=\VRY%5)\%ZH#3U7T$\DO[>OSEX]U^>E8:';"GJ41=M7 M.!0V3K,E]EJ9I?<[=`T@+4H39<5Q/A(*(?E>16T7ROTOLNPYP9#$7? ME7G=W!0K=G>J/*R=W2"F=C=_D;RF%IG5\CQ\&#L%"2P03#R2+^0UF6%N57&U MP9!G*J5$*JP1L7[W@U1&]#%C#DQ1T#^L69QN*QNA@KZF'>IS#K.7KL\]G,HZ MHA-BA7;$+!66@%:HN17X0`:_0OH([\Z]8T>W5)QEH04"F"6`(*J,,,,WUSF( M7X)IH)I=A`O0+;["0T,&3N$;(R44C0/[A?EE>#+AC2G=17@"-Z#- M3U&3KA"G`A]^4S64`=H="Y23GIIF2D(78O'>$JU:#XE9"_YLS*2.,JM M4C484:J?^K1,ND(#U+[Z=H5FL,?.;Z+[7+URN[B*0F&F&D!],B?:A_)Z0/C(%;` M[U*ZP88#J@2LJ7U7^(E(6C>Y(M5XGSHR356N^RN MJ]W@?_9Y5[P66A2@/-BS0=+O@BS0=46O%R9J6:XL#V+&XY/,K(:K4<7O$QQ$ MJ!L&2+RX)K2?&_#^2-UP2%P(EA7E9UBF"N8T('^WRK?*Y$J,@>/'(096<$^B M+;0H,,T*O=Z"]J$:!,=-/0M25=L84F M&SK_&<(X]A-[M(OVO%(-K@I&D@067*`'WJ&N.D/I]4(C`*:)QP(K1J>222/N M2WN<1@_)'2@X-)LF[VYV^P1A:.K*!G3N9-SEY_EDS`@#S_1EWH'=!CX(#Y)# M1?P\];9]VJX^?"]0A%SDDV8H-6#L!U0E9KVM&DPW\UIO7?;K(BB7''P<8 M0[2^/K=F37E\F@ZD6019:.2AY>X*I$9R8N`EE!]S%PL^R];3TG5]4+XHKDGF M&\^Q@!^OA>@H5,;/X2V#>Q.V'P,`:?WFG#(8`H5Z+ MU"]$`GE#'5_FY)JD7WS'3B0O"9G=IOYB-6N#,$R]S`ND3\E2;*7`\5LA/K,( M^,"7?1H].3A2VT%=[9TK(%1%_XQ.C;:QTQ?"JFGR9:X@!T^CP2&6BH'ASO(E M33Q#J#I)CO)S[PD9Z]A4WJPV5PM7IR5`_5&^8A,?0:M[4R)VBA$.M,P7;7$B MT8YH[)&V8IK"OYU0VZP89S_.ZA5PLKB13G:Q%M>X]P^3RR:H09R2!)WVHQ%]*E3Q"=T/O8`83 M_+&>$+P,"BXU8X\2;S*XQ*J.?U,0K:M:;D!CBHE4___2W5V^X MD.TE98U?2%+-<(E1O)1#9J&70!97`OGX"EV#N1,&Z$^L<1(B[U@O7/E.2U'( M2A_@JG?A;,RIDPDA'QD@?=LTD<3,>0U/JBXDD97 M>+5#$5K0/$97$A6!Y M%]Q`$R$E.XSCBOC&AV22TH5<(/F!;I1NE6_Q7OD<*B?#IVX/2@(C.#H]#;61 MZ7AR)'^U&E(FH_%1)),8.$/)KC@HP"X(-<]24;[Z2E!IN#%"+=P,$F/ M#A&+YH2>,>BS[BOE)$[Y`+>]P]@3UWI<9+H7OW:@@#T@V_?YFKMO;D60_`5] M2I2!=E;6E=1UH]E3MWZ(4.$9Z^:ED$=%O6!4GD!BEG-JZ1Y-$QA,1[;@9S=Q M,I2ZSP2&W_+M.C'1:*F[R311`HUFDYI;RJ?9N%+!!^]3!-W*`-FIJ]^D'?*Z M/[`.KFG!!XOFVK3J=_4N+?U)7>PO[53*=0H=D:-C%58:2M$D@$`ZJ:C(:"IA MBS%+>G(^2RG8T1225@$U^7\-_SF)*K+W@'TVO707SS"JZV,#*-0"6O&?WQ.V M'8.&C3/$3.I&*%1OZBP#/4;K=MH99!K#=_6P!1)-B)Z+J1#7]3HEO`[>R!3C MZZIUICY/M;T85;G+;5>X>EC7JUV>VXB2O-AZVAQNPG.3]>75NMIR;'/-@,-: MFG:V`,$(7`_K^'*,LF*P@S6Y-]P)CC[_)0<-XC;#B`,JS*ARH.YY]N+\W1N. MGKUBRZ5PY:`.(?W5^]=\F5IG[D$4K&S MAO*QSV6,>V;5YXK4HKO>6?G)]TT+%0AY=P3XX;;/:1!?*>.`&.2W;?.R7$W"ZBF))J% MQ74I)L1#9%D"6`29@ZA\AQTVZL`#AA5#;GIL#.B:MT;1])NU/?.V(KFKW+7I MG@F0AQHK%E"(Z83O"10UB()+B3I%5$T8^F52,@D8IYPU!5QO"DOD%D:M2@<< M8'8Q]U_F!HOGOO\R(GI0SZ[=*%LC$I77W*^KBAO8)AF'N:5T11M/\"64;LL7 MI#T`S.T%?UPNA?=_1F6>BK`:(:#VC;EH7`@XI($_6X!%NWLYO:DH<+DRMREE M]6"[S;X7W#?YR$^)KZ"UY&@^EA-&Z>H2C;5.:[IM/6VS&1&BG1^A"ICD8]<9 MIA3N(DBR0#X[3L9^X;;`M>66Y9 MQ3/0L<:3X/Q*$#?NP5B8X,O(I"T09K:+C2"V@["*T+Z9E9)VM_N6K?I0$Y42 M[#!7\6!$W^%'3%F2*!V5VTA:KCS_418P/WZ2GH!-1(\',^GDH._QS%W4Y1*Z MHLO6?:ZOB>IJ;,9PYD0'/NG>AP;&ZZP#8Y"^R9'("7':22%,7XWJ,X'UN$18 M#^/^P:!C#IH9CJL'P#>JOW4I@KT#=W7-UF@PQ@CG+)B]I-M_7H@K-*WCP?G9 M=D;$%#/:)XH@7Y@"VSR*\E(AB/%IYT&/(C'8>=J)*68)SJY]MOT`%IF1`:CK MOL5?S^+>F]X_^-Z^OCL4U\?+M&A-4JM:9-I*,(@0K\DW@A2TI?I2*2CR&(XS M5+,T%#PT.O/S<=R*@6]Y;'T2^EO.BH*+,&<_J[_'1`3M:^*S$'Y9>8C;2K71 MBG(]\-HO8TMMD2K/SJAJ88PSBD:$M)>Q19[E!X='OAL?(*`C$/E<]G*'OZ>?T+]EK.Z M,G%ATHGX.CHZ-H!*6G1[O56A27TWK!65>X4V6`.`/?=0J=.68*412R&"F%_? M+#;XF.X+0W\Y"JJ!QC+4#0\$KD7-A+,N4D/#NLW7Z]_^YNOF^*WO\'_UK\E)CU.=@S&3SMG+=NG,$$/Z^>N'_-,:%'-XV7\;&`NYQ0?MFP&*Z$%M MOJM8>94AY,O5HMKF>:RVNB;T],X074PNX"?VL41?13G2+_2A?/.%PM+9O2\N M+R[8ST+Q?@F!8JYMMF1FK?:6HG-R7USKP,DE!QT/&\<8'3P)W[H5Q6#0T##E M"AE\>GP\27;@_X>'5*^C/[85E/-Z_YPZ<]=-[2HT&F1NYHX!?/SF" M,>W#V([2R&88A??FP'UM`U:SK]M@_2D\DI:2L4+T&$&GMVU]!S(\** M'&EQ]R7&.-N?7?_K4*=(G$.V-G-S$'XWH9[/&!5LOD'A='PR]FM4Y^@!FS&W MXWU[34AVPM]'\/=!>C0^EK_!K'HR3@_W3^3O$R&BTWWYXO0>`7K3L]ZC M]/1DK%A`#UOI?[29&ZJ^<.<2:LA&P/1D0$@#4H+;0Z#1WI=VB^7V^KF6%^OB M[?DBZI(\%F6=E%./JE.ECD-T&8(ZF040M^ZA]$4P\2]I_ZCJW,B:@&L'N:)",ME+6+4/R@=$+HY=35<<0=6=]R(0WU&C32L\TU(L'A0&,%K-LV`0U-C%2G^Q-V?XS2,?#S MSYR[MKG1'3=I7ZZ4+RYV,#`''UCTP'[#VL,Q[)W0CI^FK#EY2&1EG!K8J=\D M+X"][YMD9_1T>+3XKG<7F\O=40N+,'7\1QA"X"*]5<,JHM)D9_R4*A)[T+($"\<+P8!D0^."E)WV^.F02`$A#Y8:O*::DU=]#\)U74P% M($N^G&W+;(E?8IT5G:I=C8^2Z^'9^;\<3T!/P:ZWE(\!M%HM@'1S"F-\X9*1 M1-QP5OT`:8S[2:-+RT(L1.[[^W93=$R&;V.9"F=13R#FW`Q('TLV>MO5A\/$^3D:' MK9-!B^\XQ"&,]I4EH933S78"PA>CHEW4FL60F.HTO(!CN[`J!,%LNI6CKJXL MIX'OFJ;NF_H1K(;9C$*2"KCFFJS2?*M%JP%;GS!5*TNR/+;#$RJ:2(T[XW5X M)SK.G]5^55]MM]W+.)V`*GV:'NUC?L_1WGCD6Y(/*Z,[HT/LX(6&'*5KW7?/ M%-]-S61&=L-]1+@S2BV]0BIAQY.CWNO# M0,8GP$9/X-K3/9BXN;*[7HC3T3&LSO$IM_2'GO:)`P'$*!C1B4$HGU$GBZYG')73V[)UR-;4 M$,2'*-&RMS7;]_DV6G7*_FI9=C`XGLW05+YH-05Z2\W!13'/.Z%.W5S=/!NH MN&JQ1LK96'UC4P,FG$UJ#P-?ZOIVB>]?^72R$(J99QY:]S4UODBQDI/?J5R%WN'LSM#R0!1):ZUM56 MAY,!ZDA;8+I>@Q(8-&GRG*B<\Q4'6`4&@W;GJ#C'D;M"N@@O,;5.!JP;AT%. M:XX#(_HQKZO=:45BUE4XD;)C;6=9OZ(C@?'$R(0,?A#:.!.-9S+(,W/OS*_[[']7Z)ZVUQ]/>XWB-X^J_@WR-\SGU> MS3:=204(QC?8^06';)0>'!^:_WL>4:KXFK20P0M%=,TYS*>#TV-]ABC'8==Q M%ZP)2&_GGKWDA1:R!8L=JU2D)/5'+4<'*3?%IEUAQ>`V1/T-FO:T<2N5$UT"J;\+"88R-T/K" M#'5\/<^?6350&7P8]%"[A*<(?(!E&XE.\:ZPS+'.R.D1H;;]P6"@I*C+V M_O-/?UM4%;K3I]^C5T_X('GQ._"3#U&Q]GHC'Y-D]_$`QN>:/MM^9/PDAW.< MN`C.9Z,Q$U*>OWQ4CZNF(`1,CT6SE[S3@(@8):U`3U:6U8:P21^ MSB.&BI"X[PC!PUP##29XH]I[F4^Q*+3F](*+&I^8S[`1%#WHO97LH-Q`^ZNH MSNLMHK^'FEP5HP+CG,_:U0?/SO_EX&"RS]A#JVK-!<,NNY"1DP24A^)_Q##> MOSW#TM";"FST*"EP7BS`<*XW#6?=@?BUG0C#4F`$K(#*7(\.#F%/P"([X*1A M1F'305)OEG8GK5`M^V0\3D_`8HR!O*()B^SE]B=9&6MYHB$'R9\F5_@2B[3: M\D1V@&]=\F1RE(Z.3N_S$#KQ]F1TE$[V]UW-EVPEW7GN;I<(4=&T';I1RU)%8HM;EFHD MVE*IS/_6:4L8C=CY;/H`P^=-=\HNJ6(,.;F)(,)M8--%1ADWN**",9V+QS"N".VTJ'.` MT)VSEA`TU)8C6$@`5S4GM-66O4W<9^^SK:$O7'LDBL?'8("&WB567H3>RD4I MEZ]_S9"+Q:S(L*2',$0E1X@+,,O*,283&\%=2@L*A'VJ41 M*)64T\`_E`E_"R2-V@D,]GI176$'(4Y&H4F^U.K=6`CV-:WCG?"K^% M9M%9\C:_DX:GW%20QK/SU=OG9U\]C8"%9#(OGY]]"EN`9C7(UP!]5W$'1-^A2(;, M]JCJ+O!D:4P;G^T@CH5?27]1C^@B6):69O.QLTZ2JA8OEH/RG!/TF$/J$(=\ M6(\8-M->I>C&6J75P&91=MK.5R_>X'9SM+1G#SP=8'*^`D,)GD1Q+9#%M"*O M^H7B/<1!"`CPL[8/2[XCGU:#`3!.8%X2O3*O6572+0FCY^3K"/EIYH#*&"&! MT82HMA]S-0DUNR+\ACS52CH^DMSE5,)ZO@^=R4A7]S!X>GL9$DVQ5_W[DI/T M,*1IIOR'0LOV(N7^9P*9E:/P2*S83DO[8&?'6,].;UP7%--UK9+6,>`%^0"# M1T7&O2QFNT#@7%`;87XO2R.[`].>[74Q27DN!:PRW MP>ASVM>%#LEU/\!A0.6@G`V53F957DIB0K>RU+JQ/&Q%.NL`:XJ30)@/O`E6 M(B#E>;M67"N9F>;D6`SY^K`J&K6XD'+9T:W'!6E5V9R"F*+VJG2CO.\2B;DHZ7R,P-&HH4I/JA?)V ML-[0BL5@Y9:4NE]W>N9$;9'4*]8.P'4/`BM_JP+50JKM(G]3O=V]VN[*1R[P M2D/HF-*9\7&*,TX/,-:Z`%UJP8T1&@X+%R772NH#Y<##S6"P;KF?KQ9+#@^5 MVC9\I;4BL&/+KY[&QS]T&5?VSN<_"TVS\#4?X0>+&%1W>6]E,+/1)2T*/%J` M#GKX;B9]>8PJC=^WPF7:2H#'["N)XGDV-YG$<`IJYW3?KEC7@/8F\#Z!@K:N M=GE_$[]RZA:-MJ5]%O:2%PR8Q&43*)LB:ZW=`D):TL*(ZAQWG4=1N4>P049. MFR[9IJZ!M*(:+-P]/6+6YTB$%MM3Z=F%T5&RNWM&TFP07X?@C@HLB+GE8HA; MDO&>ILA-CS+EWJG/Z0L25M;$V?4-`>V%@@U3W-H<\RPHD`L:R4QL;$&.H>YY'K,=E^,@@I"O68N$?U72=9C+]M&=]HZXGJGO9H.9"RGJ( MHU1D?!"=Y0@:@55Q5@\SSD'WCVR?7.3:Z#F0EK%@A0M\!K-BAW+2MI(-GYAX M&[KSU8LJ?75P74Q]@4$3#O6&D2*!AM=;,P=:<[;)4KHE4X!;?)DADG M51?[+6M-RCM()D@G/==?4%U-7:Q8,QL#9+>*]=Q9S")VV71?K#4UWH#"\D00 MYEHX1.QA75(WJ`Q;ZBKZM(1*N-8\)R@=6+J+MQ=`63=@V[?!-H%6*J25,I[4,M), M7('OIJ5TW1@="7$UZ]&#;SWJ2,FF%)8B<*B= MJ9Z,L998X?>C#L?)EXR*T`)-L53:&%R$:U7V>U/=.P,-V0^XOE$2@58U9-?7 MZ`-=NVKG)X?IZ6@DKN9BUGKF$RZ8`>EYTX8KDNAG5/B`/EA-D2*/ MK`QTYQ0*>!VT;^H9U-X6Z;^N1P/6N%AWER`X`KK4*]D,M$4"$2HS(UR?X=5C MY9+U\^65D\UX+\^3[J78\5LPZ9-6F0/<">84IWJ,@) M2?U2'`S+32^PQ6\.8GPG9``_';1J`ELX)\@OM-^47^88M9G#%Q\I MK5[36BPNST*JWU(0E2R&O2T.%V87QL4/;P4;F8Q;2>@:-2HY5GJ2053<4J%Z;9+[J0C:D%- M5%F)'+=B'QTJMM<@7LA^:^JRA(LII&568=`3I:!0CE`[L-YH@89KUL1*R5+V MYY'0=_U96`?)KCEMWE18I_1C;QU\WS6?SZ(>0:DT=QUH+5I2+:A( M4\I+'*='IZ,P)+]&4N;HON'<%;SO()WLG]JY-5:A$1UUU0WU50@/:&X00S;#!E.1&<"U4G(>!E]GV4A M'B3[3LE/>"SU36Y9[D4#"GFX)??B.!:5RKW+VX=JRQ",_KZ MXZ5@%U'*?''M0%H$FM=4BFW9L MHP&SS]'!GNV`S2I2)M'WIPNDAUK!9P86G.ZGFXO28SG%B**BLW@L31J?O4W; MI7)$AVDN$YN0"1HK"OQ,WH):ACTH,7U-`,4NI.=+EP5[M"S/@E=U<8N2C]93 MHYQ%::*.,'.P7D3*))5E%][Z@X<`^UYABI$U3D$B%CRNR[Q$A_)E/J7NKZ.# MO?U?R8!1BQSOC_>MO;:'\`K)@1%JVAUW^FL$MM?/3"@4=3-L+4UY2\,G6-]I M%PO0B288<>L:_WS\GK;X659^'_(?SR0SAQ@-O.E#C;"_.:+\V\)H&@'8-;)\5^+L=ASBRZ5AQ)^Z.GQ[[@Z-DWP6*2ONK2O# M"X>1D3J[>H7A7%LA4'I&![^BBKNL+#?+U!8%_R3=J:!^CA0'K$HG&T8,,VWH M`&TQR^Z3OF10^CW$B?M7TV,+J_7`Y[$5YY6QNW"$#."O(Z:M_2 M8ZL!MYFQJX!B?3]L.+[+DR!=P0^-`K^<@-V[7*U`6]3D3B:>Y;/,Y`@H!M1 MLA9LH69PQ$1C.)XS"P/:"QR^Y@+SP,C]@5VBI`Q1>Z=(G@3O_A"8)FEIL6#+ M.\-U+*2+Z:CU>SW$H>5`S2:/Z]][KDWI8E1:L)K$LAX<\AIQ7"7ZSG+1N&-2 M;E-RE"2KK2RPN`,?X97I-28-^.HZ$4CX0'4C]9Z%5Y(D00O8;3@N_=S0=5B'\$J(K#-),)S.0_D:N2A^P.:4E@NDIWE(!*=1.ZL2T[!` M2Z^C_ECM]8U6,*1(1+N.<6[U#+J"9SKVO;**XBTFK_KD5$0/\2ZE_>RCCQQ% M0GC(,,YZB.$WF19Z:A]"UQ)X`V=?(USA*J0?E9VB"VNAB(HDR2: MD'Z,1G29*;BR<`->C#<;/IZP:,M);;.$?A;?\[XJM_/&S=DD7N"_RB(026[;PV6&$ MZ2CD'R#ZD$#P:'^?OD0+)OA'>M(EVCT)1>&CNIYEL:&DNX!T1G(&`0J-$-!Z M3C77:7;O[,SX<<'KLRBK')N/[3N8/I4#<\KSQ$21T8FN.RQU?HLL;KI6//W-$]D)M.L,P^466#\C7G45%@DT[+ZB^`UDZCEP5S MN8.K_3DF+!"S3T[3X\/]_EC;H>).BTGZZ^0%&83MB_NNX?8"C\$R.`S88O(L MK.*7IP6<@;[3,B\6''`;';+[MKG)%U34(]W;*NX0+5RK1#4![)G=B0N^O#B7 MA+%[[T6L[J7O9\%E>5QF0IR$T-S:CD;.Z21[FZ.JP>,4!_J!>L1;*5_,-D5Q9CWW(O M8Y^TPRD&DZ&]&!_^V^[%'8E:S%B!%_H.(V&$AH7ZGWU;/K3TNBSX*2<0'JP!2-H!W]]+1]9]_5?SV[:FA9.CS@N>LS+GH%3N:O M="L6:`QR#S]W2YNXB/J+-]BG;[IG(1'3;?[^E!,LK@I@0=.;DGM+3BTJGJTE MX1J+)F!P2RI0QPV2!%_4Q[`M1;.DRJ1J`=2$I=7UYEJ<35*2G\3AWAY'R@U40GD!+Z0$DPGZ>40U'_XA:IW7%3/B(L\4D*V%<;3"\@S!])]*%J MA-N\]EOB+6`F_.[UABP8`EMAFMH+Y'KCFRZB M>JI84.;1,/<+LP[GG&D()!O_$27NF:I8M)7BQ98;4`T)/17,GB6O$37;QI%@ M(1">5W)^H]^MP*ICHPYK)&CY9QQ#M=J7)Z,1J!63(ZI4MMH&O!7?71+RB@V? M;&@$H>\&E.WE3*\2+`RMO[/9K.;VE.CAEFM(E5M@0^+%ML4Z)0(H9<`:L.E) MPL?WX(EM@QZX,F&M4(P305ZYQ*MHXGZ_HARIJWQ;L05QC,O/BB@G3+8!JJGX MA`JYR%TTK,4:P6]IK5Y?"E+7\VQY'TA#H>;Z6P*RKC-RRX?:;@UEZ5F3R`35PURM M(^^8>!'8T=94((_IJ0=/I73#/[8S>+_#6NC=Q+YD1D^F2[G=)#$3/9[PIL.G MG%V<(ZB)[$7)037!7QML#:V;]:U64.X&8BCHS:<=\UN3YPG=T!J;"@ MC]'6*.^GU:9!M&4"4?ER)2A[E!*4!BTHE#<$[8UU$U0'^_43W0L,U)"FZ=*G M=`KTAA=J+9\C[D)#LUO3_3$FG$'F%TU)WFUG#Z?)'R[>1X[JUZ_/*64V2K'` MK*)VN%U`27K<-9]-4W7C"YE552L#"^&CR,+;2_^\\L M1BK.KQ,RRWQ&*H&:697$O*K6)45/S"'D>^5I3B_M=.\ZP69C4+YW"8&E+:@0 M&Y,YG-M/@>,HJKW,RNQ:LAXQ(6@%)BI2"!`F:#H*\"H-N!'F%)DS[@2!/W`5 MO'I;8TWVOHTFWDKOZ0URIK$@;ZR?5,YEX7XVKN:[Q+7%T:"B3=L5KE.XMMZ5 M:FXT`H_@UG(TO]N4+5=J[[WJH*:@"7N4N^T!E&YXK]=<[ZX$TNOFI]O.*`,M M>9\+.S4Z^Z-T`BZ6CH'K4FHG2-W"@E+8&)OF-GXQ,.H-A9@TETWCB0WF MTTAF8W=VEDX-VK:O)P72!UG+*&(/Y,F]:['D_E18!W;?DG3J#G)-(IH^6KRT M[VV2<]&[6TNR9.DQO#3*QNKNJ%0+CSZ\L(Z'S6/F M-?B0N!&6,5"M]FSX-.;N!O:&$18(_G2#U6AT,$$A04 MN"V.U.*]9D]WYNWTS,;W3)B%M"+*R]LE")4HJ0BQJX'@>]2@X;UU+4%^$0IH M/\_]S7,>BON(.&G(6(ETD:*)XAGHYEQ+Y7+F>D-CWBUIWH$&'`FP$YBJ-!H? M/&%5Q?Q:"9C:P%-PQV9JHZ7)DV/*$]=D*34'.XGVGP-E\)`.I@L,I;_V=7#& MW7DR2@_VQP]:H;ZI@JP7_"*9:E]0<4'^!BX\4V7B:E,L9KN88BN^@3*_\P5= M9NK.LZDX%#N$^,I.VR-H*OFT7'S3K+)I_D]?K:36YBOWJ*;E/+S57-R;XOI& M9ZF`KJWSWM;X"OI:+P%%`L=FEE,C&RC+C`AGFI`(1&:XBUB83^'Q#Y01]IT8 M:#WYQ)U74;<%1'"C2!H==FK9)5E*-'E+.2JT0Q4Z@F)$-24!LKS,MQ;;48C4 M%K0@I:"@SMB24DE%(PY!\J?17;1@?6L<)+"KOVC2B'?3HRW_RJ/8(L9CD<>5 MC:CK,X.-ZS+DQ?FG%84>>\$)Y523 MT.+<_+9'KF\NV\A#$`LBS,S?4)4I;J$G3K@2+/V0*1\X5&DYJ5<5;;M;UE6V M$H\V(B>OQ0VUOH:!$&@^&IEN,*YNJZ?(ITN<0B*-8`R8KP*)8%=WWRVA6SVQ M0#66'DA5B1*"Q#4S.8PGBJZL_2=&D8G(I[! M?JF6H=^0W\Q>CH';2SJ5;!`F<4F`&H;0IG<'.[9PX7 M="N+V&2S1885G2\V7,`++XT8#')X&$L+%Q->D1ZYLFY_L7"P^PPZ45G1":&70J'*(=)A;1NII10M&;IRQCR M71H64G]R8-.?'6B569W.+,2+M4,LMD=:ATQJ;M(FFJAW`^*Z4FL'P<5:KQ>N M[0UM,HK_%@\T_"/'#+/0*LOOL-:'1'ON#.CT!AS@U!G0M"SZT6+S_`=Q_PF@XGD2\7J\IT#"V*&]X[DT! M,P4RV;9:@IH;57U_W&B7?=9U'M(?JRO2VDFGI`YD$DB7/XIRM4%]+QSL'S;4 MY%%RA##$!&K``G.3L4"0?+]T:*;8H=@[*\B@L6SW7Z. M/L#:@!"<&CW?KU\SZ7A@!O<1)_(DV^IVK-1W0[1EF M20R4)\EXDHY&I_#A8(Q_G<`_.]C:E'\Y.3;GR>A@E(R/DIW1 M`=P&WZ%E?][OQ(*%2$_W3_$UH_UDYP!;K\)7)ZIX#+OTBI/>)GQEZ/[EWET M.$Y&AZ/D$-;LF%=Y?#0:7.71*#V9G"1'\)Z=(WP+?'%\,NI=X\/3='R*`QL= M(Q5@;]Z=T82'!K]-#DX>TFQ4U?A98/[J+Q_46_M8>G_J])[K:?@FXZ9/9%M+ M^V<3:42TQ_O[.)V3=#P9A\L9G,7NL#0H;4I/RWPR2<:'Z<'A:?L^=]E^>K1_ M`+N1'AT>#U$M4J8M7X_C/"]NI1?/H_SM>IN`7WD`BR;I_#Z-?U>A1PH(^='$ M,>^\LB&=P.KJM2D3[?I@*@B+6A/OC^E^ECJ?9&L&7:R??\F7!=M,#]C,%31]017P;!Q&`.YNA/-10-B!N;#Z:X4]0_Q M4#$B'T[L[;(GZ0KKZGQM[+UBYEE!?:<_EE?\@4GT4:WSF$'!03@XL/\/K?!H M?`I7X[]NG9-1>@J,;E?^ST/PBPX'-=T_'+FW@-PX/>QAY[_8=,;I\?&)_7^` MM&#`^\;1>92!2A)>['E5"'M0]?)8\@64ZJO M$EG)NKA[D3Q>ULO`X#$LJBF0+?FZU^5U%\(0+HDA='Z.^<47O7KZCR!+;S53, MSJI[3,O2CK41\FQW7.4M=F$%'"K9RLWPD;%G!BS5HIJ%Y&9.Z2)4!PJ+%MR2 MCTU-Z1,JM>A`4&6%S=P4UP&['+KZ]BOOU-)P3`@C4_QK463:@X:8SJK=[D>S M//>2CWQ1YY=8?'!*&Z>CHIF"Z5F((6\B^Z&K:!6"3&=#7<&`C)@TJ;W9#+V_ MEL5'>_W\C+;:-PZ+`/:#-7^=E6'DS&/ZH!:ZHU;B=C&%:")],8*>,Q)+W4=H MJ]\X;?7/\1E2471TG+S4H_<[.GJ[R<'HB,![/>GRY4>@EG8YS3HKN2'U&;KO M0(W")Z[SW=>87_(8Q?*"6U709%YK2P)_\+#WA7:TP)FL9=LK=IL4C+6/1!S: MM\B$<^OR1RG8G"1J%%.!GO@'"'=YN'0HC,TG-6L"4X="V(R M(,LG2FUFN`)JN2(IXIW@KEJ++_05#UB_SCW]>2)4A2\%!"HNT7?:A8@.(/-` M"3,&BJZTJGR0EZ6=IKCF`36?A7`Y;KQ&!$\P'EB1@FY-XO(NVM3IW>D$M"7! M[[*>P(J/9@#:&[E%K"5B4N_ M:$C\ZJ"E4+`$.S$PROEE[#0-O6]<3*%!%DMX%N)AWH:%)='C4D"Y&6RHI+G* M"2.I:[5Y/P6MTMPQE3HUYOI;6.[16.-&WSM:XQK=PL MT>@'X0[!)>RVQ`B$;F$C`G^9?5=I3-3&R-1?-_K`Z*U+T[X-AHZ2WG6Q;(9M MP++O$9M8/#R,_2^'V7@,)_N04=?CM):.2;WY>E'CWKF10Q2CN2>,A-EO!=54 M<@[V!BC*.A.%,8=^"IV5HM`\3=%G@Q;SD+F*L,K9K%KMJPJBDJ1(\@\JL^%5,N M;&S6FYDF]-LUA-[=?-L="#MA"DG+;XIUWMMZXO,/LA['KN-N/=C&(M8]@)^" M/7-GH00X[51")U544ZZ_H:]4)E+U#(T">P/F5*N`R11YFSJNN%QRW81M<=I; M:U[*!B+B=F3BVG80BYACTS]Y,C%F5Q35Z@:^Q(C=RANB/D6&72ZPX1JP#VT] M.9&Z;Z1MLX69EX1?[&SY!C`>M[XCF\K\&OB+9+3>HJ`3AUCHT6Z?>6`:B<1= MWF"`U=IC:7KU18S@V0Q(20X8X)RDMS9K(`)>XUIZYF5=26]<#.+!8$T)X]@5 MR4R%SH^6S!6@:;90O7&Q":*=5LFDD8%E>*KH19$L!;@6VE`4WHY@,-G!!!/H M18%Q^*G4K(KY%O'V6)BZQN6.Q5.@I^\=L(%%[IR+.I<>2X?YG'+,>B-PDI*^ M\7C$CBAF;B&ZKHSP^:YP3U'W9[W"5R[O-<1_>W(,*=SW(?OT&$4^W"5*J&I. M6PU)%P&MJWWD7)T(IW72L];XK`#61#E$;*3/M!H,+N$,`@G,.VVM%3D/8"H% MUJ7EE*2@R+Z#M23P>.9\N/(#[Y$H_3+/&L(?"S'ZO&0`9WQ,;=6RB^S.A05; M5KH!,@7MQ@^X?0=FTH(2W5.WY;,)>&_^U6XAL#48K@C>_8YT^YZD!7\1&P#= M_!E.DH%O"^GLO'E$?DXGO81GELAK$VG/GO(A"*O'A6H#V6"],&B?BX3Y`L0DEKK297F$R[0B:8H MZ<@/F23BC+N;M?#B$4^P]_,ZS1XUJ8.]GF`6YY&_9]?6(XM(^HF\YYD=PY#< M:$THMFQ'O`1C47%>!]Q_#@[?XE#*4&*?,;$"VU'J#D_=R*^$^.'Y)9H7.G9R MYWWF:GZHJWT+[J8IV#^H0`I;6W]#O0C0)-QDM)G M4&F[M+>$2;).NU/>NYT[ MDVO)_F,@[KS@.!BZ2A8[L;@BX][*08@KY>YMPSX M>EY"DL=!XS;AZ4P0;9[HWLX:@&@*O+:VV@!7H;Q6A$-C[M%&?!8C[#'.I3#IFAK M8)U^7$V[QE^ZNW<`CWE=*&S@NCOF)%VCSH;D'R+QA\R(W'+(Y\(8@`;';PA%(S M@021PM!",8==M$>,R_3'^V&2K""(=!'@ M(BS)H4;WPU.)#YC!MS;<\DP$@'K#W%3:&8V?O2$IFOZ4VB`!0\HBW,\9>BP$ MV2>^:\FWH3C)R\1@?Z7:32>XU?V%\5C16_7AX@7'J$B$X;U7J$8:L??>].S% MY45HD8)_A6I`=`IU'G&G6:KQLPSH7."\_:+=D:S!B!_VL@/=M=,EA/.*'4%9 M3C%7"$_)D(H<`X*E)$<$YHZD1..?2[Z+^*E;U%<-4$%\69?\>JBN:%H"U:C/ M(M->86&90J]%U_U"4D[TR/0>$@7\AM?E&F$5<>5F@/&I,EML?U1R]&J5]\+[ M>T*!#^5$<#CEN\WLFMD3JWLM\A>(RS@L0:R(KK&YIBB'&+*_-OF@W$P2]U-N M6F\]0GHD/Q$`=>+LIDWG,3BT!``=C*^BT,6]GZ@Y.2Z3S_HA7^_E:SL]E`,Y M1[Q)=E5;'TW&:DJYQR:5Z+QJZBQ?I`P@G29_!%[/S8:Y/5O*JT.JF`]TY0J. M)I%>C'%+_)?)<:`#/?J4J@VCDG/7F-!,Q_!O,@&[Q[HVAD)=@4[)>F#:TXZ& M-SOJ2E`830D6RSH:DQ8.Y)JV[PF+V5T,;R7,+$[48";E<@$4708K5AA%ZAR4 MJ%G!/?&2%QML!PE_?"PU+O_B(V=@4-H%S5WAI`8:XV'9C:R&QZR>3-+C@WW) M3P3*($:'OL4GQX3:* M%L=D7HJ?O(=&*1^?*ZV3-]T.3UUK*Y@C.C(B&O;YWF!>CE*CJ`BY:QU%X:\= ML6W#"2XY"&] MC=_M/%H%8P,U@&;K1H2"^?GPEXP"H'1HAX#H;X@BXK MV@&Y]L4;N1:'S$$AO5`/?8N%.E5QJQF=Q'*S^Q[$5[22W,PR(:6!W1.LEBO/ M"%:\:_D!*W1V^9$ZRN]B>_)PE-ZPZQ\3HWK\:N]]$JBC)QRV)&DBR&(UWUU5 M4RPG[HL]?B8MO$UD+0;ZN(H\4.RLA%+L=(V_HN->1A?UEXC!EGPH$W]^5E2* M,WLVNT7-:7:/VVD#BTFY"7A_+V360]-[0>S^_=G9^^=G7__^]Y>F,N'SK)6A MM8RF[45'W#7+@%:A!O-<<711C+]]=?;JN3XO#0O=5K"C?.*^@JZP<9KZ ML=?*L;W?(6N8@U'"+(LD3$3F)*$(6A3]H*3X<],1$KMW6R@$RRF`(:Q8G'LM&J(2F#IJ]SEWVLO6Y=U-91W0BK-`.F%D; MK6D>W`)\((-?('V$=^;>L:-;*4X9TF#)H.N(\W(`&/D4-N$+\$'SX M3=50=BF/9)ZCT;A(.8.G958@&C0>XRG5"/K\EKWDS\I(XI`]#1TTX&#TJ&+I M4U[I"HVV^ZKH%9JQU'>T[R"Y,O)V[1E%UU:,YB`[%SN$"LM@!KY4^WC,'T0*<0(^%U*-2!*0XO+ M&GN:AI^(H'6["1O4Y3P\U?H>-^RN\+&?Z.37/EJ@ZRN,';O!FW,W=DOHJB$* MA4^Q$>N/>09+^@CR#31JS.V=,C@$_$+GG/,65)@R)B&#9/,RR;7TQ+HN`_U4_04=N`BF#N[A,I>D46"*':
I? M%Y@&A0V8Q>.!JRHG88>LS@">YS&_LB9)^A`Z&?K;';[!&%@ MZD\1JUMAUERTQ'^!7 M;&].]0D3M#H5M@*J4C.X-DUV[447$EV80P^'9[QR`7./342&]6J,9T4U6)VV M0TUN#Y*0!#<_,)Z2D>/6K_MTD15+CAX.,(9H?7V&SYI2$C4I27,`LBE0!>.Q M*@B!`N>1G!AX"670W,6"SQ(/%5!`'Y0O"J[G,)YCX3I>"]%0"%R!@U,&[R=L M/X9ETK+5.>4?!`KU.IB/4UE>)Z-@A5#\#Y@(JE^(!&JWH79R39(GOF./D)>$ MS&Y3?[$:M4$8IE[F!=*GE"VV4>#XK1#P7`1\X,N^(H"\%:%26%=[YPH(56%P MHU,CJHB]$%9-\TASA9YX&@T.,U8,%7J6+VGBU"M3TJ?\W'L"OCHVE3>KS=7" MU8])YXLH];*)CZ#5XRD1.\4(!UKFB[8XD5A%-/9(6S%-X=].J&U6W+@B3E`6 MR+<-=]%L?#ZI>6'1',0G!.SE"+:9`;R"+G1I*98-JR3]IT`:FZJMJ+:]9YA< M1EH5XEGD-D91JW6ANZ%W,(,)6:R>$+P,"CXR8X_MAFA5'?^FT&97N28C@OJ= M%\2037QR8%%41O59R^HJ(9K3[WFD;[,I\*I$=&%*0(A_EAHCNJ@(%P5SQED. MH83T34CK<+&FGW_ZVZLW7"+XDA+@+R0E9KA:*E[*(:/02R"+!(%\?(6^OMP) M`W00UC@)D7>L%VH-CS]_TB%8'N"JF'-LRXVM@0B/RD"RS/<4'P;\#NC#H`Q8 MY$6"I'T2.`$9G5\AP]>+1HHT<*]:2J4U]B.)4*34P8%6+W&TPK4I*IN06*%2 M5GT"[]F@CR9B>'A\4*EKJM(57NW`$S+23^P&;E-!?O'0NT)NDO@OW85HD=D< M;6GSWE@ME^'8D\+:2P;80..6&D/AO".O:XGPDL34*=M$C8Z(H;+IB>ZQ73'0 MI7FZ/)"T:)CRLJ)]B*@DKFG+NY@.FL88M0W%-SZJJ^2(/K]OX0:/QD?)88+1M2,$>3@<]:3P?2;Y M4B?]S>-@$0[2PY-1,DY/)\YB.CL;)!)9TDDQ@E0\FN+ZC M@#(AUSU)1OOI*2'(X,6(,7$P28\.$9KGA)[1`UC=[ZZ6DM1?("/W_A=$C(#X M\`-"`@Y74=SV<4'O7NR&'RC;#PTD^OS8W3>W`D[^@CX5S8!:,4>@TSQJ3T,& M(:"%)[B;LT+^&O6Q40D&"7'.MZ5[0D?[@51EBY-VDRI#@?],NEU8+EXG?!HM M=3?1)DJNT4Q3AGH/76%KK1#WK(`QL3%/_A@T8N;5J&S MWJ4U4JD+%::=DL).12C*"RQ72T/-G@0G2.,5!1P-,>P(:`E1SB,JE4V:4M(J M5B??LJ&))U'1^QXPYZ:7[N(91@60;%Z%HDFKDO1[PI9IT-]QAGL$B":5L7)3 M9QGH,5K@U,XNTW"_*QPND&A"H%US(J(":*?BU\'7F6(H7G7:U.>PMA>C*G>Y M2Q*76>MZM>N8&U'!%UM/F\,]LVZROIQ;5X2?X-H1"6@-W]D"Q"YP/2QXS#&" MBX$4UA/?<.-&^OR7'/23VPRC&:B.HT*#FNW9B_-W;S@R]XKMHL+5S3J\_5?O M7_-E:ONY!U$D,+O*EADF%SCL>FK5@^X@O)%U?G5FS?,X7MN0H=F>.,&NH'5= M$D?K%J#::7;WAT0-UQ)2H'G)1]S*$33=$;2:#XDKZ"VLT&Y[B5*K,&X3>#;-9CE"QR#!8:"S`P$3 M.V?)B%1^$T&G\^T>^R&^4T>`\<[N6^?D%IP%)%L2S<+BNA03HBVR+`&8@XQ- M5.W##AMUX`'#BB4W/38U=,U;HVCZC>:>>5LAX%5.KEV%$V$`%C6%+%P1TPG? M$RAJ$/F8EW!,P?3F5"KC>%);(+8S:K`YAP:SN3C-C[*HG\!HX M#GB$9*N\6YE%8F9Y4BU+S\MUGG<<31DOCWMV7&WG-W?RTG(_:#>.( M.&(O533:-84OH.BV2$C_=D" MS//=R^E-13'8E?F`*><(F_'VO>"^R4=.5WP%K24G)F#U9)0Y+X%EZ\.XQSWG M96>F?ML8J:.=ZJ'ZGJ2&UQFF->XB#K>@BCO&R4[NMGRWG#4!.=X@G1S#\8:"5_1UE-!+=6?8J&( MY2*,ZJ4U#V25Z$'%U8]YH%VM4XH-^X?:\Y1:B/F8TB"-/AZG&M*DRB+).I;G M/\I=P(^?I"=@4]+CPA[/#-+]4_!!B$X1*#0SS7]4=63K3).,NF@>-W[ MT"!'G+%C_-ZW1A.Q)QY.J?GI*_E])G`NEPCG8L(LV*`A=;N,#$:FAUR8/SL^V,B"EFM$\408Y#!31Z%.6E M0A#CT\Z#'D5BW;)XVI@IIDG.KGTN_$-:LPW=^ZH?F\4H"@P9WV.T9Y_N+8H8 M?&]??RO*I\#+M-1/$MI:%-]*[(CPW\DWA<2XI:I<*M*^;[P&N_C,-Q M%2*Q3.#YECI=1<3Y_-1G'G&\/F\;>MPAQG6KFC,9MK"&PTKA!!3!& MLK\?I'ZQY?2GF7%XP6EQ21.,-R_8]2V,_L66NP/J7VDP4'!HCVP7X+NNMK0` M?W1"BQGAP5,TL:39D"WV*#TZG/C:!8($C5,4YK*5/:(B_X2:/^?29>(^IA/Q M=71T;`"L>O1#X_JNE4F1;V=4\TC"E-MH,R*AH MKZ+`\'*UJ+8@MEN-U3$U@)$\,#-C=X;+H%TM/.(RJ1&R1@&4()K]%RBE)E?4 M^\X=N?%W^M16(,W`K]:<8!.O2"KYA)B9Q^%I*X+]16;W.('QCYI<^VA]9.[V M(J0&//Q8MN^EA>,FX;9P`RV&M>FNECBX3MM1G:M%KRN"&+PGC8,%&P,JK2U) MB9QEH.\&MMC?N_M,LRJX"?.4%B_.I:@:]_H>&"9RD(2)OV&F_1X;L#W$2^*$ M[;EE9CF$$M+NXACOHHCR'T0:#.:)^3:$%GK8BJ0)4)@^H-SHH6WEVPQEHK&Z M)Z&F:]3X-'_\=/]7)$6!"6I>4:>[PDPSXN/G`$7-*BPL*-=2O]$3R?`+I@ZP<\7A;:O?]_*U;PJ&8_=%`.W4_TZB/KTD%!7P:YQB MY`H-/U-3W47"9I+5K&R?Q"W>>DJ9\;#_UG>Q03-B*;`32:>U@)+63K&7[U'( M+UL6MT7-14_/SO_EX&"RWQLZU%@&ZC4"F\2R$FWAW=5BT^Q2J8L51;36_Y_#"`@[<[-LQY,-'H*TCBC;I.=963RZ\8; M"*+$,:HXZZ?E-O_"_`6%=]`B%\Z(5\(C=`&%"7-K9SO=6A'>)\(N\+@I,N"P MVK1*]K3V>GT=!V+N._E13S6.M3^^%2"U`W_)@*"#%I!8%4-8.B&:$4'S(%F< MG7\X^S:Y\5RH][#I$YJ\BP5T7>7.SX:B)6-1HIXBBRI*QP-MZIKV`;%R&;+` MA'/77DG0-D14W;,(;X^&OI!J$E0\[-+01-;HF9^K'!"UJ!HW#XN?V>Z,(!7< M7*/*FM[5[/(XPMZ])[$BBH@'=GY=5YN5U,2;D2_P[(1V2@%RG9'AMJ.*OBFU M1[,\6_3!`/)!X20F7G>*A^G79*"BW5!YK#!HO5IWY.B1Y.;`G&4B-&328#B[V>G=3@:^Q\G0MFE[4B49T@3H'P8GHXI"]C M(CLSTW'Y'5L''/T[V.V;BMVS0U5EC:]>POCO(MN:R\ZCD%"UM+N_8H*PC"': M6TH6;`8U$F,0#D4$`>0VW-`\JNQSRW&_PON>.BZ?LHS=KW4'V(2S^DIW)SO)[^ M[Z1D#W1\U\V."E/W]$6<=Z(!?1QT]H]M;4@![CG/%]S@?FB@)V> M$2QKW,0[#SVM!==8J!I3J?[(XN:[3^MNU2_=-TK,(J\2ZI&L+ MP#TQR\BV\>9%9'Q@'=6F(9S:J^I6D*2]K=7FN!W+I:>YWLS+]E99;NKQ\J]&>.=]<)`#/9P\Z:[GS0N%%+_S@?:T*=] M#P"3GG[L-'OI8A]?AE:=?Z6;'IU>>W^W6.TOPQU*^=_0E?3_[_CZ;[E44=?6 MGW_Z'_].?5OQ3;]$Y]9!ZB7HS>#W^_S+_H:@W3?+QCZW6GG3!?XSFGCRWQ[3WY,$_ MKL'G?=3@VCZ>2][)O_[`=%O'R42[S>/PA_[V<7Q+7P.YF)H]BOHO1,J_7"62 M3$)JD?"O_UC52./'5B,1_*4W"C_]QBY-(':/:JZ%\TR$] MS)/H<"[L&?LXME],J&>S!QL[6[(NMT=`RKS9']O'W[E?]&!LOL2V:'EA;Y' MC7$$3_\5_'N4_.K+C9CG.=C3BX868),MGL(]'R^?)SM/GFK&08&.NVK3P.'O MV#-O,(L,;3E^8O@,3OI?TO/P2^Q+!CRD7I(VRU91YWGC!PX:-^;"O'OA@=T1 MLE4W.ME/9MFV.U!T/-ZS$Z^K\IJ;J85WV"@0!)5N[U#0Y6M_\KO\![X4[SI_ M`7^?=S&JWQC@[)D"S@Z-\P)U^'PF"K9BK%.SE?>"M?1+##)REUUF+>-$$L[" MB4_^K$'`<,T'A8A^U9">1;&E8;8G&>KRXM1",YV=_++I&.3OI:!%VPSQY$>8 MYGW[0=[16G!N_[_FKFZGK1P(OTHNNBI(69I0`O2FTJ$D55>E1`E4JO:J+4[F&Z M9I6>HZE/AA)___/HG?,:-G6O7#G'M)S%VV:M[Y9V4!< MA\(NO2JWFJ^<@PO*I;X_F*SPTXNR\>;DMO3G(S\EG6@KR<*]#&\7@CTENBB^>H_O&@HNM$>*=5LR MP+U-!Q@L>7OIN:J>D_J-93"&:9=H4T]%F,E.[AO9TJ,H#0JA\"+CL4@_/9/-O^A#22HLM[O#9+0DV M6W];T68K:R7<;$T-Q*N73^C0Q\JPK9A:2:+!8/UF#K9D8O_&I2*06]S<*SAW M*OJ$P=W-U(N=B?:ZI3NB+&:[!<"<,SP[(*T"+'K6>\%@(F"Y0+J3>MQHZ-#\ M,9#T$A?%W,_%^GK/H:DOJ3%I8=T&=,E.4.AK?9D#449>7K[Z3ARD/[G$LXLN M!_Y9K3D)AZF":@H&W=+Q[_QH8+9F+%9P4%PD#-:@'^N[8W[Y"`;I:/"7,23- M>@64T\PX!-=/,#7S1QJLKC&47K.W6,&.S`"Z^`?;P0QY]DDK_8XQ2MXQ-MX1 MND/$S2A@1XO)$`:F"^>RNSOCU?APX]9>83-F5$8*MC)"E@\0RJ)B>(T;%.TE MFAM7`]?8C1K(!+,2J%U7%,0W6:R`X@DK;,LRT#N%R_OB^\T3=P"\H$_;AWHMY4GMZ8NZ=!>:;"L_`$&`=NUM?KU3V>0^JN M/1JEE-`''['*:B[HS2JQ#]MHK(S"@CLLS45.:>XG^_MGR-O[4M'QIDE\.$CJ M_3]@"%LXBKQ[\RVE5#)6E\.T"+?XH1@P&7'HVYT=7BV$MS_J:#,L=VJ,NK1C8X/CKG.%;'(ECHDB M0`]&>3Z$\_+024_X:4@;#:XC8;YM?/;K7'/#0;K)AB;Z=K>SD&18/ARG_='3 M+RV1Z*8N;'C;HPJGG=4T]B$\..(U_;259CV!%:!3DE]&/[(\[G-()8L^,"^T M-Q2HCZ+L:_Z7H7::LKIY1;:G_=Y)>;U8PC:)RQYWK7&,4=1;$+/;54+7::&++&N>[&68AP(%4,&KL)W]H%84X>IX=6-L[6&:\A^4^D++R&$'9` MDK*HV%^]X?%^DEZ38#:*P^IEZK`Z/DK]5Z%"QI\E[W8*15*WB5NT-PU"G%F&6QDWAVS(X6&:#[W]@S15\NSS M@P>I!YEJ!Z]$AR#!!Y4<'"5[:TL>RC;O?)MB*)XZF;+WJZ(.I!A?2'&IITN% M,._.%=A7-?/%NSVWW(SJ954@1I'7KC=U/S%6Y`0Y,H^I59-6($"YHL(=4ISH MP_:E?8T2ETK?S6;ELOR.@VM0R0D9[A%_5SA#`R'%?QN$**REL-"X!)UAI/IS MYM,9IB:I[P]F_J>E--/]=PE.6)K`6"R7<.5F/,(V7Z;O.>XA$Z,WP8RS4P%+ M[**:GT6=FL,TAS-GH.-^I-CH,YYWWC3CNJPV-^4OKK0N[0C'*35&F5S9HT=G M9DX\@TP<"DG]Z;CORG&12"N_(*EW6(=Z1O50+PP.9-T M,2U\5@=&/I^QO*'3!'6M@T3E60+"0%OPJ\\!-2^7"S`U@7EF6L<*Y)1#X+T7 M3;]J5/4IC<55QH
,*^>PJQ$XG`XH!$M+N MN,;--S;#VJ=2'R\/^C`K$_W//B`E9>IN:LM5].1.Q3S9I4KZEG6(U&D/3\@) ML^M=["OJ"8`UE(37]/+7SX;#:1/=$D%DG^_N,/.$W9T+#/`I*7N@3N!$Y3YR MZ`PDZ"WO5L\Q'.3^(1M-A?0@LRS_2_';O:KP\4A(#*8D&^8PDM)T('I]B1>K MU?WKWU!+`0(4`Q0````(`#&%9D?6X#P>EP$``+H1```3``````````````"` M`0````!;0V]N=&5N=%]4>7!E&UL4$L!`A0#%`````@`,85F1TAU!>[% M````*P(```L``````````````(`!R`$``%]R96QS+RYR96QS4$L!`A0#%``` M``@`,85F1WL7M"54`0``6!```!H``````````````(`!M@(``'AL+U]R96QS M+W=O&PO=&AE;64O=&AE;64Q+GAM;%!+`0(4`Q0````(`#&%9D<< M!$QC7@(``-(*```-``````````````"``:X.``!X;"]S='EL97,N>&UL4$L! M`A0#%`````@`,85F1TQ/?Q%``P``L@D```\``````````````(`!-Q$``'AL M+W=O&PO=V]R M:W-H965T&UL4$L!`A0#%`````@`,85F1R`VDHT;`@``2@<` M`!@``````````````(`!Q!L``'AL+W=O``!X M;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@`,85F1]W3;7"@`0``L0,``!@``````````````(`! M\28``'AL+W=O< MO;P-H0$``+$#```8``````````````"``<*@``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M,85F1_[H"W^B`0``L0,``!@``````````````(`!=RP``'AL+W=OR`@``*PP``!D``````````````(`!*#```'AL+W=O M&PO=V]R:W-H965TVT]C0K`$``!8$```9``````````````"``1\U M``!X;"]W;W)K&UL4$L!`A0#%`````@`,85F1[M8 M(A1R!```4Q@``!D``````````````(`!`C<``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`,85F1R!P^1G.`@``:PT``!D` M`````````````(`!+T$``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`,85F1XU`@"-8!```HA8``!D``````````````(`! M=DD``'AL+W=O&PO=V]R:W-H965T=6IG!Z0$``)L%```9```````` M``````"``&UL4$L!`A0#%``` M``@`,85F1^(I9@JU`P``6!(``!D``````````````(`![E(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`,85F1R`0ET.Y M?```[](!`!0``````````````(`!,%P``'AL+W-H87)E9%-T&UL 64$L%!@`````B`"(`(`D``!O9```````` ` end XML 24 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 25 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 5 - Stockholders' Equity (Details Textual) - USD ($)
$ in Millions

Mar. 03, 2015

Nov. 06, 2013

Maximum Aggregate Offering Price $ 150 $ 125

Remaining Aggregate Offering Price $ 10

X

- Definition
Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.
+ References
No definition available.
+ Details

Name: bcrx_MaximumAggregateOfferingPrice

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represents the remaining aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.
+ References
No definition available.
+ Details

Name: bcrx_RemainingAggregateOfferingPrice

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 26 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 4 - Royalty Monetization
9 Months Ended

Sep. 30, 2015

Notes to Financial Statements

Royalty Monetization [Text Block]
Note 4 — Royalty Monetization

Overview

On March 9, 2011, the Company completed a $30,000 financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of $22,691 from the transaction after transaction costs of $4,309 and the establishment of a $3,000 interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.

As part of the transaction, the Company entered into a purchase and sale agreement dated as of March 9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii) the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the “Currency Hedge Agreement”) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company’s collaboration with Shionogi was not impacted as a result of this transaction.

Non-Recourse Notes Payable

On March 9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the “PhaRMA Notes”). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March 9, 2011 (the “Indenture”), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14% per annum, payable annually in arrears on September 1st of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.

Royalty Sub’s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company’s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.

On September 1, 2014, Royalty Sub was unable to pay the full amount of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the Consolidated Balance Sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company’s future results of operations or cash flows.

The Indenture does not contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.

The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.

Foreign Currency Hedge

In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2016 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $1,950 will be required if, on May 18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.

The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company’s Consolidated Statement of Comprehensive Loss. Cumulative mark-to-market adjustments resulted in a loss of $460 and a gain of $4,082 for the three months ended September 30, 2015 and 2014, respectively and a loss of $793 and a gain of $732 for the nine months ended September 30, 2015 and 2014, respectively. During the nine months ended September 30, 2015, the Company realized a currency exchange gain of $1,654 associated with the exercise of a U.S. Dollar/Japanese yen currency option. The Company is also required to post collateral in connection with the mark-to-market adjustments based on defined thresholds. As of September 30, 2015 and December 31, 2014, no collateral was posted under the Currency Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of September 30, 2015, the maximum amount of hedge collateral the Company may be required to post is $9,750.

X

- Definition
Royalty monetization.
+ References
No definition available.
+ Details

Name: bcrx_RoyaltyMonetizationTextBlock

Namespace Prefix: bcrx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 3 - Collaborative and Other Research and Development Contracts
9 Months Ended

Sep. 30, 2015

Notes to Financial Statements

Collaborative Arrangement Disclosure [Text Block]
Note 3 — Collaborative and Other Research and Development Contracts

U.S. Department of Health and Human Services (“BARDA/HHS”).
In January 2007, BARDA/HHS awarded the Company a $102,661, four-year contract for the advanced development of peramivir for the treatment of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a September 2009 contract modification was awarded to extend the i.v. peramivir program and to increase funding by $77,191. On February 24, 2011, the Company announced that BARDA/HHS had awarded it a $55,000 contract modification, intended to fund completion of the Phase 3 development of i.v. peramivir for the treatment of patients hospitalized with influenza. That contract modification brought the total contract award from BARDA/HHS to $234,852 and provided funding to support the filing of an NDA to seek regulatory approval for i.v. peramivir in the U.S. In December 2013, BioCryst submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December 2014. The BARDA/HHS contract expired on June 30, 2014 according to its terms.

On March 31, 2015, the Company announced that the Biomedical Research and Development Authority within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This BARDA/HHS contract includes a base contract of $13,314 to support BCX4430 drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $36,169. As of September 30, 2015, a total of $16,300 has been awarded under exercised options within this contract.

National Institute of Allergy and Infectious Diseases (“NIAID/HHS”).
In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The total funding under this contract as of September 30, 2015 could be up to $34,002, if all contract options are exercised by NIAID/HHS, over a five year period. The goals of this contract, including amendments, are to file IND applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase 1 human clinical trial. As of September 30, 2015, a total of $29,875 has been awarded under exercised options within this contract. BCX4430 is the lead compound in the Company’s BSAV research program.

The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions that are related to the development of peramivir and BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company’s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.

Seqirus UK Limited (“SUL”).
On June 16, 2015, the Company and Seqirus UK Limited ("SUL"), a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the "SUL Agreement") granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the "Territory"). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment in the world and was approved by the U.S. Food and Drug Administration in December 2014 for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. The Company retains all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S.

Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion. The Company will exercise sole decision-making authority with regard to the development and commercialization of RAPIVAB outside of the Territory and is responsible for all associated costs.

In December 2013, the Company submitted a New Drug Application ("NDA") for RAPIVAB to the FDA. Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory filings and interactions with the Health Canada and the European Medicines Agency ("EMA") until marketing approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.

Under the terms of the SUL Agreement, the Company received an upfront payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from the date of the SUL Agreement (the "Royalty Term"). The Company developed RAPIVAB under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.

The term of the SUL Agreement shall continue on a country-by-country basis until the expiration of the last-to-expire Royalty Term in any such country in the Territory. Either party may terminate the SUL Agreement in its entirety if the other party breaches a payment obligation, otherwise materially breaches the SUL Agreement, subject to applicable cure periods, or if the other party suffers an insolvency event. The Company may also terminate the SUL Agreement if SUL or any of its affiliates seek to challenge the validity of the Company's patents. Termination does not affect a party's rights which have accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations exercised by the Company, the SUL Agreement provides for the termination of any sublicenses granted by SUL to third parties, and in the case of termination by the Company for cause, the ceasing of SUL's activities with respect to RAPIVAB, the discontinued use of all Company intellectual property and the termination of licenses and rights previously granted to SUL. If requested by the Company, SUL shall also promptly sell to the Company all licensed product it then holds in stock, otherwise, SUL may continue to sell such licensed product for designated periods.

Shionogi & Co., Ltd. (“Shionogi”).
In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan and to provide rights for Shionogi to perform a Phase 3 clinical trial in Hong Kong. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan. Shionogi submitted an NDA to the Taiwan FDA in late 2013.

Green Cross Corporation (“Green Cross”).
In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.

Mundipharma International Holdings Limited (“Mundipharma”).
In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (“PNP”) inhibitor, for use in oncology. Under the terms of the license agreement, as amended, Mundipharma obtained worldwide rights to forodesine.

Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (“AECOM” and “IRL” respectively).
In June 2000, the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the “Licensors”). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000 per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement may be terminated by the Company at any time by giving 60 days advance notice or in the event of material uncured breach by the Licensors.

In May 2010, the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i) any milestone payments the Company may receive in the future under its license agreement dated February 1, 2006 with Mundipharma and (ii) royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.

In consideration for these modifications in 2010, the Company issued to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally, at the Company’s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination of cash and shares.

On November 17, 2011, the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.

On June 19, 2012, the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.

At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash, in shares of the Company’s common stock, or in a combination of cash and shares.

On January 6, 2014, the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (“VUW”) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties, the terms and conditions of the contracts are substantially the same.

The University of Alabama at Birmingham (“UAB”).
The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company upon three months’ notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties’ proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.

X

- Definition
The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 808

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name: us-gaap_CollaborativeArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Collaboration Receivables [Member]

Assets

Receivables $ 7,495,000 $ 3,849,000

Trade Accounts Receivable [Member]

Assets

Receivables 5,641,000

Deferred Collaborative Revenue [Member]

Liabilities and Stockholders’ Equity

Deferred revenue $ 2,102,000 1,481,000

Deferred Product Sales [Member]

Liabilities and Stockholders’ Equity

Deferred revenue 16,000 5,605,000

Cash and cash equivalents 46,627,000 54,540,000

Restricted cash 1,622,000 150,000

Investments $ 23,700,000 18,232,000

Inventory 683,000

Prepaid expenses and other current assets $ 4,970,000 6,172,000

Deferred collaboration expense 88,000 76,000

Total current assets 84,502,000 89,343,000

Investments 47,787,000 41,116,000

Furniture and equipment, net 1,146,000 207,000

Deferred collaboration expense 282,000 177,000

Other assets 5,239,000 6,031,000

Total assets 138,956,000 136,874,000

Accounts payable 3,782,000 2,849,000

Accrued expenses 23,027,000 11,329,000

Interest payable 5,517,000 6,029,000

Non-recourse notes payable 30,000,000 30,000,000

Total current liabilities 64,444,000 57,293,000

Deferred collaboration revenue 10,122,000 3,552,000

Deferred rent 345,000 394,000

Stockholders’ equity:

Preferred stock, $0.001 par value; shares authorized — 5,000; no shares issued and outstanding 0 0

Common stock, $0.01 par value: shares authorized — 200,000; shares issued and outstanding — 73,337 in 2015 and 71,955 in 2014 733,000 720,000

Additional paid-in capital 556,095,000 542,943,000

Accumulated other comprehensive loss (1,000) (130,000)

Accumulated deficit (492,782,000) (467,898,000)

Total stockholders’ equity 64,045,000 75,635,000

Total liabilities and stockholders’ equity $ 138,956,000 $ 136,874,000

X

- Definition
Represents deferred collaboration expense.
+ References
No definition available.
+ Details

Name: bcrx_DeferredCollaborationExpenseAssets

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26626-111562

+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26626-111562

+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DeferredCostsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.26(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 25

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39927-112707

+ Details

Name: us-gaap_DeferredRentCreditNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredCollaborativeRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredProductSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 1 - Significant Accounting Policies
9 Months Ended

Sep. 30, 2015

Notes to Financial Statements

Significant Accounting Policies [Text Block]
Note 1 — Significant Accounting Policies

The Company

BioCryst Pharmaceuticals, Inc. (the “Company”) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.

Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash and investments of $119,736, to continue its planned operations into 2017. The Company’s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond 2017 it will need to: (1) successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2) out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3) raise additional capital through equity or debt financings or from other sources; (4) obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5) reduce spending on one or more research and development programs; and/or (6) restructure operations. The Company retains the ability to offer for sale approximately $150,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants, and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on March 3, 2015. Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on November 6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.

Basis of Presentation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (“Royalty Sub”). Royalty Sub was formed in connection with a $30,000 financing transaction the Company completed on March 9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.

The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management’s opinion, necessary to present fairly, in all material respects, the Company’s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.

These financial statements should be read in conjunction with the financial statements for the year ended December 31, 2014 and the notes thereto included in the Company’s 2014 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December 31, 2014 has been derived from the audited consolidated financial statements included in the Company’s most recent Annual Report on Form 10-K.

Reclassifications

Certain balance sheet amounts as of December 31, 2014 have been reclassified to conform to the 2015 presentation.

Cash and Cash Equivalents

The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.

Restricted Cash

Restricted cash as of September 30, 2015 reflects $150 the Company is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program, $70 in royalty revenue paid by Shionogi & Co., Ltd. (“Shionogi”) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,402 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.

Investments

The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company’s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company’s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company’s investments are not collateralized. The Company has not realized any significant losses from its investments.

The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At September 30, 2015, the Company believes that the costs of its investments are recoverable in all material respects.

The following tables summarize the fair value of the Company’s investments by type. The estimated fair value of the Company’s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.

September 30, 2015

Amortized
Cost Accrued
Interest Gross
Unrealized
Gains Gross
Unrealized
Losses Estimated
Fair Value

Obligations of U.S. Government and its agencies $ 23,119 $ 42 $ 28 $ (2 ) $ 23,187

Corporate debt securities 27,249 141 26 (14 ) 27,402

Certificates of deposit 20,909 28 10 (49 ) 20,898

Total investments $ 71,277 $ 211 $ 64 $ (65 ) $ 71,487

December 31, 2014

Amortized
Cost Accrued
Interest Gross
Unrealized
Gains Gross
Unrealized
Losses Estimated
Fair Value

Obligations of U.S. Government and its agencies $ 20,307 $ 22 $ — $ (23 ) $ 20,306

Corporate debt securities 27,152 151 5 (47 ) 27,261

Certificates of deposit 11,838 6 — (63 ) 11,781

Total investments $ 59,297 $ 179 $ 5 $ (133 ) $ 59,348

The following table summarizes the scheduled maturity for the Company’s investments at September 30, 2015 and December 31, 2014.

2015 2014

Maturing in one year or less $ 23,700 $ 18,232

Maturing after one year through two years 27,183 25,459

Maturing after two years 20,604 15,657

Total investments $ 71,487 $ 59,348

Receivables from Collaborations

Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, and product sales to Green Cross Corporation (“Green Cross”) and Seqirus UK Limited (“SUL”). These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At September 30, 2015 and December 31, 2014, the Company had the following receivables.

September 30, 2015

Billed

Unbilled

Total

U.S. Department of Health and Human Services $ — $ 5,444 $ 5,444

Green Cross Corporation 129 — 129

Seqirus UK Limited
1,922 — 1,922

Total receivables $ 2,051 $ 5,444 $ 7,495

December 31, 2014

Billed Unbilled Total

U.S. Department of Health and Human Services $ — $ 2,778 $ 2,778

Shionogi & Co. Ltd. 1,071 — 1,071

Total receivables $ 1,071 $ 2,778 $ 3,849

Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company’s calculations of its indirect cost rates are subject to audit by the U.S. Government.

Receivables from Product Sales

Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB
®
. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.

Inventory

At December 31, 2014, the Company’s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (“FIFO”) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories. In connection with the June 2015 SUL collaboration, the Company sold all of its available RAPIVAB finished goods inventory to SUL in accordance with terms stipulated in the licensing agreement.

During 2014, in connection with the Food and Drug Administration (“FDA”) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB commercial inventories.

The Company’s inventory consisted of the following at September 30, 2015 and December 31, 2014:

2015 2014

Work in process $ — $ 267

Finished Goods — 416

Net inventories $ — $ 683

Patents and Licenses

The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.

Accrued Expenses

The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:

• fees paid to Clinical Research Organizations (“CROs”) in connection with preclinical and toxicology studies and clinical trials;

• fees paid to investigative sites in connection with clinical trials;

• fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products; and

• professional fees.

The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company’s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of September 30, 2015 and December 31, 2014, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.

Income Taxes

The liability method is used in the Company’s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.

Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders’ equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the nine months ended September 30, 2015, realized gains of $13 were reclassified out of accumulated other comprehensive loss. No reclassifications out of accumulated other comprehensive loss were recorded during the nine months ended September 30, 2014.

Revenue Recognition

The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the seller’s price to the buyer is fixed or determinable; and (iv) collectability is reasonably assured.

Collaborative and Other Research and Development Arrangements and Royalties

Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.

Under certain of the Company’s license agreements, the Company receives royalty payments based upon its licensees’ net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.

For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has “stand-alone value” to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (“TPE”) and (iii) best estimate of selling price (“BESP”). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.

In June 2015, the Company entered into a License Agreement (the “SUL Agreement”) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (“EU”) marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.

Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.

Under the terms of the SUL Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (“Health Canada”) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17,
Milestone Method of Revenue Recognition
, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.

Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company’s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (”BARDA/HHS”) and the National Institute of Allergy and Infectious Diseases (“NIAID/HHS”), revenue is recognized as reimbursable direct and indirect costs are incurred.

Product Sales

The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, the Company sells RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations. With the completion of the SUL worldwide license of RAPIVAB, SUL will be primarily responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales, and the Company’s commercial sales will be minimal.

Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.

The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.

The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.

The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.

Rebates and Chargebacks

Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB’s selling price. As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.

Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.

The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company’s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company’s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.

Discounts and Sales Incentives

Discounts and other sales incentives primarily consist of Inventory Management Agreement (“IMA”) Fees. Per contractual agreements with the Company’s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.

Product Returns

The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.

Advertising

The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB.

The Company recorded the following revenues for the three and nine months ended September 30, 2015 and 2014:

Three Months Nine Months

2015 2014 2015 2014

Product sales, net $ 5,699 $ — $ 6,236 $ —

Royalty revenue 126 5 1,776 1,951

Collaborative and other research and development revenues:

U.S. Department of Health and Human Services 4,582 2,937 12,788 5,323

Green Cross Corporation 132 — 132 —

Shionogi (Japan) 296 296 888 888

Seqirus UK Limited
152 — 21,835 —

Total collaborative and other research and development revenues 5,162 3,233 35,643 6,211

Total revenues $ 10,987 $ 3,238 $ 43,655 $ 8,162

Research and Development Expenses

The Company’s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company’s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company’s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company’s on-going review of the level of services actually performed.

Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (“AECOM”), Industrial Research, Ltd. (“IRL”), and the University of Alabama at Birmingham (“UAB”), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.

Deferred collaboration expenses represent sub-license payments, paid to the Company’s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company’s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.

Stock-Based Compensation

All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company’s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until “performance” has occurred.

Interest Expense and Deferred Financing Costs

Interest expense for the three months ended September 30, 2015 and 2014 was $1,241 and $1,217, respectively, and for the nine months ended September 30, 2015 and 2014 was $3,862 and $3,684, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended September 30, 2015 and 2014, and $329 for each of the nine months ended September 30, 2015 and 2014.

Currency Hedge Agreement

In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement (defined in Note 4) to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company’s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the nine months ended September 30, 2015 and 2014 resulted in a loss of $793 and a gain of $732, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized a currency exchange gain of $1,654 during the first nine months of 2015 associated with the exercise of a U.S. Dollar/Japanese yen currency option.

The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of September 30, 2015 and December 31, 2014, no hedge collateral was posted under the agreement.

Net Loss Per Share

Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company’s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended September 30, 2015 and 2014 does not include 3,821 and 4,240, respectively, of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the nine months ended September 30, 2015 and 2014 does not include 3,673 and 3,986, respectively, of such potential common shares, as their impact would be anti-dilutive.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.

Significant Customers and Other Risks

The Company relies primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company’s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company’s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.

The Company’s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company’s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company’s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company’s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company’s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company’s ability to complete its drug development activities.

Risks from Third Party Manufacturing and Distribution Concentration

The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development.

Credit Risk

Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company’s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.

Recent Accounting Pronouncements

In April 2015, the FASB issued ASU No.2015-03,
Simplifying the Presentation of Debt Issuance Costs
. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company does not expect this ASU will have a material impact on its consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09 –
Revenue from Contracts with Customers
, which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 2 - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details)
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Expected Life in Years 5 years 182 days 5 years 182 days

Expected Volatility 83.00% 87.00%

Expected Dividend Yield 0.00% 0.00%

Risk-Free Interest Rate 1.50% 1.60%

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 31 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 4 - Royalty Monetization (Details Textual)
3 Months Ended 9 Months Ended

Mar. 09, 2011

USD ($)

Sep. 30, 2015

USD ($)

Sep. 30, 2014

USD ($)

Sep. 30, 2015

USD ($)

Sep. 30, 2014

USD ($)

Dec. 31, 2014

USD ($)

Dec. 31, 2014

JPY (¥)

JPR Royalty Sub LLC [Member] | PhaRMA Notes Member] | Currency Hedge Agreement [Member]

Collateral Already Posted, Aggregate Fair Value $ 0 $ 0 $ 0

Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments (460,000) $ 4,082,000 (793,000) $ 732,000

Foreign Currency Transaction Gain (Loss), Realized 1,654,000

Maximum Amount of Collateral Required to Post $ 9,750,000 $ 9,750,000

JPR Royalty Sub LLC [Member] | PhaRMA Notes Member]

Private Placement of Senior Secured Notes $ 30,000,000

Debt Instrument, Interest Rate, Stated Percentage 14.00%

JPR Royalty Sub LLC [Member] | Royalty Monetization [Member]

Revenue Recognition Royalty and Milestone Revenue Recognized $ 30,000,000

Revenue Recognition Royalty And Milestone Revenue Recognized, Net 22,691,000

Transaction Costs 4,309,000

Interest Reserve 3,000,000

PhaRMA Notes Member] | Currency Hedge Agreement [Member] | Japan, Yen [Member]

Derivative, Forward Exchange Rate 100 100

PhaRMA Notes Member] | Currency Hedge Agreement [Member]

Payments for (Proceeds from) Hedge, Investing Activities $ 1,950,000

Required Foreign Currency Hedge Per Dollar | ¥ ¥ 100

PhaRMA Notes Member] | JPR Royalty Sub LLC [Member]

Percentage of Carrying Amount in Excess of Fair Value 50.00% 50.00%

Currency Hedge Agreement [Member]

Collateral Already Posted, Aggregate Fair Value $ 0 $ 0 $ 0

JPR Royalty Sub LLC [Member]

Revenue Recognition Royalty and Milestone Revenue Recognized $ 30,000,000

Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments $ (352,000) $ 4,082,000 $ 861,000 $ 732,000

X

- Definition
Represents interest reserve established as part of the royalty monetization.
+ References
No definition available.
+ Details

Name: bcrx_Interestreserve

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents maximum amount of collateral required to post.
+ References
No definition available.
+ Details

Name: bcrx_MaximumAmountOfCollateralRequiredToPost

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represents the percentage of carrying amount in excess of fair value.
+ References
No definition available.
+ Details

Name: bcrx_PercentageOfCarryingAmountInExcessOfFairValue1

Namespace Prefix: bcrx_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents private placement of senior secured notes.
+ References
No definition available.
+ Details

Name: bcrx_PrivatePlacementOfSeniorSecuredNotes

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The Company is required to maintain a foreign currency hedge per dollar under the agreements governing the PhaRMA Notes.
+ References
No definition available.
+ Details

Name: bcrx_RequiredForeignCurrencyHedgePerDollar

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents revenue recognition royalty and milestone revenue recognized, net.
+ References
No definition available.
+ Details

Name: bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue recognition royalty and milestone revenue recognized.
+ References
No definition available.
+ Details

Name: bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represents transaction costs associated with royalty monetization.
+ References
No definition available.
+ Details

Name: bcrx_TransactionCosts

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4H

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624258-113959

+ Details

Name: us-gaap_CollateralAlreadyPostedAggregateFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Contractual rate at which a foreign currency can be purchased or sold.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeForwardExchangeRate1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30690-110894

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30700-110894

+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossRealized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

+ Details

Name: us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 27

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3581-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3098-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3095-108585

+ Details

Name: us-gaap_PaymentsForProceedsFromHedgeInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CurrencyAxis=bcrx_JapanYenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 33 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 2 - Stock-Based Compensation
9 Months Ended

Sep. 30, 2015

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Note 2 — Stock-Based Compensation

As of September 30, 2015, the Company had two stock-based employee compensation plans, the Stock Incentive Plan (“Incentive Plan”) and the Employee Stock Purchase Plan (“ESPP”), both which were amended and restated in March 2014 and approved by the Company’s stockholders in May 2014. Stock-based compensation expense of $7,773 ($7,553 of expense related to the Incentive Plan and $220 of expense related to the ESPP) was recognized during the first nine months of 2015, while $6,550 ($6,388 of expense related to the Incentive Plan and $162 of expense related to the ESPP) was recognized during the first nine months of 2014.

There was approximately $14,839 of total unrecognized compensation cost related to non-vested stock option awards and restricted stock unit awards granted by the Company as of September 30, 2015. That cost is expected to be recognized as follows: $1,782 during the remainder of 2015, $5,632 in 2016, $4,627 in 2017, $2,508 in 2018 and $290 in 2019. In addition, the Company has approximately $11,982 of unrecognized compensation cost related to outstanding performance-based stock options for which no compensation expense is recognized until “performance” has occurred and the award vests. At the time of vesting, compensation expense will be recognized.

Stock Incentive Plan

The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company’s stock at the date of grant. Since March 1, 2011, stock option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013, the Company made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully vested after two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of September 30, 2015, 75% of the August 2013 grants have vested based upon achievement of three milestones: (1) successful completion of the OPuS-1 clinical trial, for which vesting occurred in the second quarter of 2014, (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of 2014, and (3) initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers, for which vesting occurred in the second quarter of 2015. Thus, as of September 30, 2015, 25% of the August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5 to 10 years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.

Related activity under the Incentive Plan is as follows:

Awards
Available Options
Outstanding Weighted
Average
Exercise
Price

Balance December 31, 2014 2,362 9,605 $ 6.21

Restricted stock unit awards granted (155 ) — —

Restricted stock unit awards cancelled 1 — —

Stock option awards granted (1,319 ) 1,319 11.99

Stock option awards exercised — (1,102 ) 4.36

Stock option awards cancelled 28 (28 ) 9.05

Balance September 30, 2015 917 9,794 $ 7.19

For stock option awards granted under the Incentive Plan during the first nine months of 2015 and 2014, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the first nine months of 2015 and 2014 was $8.15 and $8.19, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. The following table summarizes the key assumptions used by the Company to value the stock option awards granted during the first nine months of 2015 and 2014. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company’s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on zero-coupon government issues with a remaining term equal to the expected term.

Weighted Average Assumptions for Stock Option Awards Granted to

Employees and Directors under the Incentive Plan

2015 2014

Expected Life in Years 5.5 5.5

Expected Volatility 83 % 87 %

Expected Dividend Yield 0.0 % 0.0 %

Risk-Free Interest Rate 1.5 % 1.6 %

Employee Stock Purchase Plan

The Company has reserved a total of 1,475 shares of common stock to be purchased under the ESPP, of which 497 shares remain available for purchase at September 30, 2015. Eligible employees may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year. The Company issued 41 shares during the first nine months of 2015 under the ESPP. Compensation expense for shares purchased under the ESPP related to the purchase discount and the “look-back” option were determined using a Black-Scholes option pricing model.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares

Sep. 30, 2015

Dec. 31, 2014

Preferred stock par value (in dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized (in shares) 5,000,000 5,000,000

Preferred stock, shares outstanding (in shares) 0 0

Preferred stock, shares issued (in shares) 0 0

Common stock, par value (in dollars per share) $ 0.01 $ 0.01

Common stock, shares authorized (in shares) 200,000,000 200,000,000

Common stock, shares issued (in shares) 73,337,000 71,955,000

Common stock, shares outstanding (in shares) 73,337,000 71,955,000

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 35 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 1 - Summary of Receivables (Details) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Billed Revenues [Member] | US Department of Health and Human Services [Member]

Receivables

Billed Revenues [Member] | Green Cross Corporation [Member]

Receivables $ 129

Billed Revenues [Member] | Shionogi and Co. Ltd [Member]

Receivables $ 1,071

Billed Revenues [Member] | CSL Limited [Member

Receivables 1,922

Billed Revenues [Member]

Receivables 2,051 1,071

Unbilled Revenues [Member] | US Department of Health and Human Services [Member]

Receivables $ 5,444 $ 2,778

Unbilled Revenues [Member] | Green Cross Corporation [Member]

Receivables

Unbilled Revenues [Member] | Shionogi and Co. Ltd [Member]

Receivables

Unbilled Revenues [Member] | CSL Limited [Member

Receivables

Unbilled Revenues [Member]

Receivables $ 5,444 $ 2,778

US Department of Health and Human Services [Member]

Receivables 5,444 2,778

Green Cross Corporation [Member]

Receivables 129

Shionogi and Co. Ltd [Member]

Receivables 1,071

CSL Limited [Member

Receivables 1,922

Receivables $ 7,495 $ 3,849

X

- Definition
The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_ReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_CSLLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814

Document And Entity Information - shares
9 Months Ended

Sep. 30, 2015

Oct. 31, 2015

Entity Registrant Name BIOCRYST PHARMACEUTICALS INC

Entity Central Index Key 0000882796

Trading Symbol bcrx

Current Fiscal Year End Date --12-31

Entity Filer Category Large Accelerated Filer

Entity Current Reporting Status Yes

Entity Voluntary Filers No

Entity Well-known Seasoned Issuer Yes

Entity Common Stock, Shares Outstanding (in shares) 73,336,871

Document Type 10-Q

Document Period End Date Sep. 30, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q3

Amendment Flag false

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 37 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 1 - Inventory (Details) - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Work in process $ 267,000

Finished Goods 416,000

Net inventories $ 683,000

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryWorkInProcessNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 38 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814

Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)
shares in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Revenues

Product sales, net $ 5,699,000 $ 6,236,000

Royalty revenue 126,000 $ 5,000 1,776,000 $ 1,951,000

Collaborative and other research and development 5,162,000 3,233,000 35,643,000 6,211,000

Total revenues 10,987,000 $ 3,238,000 43,655,000 $ 8,162,000

Expenses

Cost of products sold 1,346,000 1,361,000

Research and development 20,067,000 $ 13,036,000 53,711,000 $ 33,286,000

Selling, general and administrative 2,731,000 $ 1,812,000 10,326,000 5,413,000

Royalty 5,000 507,000 78,000

Total operating expenses 24,149,000 $ 14,848,000 65,905,000 38,777,000

Loss from operations (13,162,000) (11,610,000) (22,250,000) (30,615,000)

Interest and other income 134,000 14,000 367,000 50,000

Interest expense (1,241,000) (1,217,000) (3,862,000) (3,684,000)

(Loss) gain on foreign currency derivative (352,000) 4,082,000 861,000 732,000

Net loss $ (14,621,000) $ (8,731,000) $ (24,884,000) $ (33,517,000)

Basic and diluted net loss per common share (in dollars per share) $ (0.20) $ (0.12) $ (0.34) $ (0.52)

Weighted average shares outstanding (in shares) 73,262 71,801 72,752 65,057

Unrealized gain (loss) on available for sale investments $ 91,000 $ (1,000) $ 129,000 $ (2,000)

Comprehensive loss $ (14,530,000) $ (8,732,000) $ (24,755,000) $ (33,519,000)

X

- Definition
Collaborative and other research and development during the period.
+ References
No definition available.
+ Details

Name: bcrx_CollaborativeAndOtherResearchAndDevelopment

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total costs related to goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

+ Details

Name: us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).
+ References
No definition available.
+ Details

Name: us-gaap_InterestAndOtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 39 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 1 - Significant Accounting Policies (Tables)
9 Months Ended

Sep. 30, 2015

Notes Tables

Available-for-sale Securities [Table Text Block]

September 30, 2015

Amortized
Cost Accrued
Interest Gross
Unrealized
Gains Gross
Unrealized
Losses Estimated
Fair Value

Obligations of U.S. Government and its agencies $ 23,119 $ 42 $ 28 $ (2 ) $ 23,187

Corporate debt securities 27,249 141 26 (14 ) 27,402

Certificates of deposit 20,909 28 10 (49 ) 20,898

Total investments $ 71,277 $ 211 $ 64 $ (65 ) $ 71,487

December 31, 2014

Amortized
Cost Accrued
Interest Gross
Unrealized
Gains Gross
Unrealized
Losses Estimated
Fair Value

Obligations of U.S. Government and its agencies $ 20,307 $ 22 $ — $ (23 ) $ 20,306

Corporate debt securities 27,152 151 5 (47 ) 27,261

Certificates of deposit 11,838 6 — (63 ) 11,781

Total investments $ 59,297 $ 179 $ 5 $ (133 ) $ 59,348

Available For Sale Securities Debt Maturities Fair Value [Table Text Block]

2015 2014

Maturing in one year or less $ 23,700 $ 18,232

Maturing after one year through two years 27,183 25,459

Maturing after two years 20,604 15,657

Total investments $ 71,487 $ 59,348

Schedule of Receivables from Collaborations [Table Text Block]

September 30, 2015

Billed

Unbilled

Total

U.S. Department of Health and Human Services $ — $ 5,444 $ 5,444

Green Cross Corporation 129 — 129

Seqirus UK Limited
1,922 — 1,922

Total receivables $ 2,051 $ 5,444 $ 7,495

December 31, 2014

Billed Unbilled Total

U.S. Department of Health and Human Services $ — $ 2,778 $ 2,778

Shionogi & Co. Ltd. 1,071 — 1,071

Total receivables $ 1,071 $ 2,778 $ 3,849

Schedule of Inventory, Current [Table Text Block]

2015 2014

Work in process $ — $ 267

Finished Goods — 416

Net inventories $ — $ 683

Schedule of Revenues from Collaborations [Table Text Block]

Three Months Nine Months

2015 2014 2015 2014

Product sales, net $ 5,699 $ — $ 6,236 $ —

Royalty revenue 126 5 1,776 1,951

Collaborative and other research and development revenues:

U.S. Department of Health and Human Services 4,582 2,937 12,788 5,323

Green Cross Corporation 132 — 132 —

Shionogi (Japan) 296 296 888 888

Seqirus UK Limited
152 — 21,835 —

Total collaborative and other research and development revenues 5,162 3,233 35,643 6,211

Total revenues $ 10,987 $ 3,238 $ 43,655 $ 8,162

X

- Definition
Tabular disclosure of available for sale securities debt maturities fair value.
+ References
No definition available.
+ Details

Name: bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock

Namespace Prefix: bcrx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure representing receivables from collaborations.
+ References
No definition available.
+ Details

Name: bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock

Namespace Prefix: bcrx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of schedule of revenues from collaborations.
+ References
No definition available.
+ Details

Name: bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock

Namespace Prefix: bcrx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814

Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Description of Company [Policy Text Block]
The Company

BioCryst Pharmaceuticals, Inc. (the “Company”) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.

Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash and investments of $119,736, to continue its planned operations into 2017. The Company’s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond 2017 it will need to: (1) successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2) out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3) raise additional capital through equity or debt financings or from other sources; (4) obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5) reduce spending on one or more research and development programs; and/or (6) restructure operations. The Company retains the ability to offer for sale approximately $150,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants, and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on March 3, 2015. Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on November 6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.

Consolidation, Policy [Policy Text Block]
Basis of Presentation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (“Royalty Sub”). Royalty Sub was formed in connection with a $30,000 financing transaction the Company completed on March 9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.

The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management’s opinion, necessary to present fairly, in all material respects, the Company’s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.

These financial statements should be read in conjunction with the financial statements for the year ended December 31, 2014 and the notes thereto included in the Company’s 2014 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December 31, 2014 has been derived from the audited consolidated financial statements included in the Company’s most recent Annual Report on Form 10-K.

Reclassification, Policy [Policy Text Block]
Reclassifications

Certain balance sheet amounts as of December 31, 2014 have been reclassified to conform to the 2015 presentation.

Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents

The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Restricted Cash

Restricted cash as of September 30, 2015 reflects $150 the Company is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program, $70 in royalty revenue paid by Shionogi & Co., Ltd. (“Shionogi”) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,402 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.

Investment, Policy [Policy Text Block]
Investments

The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company’s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company’s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company’s investments are not collateralized. The Company has not realized any significant losses from its investments.

The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At September 30, 2015, the Company believes that the costs of its investments are recoverable in all material respects.

The following tables summarize the fair value of the Company’s investments by type. The estimated fair value of the Company’s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.

September 30, 2015

Amortized

Cost

Accrued

Interest

Gross

Unrealized

Gains

Gross

Unrealized

Losses

Estimated

Fair Value

Obligations of U.S. Government and its agencies $ 23,119 $ 42 $ 28 $ (2 ) $ 23,187

Corporate debt securities 27,249 141 26 (14 ) 27,402

Certificates of deposit 20,909 28 10 (49 ) 20,898

Total investments $ 71,277 $ 211 $ 64 $ (65 ) $ 71,487

December 31, 2014

Amortized

Cost

Accrued

Interest

Gross

Unrealized

Gains

Gross

Unrealized

Losses

Estimated

Fair Value

Obligations of U.S. Government and its agencies $ 20,307 $ 22 $ - $ (23 ) $ 20,306

Corporate debt securities 27,152 151 5 (47 ) 27,261

Certificates of deposit 11,838 6 - (63 ) 11,781

Total investments $ 59,297 $ 179 $ 5 $ (133 ) $ 59,348

The following table summarizes the scheduled maturity for the Company’s investments at September 30, 2015 and December 31, 2014.

2015 2014

Maturing in one year or less $ 23,700 $ 18,232

Maturing after one year through two years 27,183 25,459

Maturing after two years 20,604 15,657

Total investments $ 71,487 $ 59,348

Receivables, Policy [Policy Text Block]
Receivables from Collaborations

Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi & Co. Ltd., product sales to Green Cross Corporation and CSL Limited. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At September 30, 2015 and December 31, 2014, the Company had the following receivables.

September 30, 2015

Billed Unbilled
Total

U.S. Department of Health and Human Services $ - $ 5,444 $ 5,444

Green Cross Corporation 129 - 129

CSL Limited 1,922 - 1,922

Total receivables $ 2,051 $ 5,444 $ 7,495

December 31, 2014

Billed Unbilled Total

U.S. Department of Health and Human Services $ - $ 2,778 $ 2,778

Shionogi & Co. Ltd. 1,071 - 1,071

Total receivables $ 1,071 $ 2,778 $ 3,849

Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company’s calculations of its indirect cost rates are subject to audit by the U.S. Government.

Receivables from Product Sales

Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB
®
. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.

Inventory, Policy [Policy Text Block]
Inventory

At September 30, 2015 and December 31, 2014, the Company’s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (“FIFO”) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.

During 2014, in connection with the Food and Drug Administration (“FDA”) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB commercial inventories.

The Company’s inventory consisted of the following at September 30, 2015 and December 31, 2014:

2015 2014

Work in process $ - $ 267

Finished Goods - 416

Net inventories $ - $ 683

Intangible Assets, Finite-Lived, Policy [Policy Text Block]
Patents and Licenses

The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to general and administrative expenses when incurred as recoverability of such expenditures is uncertain.

Accrued Expenses [Policy Text Block]
Accrued Expenses

The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:

•

fees paid to Clinical Research Organizations (“CROs”) in connection with preclinical and toxicology studies and clinical trials;

•

fees paid to investigative sites in connection with clinical trials;

•

fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products; and

•

professional fees.

The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company’s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of September 30, 2015 and December 31, 2014, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.

Income Tax, Policy [Policy Text Block]
Income Taxes

The liability method is used in the Company’s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.

Comprehensive Income, Policy [Policy Text Block]
Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss is comprised of unrealized gains and losses on investments available-for-sale and is disclosed as a separate component of stockholders’ equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the nine months ended September 30, 2015, realized gains of $13 were reclassified out of accumulated other comprehensive loss. No reclassifications out of accumulated other comprehensive loss were recorded during the nine months ended September 30, 2014.

Revenue Recognition, Policy [Policy Text Block]
Revenue Recognition

The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the seller’s price to the buyer is fixed or determinable; and (iv) collectability is reasonably assured.

Collaborative and Other Research and Development Arrangements and Royalties

Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.
Under certain of the Company’s license agreements, the Company receives royalty payments based upon its licensees’ net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.

For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has “stand-alone value” to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (“TPE”) and (iii) best estimate of selling price (“BESP”). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.

In June 2015, the Company entered into a License Agreement (the “Agreement”) granting CSL Limited (“CSL”) and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (“EU”) marketing approvals. The Company received an upfront payment of $33,740 from CSL of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the current quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter when the inventory transfer was completed. Approximately $1,223 of this revenue will be recognized over the expected period of involvement in these regulatory support activities.

Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.

Under the terms of the Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the European Union and (iii) by Health Canada for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17,
Milestone Method of Revenue Recognition
, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.

Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company’s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (”BARDA/HHS”) and the National Institute of Allergy and Infectious Diseases (“NIAID/HHS”), revenue is recognized as reimbursable direct and indirect costs are incurred.

Product Sales

The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, the Company sells RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations. With the completion of the CSL worldwide license of RAPIVAB, CSL will be primarily responsible for sales of RAPIVAB other than U.S. Government stockpiling sales and the Company’s commercial sales will be minimal.

Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.
The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.

The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.

The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.

Rebates and Chargebacks

Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB’s selling price. As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.

Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.

The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company’s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company’s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.

Discounts and Sales Incentives

Discounts and other sales incentives primarily consist of Inventory Management Agreement (“IMA”) Fees. Per contractual agreements with the Company’s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.

Product Returns

The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.

Advertising

The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB.

The Company recorded the following revenues for the three and nine months ended September 30, 2015 and 2014:

Three Months Nine Months

2015 2014 2015 2014

Product sales, net $ 5,699 $ - $ 6,236 $ -

Royalty revenue 126 5 1,776 1,951

Collaborative and other research and development revenues:

U.S. Department of Health and Human Services 4,581 2,937 12,788 5,323

Green Cross Corporation 132 - 132 -

Shionogi (Japan) 296 296 888 888

CSL Limited 153 - 21,835 -

Total collaborative and other research and development revenues 5,162 3,233 35,643 6,211

Total revenues $ 10,987 $ 3,238 $ 43,655 $ 8,162

Research and Development Expense, Policy [Policy Text Block]
Research and Development Expenses

The Company’s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company’s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company’s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company’s on-going review of the level of services actually performed.

Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (“AECOM”), Industrial Research, Ltd. (“IRL”), and the University of Alabama at Birmingham (“UAB”), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.

Deferred collaboration expenses represent sub-license payments, paid to the Company’s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company’s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Stock-Based Compensation

All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company’s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until “performance” has occurred.

Interest Expense and Deferred Financing Costs [Policy Text Block]
Interest Expense and Deferred Financing Costs

Interest expense for the three months ended September 30, 2015 and 2014 was $1,214 and $1,217, respectively, and for the nine months ended September 30, 2015 and 2014 was $3,862 and $3,684, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended September 30, 2015 and 2014, and $329 for each of the nine months ended September 30, 2015 and 2014.

Currency Hedge Agreement [Policy Text Block]
Currency Hedge Agreement

In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement (defined in Note 4) to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company’s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the nine months ended September 30, 2015 and 2014 resulted in a loss of $792 and a gain of $732, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized a currency exchange gain of $1,653 during the first nine months of 2015 associated with the exercise of a U.S. Dollar/Japanese yen currency option.

The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of September 30, 2015 and December 31, 2014, no hedge collateral was posted under the agreement.

Earnings Per Share, Policy [Policy Text Block]
Net Loss Per Share

Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company’s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended September 30, 2015 and 2014 does not include 0,000 and 0,000, respectively, of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the nine months ended September 30, 2015 and 2014 does not include 0,000 and 0,000, respectively, of such potential common shares, as their impact would be anti-dilutive.

Use of Estimates, Policy [Policy Text Block]
Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.

Concentration of Market Risk [Policy Text Block]
Significant Customers and Other Risks

The Company relies primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company’s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the CSL transaction as CSL will be responsible for commercial sales on a worldwide basis with the exception of Israel, Japan, Korea and Taiwan.

The Company’s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB (i.e., peramivir) and BCX4430 development expenses, which was earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company’s collaborative and other research and development revenues. The completion, as with the June 30, 2014 BARDA/HHS peramivir development contract, or termination of the NIAID/HHS and BARDA/HHS BCX4430 programs/collaboration could negatively impact the Company’s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company’s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. The Company’s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company’s ability to complete its drug development activities.

Risks from Third Party Manufacturing and Distribution Concentration

The Company relies on single source manufacturers for active pharmaceutical ingredient and finished product manufacturing of RAPIVAB. Additionally, the Company relies upon a single third party to provide warehousing and distribution services for RAPIVAB. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB.

Concentration Risk, Credit Risk, Policy [Policy Text Block]
Credit Risk

Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale receivables discussed above, the majority of the Company’s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.

New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements

In April 2015, the FASB issued ASU No. 2015-03,
Simplifying the Presentation of Debt Issuance Costs
. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company does not expect this ASU will have a material impact on its consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09 –
Revenue from Contracts with Customers
, which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018, however early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements.

X

- Definition
Represents accrued expenses policy.
+ References
No definition available.
+ Details

Name: bcrx_AccruedExpensesPolicyTextBlock

Namespace Prefix: bcrx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents concentration of market risk policy.
+ References
No definition available.
+ Details

Name: bcrx_ConcentrationOfMarketRiskPolicyTextBlock

Namespace Prefix: bcrx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents currency hedge agreement policy.
+ References
No definition available.
+ Details

Name: bcrx_CurrencyHedgeAgreementPolicyTextBlock

Namespace Prefix: bcrx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
The description of company policy.
+ References
No definition available.
+ Details

Name: bcrx_DescriptionOfCompanyPolicyTextBlock

Namespace Prefix: bcrx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents interest expense and deferred financing costs.
+ References
No definition available.
+ Details

Name: bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock

Namespace Prefix: bcrx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.1(a))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

+ Details

Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for comprehensive income.
+ References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 55

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51676700&loc=d3e61082-112788

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28088331&loc=SL29635902-196195

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51676700&loc=d3e61044-112788

+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.3A-02)

-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph k

-Article 1

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02, 03

-Article 3A

+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsFiniteLivedPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4492-108314

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4556-108314

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 206

-Paragraph b

-Subparagraph i, ii

-Chapter 2

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2,12)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 325

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6872867&loc=d3e40691-111596

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section M

+ Details

Name: us-gaap_InvestmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6378556&loc=d3e10133-111534

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e4975-111524

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3-5

-Article 5

+ Details

Name: us-gaap_ReceivablesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6132-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 3 - Collaborative and Other Research and Development Contracts (Details Textual) - USD ($)
1 Months Ended 9 Months Ended 50 Months Ended

Jun. 16, 2015

Sep. 30, 2013

Feb. 24, 2011

May. 31, 2010

Sep. 30, 2009

Jan. 31, 2007

Jun. 30, 2006

Sep. 30, 2015

Feb. 24, 2011

Mar. 31, 2015

US Department of Health and Human Services [Member]

Contract Term 4 years

Collaborative Agreement Contract Value $ 102,661,000

Collaborative Agreement Additional Contract Value $ 55,000,000 $ 77,191,000

Collaborative Agreement Adjusted Contract Value $ 234,852,000

National Institute of Allergy and Infectious Diseases [Member]

Proceeds from awards for Research and Development Contracts $ 5,000,000 $ 29,875

Expected Receivable From Awards for Research and Development Contracts $ 34,002,000

Collaborative Agreement Period of Contract 5 years

UAB [Member]

Period of Agreement 25 years

Renewable Period of Agreement 5 years

Base Contract [Member]

Government Contract Receivable $ 13,314,000

Additional Development Options [Member]

Government Contract Receivable 22,855,000

ASPRBARDA Contract [Member]

Government Contract Receivable $ 36,169,000

Proceeds from awards for Research and Development Contracts $ 16,300,000

Green Cross Corporation [Member]

Proceeds from License Fees Received $ 250,000

AECOM and IRL [Member]

Milestone Payment Maximum 4,000,000

Milestone Payment Minimum 1,400,000

Annual License Fee Minimum 150,000

Annual License Fee Maximum $ 500,000

Advance Notice Period for Termination of Agreement 60 days

Stock Issued During Period, Value, for Modification of License Agreement $ 5,911,000

Payments for Modification of License Agreement $ 90,000

CSL Limited [Member

Proceeds from License Fees Received $ 33,740,000

Milestone Payment Maximum $ 12,000,000

Royalty Term 10 years

X

- Definition
Represents advance notice period for termination of agreement.
+ References
No definition available.
+ Details

Name: bcrx_AdvanceNoticePeriodForTerminationOfAgreement

Namespace Prefix: bcrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents annual maximum license fee.
+ References
No definition available.
+ Details

Name: bcrx_AnnualLicenseFeeMaximum

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represent minimum annual license fee.
+ References
No definition available.
+ Details

Name: bcrx_AnnualLicenseFeeMinimum

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Collaborative agreement additional contract value during the period.
+ References
No definition available.
+ Details

Name: bcrx_CollaborativeAgreementAdditionalContractValue

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents collaborative agreement adjusted contract value.
+ References
No definition available.
+ Details

Name: bcrx_CollaborativeAgreementAdjustedContractValue

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents collaborative agreement contract value.
+ References
No definition available.
+ Details

Name: bcrx_CollaborativeAgreementContractValue

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents collaborative agreement period of contract.
+ References
No definition available.
+ Details

Name: bcrx_CollaborativeAgreementPeriodOfcontract

Namespace Prefix: bcrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between the contract date and its expiration.
+ References
No definition available.
+ Details

Name: bcrx_ContractTerm

Namespace Prefix: bcrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents expected receivable from awards for research and development contracts.
+ References
No definition available.
+ Details

Name: bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents milestone payment maximum.
+ References
No definition available.
+ Details

Name: bcrx_MilestonePaymentMaximum

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents milestone payment minimum.
+ References
No definition available.
+ Details

Name: bcrx_MilestonePaymentMinimum

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents payments for modifications of license agreement.
+ References
No definition available.
+ Details

Name: bcrx_PaymentsForModificationOfLicenseAgreement

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents period of agreement.
+ References
No definition available.
+ Details

Name: bcrx_PeriodOfAgreement

Namespace Prefix: bcrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents proceeds from awards for research and development contracts.
+ References
No definition available.
+ Details

Name: bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents renewable period of agreement.
+ References
No definition available.
+ Details

Name: bcrx_RenewablePeriodOfAgreement

Namespace Prefix: bcrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between the date of the Agreement and its expiration.
+ References
No definition available.
+ Details

Name: bcrx_RoyaltyTerm

Namespace Prefix: bcrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents stock issued during period value for modification of license agreement.
+ References
No definition available.
+ Details

Name: bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of receivables that are derived from government contracts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 912

-SubTopic 310

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51666815&loc=d3e55295-109406

+ Details

Name: us-gaap_GovernmentContractReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Cash received from licensees for license fees during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_ProceedsFromLicenseFeesReceived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 1 - Summary of Revenues (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

US Department of Health and Human Services [Member]

Collaborative and other research and development revenues:

U.S. Department of Health and Human Services $ 4,582 $ 2,937 $ 12,788 $ 5,323

Green Cross Corporation [Member]

Collaborative and other research and development revenues:

U.S. Department of Health and Human Services 132 132

Shionogi and Co. Ltd [Member]

Collaborative and other research and development revenues:

U.S. Department of Health and Human Services 296 $ 296 888 $ 888

CSL [Member]

Collaborative and other research and development revenues:

U.S. Department of Health and Human Services 152 21,835

Product sales, net 5,699 6,236

Royalty revenue 126 $ 5 1,776 $ 1,951

U.S. Department of Health and Human Services 5,162 3,233 35,643 6,211

Revenues $ 10,987 $ 3,238 $ 43,655 $ 8,162

X

- Definition
Represents collaborative and other research and development.
+ References
No definition available.
+ Details

Name: bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SalesRevenueServicesNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=bcrx_GreenCrossCorporationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=bcrx_CSLMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 1 - Fair Value of the Company's Investments by Type (Details) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

US Government Agencies Debt Securities [Member]

Amortized Cost $ 23,119 $ 20,307

Accrued Interest 42 $ 22

Gross Unrealized Gains 28

Gross Unrealized Losses (2) $ (23)

Estimated Fair Value 23,187 20,306

Corporate Debt Securities [Member]

Amortized Cost 27,249 27,152

Accrued Interest 141 151

Gross Unrealized Gains 26 5

Gross Unrealized Losses (14) (47)

Estimated Fair Value 27,402 27,261

Certificates of Deposit [Member]

Amortized Cost 20,909 11,838

Accrued Interest 28 $ 6

Gross Unrealized Gains 10

Gross Unrealized Losses (49) $ (63)

Estimated Fair Value 20,898 11,781

Amortized Cost 71,277 59,297

Accrued Interest 211 179

Gross Unrealized Gains 64 5

Gross Unrealized Losses (65) (133)

Estimated Fair Value $ 71,487 $ 59,348

X

- Definition
Represents available for sale securities accrued interest.
+ References
No definition available.
+ Details

Name: bcrx_AvailableForSaleSecuritiesAccruedInterest

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26610-111562

+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 2 - Stock-Based Compensation (Tables)
9 Months Ended

Sep. 30, 2015

Notes Tables

Schedule of Share-based Compensation, Activity [Table Text Block]

Awards
Available Options
Outstanding Weighted
Average
Exercise
Price

Balance December 31, 2014 2,362 9,605 $ 6.21

Restricted stock unit awards granted (155 ) — —

Restricted stock unit awards cancelled 1 — —

Stock option awards granted (1,319 ) 1,319 11.99

Stock option awards exercised — (1,102 ) 4.36

Stock option awards cancelled 28 (28 ) 9.05

Balance September 30, 2015 917 9,794 $ 7.19

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

2015 2014

Expected Life in Years 5.5 5.5

Expected Volatility 83 % 87 %

Expected Dividend Yield 0.0 % 0.0 %

Risk-Free Interest Rate 1.5 % 1.6 %

X

- Definition
Tabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 1 - Significant Accounting Policies (Details Textual) - USD ($)
shares in Thousands
1 Months Ended 3 Months Ended 9 Months Ended

Mar. 03, 2015

Nov. 06, 2013

Jun. 30, 2015

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Mar. 09, 2011

Currency Hedge Agreement [Member]

Collateral Already Posted, Aggregate Fair Value $ 0 $ 0 $ 0

Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]

Derivative, Loss on Derivative 793,000

Derivative, Gain on Derivative 1,654,000 $ 732,000

JPR Royalty Sub LLC [Member]

Revenue Recognition Royalty and Milestone Revenue Recognized $ 30,000,000

Certificates of Deposit [Member]

Restricted Cash and Cash Equivalents, Current 150,000 150,000

Royalty Receivable [Member]

Restricted Cash and Cash Equivalents, Current 70,000 70,000

Collateral for Credit [Member]

Restricted Cash and Cash Equivalents 1,402,000 $ 1,402,000

Maximum [Member]

Maturity Period of High Quality Marketable Securities 3 years

Average Maturity Period of High Quality Marketable Securities 18 years

Maturity Period of Short Term Investment 12 years

Average Maturity for Portfolio Investments 1 year 180 days

Minimum [Member]

Maturity Period of Short Term Investment 3 years

Long-term Investment Maturity, Minimum 12 years

CSL [Member] | Agreement [Member] | RAPIVABMember | Contingent upon EU Marketing Approval [Member]

Proceeds from License Fees Received $ 7,000,000

CSL [Member] | Agreement [Member] | RAPIVABMember | Revenue from Sale of Inventory to be Recognized When the Inventory Transfer Is Complete [Member]

Deferred Revenue, Additions 3,740,000

CSL [Member] | Agreement [Member] | RAPIVABMember | Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]

Deferred Revenue, Additions 1,223,000

CSL [Member] | Agreement [Member] | RAPIVABMember

Proceeds from License Fees Received 33,740,000

Revenues 21,777,000

Milestone Payment Maximum $ 12,000,000

RAPIVABMember | Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member]

Concentration Risk, Percentage 90.00%

Loss on Sale of Investments $ 0

Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax 13,000 0

Amortization of Financing Costs 110,000 $ 110,000 329,000 329,000

Investments and Cash 119,736,000 119,736,000

Securities Offered $ 150,000,000 $ 10,000,000

Restricted Cash and Cash Equivalents, Current 1,622,000 1,622,000 $ 150,000

Revenues 10,987,000 3,238,000 43,655,000 8,162,000

Interest Expense $ 1,241,000 $ 1,217,000 $ 3,862,000 $ 3,684,000

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3,821 4,240 3,673 3,986

X

- Definition
Average maturity for portfolio investments during the period.
+ References
No definition available.
+ Details

Name: bcrx_AveragematurityForPortfolioInvestments

Namespace Prefix: bcrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Average maturity period of high quality marketable securities.
+ References
No definition available.
+ Details

Name: bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities

Namespace Prefix: bcrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents long term investment maturity minimum.
+ References
No definition available.
+ Details

Name: bcrx_LongtermInvestmentMaturityMinimum

Namespace Prefix: bcrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents maturity period of high quality marketable securities.
+ References
No definition available.
+ Details

Name: bcrx_MaturityPeriodOfHighQualityMarketablesecurities

Namespace Prefix: bcrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Maturity period of short term investment.
+ References
No definition available.
+ Details

Name: bcrx_MaturityperiodOfShortTermInvestment

Namespace Prefix: bcrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents milestone payment maximum.
+ References
No definition available.
+ Details

Name: bcrx_MilestonePaymentMaximum

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue recognition royalty and milestone revenue recognized.
+ References
No definition available.
+ Details

Name: bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represents securities offered for sale.
+ References
No definition available.
+ Details

Name: bcrx_SecuritiesOffered

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 8

-Article 9

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4H

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624258-113959

+ Details

Name: us-gaap_CollateralAlreadyPostedAggregateFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueAdditions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in the fair value of derivatives recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (a),(c),(d),(e)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

+ Details

Name: us-gaap_DerivativeGainOnDerivative

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of decrease in the fair value of derivatives recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (a),(c),(d),(e)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeLossOnDerivative

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Sum of investments and unrestricted cash as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.1,2)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_InvestmentsAndCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The difference between the carrying value and the sale price of an investment. A loss would be recognized when the sale price of the investment is less than the carrying value of the investment. This element refers to the Loss included in earnings and not to the cash proceeds of the sale.
+ References
No definition available.
+ Details

Name: us-gaap_LossOnSaleOfInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cash received from licensees for license fees during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_ProceedsFromLicenseFeesReceived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before tax of reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

+ Details

Name: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RestrictedCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=bcrx_CSLMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=bcrx_ContingentUponEuMarketingApprovalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 1 - Scheduled Maturity for the Company's Investments (Details) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Maturing in one year or less $ 23,700 $ 18,232

Maturing after one year through two years 27,183 25,459

Maturing after two years 20,604 15,657

Total investments $ 71,487 $ 59,348

X

- Definition
Represents available for sale securities debt maturities after one through two years fair value.
+ References
No definition available.
+ Details

Name: bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents debt maturities after two years.
+ References
No definition available.
+ Details

Name: bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26610-111562

+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27198-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 3

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 47 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 2 - Stock Incentive Plan Activities (Details)
shares in Thousands
9 Months Ended

Sep. 30, 2015

$ / shares

shares

Awards Available (in shares) 2,362

Options Outstanding (in shares) 9,605

Weighted Average Exercise Price (in dollars per share) | $ / shares $ 6.21

Restricted stock unit awards granted (in shares) (155)

Restricted stock unit awards cancelled (in shares) 1

Stock option awards granted (in shares) (1,319)

Stock option awards granted (in shares) 1,319

Stock option awards granted (in dollars per share) | $ / shares $ 11.99

Stock option awards exercised (in shares) (1,102)

Stock option awards exercised (in dollars per share) | $ / shares $ 4.36

Stock option awards cancelled (in shares) 28

Stock option awards cancelled (in shares) (28)

Stock option awards cancelled (in dollars per share) | $ / shares $ 9.05

Balance September 30, 2015 (in shares) 917

Balance September 30, 2015 (in shares) 9,794

Balance September 30, 2015 (in dollars per share) | $ / shares $ 7.19

X

- Definition
Represents share based compensation arrangement by share based payment award options grants in period awards available.
+ References
No definition available.
+ Details

Name: bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable

Namespace Prefix: bcrx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation arrangement by share based payment award options forfeitures in period awards available.
+ References
No definition available.
+ Details

Name: bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable

Namespace Prefix: bcrx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price of options that were either forfeited or expired.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Net number of share options (or share units) granted during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

ZIP 48 0001171843-15-006102-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-15-006102-xbrl.zip M4$L#!!0````(`*B!9D=A.'$YN/L``(Y*"0`1`!P`8F-R>"TR,#$U,#DS,"YX M;6Q55`D``^P7/5;L%SU6=7@+``$$)0X```0Y`0``[#UK<]LXDM^OZOX#SK>S ME51)MJB'9=F3;#GV)O%>'C[;LS?S:0HB(0D3DF``T+;FUU]W@R_)HBP_%#L3 M;>UF91)H]!M`H]GX^1_74<@NA392Q:^VO.W6%A.QKP(9CU]M_7+>/#P_.CG9 M^L?KG_^KV7PG8J&Y%0$;3MG%)(T#H8]5)-BO;\X^L"9K[>U[[=./[)>+(]9N M>;VFYS5;N\WFZY^OASJ4^_@O@_%B\VIK8FVRO[-S=76UC8^WE1[OM%NMSHZ, MC>6Q+[96M?97&5D^+#@3;"'][K"YW MLI?8J=-L>[>`&FE4M^WUES'9M<@[A#+^LJ0UOAYR4X@DYM(WBW&B5XB2-XM2K.(X MC1:/$5B]8Z>)V(%&36@EM/3S?D;ZBP>"%PN&,3;1->WAS8(.UFEQ`%H\@]S9 M\;NW$N@>&U2SO'5JFF/.DZ+EB)LAD9"]('6<'2"UNI:S@QUXFS?$%\&<,F7M M=G?0<3NKXAWZL.M?8&@\$.O2V:FD7M`*JW\^O'#^?^1$2\>0.^D7?I M]?H__X.QGW'4?4.OSL2($1;[$RU&K[;0Y)NY96]?FV`K>XU:\FK+R"@)Q=:. M@X.-]P]]7Z-`RGL%VUL'T% MUEI%"SW-?9ORD/&Q%B*"MX9=23MA=B)UT$RXME/8\,:!@DY7$\42K2YE()@6 M1G#M3QB/`Q:(2Q&J!+LW`+DX'2%4#1N"!KU7=B(T,T)?2E_@X`!>,*5AW\SU M%/!(M8&_1VR8&I"X,=OL''?*\`0:PJL<4\.X%LRDPS^$;QF0`#H/NSH5BR9N MN0(`?:FD#P/3N,6(V`MV)K`0QOVX@AT\O&?`-J`,'B3`5A70<,#G;59EG18^ M(&I8*/D0]CA6`CC:!# MJ#(->)&D("UNB.V@`0U"-HVE#]A`#Q(Z3Q(P+CX,2_*!-09VHR)$;DM4,5#T MDK%VPBU0$`,A)1FXPI"5$G4'",EB5OM@:FW!C ME"\IA.(K8PM&@:40]XNNQ&M;$1KR-E:6387->4R<`[RTT\8K":R`)G(D!4F^ M$*&Q3@$B_H?2$M2_BJ/3?FUR@#.C1L#P"=@8Z#<'/#DT0TP+9A44SFI8Q+_` MRXP]PCADG&<3F6<#5N!CP<'@ACS$C2$S$P'4!=`%!T1FC\"<8F!8""X%'CL] M=':A'']&A3KX4OMIY/:89A8?9PV@!^@O0(E&4D?&"<0'`7"?6((#ECAG/D,L MX!2.YDCD`3I*AY8QOQ(01*KK\&>0H9;!Z/RVBPP8+>H!?M"CW?%ZS*BE0:O^T\ER]"A=*G/[[ MNMUJMV].V'?&T'L<0@?KH'0DT/ZY#-"-'@$`')V=Y9/H9SWFL?R3)@;#7A1\ M\?R#H[//IOP[.'B)UNZC2_9I&B'+2V"6RH&2]U37$I1*C<%5VS20(C/ZO(W5 MX"7,4I[O5'1JAU1]8VT;:_L.K>#:#M9T0>J>P3H--FU,\RN&:S4RF08+=#K&W9E;5KJM(3[*.IH* M1^#=QL(V%O97M##0]A%L;,!,8#9!<]M^:DW_7L)4N%9;_FT"&DOB,YJ M=H;.0PPS&^?*%A3[^@+F?!=0$"/8>^>0*>B3:I/RV%;]8+:1C=+02MB/EE$N M/(Z5-G7KEM$4P_5]BJF.P^DV.R3U.1>)%=$0Z.ZT M&I1F1/0=@V6XIQX][;H!?*[U%+&_Y&$J%@>B$G!OUR6#I0;IPS^N1P#_`XUS MS\T$2&JB)@/=UH:DP#=]X>9W[>^?=U;(UZ@F=@27J&F?P"/XXI34\ZW2%Q1_ M)A?Q>728>Y)5TCQ^OY@F`OIHS>,Q]3J\EJ9Y^,^CSQ\/X^#D[,-'4J,B':3? M[WA[6Z]/=UO'.>YW0*E*21R#1G^`/D#Q6R$^;5U M\NGM#.+]+7!X,H/M4KZ:J0FV7O=:^)^:#CTR)3S!\R-P2_74G-!^&\E`NHB47\[?H>^-B;:Q M@"E.F&,QM"7TFQ0V.R6!NX/VH([`;KM"WZK8KYWB(Z43A=F?=R.STZV58]=[ MEG3BXGJ$ATC"?!X=BT09:6^ELE:8[;VG)K(>ZVZM;-K>T\FFV_3:S8ZW'JOK MU@OJZ:QN"<7WM+I>O=7UGJ5D[V5UO5IA[CXUC?5([]:+IC]8%]JH/1^YS2&, MH.OG6%Q,M$K'DXLK]1L>[;Z%5>^_:=%[=U?2;]7:5=_;ZZQ"U]UP_"9DWRK, MOE=+=J_;6TF<:R>[Z'N!C>^3%-V$A>2:$J)=%/*60"&C:`\@0JD^6SD*]8'( M^4AD)=)8%T,;*FM55&E91-L6HKY"E&ZNWZ)<,981W72C0\-5X`.9P!S@1V?K M+F-5XV:.DT4L-Q]^&')0#&\;T&`&]F0!(8/Z\&.0V5T6RKQ-=V`8`#L&NXT# M5$JE]YD>#U^T6]U&N[/7:/=Z+Q?I5Z:JN[V?;IC)+#6A&#FV.=N.QQBW4;%@ M4W`1&'_!-*MZ015QYAIK7$&EZT'48/JWVV%U;P.F4;I.0IT&&/0CHG<'FMO? M+]L\T+U.^YNP[:'V\G\3:<4*3O@VP^`XC9:V8=ULRNR5H@=+K.31O/V]%6Y5 M8^@W8&'U!`@]8Y;T&K#H6A]"WV(VN!7'^MET3OOOKNSWG*AGEV.UD^QC.N4' MCE51F59CMW5CVG\:HC;2\'J-W5[_*8GZ5A/87\_Y/BE23X_!4[+EFUV M+T^)4):'6=XB'<0_P`M6P-[#.;TAG^%@L$"EPU`\PJK\P8.4"M/W&MV]U7W@ M`^AYE#GI+RZ-WJ#1Z>X]K33J\ZGF3]4?%A&\1VPQ7W)2V#(/5MXG?-RNC:.V M8'UV]SCJ0L361^#M@>)._8$,+'G60:#0?"PBUV$*T$Z5MB-8):GR^,6LE#)Q MAH?X=$J390;<2)'P]KRMUZ?>;]Y>F26QTOCU"+O$BL^C]V"*_YN"L=CI1ZZ_ M"-+_DBF/1$!K@#D>WMYOB[%?$9D*-4<8BA[BR9V\%$4ZR"'X3DM9E$=9SMG- M@P#Y9_PPT+R95DY0CP5^ M`HL=@![!0XL0WZ<1C\^S5*[;W&KO[MYJK7=C5>XIBPS=E?SSHW#K$W=F<9(E-F,"6A@*/9YB MRED\HF\_4G,L83!3,J[DU*`#OEB%Q0`@N)FTA5_KS9Z\U:XF] M5JW[[7F[M2:P%*''(J-;DM&]E8Q:/]AI=SI/2L:BD_`Z,KS:S(=.;[?[M'1T M2SIN%8=7ZUIW9[+!UD[&&2;PIS5+NSDC^?T(2SH*354]/O'H(7ZSRHY^RZO= MD71[>_P$HB/M#(FS\V$5<>M?*C/9N]\G\YD*1LJA-=]@L"N MS7XLPU=;5J>SM3R_J?'?3YJU"[!G*,V5;'U5:=8MV=8OS95L\WP":*NQ!+A' MZH,-;A-DNSYK=;#[W`2YDEG>F0/U&^IGQH%5+?K.'*A=Z.U]IQ/WG3E0NZ9[ M;AQ8U0$KI!9MP![)O/O*I*J73NUO;U.[[G) M:B4372RKIULKK1A[`AP?/_;T[>QF"5F/'XOZ=O-@/5F=-<2FOIWI+*'K\6-5 M"\F*\0,"G7W4[4[\SJ3Y\J#K!3S\5FISO<`&X@;B!N(&X@;B!N+W!_'1ZO0] MU44#YW(-@*6R<*?I:LF/M>#T$="$QVS0^HDJ7X5A/D!>OY(9CC7*`3NJ MNHZ8S<))M`@4%C:*+:"+$+(R8`LKOZG48J%,3!#.2M5A@EQ6_6MF2%<=+E3N M7@#\4`\&BY2NE&6KHQ/^R_Q,9?&BA3#`DG&TQ,=*]8"6;_,J;-`$861UJ&`CL.5YP><7C&T7*UF@H3VV=LSKI;'3*C`+[(_72;JN7W_1` MMUA07<"0*L7YW$RH;B"@"DR,F'1U][20T1"O]52 MZI?$]S='OW9ABUV]2:2H.=?(:O9=P>"P%XU!A5QA0KRKH9F$J6F.Y+4(FB-1 M+4](DG]S>'9\N//^_3F-\NGD\.08_VJ0-F&.$YK!_(4?Y*U`46HZH[X6Y-7; M?)44Q-1=!H$5*W-65`D'>Q\#1\#4#\LJ?HV;;'1F5BF/F6"-2BJGR$QEFDJ4 MSI6]U@'YU0U_Y:*6NKM=5,K%"999S.NDH>&D57R8"$_D2YJ2EYR=RZBHJ/ ML>Y'4\QPK@!1+&1QW%V95/LPME7%F< M1E[U,LX*/0(HTD1W$RE)AZ2E.8D4-T?+FFJP$4%Y=$RNL M8A%)U."R:3%PJ>H.;CX)X/TS&L4Y2JD6YW":"^X&T<`C*OY*C%G(UAF[GR6- MRE97U13GI$N71(\56,MRH8!!.;7AEV*)PUWJ@,UY6`-2!4 M*NZ"PG&P\RJ:6?((BEZ:3*\KEKZ":KN+BZ:N%JR[!(G\T!(B_S(S(/U;#G7/ M#0`M$TF79!D3TFR'ZM77;G"JOFJ!WW03$CTA]L2+$5EV3X!.&=P^A/Y*F2V M.#W.HJ2H-];ZT`DF8TF:#+(8R5B:"59ZSM;2,S>3S2QOR\\$<-*U-W%*$UI= M9GA5K=N6=Z)=@6>8*+S"S"E#4%6&HO0OXE\,?"Q`_XH;T2J$XFPXTU\YYY'3 MXOP`#_`R\MJ5?#&]$#NCFYBH[5MW);GX7'Q.N>OHQ M>V#BTO2Q0/+S_$RB.$/JMEM;KT^[9;9_B7J5HNSF]_4.=G;+$T)%R?$,!3RI"K+; M@I#^[%JA2@1>QDF:H:.&N/NG^%X1A<6S@#C_JU$&\A&U#W0M4#N79.6"G8D4 M&O>`4XRXY[H.))(.OCL\/%T2@P:U"DE!\$0PTU!Q[=2^9+;7V.UU6.!B)#2Z MU,;.R!::.5'.69`[9L/0@[O-G3NTCLDT=F9LJ$!`T9G<&L.-S\AW+@U^29,? M$GQ-I78WGB6*BN:'>`6:I@#70J^ZQ#0KMW^#>DU@3BS5)O<3-=[J[E=(Q86C M+5'&0SLDHSBTHPNKBC&>0PCG>_F=!U]6B;)4HC+'8B2@1W!4/1_+[I(Z-$;8 MU4I0M2J?O_?K[Y)H5S_WOGWH!^*YH)+4#)Z[M2G=F!C]^'@>N37$2?P9#SO1 ME[ONAW'P0;ICF!7+,-67'AC4?H+E>2O2M!J::Z;Y+N46!K4?736[O;71;'PM M$Q?0S;ST0V*9_4%_T-O$,C<0-Q`W$#<0-Q`W$+]#B-]I++.:Z/0CAR]O;,'? M2'6DI[#-/IW))0$H)[&_S5[@=K4,H?D'-Z)JP<%+VKNSH516^)-8A6H\I40K MW-93\"@0&!@"F!CMB"@!L)):B2%!C/>8"+-'(Q4*/\5(D4['6?!I2(O-+P+C MH'].(PI/7:KPLMS$)]Q.U%C$`G.>8=,>9'7[9E-;1\JG4%>6U%<$&BG/E^)F M63<$>S.BE<:1L"P2`67;Q$($>)VZS++Z2,HN*(')93Y/RL4_OL><56UA@%F< M,$`@8S^_N9$HPJP83*;!W]Y@;Y?Z(]")X,'7E&N+B4!`*?"EZ)/J"8\:[)/2 M@,$1U[!4C_GL6)B%.-;%W>!`K2\3-!SB&0@01==@/BH$R`(32Y,)/""2`5K( M_(F(,"MG2BBAD%/\<(!BB10P4P25;AJOB'A>MK.)2Z:\Q+K*XH M"1Z&2RDGJ#E.)<8?SG1P['O1&1V%@`/J M+TEC+;!PUNK2?"OIH#P(-.H:.`],M75M*-Q2>*;%&`\4%!@0IJ;9XKC%9:=1])J*Q-_@0%5;TR%^ M.&,EINL!AE/ESA3Z*`?"'BD!"/OLA??R_]E[U^>VC>11]/NM.O\#CJ^WCE-% MR@3?M'^;*EJV$V7]T)'LW;N?4B`P))&``(.'9.:OO]T]#PQ`@&]*I(34;D*1 MP$Q/3T]/OSLE)0'V.,'7(BQ$S;@9W@Z1ZPDCNNJ92S'&(C1.+),BS6OXAI?0 M3WHTG4H]>&N\:FK3!DE<]WC/;5XKGU*(I#,JB\/(H#2B/#YKF`^%KC-*EN&< M.9.)0]&`/(E(''00<8"T`N!M`$Y+`R>TT#QOJ8A'Y-0H*B@FA`;HF!P4#AO% M&$9I^>@Q(=@XYZ`T`1Z=B<.W]=6.:%G:^$O+T:G`FF/T)%VX(LN#EH)76<@? M32,8%0.#*3OZBAB,3[E'8K_\3(Y4:3J#W-"W^,MK>/Q5-S.J8KP:\>5S17"Q M_#;1CE4P'@-^T"V$,>=\C3\HW!T([Z79:=0:C0;N?*2JH>M$A0&<&#&*T9DU M3##A5BWYA[S=Y#X9F6_G"(O@\>',WE ME:V[K0?AU6+A.I+%J],)'$-KXF,39B[)M9.;+AJV4'K-51VF/D_(`@E:[ MT=!W8R\,::B^$MF_,J0"7^#R]D>I7.+.1?NF"K4J]WHU8C5B-6(U8C5B->(9 MCGBF[G4IX!A"PA$1TL*FJ(0<@Z23I)`NYY6@ M0_FE66O"1_R./O:R^2,UE;:Q?=H*#=^J];L\304^=OOMHN$I38B7B\ND/A7D M.A6E+5UP8DD31HJR+58..K7NF#%BF&W!/3P\^0,]@.1:1U,XGY+[_O^0;IPW&P@=% M@/,*&I1-HJSG:ACR"LU8/`V<"V/(9U(%HQQYY)332@"GKW8)(DXQ9H,H@NS9 M`JH=2;`F**,Y6!IQ!:VM&+`REV]O+M]1YRS06M%_&!896D$5;:7=7^'CX/6&V8WJ&%V4Y8?63NO!N/G39I21X?OD-T#B%L2X"V! M*`!_+MZ\G0+#^Y99^X&0W!@,BD!>,?%QP2QKGMYH9&AA6SAIU.%D$J)KDWU% M'S(: MG;T@G"'+0LXE<_UN1.;BM^":YRT6)Y4]"(]\ST8QVDO#A"RN^"07,6A2]5`( M,Z%XD3Z*-9MXTYG"-+LU/+5;VB=IT.L4X'H-#G6LRW`>45A1C%!XJKKIJ>JN M;ZKS^S6/S_D:"JL[OT]X+3#Q"*+[ZU@S7-,S&V+%+&^993:S)%B\R)W18';U MCV5H^,2+-ZZSF[?*G1A'74:>1Y;LQ8?+KY_1'W!3T"(JMY#RMK3M?=>QQ;U_ M@'649T*V5ZYC24KXDN!47\?JR<@:VE.7883UQJZR]W"$^1J2"6C:R)W%\L";\5#_R;4?@H_8Z?O\\#_U;%-%ZJ:!OZW/@4-0[1^U@0@O+3"$&L)\\OHRO_P`PGJZ_BCY8;_QJ(39OE5 MOM$UJUWB*Z[LO[W(JPG@EDSJ_R M9.-HUR)H,#W+*TY?URQ=;;]PN:50;[K,#[[ST&ML[KE&#G+)`F\MSPH7($() MD+2WM[EH#[761NE:S:*UKH<^NVQ2>U:PIJ/%)7R7XF&&9Z$6V>S\-UU8%CX= M=I*^$8DVX]5(;YGO!B&%NS*'VP)/Q>BR":57?CV*SDX(I"8!"):IQW!4UK6I-,X.:R> M3UQ4:2Q@<]#O=0Z#4QXPC-+)H2P\O=*`7#/+7-9,G0'29_?(,4_N>FFA]4_= M+N5P9A;#32HP!W,G?L:N`^_QZF2EI84>T)*4D_X[15KZ'_,%[:M"P`9KR^"" MTC9$6"0>'W'7P58I92[[T-]P[;""?3]SYT>I:M5L=@>F?FAVQ-@RUL/MQE@F M28GG[14J?>V-?BG#:.49QBYP'W'AYT1@I3:V@R-Y&;8=(FBC?J/=:S]`_&S^ MF5R8R#[1.SQR0BO7T'ZKJLSJZ"GS'!O&+K`6!LWL-M2.T4=?[]!PS^Y/8UU+ M83Y%HW\5*:'I+`.*>3"SJ9^R71'6+'W9HI3.](TTQD/O&A@'&%^!>YT6_,VU MB,*P"I4>G3:,2NM3WDYAI&#BIL4PBQ*PU5,BN=M)NWA)^*D3GDKY%O4Y9?LI MC$6AHJ@(4,UPQR(96C23S/4WK,G>A+D$9$KY=JC!U5R(IE1*H-FLP46F84O" MEFFQ.*:VE]HW/%P&!VC76HU!^KYLW`58`Q;K1E-9.`1W)KLQ::R.B)P0Q8US M59]KAG5GN9YL>S5EWMS@E3/4`!%Z<\>6YRW5"1BFC?9*I\.2#!3_Q#/^1:?* M3&*MC/,"TFNF`PF2N#@&Y1_W7`TCJG*L`IC2G5U93SO;;972J=.BU13Y91%1 M%)]9CM#,SMYCX6I1+4(=!@1&Q&?!K%E*@#,[$7%H\12+#=2,5ZZ6C8^YU.E) M4I4.9$7OU2>;:%\=5RMT*[YYF3I$9<7I,X6)YDG,MWB. M%B4CMR$EY80UHKE0NZ36*3OQS2V7ZH$HW$EN)DL\E^P%O4\OPPM:Z?1H11F3 M;&M'`E1-B\%[6)B;-\#BE&J)XN*B$U^46=))'>K#"0%?`K]^(YLQ<(5)B!<@X55VJ`_Q6(H15'5>VD&TOI,6.8UD M5181ELJ-L(:PPAIF^Z+Q#X%C)V$`8+.Q7"E,#VG-G$I.Z)F(5^H`B<&\O,:. MOE;!5WSCBG"78"^`#5CR$CCJ]0PL-:J/[R.;B>_QJM2GQN_IA+ZS_#\-:6XS MAB(0639^_18F4*1:IM)&Y3$4B<6;!8*[72Y%1*3+JFPI,C@>N1*`:B M\?[=I;C,%92_G8*EM,-630@F,,RJF@L$%L<=O M8GF7T>^T,EEJI`"_/*R=WE,-5=/.OOJ%,`:N'=SS[N;S;#M8'1<7QG%YRG%' MUR@A>V<%("1/1,$JT7%WOOGYX%TCTA&BP,.R-MBD,4>D^"3>B$$2&ZH9+PIU MV&F69`G8G0B/:EK\1J/[FFB,+M,48,W:/A7W"/>(O`6+%-6BY&I(4-=AA#]5 M'9BBS=>)_-GN%VEMD!46V!*[&W)=[$V$W#<:%BJ5U M(-F1Q8"T4>:)PD?%C8[P8=0/;`^K\`G(M1X:/#),KAPB$$9E5-7!T>9M%^AGX; M,9^-71JKK'TW/[VD;A'$]U2UCDB")+QXT_M%%`]=&FO$M/:Y%B4:,>?">)^H MQD[9_N86KP17M('"-J&HAQKU!LA(7_@&!;7] M1AQQLDU2&=9RFBZLW$-#N$S1RJ60A2QV"PEK11,JQX3%YRDI<2(\%- MG.8RX2A;]\\/8(F@$(>X8-4*)X_?#`:Q@F/!KMM4TA%P"0/!W8@%(Y'KT+$O MO&[QR_3*+;IJ,_20W:5:,?LH(D=QMS%17(-,7\C8K&SW*$X+P8I>7I(&B(,1 M56@U,M&`J(JVY6XI_`>_^=_UNO'199[S!E3%">B6MX!PV".\3_IO#8J5>V.T MC'I=OI>[@>;P5GT$!_O/^HC:E+TQ+._>6D3RWJG'P?R-T4TOHOHHB.-@!A,T MA7L`1U6W$)\A>^-I4+Y&,!4XA[D.OV7XG.K0AO(%U;'$LLG:L!6P\=L,9+[>7K;TGYUQZY0.O MH`I?OQ?TIE^?DL-SG8IZE$<$".J\H9(#G42"@W\)70Y9FL-FOHHF7?H=Q^0W M"C(<7/===3;1UECCW!RSQU>M3MEZ M<$B2;T'X,31)^:59&W0TOYTT[:=RU[C&B_5@VGSI6JI#C>L:02$N$I4BRUI9W?8?NV:H].M27L?AUA2WJ[ MMKN-?&_7=JW1;^Y;\R-;?D-,H764;15TE-VD_,?&4Z+:J!2IK0;B8R2R0?UPSF(NQ6&<@V`:X,);7,9*D5;JGQZKI+!Q<#6_UR4.MU&J4%1F20 MVHH8L^50-$R_/V1&KI:"V\7D_\9_LV#A?!H4MS8@(_'8U[$6$8CAVIFVD-$W M_'Z76I-ULW^L.#DJ!`'"D>?-T?KB3RBJ$/^.YI8M_Z9R3@`(25TO)`@CZIM1 M)Q*81S"R_/3V+9"W$T_?&+U&8_Z#2[5TK\6A?/D.6_.`]B9+17$U77O2D4\N MW7_+P7B9HE,&6%!J`-"6_3IV"F8J?2-[5V??A44#J@`[6*=Z3Y`%1N7\ M(\\".C$O``Z#;DR"9OF(YJ%Z'8=G@O%-9EHUZGKU*D?RI07'RG:U]3";NLMB MWL$5PIPU"ZD0O3^BO_NC+5!]*FAHIOX+4'//V/K\F<+\:HI!)5$X58EYS>=KU5\S:(4H@?[E^K.:ZP<@VD8(H MHMP/".1^*S\7Y'5J[7:[PMK)8FU?UO.?*>@/&\E2A8#]$F*0P66(%H1+T9E2 MYHUL,C-Z-7:@R7C_,-NALY>7Y.S1QG>BKMM5'ZE3:R? MNQ#_-A;WDW(X27^X(=W@^]SA3W(G'LAWH3E\GO9",PZ7I[W4U"E2.4+.Q"I= M.4+V0%ZSUNOU*ZR=+-9.21^7#%NEEQ'8^'_C,K@P/L4B!:"R[938=AJ]S17S MRM!6&3^?V9X\^@$Y4;=490?=Q=JS'355IK@B0#-QN,F`CRJA?:$#'Z]!S(.47;:YP`SNY[!GB8QNQY^ECPZSU>A5]Y`*:5T6C/C9_.Y#%/E,"J-[,&!7Q MB3=&4^Z29GH2A?YD/5;>,X^^9)W1F^>`#4\*E"/#T&%E@HMYX&6QPP[ MR3)3LX"9MN3^'"8$[FQVOEWK]%=D!SW#L]"L#5J]"B,9!:76ZZ]PM3Y#E'1J MK6;K='GE@:-&)28):+$$I2\3!JU(W!YM+$SHZ5:&;$]F**M?C]/:D M:=;ZKV:UNTQ/9C!:( MIRNLJ=5F/.AF=&K==K4;)[(;W5K3?&X)K$_/1%"%'51HJ=!R!F@Y)6VA($=_ M;[G^B:*-*"G_(W4"QOLK0/Y'-:+=JWB6@@M^)_V\87A,-N=65Y$)0E4K\9&K_?" M2'R7O^Q&01N^K2>1\^)GL]/@_TB@\_-N!U.K;IKU1E?[6`[3H!2F+4":6B%[ MA_U,L;\F\R-"ZS`,L4LK&O7>+?`1ZGAZS;N`#N^MT/G,FW9^2;!ZZ]V28P`VFW)O4,;C=QKI MVV)>@-*OU!F7(S.+^2L?DZ;=.PW;OW]S8SQS5SZ<1M=)+(^>_!+XYK^=SO,;X^00R"=(R6B,:,K7TR#OT3#.\OU>-&2]8C7J;/> MT@]HNZ.1YX]1Z+GUB(@(3FC+'&Q-H;NM(8^KT?8G@8_XW;]CV(\89D&BL29; MT"5N&I'1,)DD48S<35!;EFQA['$0SK!].C]OFQ*M(!;Z'3]_GP?^;6+;+(K& MB8?+]1@N%L[Q'+9K[-KO4\?%9]>#5P*?1QCKH,'6=XAUU%4<(O_!ORTL8#/0Y<)`6+$X:GUQ`>L14]_%E=#3J MC8Y`!WULF;\C[7X=:^!S7O7A\NOGH>]0P]\T0IG<0A(^>-=FJ(WK[Q<]C@(C]S^NE M<=+A>;?[^*,;V9;W7V:%'WQG4UE-S@03U>MF$RB03U4V9CKK^\!.9NH13CL? MX;N"_5^QP-:+G_]OBT]9.F#9G`C6]C,V@7W`MT5SJ@&79^3@[(!8T^3S\6^S MLV8&79X3Z7NKJ1JH;]7_;W82'"4=FY^C2_@^M#R0J]F/?['%5K7Y0+Z`?_K] M9F_0Y3,5CKDT)9Q#N$.1Y_"K^&L21['EH\6C2#>#A;3,8BY7'Y1>#'!:6]U^ MS\P`MF+F)2@YV=^P>1"B`'`;6_%V]-5]\?-_6929OW#,_,P?06@(+X$.)D&X MU89T7OS\R0I!?@*6RF`,&,(Q:#0=B,SP^;EOV,2-8I3<42C:BN1>_/SNZNOE MS7]OOQG7OPYO/@\O/WS_=G4Y_'1K7'VYU"'(3I('X=^!!XS="CF@6V&\]^+G M+X$^4VZL_%3_89[W+S^X]V^9%<$UX-`=&&XS97]IDTL&3>>&VP$)[G8Q&P7> M-G,!A\3KA4^6&84/GD3UB67-W\@;%40OD'V7T\N6QYWKS="A9<)FX: M/Z(WONO]\T4<)NS%ZT??T#4K*MO/4O;2Z;;-W?<3<.)\7?VUR_E M,ZU&LY<'L'C:G:%;RP7+#>UFJ[ET'#:$+IDE'HH-4F&:AVP*VIY[QZY\.YBQ M3T$4`>J_CK]9/[;'Z,`L@[F^M-_;0'+@9:Q#_:!9OHQ6XX`+<1P7622H0);K M7/F7UMSE(=!;XKU?2BN=3K>1OSJ*9]T1M+6X;)2"UFX.VJT=0/.\P$:$%QNP M/_S`C[MX+S03VDZFQ#*S0MLLW1Y][1LMZUBH*(/=+-^_7J^7V[U'7<'.VV.6 MIW.Z2]S1?VF6<[=FL_%HJVVGJVVO(\E2N:+;Z9S2"O8@R5(5J-OJ]T]V MB3N39*DD9G:;^Z]VAM:8OX5Y6\F\)19L.&N]C7CC8(6<0,9W'>P5(.P)[&:, M'(`M52Z7I,DC`=M.,;ONB)>K@@^%V2WX4;OTL.Z!6>`4CNLER"_22)H//VPO M<9C#(Y)F\R060WVP0A\&PD`1.A@%@3`;$'?&*6=VVZ6VUU:_F9/G#P'N@V!@ M-1'F,%`>2M%NMAMGBH$M'+-F=]EIK6B@FQ?_S@8#J\]V#@/E'HC6H-\].@:B MB.78TV:VC5)N;[;Z@TX.;IIDLXG7FBW*.3>Z:]H;3KRS4:=3NO!^N]-H%DQ? M;"I9#<4Z+'1*L=`?M/)*[PHH9%S"QR"\M3R-J#9"C$[)W4&O%":XPOHY@^YN)V)+_."O)K=LU'7=$NY-==H4SV M^H=>CV:W_@4KFW[W0V9Y[M_PI^7Z[]@X"-DJ%\"1F&2IL;&YZ?G;<&&/B:== M^6WI]=C<]/R>`W)V8MVE=).W%IP+:E:LM90,NNTS6^M!;CSM1BBC@M7N]`== MUZZ77;EH_'3V?.71UR[*$]OF%5?Z^>P:.JD?[=8OCQK85(O8<&&/B:==;_U2 M9U?=W)_?GPYV=KKVRPDG'R]V+KA9L=AR0NCNSTX>=K''5757L)/6TT'4KI)$ M.1FU-[5"G0-V=E+!RRFG>Z:4LV*Q*RZ6UF.MEOM'T:PTA47?GDV@-GL;>"U[G(..^417F:_M;%Q]W@K77%1 MKDBR;@Z.2I!(39^M6/SU'S>>NOY7GU'RJN6&E+^]`V=9E?C0:VQJ,=T$N.,N M=/W6E>=0])NM3<_7H1>:_K5SE$.YYKOM#BX!<^"5K(N4*/>Z;KM%!UK)E\"W M=PX^*:\?T.MM[.0O@^?PZUD;QE*J([1-T]S4Z[3O>E2AM:W2E;LO?L;J;EIK M'L>-YIZU>&.XON?ZLJ;=4LY^8USMAGB>J M^!'2\.]H;MGR[VQI.VIJ,(]@*/GI[5OCWG7BZ1L#R&+^XZU6175-(=8CEI06 MB[YG6+D/Y_.<'8N0PS(!&_X_7V#NRQ:3Z57],%R>A6^-=56_1:.E>4PRB-%J MU`RDAWV*W9X7CEL/@V(EPN#\H]!X3<"@//,<%L]3+#-+O\+WV;-8/EEW,HM/ M33V9K]$OM4W)YB>/$#2$;57$^EPQ\B&"*]2*<\M'"3D%DV3EQ^BY(.[:5N^:LJ' MV+[\KQRKL6XPK259JV::@P."M]^:SP5M[16ED2N4%5/:BD+K%&`CFY$2N7>6%PYW?XIS5ZMV5YQ&3W# MEC)F>T5OK6>(CV;5Z3QS0YCM?:%9<2^<#1J`<;0;*R[+Q^;Y._4X+],@=6<> MJB\.=^=ML?IGUZ.PV:@-&BLNEJICY(/NQN8MEZJ=..I.F(W36%"U$Z]6R;V' M6M'F5_TSW`&X(_J#1^5,#Z59/CTQN.I'6J&E0DN%EG-%RZ/HE\LNM+7]?5T5 M6EJU^"TEF)Y9:_:J%K\GLAM-\`7!+MQ^X#O[Z_,GZNHG&?1S2N;-=IM$P*QEUBUE4P;A6,6P7C5L&X53!N M%8Q;!>,>)8JM46LU'B:*[4FAK0K&W19E!.+_^P/%O$,"^3R0]ZK9.B!L3SLN M%SG:BI"]*B[W'%P@S5[-[!PQO.X,46)VJKA<'1\K[(G/$!NOVBNDN$/;3D\7 M#1C/WSWB.:G"-S^VNT/FJ M^-R'N2QZ_M49U)J#*C[W1';# M[&V>^%9MQ7$/1K41I[$1K\S6YMIF%9][I$NBU=[<-/E(\;F;E/+]QD0IWFSM MWDLKF@Y]!__SX:_$O8-W0&H8QI=6&"Y@HS8;C=[3:SY90W`N$@ M4*\KFES>U'3S+66?$ADKZEEWRRE$1/@[AR)2*Y9 MZ`;.E6^'S(K8>\;_NUE]ZM*5E%9"K_<&9FN#A11#=*&ZU1>%P`'+0&_2/53R\&K$:L1JQ&K$:L1JQ&O&((](S_&?C&[W_ M!=Z_P?=K_(N:<0ORQ?BM,;/"B0M:%#[:X/\&W110Y*S-GK10 M3YEQ&5Y"Y3R(A"$+=9H[#4_2N MZT=QF/#O[MUX"N_)7E(X:#P-&<,1XRD-X;$H,JP8OF=$^/C,/`GM*8B^%P8N MW!;:BG%'.A/\;DNJ65JW-9^'P0]*!8J,L>6&XB4'_@\XP4FB:1#&]9B%,\-' MR!B'BH'\[\9L%EUL2GK59]V(LI%BLHDN8:4G`=4;+2%EZLS#XN,DE:E[0S7 M*$A!6>ZL:(1L[#$;U(N79J=!2H14QMP(?@39-(0Q0+^86:X?P_]1&;+PW[Q& M!^AB5H@:C*9A:0H6OAFQ\(XA!%2B)T8-#Y8;&A9\(9,C;9@%G@9]R#%`S9F$ MUJQFO.PU<+8P6%A>O`!H[I@/RL[<I6'S]MO,*_2=\_8G@#4"_1A++!!<:FF!3PBYGEHWGX?&EP`5KU<.&P,9 MD,J)WQCMGTA=>VEBJX&-$%B$"8_%\">7+8#V8G M6!>!YATEKN?4@R3&=[$@`C*>=VXX@SV96C.`(((-LJ>@,=JN1ZIJI04>4`O< M3*7+*8>X^R,D?/>.#RRHD+N MOL%02_QY9WP5W#E8%26%[#V;6R&9K)`9_,J`:W+T_)K`YN+]<>?:R,-TEOAN M>/-^^/K77V\S/#'#(XPKW_C-\A,K7,"ET>C5#/628=T#RT8&IS$^"[AAHUGK M=LT:0)Z$]07L%%$R[@MQ/'S<C(.F:76Y?IC M+V'^W]:%\3ZAJP=@&M2TUVQ`&@;@9@:.INXXYIQX'-A)A-S=18C@4@G@3X=Y M0&"P0D38TJ33()H3XO^&(>9`BWBV+XQO<+LE<[C#T,@'_)Y&K@$"TIL6@4O7 M/@L[V: M.3`OC*^^\9&-0MRLE#*:;;KN83\R^^3#RFD'XJD5:YLZM1P%&-Y%QLM.I]9H M-(K74:,;TQ>K0)C0&#N'*PT7R2V0>(E&>+9S>YU;:.&&2W1G-X%N18T6ON$2 MBO$\"H,$.`T?F0*BU7.T2F,,W$];/JSB9;/5KO4[34(YH/_.Q>5)?,?ZML,V MP,4*WP*H<,J^O!]RH8?]"9?O)(%[/D"J0NOMG;COQCK M`V?-#2[#!8@C43*:N3'2L)A&S%LPHK`'?X2')#GC"T1P!`@78/29VMPBG6)! MX8C]F),,`YC\+?&9E!W;9"X/)4)0]D#+@?(U@*G`.P^?A<'ZF2TL44^RL/)#X M$^S^#`1"Y&:E-]XPB:=!Z(*(C(="IZ8-;X24]0_>&E_'<'"DY\`81I$;Q18, M<(M!.S'>`4APUR$.S1R??!PP(D`W#WPXXY)Q*+JUEED_?N&"++_$^]]=_G_M M=JN!,K)ES$$<@.=@Z2D_P!'@>D3VA[ZA)&*D"]Q\&2*?F`83YD?(D&PO(Q!52O'7X)K1,F$]AM/P$A M.Z8[J88KN&>>A_]]V6P"+^F0YN2`<`\\*7Z(RVW8:=&9&<']JN6!\B M;:*JG]6`I<$D=/+@AQ1/RHTDD4S`(S]K=6MF=W`!^UFL".*EQ7DC+;5;:P&[ M!YX-D#!?[2GP/W@GA4S"K>C.C=2T%T<1E$Y2#/MBB3V]\J/8C1.N`@\]CX43 M+E!<^6/0LET4--Y+ZLV(85^NAE?OUXMANER!EX-Z3:%=5Q@E7Y'';M5ARQXQ MX%*C))P8='3D@;M(IP-Q"QB+I+3E]4NQXRK+^_Q(O:$ MA!))NX.21JF$?X]2R(;9(A0;5:AB%2X735B57'B+%;M]`=0OZSLBU+.A!4Y M"6(ZW3HNQIG&E.X/)6B#"FQYFS*7YJ#6[W7V9"YJ26XD;2-<[,3\.BE1"8K2 MKS=@^[?#?Z=F$2%:GR&S^J:Q>!&.H*EE@(24-R#IV4$4U^=>$M7'[@_FU,=, M>UV(SVZ4E4<`MWBQQ!X7[4,0%_$@A,R=`;E%3!$1/U<1A4K821AR\9++AZCC MI2PIA9BDZBB]]A#(D'F64-(*^%4JW^+R)`'@FNB(_D`)G0'9!Z0QC5VDDA*, MW+L`\F/GY#U>N(A6XP1A!/+)R5:WJO`/ZW[2%+U=Y\> M_Q?<8$[`K0X6:I^1Z[@H_\-CE[>?Y-PU$O#7CSQ,(B`JS[5J!I4_)AX!U&C! M0#9#S6$(!X[SE%?X8F9)Z8_:X@Q@W7@H)P8^H4H"CU$QIC"I^R#TG'O0W>7A M@/D$4ZEI`CN_\=((,EB!<3.\OOKW$WQ2M?3_R`ASO]IC64*+C$;+D'U5#JY MO%*C!/4X&.R.1X_!2;V*0HMY->,W:XY.GW^!AFL17-\L]QXN6\+)',\BV0`F M#"^N^=2E,SUAQ!XP;(X$,*D:I,CZQD)0$0-A%>+XNU"K="/AU%$22%9*L&P4 M:D$W1<,..7D<;;F$>;BIM6FP&' M&U;"B)=Z#GP850P=@G>17OPQ"/@3[U%S&SK`WURD3N+M M><-(\6:OQ@B,HXQ@1UT3%-O48,:"&8N3:1':#`1C*'=QT& M7P)+"^P_Y\)N%5*@)-[QR%''3)"`2))G+(3-+ M$F-$IQIU5XO\EM&KA[H+KG%Q:`81HDF&)=44XDBN&+$L+R':`X[Y?R*-B]9P M",(G<()HSL2SQ`I2.IJ3TY/(,IZ2&9,'>B:@/!`C1H&=5"\R5,KMO0/1"ZXH M!';B!2/+$Q&N0$4(N)!^%/NKY7@?CB7E<$H*0S&M#N(2Z309:Q-*T@!\7"2R MY9FJ$IU2;"ESE6)/W*O):%P,`D:Q0XJ84CPD45/7LR++8Y&TU[J0:L"S!?W@_U.U[G2ZE=^P+N$BEAD-E98CMW,)<<\EG4CQ,/ MA`5B4+@+-'8W3\W_O`@Z?NG'L1X.($B=NG:'8%LDO*@;R,A)\!EGMAZ,PI M-0:F4D>$ADAUM_K&I>5;CJ4TFP_?E_!D>5&PA"S-G<%=#\I.P5!;4,HZ#2:, MS?FIDC"8,[C6/J-1&U4?V"SFVPN=`#Y\SA!``LN1#"RS*SIE`,S!".]$YLB; MT)WX7)4D'%T5ZZ,KR(5$;?@9=38BW#\"ERXUQGC$"Q%%S#C[!-)ACO`!,=3D M##^APP!?A6R.!@<_)B=VQ*]7TI/0BK8@0PW>FA&.!1S?A1/"N0SY5X2FIMEC MG%0]59KH"H94R&-IB87FZ"4/SA&YSV%NY^UY@;!ED"\MF<.&P,[.K864[EZV M6K5>N\'/[LQ2STN;HMDDRV76HC\#T0A$'I_)D:*\00/$?ALV#?@`$".([G=, M3JB=+35,YHHKH/]7[D]2JD5/'X\DFL/!LC`D!=YUE(?VE9L^"\>+/XO`)UZL M/2@IY<-W6CB\Q5_+'N85+_,GLG>O9"?*E)3JAID-TDU,(#JC@LA#OU#%03L# M:C_8.@?]^[0X7_7&/5%$"F.)7-6'](H5(@[JF@8WA5@Y`C.',% MH>,/(9I*1<9`7D!L3#"@N1JN/]EK*)B)5H7(V+1-#Q?@2-")9_T>M>PX?1O@*7 M8+BHCQ9U\1'-C6BN)>+F9A810(A<`;^@`=15X($XBQ(PL),(C0ZH37,KA!Q0 M''AX&512KK`J-;`)24@GODGB/Y@&*PG+'."$WHZ4K(G%/`B6&DURC#*#I5-X!@B\I9AG.CR+`L M)J^/9.B>?B3#(?T/E&I82!?15/K:T,^_FHJ%A+=,M)RN022/@SH_#X9.8#P4 M>9$EXSSON#`^N,0\2-2BNSQC_\[!C=IWS-T>(<-3PJ$(M"&XB9N"!):/N6!5 M]ZAF8JHF.L8\[9T"L41C4\(G2'U0R5Y#SHF(7!H%D$3)>,Q"8;H#I?:.)&EB M7=D3AZNF.WCETL?T!5WN"QE.K!E3*:0)>2EN+8.[E<8`0<1UA-=".T;`"^=6 M+*+DQ*2XJTZ``:=!C`/CHBV^E/^CW!?<($+&,8OWAH0+UN5*#^Q(4#-&2=$T"@S9!KZMI0T7*0AEA^ MK0"_(HPL2NV).E!C0DJJ*JLRN62T6?Q<4H"%?HD`I<6,*J0?>7H!Q1!)G.T3J:`F:HS&:M-]L MC`$!K(S4\"3I52[1E6]PL1#O1Q3AM!/-Y\##I!B;U*Z)!RV-2-%*:7:!.,Y[ MZE?G%1MSJ"R-I5`8&>4J0I+UW7=I[#KN<:< MA('$1E$_A2+S@@@2E'XY$2PCN+O<#20,G:J$[Q^P22$TZ6EHY:)H<']^#8`V M_@7_NDC'F%J11HY(3%;B@TBQO&%9F M!7@+]0LR[)YAJ,RNO.N7$-USEZ3ERT9^J;%:<"OMH34I%*@V`[5V5S.K'&O2 M8=B<.PE_ZGIVH@\OG5=%_@G-/%C3C%6U$F^(#`:2@&1]E]+T!OP!^"&&CB@6 MPQB/$>LT^$OJR(HKG4M0*CPZX]^!RS\D4P.WR)"U/_%(>U>:+!H8EO@A`:D; MVXJ?%.>"GO9U4P\B*6?N07,PB+X?DQ"%!W3G%N!Z;F69'/G[9FXRXW&'N`1$ MI`PYAD.?397(>Z5T7JO,A9DE",%$VYKGHQ'X&-G@\FB ME/,L+8D,KN*.KF66IN2;HB">="D7QI&I[21I>>B!Z!,;'[`B%4.[>P`J%S=, M2\\:?OXOBZ;NG85Q-^A>Y@,):K)944R>'##Y=?/^O;3B_K3US=9"+9 MI,X(DWF+\@NPD3T;2FNR,%58FM!(611X"3O^"N$SX'`:/F]A0B'BU;&MS>%(&YGQLL3N6[Z-I21,9(QE'A:E3?`,$OCN$[9<=SG-$E#DOL4!$ M8TTPC`XK_Y&Y2O-BJ9!KM2BMT%Z&4-U(NZ'1.#1*S5S+BJP>,`T_34`L@WWH M:D2`T7XR.1I-I2[W2`F2(NLNXEQ:ES$&,2%=E8=>B_E2$,_O5KS"-$D4H\S< M55&@S&>4_U\`UY.?'E<7L)JEG+HK9#AW5SXU1H*AV[.7QTM[4>:UK+;+2+F1Q^?/47.[)PG/Y(%:;D4*-0N M]/%IA09H'Y>9EAM%"5NF='ZO1M+1AF)-(%P.G`+(%B3E!Y79^[)3&YBF"/=U MG=R8+P<4E(0UGRZ,H0I-0JDX:S')9B910*R0^7#D@L@)P4\HW@`#T6AD496/,3=!J;N3O+H2N5K`9KH9]^AUXH7X![7(>!#4-$QBL+ZZU08-%/I1;_E#D/!>2BS`#W]@[+C2)TRTACIKQE M2&5\#>KB>>XVZL[:3@]HIYO;[[1"0V:7A4L9DP1#8&="PJ(MWM(1SD0LGTB M`[LDJ!?&AS03E>?P\O10?@Q5)%&J5G+G@>0[^3QWGA!.PU@RJ($K*K.S2O'> MR_:.&Y0E]Z%GC2Q4`6.]]&:&\K\/WZUP'NG6SC2+5IF^M/L;PR]XL1"9(NBS M!+U[ONO(TAV\^MHL:S\OLR#H[!\H`<<7L0I(U"(N72LC*AQ.:;07YJ(FH2\R MA&19#2W`(V.INZ`9<&4JMDM?N[@%4XL,Q:9@Q-D=MYZXTH)MH>DW[^%5\Z?A M+'`3XHP`'*7O>'JH2[Y0SK(M/&MY+#>QKE&,,Y94U]_97KH,H*BT)_"HUI_> M\12OHS985GC`K&*-M"C<4M9X:79XP4:B$EZWQDI$?K(PNOOLWE(I=`"X]H(T MP@4\2I-BGO187A$6ROW5A=4EE`+`0]O3GBJ9,F7",$K9HGR+#$`.5(U-,$QQZXC\N[@:&*5#R7E M24.MX+/9.251PB4B\LLT5PJ^C2OCCR)9896-A`*O]'Q!^`(?6S(3T6XCQ>FY M^7X@0SU1U(OO,28A'SU%)\8O8`\8>WL_S;VA@CCISHV9/?7)"UP390Z43TA% MJ6)LK`@_RH9%R)P[?4Z,6]4C7:(TBB&;7H41:+R<3ZZ.35&LVIC,E6'V&%LS MWO\'C[=(O"FMEJQ5!MZ\GF]!(6`J`SWT@)TYB^L`(UN'TNKST7+#U0UW?W\/ MI'5'$U^IYD0W;O3G\(<;U2]IT^W%K\R9,*4P?R:S04G3VT&OVRYK]MG(+7D3 MR`^V8-&K]Q@++FV7^Z@+ECL\%$VIJ/[XIP`$NZ'O?.3IP?[DALB4Z@2]6WS" M))\/F&:W^#J^Q+=82!?(M\6<$8)^N[X1&12WR>C3ITN.&D#J*$[124_RJN6C!G*KWR@&N0[B:OW'*/3<.KB<9X-0(>VG5":.9-MV3(R MCO$)DV)+[.?YSP?`AG#Z`GP3^`H+/+GCQ98%8P\+RE)C3AUCW+]D9S#FH1?$ MY7Z]T!4E!1,_9**2[(27_46O:H`%ZWD;,TRL$?[6.\OUT"B));_J%$`LJHXZ MW!O!:WEA-/K+BBQA0YQ/(^/SS>([-$T6%SDT5>&%\"[649&[S%"&I^CB=GJT6U+\H) MN_J\4:?/#?6TO';G8[PKCQ!'Z_PEI1GAIRT5N@%HRY5"5XU8C5B-6(U8C5B- M>'XCGJE"QV46`X662F_3]39LZTY*D.CK+HHO:HH7%H901?M=%:!4 MWD3*47?H.%4*BO2C=Y9'2>.W4\;B7+"HP^9!1*5-?V`) M"RE*0@)&=4\. M1,%A"4D6OA'SL!XZQ=YA8*M*"T#=+'$=WBA-Q#Y+M,NL/WU-/*3_CM)A'!ZE MK3I!BW!,T*P=P''5TI**OL3RTU/F(280LVS M91C,OE0&`2T>0]WS:YQ6-Q71QV0%"--P)3(%)!&9`D;!G2@(2F2P7,@UF]VC MCT):?Z8Z"C\%B)CR!D*9Q&4>FXH1J1'&MCJB-`,1?FG@9?5YM?):JH:NT5>O M5<*FN8G"^OO2`.\6[YAO3['T&$6FW6)0_`T6K$C8-:?%3W"(15!;P>LJ6.X2 MK@#0NL.E9\2[8K2OH>A@32^)*K7+D6^F%JIA]I;#F>9PG#'F:K`"BQIREM`H M&#`\N8\CMS?H#;J5WE^-6(U8C5B-6(U8C7B&(YZIWO^.^G!@:2K5J"SP*PN` M;@'XQO.@4VT[U9BCU"\IRR*2-BSR1W(:E6I4S//'Z_G\\9KQV_6-:G1RFXR, M3Y\NL]G$VH^YFI;Z:]C^5B3R%A28LHR7K4:V_.!8YK;P!'+>TR^;H*O230.L MT1;:T_1M7I/$O`"L,@/35XQV3<'S.?!9+&K1@`G+R:&*ZK#B1^53=<1#$ M/B9>49L15W0`4,`1//((%&(.B!]-7(5(#=G8HY8WV*%$:S\FZU)2A178;&N2 M]CE7>Q;,79^.#IQA%D68>$Q-!XA;&V/+#;'&%VX2]2<3I2%%D9ZL$6HC8B`3 M'4W(L]EYBYRY*(`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`;^(7[^KX$OKTK MIOJE@+7:G4+(BN;=!\*UB<2EG+8U:.\-(3DK9>'D8A[737E=_%6@;7I5[W>2E4EFKT]D1N'D(SF0U\-R".BWJFM16H3E$-#+(F5P:=Y;(:A%O.,' M"OEF.9N1]OCI;7:@8E6HV91=*J)9>AYQ?+];_ZZ=^;;.GJ M1<+LS)WX!]D6'YC(>F[X*!54>H.\C%FVS!PZ5.E4-&;,T+["0S%Y MP5?2AJEXUCML3W0MZBCO$'@9]1OMWD/4S\D_LW,WT.6@#_*U-[66E^VW!I7/ MJA-V#!V!95;U#0JJ/WC3#/+B%"5MZQ$)4\NA:M:4N5[GW:ID8TGRUGJ6S:@H.'LLF-*X(L4B\=Q?\O=\O)M7/2LOCY&`N>&2[(@F,I@QS& M;9B4`-^KP0UHO(+_=CHM_$;^F"VWG,?J*XE%#IRWIZ^]@- MHSB3Y`YC\3T'5'G,>-D%F!H`6[?6ZO>WA,WL-H\`6_L,^]$(9ST6@LCDD[PT MV[5^:T#A$4%,O24U9&0(QN:>385"[$J#*2P8RD3'0?:Y0;DH4F0=NG;Z"-X9 M\@'9#B#?+K.$":#;UXHY%&Y$>VH+2$9,WT&*@?(P1N$-]E_M]9OZIO+N=`[O M8LH)[66GUFTU#=[*K5O#'JW=9D_\W8._F[5.HR_^[@NJYVW7\/BM:V6:P[=9 M&_2;LL;'9I@.M$J5HE4#^K[%J=:1'VG9-GY0?.#=#+UC.(^7:9ZLS9!I]4SM MC6W2PAS%$6DO#22#Z,(8\@0WZG0*"Z3FO_ZD5@R&;->5PG):Q^J4@C6+;J]- M/.=[+_/8/$F=%&(&T6Z,!`-7,"50-I>N&8X+5,4[K8IF#1A+0C.D?3*RZ-2[ MI61_J15#!>Q4IIW%J>.*FN^-\9B>ZBEX?WIAB)BI MB&&O*;V3.-^$5\V?C(_OAT+:M2A>4WA%-A@521..X-*HU*&W]9-H=",78!G7 M)+7GX:=#@FU795,MGA]<,WB723OXT\609IL3K?S26?B@)-H\7)).5=UR,($X M0H^W@UT.>RV0J@'4*;.\>`JT&GCHOJ)VZ#NBC,2A!/E;*6DTBTECF98%L1"Y M-QKJI)H`DG;6G7/'FHJ>GX?LS@V2R%/GL@P( MH>:4\SZ4596.J&Z'?)A^CB^2T(^=>NX0[3X3T8<8FU[$R>BPR;YIQ/EETZT. M@F!J8?>"-^$%*'==NSN".S>2>*#0X>QRRFXPV:E--IC$8&Q/]B_.]Y*739,T MQ;&N-$T]V)ZZ\8C&3$S2IL_O,,O@]B41J!J'@6>DC5[EG+E[-BM);-+YL?T$ M.C\N2S_"L)6V9BK=5^P5F.HTQ[;A2$3`7S$UZ0(J\N:HW_@3L@+BW]'@KCDQ-,W1J_1F/]X^R*E`SEK*,>` MS(O`!:#`F:Y>8WX"$X^"HW7!,Y0%H]\5HCXRL6V M#":TE@S/"A?_H6&8DR,+JD.2^>Z#N*`R7UZC.I-?"O\[S/R][E`#M`#=)`R` M"R+3",(W1C@9O6HVVK5FJP]2>.>GTH,O&$JG\X]BP[RLDJ,D&ID6L&:GQ;AF MR;`;LY'R<;(;Y['QCB,WUPU-_35I[&:MU6T^.L!/"J6#6K?1>72`'QRE+P^/ MR>Y%TWPX1!Z*4?UGZL9L<[$D#V5Z7>!?VM;=;&`^W^ZRVE/\V8]0-Z2!5V9G MW6':#+"?GAYN=(_OHP)8(>MQ19XC,14;Y23/>XIL9=V]4IV7BKF<)K).74Q9 M87M]>OO^RJRUS$$EGY0PV8,AYRGS#M.\&!P;2V8(K9LMOV1:M[)GSD8,*'9E+?BJ/LJ-H&RQ[LD+'"<"WBG!4J'J M?%#U2.):GM)J2@16.#8S&YVF+&"8]L^*T#UHF-<9( M(BHNS(]1_=:>!EB96D")23?X\RQPF)>FKF$'*I$UAV5P5<`R#WL=,2^XYS': M]R)&3O7GXG,2!!J8NZ8\B!Y M#H$@*+FY-Q81UQ(QBV"3.8W*>HUY7%2X6.)WF?CV')URRUQG'K@R MF8<9LCX/$>@K%[,(L)ZT3)+Z"4/Z\X#A8UB:><%B]9@$EA[,9S;D4'H78!,^ M#P/90R:JE/-=G[JPF)#2;+2'@A4UE.=P^[FV1U7_'9X<.PM$KD*VAR`EV(I. MP8V450).30V8!MRF8AIEG3N(.G=P'E(I@/5C!# M1CG+R&9CJ+$AW$IN,>:!X08/E#=^4?E#^E).:5D?5$HGY36JO*:R>_CXZSAP M;DE65G[$9)(]!>VS3A'815<_]P4O:6\/;GA5A+UQH+,L/FI\(O'&-_Z+:89K M=NY)!N1W+IYA./Z30>@CV3!7GZE_*]'UZ5FG^ZV#@/6/)XB9=?;6'3'SV&Z\ M==3^7NI/_T5UY.GM:^.B49'\`Z/FE-@Z5LJL?T1E7#:F,+""Z]/;37/MQ?UL M"=V\.$SLW%I"W]OR?YP:7:=4X&Q58V':.:20Z#Y MMZC$X@>@;1`5X8J;W@ MGEUV<&%$^"X50(RN`4!`5:H=3O,U2=KFW*%&WE! MLN1RD2D/K'PZ2!YBT#)"RQ=031'E1M2V2GD,]'J27A!@`5K[STPU26%CITJX M#D-S--4,VMR/5]I"4:L]O5]-Z6R!Z@]6B)0:7;-0ON/:0]]Y[WJ)Z!^Y5(!Z M13.Y3/GY;K^LP'A]SL(Z+T?/-^?%SW7@6UJ![35P[;F(U9WG\HLH:390O`BS M^5"+6-WN(;^(DA:'Q8MHM1]P)U9T?<@MHEO2!J1X$9U#[42N)>?F1=D!ZKXY MZ/8?H"Q[-6(U8C5B-6(U8C5B->)1FI[PGXUO]/X7>/\&WZ_Q+VJ@>(;N^+3L M#U]`7\/^-`9(,@:),IM8'0ZT]JQ=Z8\DBMWQ(F=:`"%MI:GBL*#H!@V%'P_Q MD\8XJO`Y51QV*>3)3\B\H%DSA'E#"W33%%@>>WAA2!%X>4+V5^+>H79,!6Y' M*)H"?2Z!AJHL!M3)8$81C@9#8A<,T+1'S+:2U$ZA#2L@'`/%@P"=1MIEFRSP MHO+ZDG+M*(2>GJK/A7%NRJ3`1U?J-/:M$3UB_-BM.X@/]TX$EMF69V/G4E', MVA'(8D(4SZ&!XEEY?6]N$^`]9Y3M)Z4F:01*(U"=@%%D+)P>VTL<9C1JC4:# M?J=/V7!4LD)%B3TUY@&5?K>\+(XH"H^;C%Q`AAT;]T'B.8BN@RQ3MWR MKJ6DMR$-HEJ+DC5;5)L%'3HMO44_K.ZQUFR4-_)M]UN#3)>UHZWTQ!!ZG1:` MI\E7-VKM-6WM-8Z]@M$(>2&@2B01TI9'\"A39;7 MB/IC?@HL(K2/K@\H@G,"0#"XVD8>B]XM/K&)Y7T`)A0OT!Z:=M!6Z/WM^N8F M6%A>O+A-1I\^73YX4TY]\UK=\@.0;[JX.5*SFR%__>KG1BA:#>+XO>J0.(Q$ M'T7M@4V,P$]YQ\J[AM;;W6R3^`-C_H&W==DL_J2WM;3==;N18Z+GO:W/B[^6 MN6O@M.:[N)[WMA9T5W[*VUKBP%INW7S>N[K:OYIM@]XNQ4F]U7E*2%GMK\TB MI5/B)'P&;'T%4LPRI/2[YA/"R6IW<@XGI8+XPW(4WIX+&/50-%@+:<0/(H)E M+P[1+)5QFKU6;N-7P[$GT-NDU^Z6ZFMEJF5GU>A60QUO.4/14MKSW:5],84U;O[S2H]%L]CN=4UC> M[?7-N^'-^^'F6U9ZP(A,3#<7EY"XFTF13/53Q M+<<=P\N8'8/=P>-[K,DTYJ98R\-J4EBX3-;.@N'Q1=X^!OGFC$+T.^C9%B M4&K$:G4;!P;\O3CQ-]A3/MD7Y:76%7,]X#E(]@9\*XR7.Q;Z_<:A`9CTC@`]'`PL'LGV)?9R5W>WOX[8-2CV`K@(SQJ(99S$^!&] M\5WOGR_B,&$O7J\#X1H$)LMU)&\11N>A[WP%T24\!.<8E/H-ZV@Z7H/-3>`[ MSAJWHO-2-V!S\``+U`(0]B3\[E[R&RN.ZI;`2R# M<2^M:+H7E@>-4KG+;/?6,?4L(/N"O06J!XT5Q+$7T+'E4QD)3NP?79B#?8(K MU^%B_=:>A7;E6:A&K$:L1JQ&K$:L1CS#$<_4LW!MQ10^AU;B3ZZ-@GSE85CR M,,CJ5!%C?T;&G'!FS,,@9C;/W_0I'9?*=?GP:0$2*07T,`N"HY!%=AL MC(^1CA&9TTDO."YV<:">*8EOLS"V7+\RY^]HSE^C"2PI#F0@DKJR\.OM%_E= MJLB;K79.R2F:?3<(MPGB;*_(\SP:@-O8$-JEEN)6-V_S.R@*-[89M$L-PIV\ M#7YS`'<,*]9S,@[(FG%525A:GT7+:`XK:'29B]+T5SIK*,YQ)XNKU>J=FUTRG9M^R4NX'5 MKIO->LLL!ZMTZ[J-)5OI)F!Q"_H"[XIHRIQ?@L")OK#XZ_B&ETV-5J`NM6V5 M.N;6F--WF+T`0SI[PJTI3;0QNSD,K9V_!."\9Z<$+[UV&4?:#"^%TZPCD78I MQUEVOJ3SE$"P;Y1RJ[(E5B-6(U8C5B-6(U8CGN&(9VI+5!),94#4#8C#HDX$ MO)\EL\6W9DUK#%T8K^Q*Y*(\&+D1-8H>&S?#ZZM_#]]A.#&)T\8$Y6GM:>KM M&H1_8IBO,$5>&&JGT`88Q61\S'KC5[T8_D\JC#J0W0.R9?^5(9.;0/-E^+G15%3*<[40)-%KP@KM*:W42?,H MTS%%&#@OEIA:23'ZV^-F43RD0,I4\I%Y+L/6%10NS1O>&@QP'LQ<&W[UV9@_ MF(NB#E4UK)IH52'LMAXA&5;D4AMOK"498A#'G+H9AVR"10!II^:PSCO+NS"^ M\X>6?LF0!^_8:UMS.H)_8R_J4<3^2KB.NPT6EVR_1SP,CW("W_,2G/R$`37` M;OK"QH;1,T?63S78L76SK\,9N_19@K0G9:ALWU@6SBA(HOUW1_JTU#N]3YSL<`"UEWV+`F#-[E M$0:DL"*H'F"Q"S-+.4<1AN\7MQ?&+QKP!6M9:(/4L-4@6XAI MZ/%9$@/::`MU*H4G02.RW;E(4H,US0,L/H==!T7>VRB@;=?0.K>PPR$EM6'J M%$6&!&$\`4#J:*["GI0:,(!,H(\`'7C4[(O>CA?&+>8+B;.8V=5"'H+[/(6)Y$Z%;O0G8HB*%UJ^+/QG MP++]">,>-G9G`2,`A+HB8T$4"R2:H.*,ZKR.L"W0HXC8#A`$1YP/%7.3L@*?,22L>)H` MPN\"UY&5$/$'7J_086R&FZ'31N@&=%H1"+4E#BUB2(<2AO%RIU`UTA0Q0DA1 M0$I$(8!%)&IYNOE)U5!+F#`L^#=5G,3NJ[GUP^&4`4-KPL`DPC!1%,$AQW^, MKV+X498?(GSX3"A;[M$>P`7A`G?%@"2\!EA4#%%U5=L>,"=`%9YFSY.L/+,) M2'9PF)!WU,=!6(\LCV$%487Q"=QMH@PGQW7@+VUC&CW&XY-F<$2G<+/BI8QO MU8S$]_`V`S).TJ&I+;`;<38/]X^*1B,^R?E*S&;(C<,%A3YQ,<&VQ`DO&FL* M2.(#!<"AZ0;/7[(428=^!@_YZYW+[I>/,U95+0(#+6LH1!+O&EMN:-Q97L+P M4,%QQK@HZGO,,89YS5AOU,`"@C`HC,G9&+UMNZ&=S+#3,MWY/H(4,\XX8FJQ M&X8+"@12[`MY,ETWR.GX64YSI3V67:HK[Y[#&,-1.M&`N6BL73VQ#L`M;J_1VP18+U"#@U!'O<`45A0SG8PH5;4IJIY#"(A859FBHF2&9U:H3AJ;VDQ%BHS1PH@7<\%0X%MW1D=PPY'&[@\ZX.(H9_D\PV-<$Q@.KPDX.$KXN"4:OX!L0,;&IZM].A5I5J3Y M*"!_(N-(19L[H.Z#5$S/9K,_@NZ6;M"_48G;=.^SM3^>R2#RR_?-. MYQ,*L@PWR(5!+"]M4[0?./VGV:LUVRN8X[FD,9EM\_P7T5R1M7SL<-@\B-SZPQK$J)>KQLE^;C=J@ ML8*G51G$&^!PA5!5X6\]_LQ&A;]]\/=JE5"R$ZPKA-\GA#?@??W!PYW=@XO3 M)RK55!G_U5JJM9QU58E-I.FM"DQ\"V)1\DY/*WKZU1%Z9JW96V&I,;(K) MIKG":%&A<>-R'2LL#A46-\7BJ^Z*\H$[@[J%U'W6V`.FV%YEL7Z\JC$'B/0L M`N2A9TAQ^A3C1M<2O1X(>C@Y:1L0Y4CG$=JZ5+_\H=%417!4`:W/:*NK@-;G ML]E5U&`5T%J1YO,DS2J@M0IHK0):'SDZKE%K-8X2'7>R*WY6`:W/JFW#J^:* M6LM/)Z`5C^R*Z+XJH/6`,7QFYW`Q?(^V#K/S!`):5W@4SF4)K]HK;MK3CV=M M=@]'1E4\ZR/%$IJU?JN*Q]P+AP_7#^=)HJ_JQ[07^EYUMVTH4D6S"L[7ZV\; M(U-%LU:1AM5:JK6<]%JJ:-83"=SJ#&K-017->@!,FKUM4W8J-&YG,ZF0N'$P MJ]DZ1@N_YQ+-"DRQU=[6XG`NT:Q;%-M-:^WR0MNR0X"35E;&VJ^;E<37"B>G M:)#U-LD9*8,6M9]%].(#U&]5>'C&8;ARI(/'N+:.$.):5*;U_):P5V#NGI$# MO;S#3O&ISW2\J0F)$?B\A8HLUUZ.\Q/S.;9J<)9VG_O\?,DF['CK**$"#^ME M5=1GC>$DI0083V'0R=2([P/>U.=D-&3TNJYJFGPNFGZS4VMW#E<.Z32T?,GG MH"FYV:AU&]LF"E9NC%Q,0JW;V=964IGC*U/I$V"BE:GT,7)^4GTN__P_KY.H/K&L^9NTU=8U=?+\!GOQS@OL/W_^7_^/8?S/\F/1T'"UJPMP>OV!N7@M?J#3A:\==/O"VR[;C;K+;,`)_\HV%LR_8=O?:6I#U<'L, M=@RH3_KX+BY&I7(?!G>LPY]WB>\2<*_\C[U3M3X;8RXP3`<#K^@E\]U5U MZMQV$?66AN=!LU%*C2WX44?S?F`>=\GM=,GMM4LVRWF_V6EW'WK1G"Z.O,]F MZ:+K9J=A]C99](:`'G?1V^RTV2R_F?!F36]EG]T:(;F7Q M:^3^S;C?^874XZH1JQ&K$:L1JQ&K$:L1CSCBKA%I_-\7S8[K9^W;?R2@V8P7 MFT._7,MDH]?H1_@NAGEM_MX-PW@F(Q5YC*S,LZD1^7`!>UF<[-:%_5BQ@U>^ M,9R'KD."9^'3(/"P7Q\3UA6EW`T%',+`>?PM'&+`SA M(7L*.\,NC"L$Q6#C,4/%D%%DJN7[B>7!>',LQ0CS@'[H!K#4$8/-]--@$%4O M$[<-M^?"^&"%WL*PG&!.,,/8\/+,C0$PQ)\*>36<`#E$$`/^YC`WK`">Q:V^ M=SW/F%H`BX4!LS`U^DWA)7@(1^1V30H.H.6.N:T*'H*=B?GY.F+DZXD?I,_6 M@F)_BX^1T/B,-."X]7;GXW3#[IB?,$Z7:$T(88LBV+]X:EP">D`1##,'J&;< M3UU["@>"C!-(W1$0D\=JL*,S."93YD=(A*$8.61V,`'E$REI%CC,X^0)]&%G MI[/E=)S&["#$8^<"63`(\#P!*Q\,ZU,=`[2('`TPSCB]-)TX5L[#$$E\XO MD"^LG]M<\$V.%OQ)P,3/!(TZ$E]B_#B,RW[`R?4G3(20!Q%;!D8P*EPN:/2* M&0&^'8>0"3B!7;:]($H`4=8H2&*:W<=8+]@-#GD-KW$Z[+YCX-45QI;K`W2` M3XDC_,E&%^78"^YA@M#%'>4D(?&1;E8-5F![";KD8>62R'D46M4Z_\9@%3#1<& MC\WOUXQI<`](#`U6SC$-9)0H2\G@.P`B"-T)0IJ#II:;H'KS)G$(V]KBLI8\94D^E-&S5>IHK)LMLYNU MZ1?,O@-XVQA`6Z7^];IIDO']X.!M8UAOE;K;Z\UFLW,,\+8QLK=+W37P6M?L M;`D>\(UP2+?`E\"W=PV9Z)8Z5#K-UB`+4M&,.P&U+B*@6^K,ZS9R=O9-@;K4 MA2J.T[1X[*^@Y`*JL6JP\.*KLFQ#?HN_I[CO:Y+]O[#XZ_B;]6._H]XM=;D, M"E9X!/`?"TG;,)QN:;A*_6DC:1NVMR+`K5EP@I\0EK;AOMWRNZOY"$BZMA8D M97P,0A`[;,:6C>?AQ0M M]9G,$_!0Z-Y9,2U+/GKC1G_2XSSRS%X0&,-)R$@4XF^6!5BV.N6A%X/\LU\,(,!@.XZ[2;2#KU7ZQ%:6'JMUOM5N%J]H0L`.O:JOP MB?+XS4Z_TSSBJF"[R79WQ_AEO>?NE`8'F(U>=_4R\I#L#?A6&U`:0M`V]P([ M%,9,"K.]ML*OX2WJA@[5'`=&=#NUPLWB1:^^?-1/=Z_D=-=!0*W_&(6>6X]P M[.C%SXV+1L/4EK`13(=91X%$F5]'"G:_5-TK!8MFV@&4==IUOU2IVA*4N>4Z M'W[,04AF0]_1-/&=$SC:I1:<]J"WQ#W6S7\`@-?ALE-JT^F:O>:^`+L@)I,. M<<-LSXHB7K_9#?RA@SXW%!#>L\@.76XNWR9.L#?`S*,J3K`:L1JQ&K$:L1JQ M&O'\1CQ`G.`CA01FQ)DJ!C`3NG3)HTOR$7`4B!)A)!S%Y^7:,_-P@1%C/@:% M"/3R$!"0"\=!.).Q#E0M40_$JV('=HH=V%8^STOWJ?U;QEE^'5\&LUG@D\ZU M9Q)HJ:'1-'N=G&*R!I*]`=\JD;-4438;W>Z2"6EGT#^Y-NIA'QF+,$+9OSX":.=E MHO-KZ#N?105C@+S4,[:GFZO4'-;JY*NM[`C@D5:Y%<Z MGZ,//UAH4TSS?E=O>8V5?BY#?2TD>P.^U4:4^[R[N3I)^P)^#9+MOF4N2KEU MJ[,&6)I]-PBWPF?Y\357D'4YA'-0#!;X4PQTCT64YL@LO[`=+.V=%56QVDOH M*YUX'Q#7VM9+-[C9Z.T((6?NR",BK`ZQQD_QNX@-CBB`YE,`>P*CJX(PVF#O M%N]<#Y3>"-2 MPUY9G.;)GK8M**/>]`Y$E1"1SL'GKZ;(M0O$U8/P:$.AKUS483ZI5)JL]?KGPZ-/@PV!N6& MS9/"QF.=V-LI2++!Q,5*Z\&G>.V-.R@7:AN]8]U"9W6&RS"JX;!,GGTD?G<$ M*EF5&W3R5+*=7#8HET'/8*W;RF6#E8&M M1JQ&K$:L1JQ&K$8\QQ'/-[Q;RC"R(*+G62/ANGB$8._M.K0?:](EM-@9M!B8 MV([U_$(':[QA<4<1\>TD3,9NRV)RLKXIE5=U9Z,DC*CY$D9U6Z$]I1J!#LC5 M7D"!$*(PH"J;^OWB]L)(+1P84:H`<4NX#><-;<"J9MI^,1/ M^'\`]<(`=>VBAJ4B,>S3B"R/5XWGPQA@:?Z>1'+3(M( M$L7S^/(=%F.)0)\9[MC@J,':CU@<$*MC!O.9&H)]L\D;@&=[!#?:,Q_O'UAV,SS1`=*"O/! MOZ.Y98N_4T#6]"#+U/Q$L/=L4_L(^U#P13[;4WKQ9;0;[!9W(9SYHN0QIECG8G6(QT) MZCU\J%.P:[=DP1R[O7^4M*'=YGXNWR$QC?F/C<^7>F/[9K[BU?X_RGKVUG>? M=BO03V*QG5J[W:X6?(`%'[R)?1'?47"4B*;+"]L4YP=N#V\V!P>S`=W]6O2BYV_=@B-L,K.UD;=!L/@*T3PB%*\YS MA;Y3H\`'NT^764SSHMD1VT1BN&X4V7RGM5%VWA,^AN$$"$P18!V>-L7C@8WD1YFR6LLIKJ6R M*CZF#6<73E89P[87."M$;HK(5JW?7N$A?0I6Q5,N(?T9AIMZV*W[+J">[!@W M&R4CT4M;1!-O8Q#8,>1XJ0652"J"1M8ZK.J M(+\ZU2`;@K]CI@%_&%3N'?P MQI*\"&>>QDI1&;))!I./E22P*<%5G_6:^>7IS4MIT)F"^E@8=6C;R8RS_+(> MO2*EFA?E?\>`M-D.C8,S7;)*"\3\G$WL/ARX#XJ)U15WL^71RPLKM/)I[L?# M!A0S5B-6(U8C5B M-6(UXAF.>+:6&_$9Y7Q+R!8U"0(G0L-,)"W/\=2*C7L7 MP!TQ(R$K<`@PH;E7V*_&29R$*TS1EAV[=[Q5$6+1$;W-Z3G;FA,Q_XW8NTWP M;=EI49C))C[^B(T7,SC'=4O,<*#YV!YHM"$'4G]$+0>?FK,06S)NM6$U!,R? M&`'JSW``V0P(#P:*`M]G'M^JFG@8S521Y5DA+=E'HY;/QBX^`&2;C`$A2<@M MY?26#2<<#6\U`'>":GH0+FKT8AS\<-%'.UFD*U#0HR'\\N8KC1K#$0`%BEZ* MDOG<<_%@X%]H()\RRR%3F^CXB=I-Y$9D3P/JN,-6;PF\[,P`D"@.R2!(;P.L MKL?W3J)2>!8^HY5^%0%FETJ;+=9)?\RQ4:;X.XH!:?G-X79^-W3J5)*2EGH! M4T6"5.5+2_B@82S;#A,Y2&I016S0%P*=^+:+U!/-00>EGIW"H2&]&!RG#)`U M4RX)BSI,,J>&%LV0_97`V84_N),DF0=^.58"OSX)>$F2.Q//0<<@HC6\=U'QA&Y0&BO MTAVSWPX_7'[]G'[AO/VI9ESY#FP_'CC%/VH4.IA]]>KF4^Y%.M+HNDHG`Q"& MGC6R9A;:NM^Y:"B?3*U9=JCOPW>YH>ZG+IG%B?:,,R'D+%]+3WU?5@1>JB,Q+?8Q'>#6PA&+7FGN3U1/G%D?;%E6P?F:2` MWH;S0OA0\R[=#]H-H(ZNG$S,))^A(D;\.)>L2E]\T;*>_`%[+U&;*7Z5(BAD MHC,Q$D`]3P%PWUFNDW-19;F;95L.F[DV'4FZH)L'9`<^,[G' MY/5C![,9-K"#8R5?%U<8W;G9-R4H01(6S(KWPRQPE!&2>G%)^H%.R.@7(?H(DUI='W$?15@X*K018L5=\&0&T?CP5(X:@"[CHD@*9 MCGQB?'5%!X._DQZA[+$8@:P$#XJ#"EP4MX^*"N-;<<@L'I=@89?7.7"[F,%M M!)>@#;C2,,1Y,*`SB@+;U0&X*"?RZO-F#KNUANHERS;<2S;LP:45X6OX'VS( M=V=Y1)&E?3[6O5G\K>@/["'=A9;W,0@OX6"X:WK]-LJK-IOM1KY[RVJXMEO_ M,+ZTPA"C5/YM>0D[#CK0C4Y'GD5?Q^\9N=K7(:3\G&'J MBUZ'FE(?4.\$,5/:3[-5WD*NN]2PZ#$7LJXQ:+NTK\:!234&:8TY'ZS0AR7$7V]W>_U!ON[^MA#3-7V3 MRL][5;TW!]U&Y06M1JQ&K$:L1JQ&K$8\PQ'/U@O*31Z:+%/Y/4O\GJE%*$JM MM?F:^,+_PTUOY:Z],+3\"1/F05ZI7CJ]LE'OY+0+&7?U<1`Y>LKXA;#Z"V\JK\K?(S<*1'8PA:HNTQ34Z'TD](8^B#5YHIA]ZK4- MT2DE['FC9(&^1M@<]P>?0H;26Y2CA9AXY=YIP^(&,CNV1NBT6P@D1@$^OT`# M77)<*_8M=/D*\(9RRYD((18%SFL(5+`\C1^=!E+U+>'#V!)SN2G$SY)BZ, MC]RWA^8R\KSA\QR%Y%=/W7MDQ\]YXT1LAC[[6A\;<$'I[G:$0RW-X2&/.@QD M"1ZI$@/+EZ#0*VX$YR=RKK"!25$2P='#S]P M4R0#^]'&!VDP3E/)[(`'R\B-R3J(=#%!]:`1X@*/>Z*`(B0WERX8N0O"!R\# M>7SN;WS$>^DTO*\?,=]-OR3HP&*2L'?'1&R7$"U@;V9!B%\"?@,?"-RC=VH\ M&T[L5TU%L0".7Z.4A.(TGJ0D(G\1-0>(F_%XK+<3&9&DJ!&S)^$,WB# MQM$6Q\%+F=#:%PP-A7AFB95G)=BI"X_"C;?@$5J`H(B$6`-.H!.$=1&P9,-M M\@?G:!E1=FRY(7^M1O)K)I1*?S`+:R;JY-OUATS4B1`X<;01+#8][ZN'>??A M]CHS#D<7?@TX'B-CB,B/OS3H/?=,YW?@7F:*NN,E,KNGRQ^CZ$)@+5'@+8>` M^4CA&O7!IKO`^JY\.'-13%$I4>8-]'4CC.)@`5J0W`C^L@VQ`HMY]$'K./=`1WU;4"'[(L-JK*+285S-^L^:(AG_!)6G1&-\L]QZ_ M(0(A]4`/MF5""I'Q-7"(9!X]/Y'I6N%N1>[(8XAD:%*\F'.)*=5*TE!?"TZ. M7P=.!K(Y46XR!SV'ZR8`A`OT'R.?R6HT,FI:*HGB6`$KDN)A"I,X4R[I$O!E MYFSQ6T$2OD09\7R0+>#%``2*E'.G(<84*!R$=&J#$0FFER#8.Z[%FP%^2,)@ MSN"/[SX>OW4:@P#\9;3V%"\'%LRQ,<@4&QI/X$0C!];YLM6J]=D-T MK`3J(>Z/08(O>[5&HT%\7;LQ`>016^)6'[X7`$)KD0'L2O%!MNJ)T"KR>W(@\Q0I-AVQ3#F]F"O&JE*:4RPEAT/0?A*XQ1QLF! MP#&R#01S$`U$\#GC15ST_>=7HP+(X8'9I+=1"*V`(]69T]=C.-C1&'_3%=LE MB,U:L]GB$+N:#BYP7Q3+R:_65,_D0*-`S`F?`*$"$TM4FZ85/'G6_7F)AQ28 M/%*;@$2\BD2'JQ5#_>1A2V/=%7.*4)9Z16(BTUB62Z'`*"R1@`G;`1*_9*<% M(V??OK>X4+&LZQE"K@,FRN9TL>>-!M*Z*4!29IXLJT6FN2A@L2F[`8D1;3-8 M/R5VH_%"D#R1U'+X<,9LK(JT$.L1?$.%-CYQDOM>;)=2=U)6@D!93:`Z)/UN>/-^^/K77V^7M22!9GKJR=T#ZP0*5(9A67`N5"HJ^?#%]N]*?4L.ZMT*$1 M@GO,F)FZ<^Z`ESI+J-F]A#E9IL^!YHAI"S`P^?$C:?EUI%$3!N->1E1+T41) MHC.Y0AQ,E'5'"8@F@)4$M$E7F<1NF>?5OTW#()E,"^5,?E]18N^%*J68+0\H M#J!4QD(ZF45Q"]SM5Q2Y4!-X1-/['.U@3DW(#VA%5:9S_1K'0U[;W&6S&G;T M-:'Q6]G%5;4_``WP1S>J""],7,U4V$=<*O/74\:#:*\*[PT04U$]0AH,&]\ M9GE/AN^734H<'`Z+$#E4(CTQ"Z")A!050;!$?T0HE'!LN7#\^*=0#ZZ:I-MA M`4.R9?P4Q[`Z)J!H*)T'6)O#M)_H!$OZ1I*2?D%4FW]*LQL5V,LBF?J)6%VH MQVM(.A)23F3-4O=ZU@\AB0)H//7>HX,E;),F=<<[6GV M9WJ_D.*<7K)R!]$==F%\$""0?PR!<#A\HM(%K!>H2#J$4L\1*MWD-^$SC'BN M"5]5,9OEE(#\2=1O!C#=4#,K4M4#Q7/!MR&\K53 M.$1&;>K;%-4O0B(\;AQ(%11:IS26PC4SLVR64-%;%&0F\*J/ MUA1+^+FI['<:!_`0N#F7;:(@,V``$T#ZWTJ.BVPX?FC:Q?B1<8*G/!M8$,'J M*#_5CY>VM2:C:;E\+&-3M#`LF$/Z;2,I1NL2F-S12-IW@"!XS9?4EZV&D[%] MO(B%JT)7E@YXGFL^&SHX5#3KC1!)$-^7J7Q=1:;>KI?:LF)9*L&%+(T72H6_ M5"J#@62M]HP4G0EFT2AY&,F(NMCZ4]K1?8S4HBX-HIQ$R*]T_8CPDZ9L=VB8 MIN)!<):LB:Y"(-=.5U4@@:*)/@PFH36+\@9^U\<+/U(RE:&7KI];"^[YEE:W MB*F!1!P5BJU!*HD@XWGRZH)VT@S;LUQ1I*I$6LH0%)DAW/&8H8N82GN-6'R/ M.04RK\*R@6U&HNQ-R$N#X;X*;T;9)+#K,#"%TU,8_^>W%RYB?`*G#R\X&8TI925FN;M+0@R5GB1>[<\`O M82].R:_K#TR*2J5DW7J%)6 MYEGWD3#UPO4[#UDL@M8U65R2#K(;\A36%(%*8GHU`C8#R@2P*R_+_(2BJR8$ MK/D@SL2\B@Q_Y*<,<.B9`9%B+G3(&2W8AQD+)5\$LJ"9%4?P&?IJ+8PJT912#/V+T^OA`DY2 M''NI+Z?L.,2+.4(K;;#2GZ+?>[R)2N"*Z`6+PB@#$3\2,UYB,J'><\5S<$:Z MIOJ2+I6F'FMUW8EP1%GMCR>E:;_Y3(4EH;H3DK65N73!*H&:1ZX*$X6,_Q%H MEA2YOGC2TY+,#B7BOL^8P[BE[LK'WN&8+E%)NEG\<,F/ZW^NPI)F5M8LFU>* MUWU.$W^TZ-!,T3<@"M`1GP6[C08]2'R>L)D^$:E`\Y MRV#Q.^`Y'+6<,T;,RDX0X776JF`$"?A#)9\HVO1&31D<$$ M+@D9W91!=:BTFB1-'9$">,5C=O+DWG!?5<54=,)W`B;C_5!8P).GKC1$E];L MRR)55[T0T/5,\7^"^LGD3R^)W`9ZRQC!G3Q&]YCRS*(1C%*MX0RQ>DHP2P+UR&")3%SY:]&DIC'(+ M.!R164!\7MY"ST%KUH-"R`>9-5&G52E$7C7/>D"$ZGH!%E<`20^//9803%?3 M:M0HS87>P#)K;XZ_O@VI$S_R=KQD,!,PB(Z\5']C'L$IE)_>;@'=O>O$TS=& MK]&8_WC[PK!!TQ9=C:FJ'/X=@>(A_DX!6=,P7'MRXY;IR]5=EAJ'FYMT5P8T M`,C^/U_T7JP86F<=-B4S8?O+@A[',*=!L8:"$)&HJ%GOBE;E9[&4+W@JBE>R M36_XD]CJUA'P@\S@_)?0/O\E/,5=V.:$P20PZ"0$1=Q!=A^$;XQP,GK5;+1K MS5:_UNQT?GI1@!S!VSO=?Y2T9L\$XM4P]*X>TX*/L[KXLYC]34$^*^$HA'#?9 M:B_+"]H4SSMO:3%JS>8*2MIZKD=:Q(H;\%R6@*G13V`GS-J@8QYLMH>0`@I! M6BY4MZ9HH]2NWYS,3AQERFHMU5J.NY:'O94I=V/#I,*3P7J[UND?CL<^VC*: MM4&K=_[+,)NU7K]__NOHU%K-ULD.W>3N%(!A/7>$4UQWXZ&80V!T]`!WL2B^@_A3OUD(MX MC!NUW%N@%2,L7^%.KH:L][;$;["'97.;@;7KHK-"-CH:K$$@2NNJ@I]Z]'7 M-&O]U@HS9X7#4R+!!Y.FRAGTMR"F<-H=[9C/@B`Z-;.[0@NHSM1Z%+9`GJAN MQOU0V*EUVQ4.]$AM]8T5YA$3XR]KQ+%3U23J;P6U5K.<"V/*(@U+YJ=C"RV MO6BE#;$SZ^1C&$Z04'N[;4-SMAU3TY@;M4%_A7]G9VAWN=K.&I,H8ZVP(U6( MW!21[5:MV]E6B:XP6638W$%SV@^1.B=_37D>Z9\;-*2M/L=O_^=U$M4GEC5_ M(ZJ0:T7(KT$0MA??8$_>>8']Y\__Z_\QC/_)/CWM+@:+2:97"8#;@8]X*CG<+17@M' MJPR.%EPK^Z+#W!@=[3(PVBU@RONBP]P8'9TR./K`TC8!@P?R?N!5T?>AD6Z_ M64JK.81DYMP.GB):22'`OPHA,'Y$;WS7`TDW3-B+UUOC8$/"``C,O[[-X(,5E?%MEP_V8\F_^%5'EX M(8`UV?H&:9\`"*6JOL@IKP5U`_+E`#8V+199$`M!WS0W/'U/X."(.;YKYM+U M^)*DWQ'WMUQLG;G\1);YF-G-W`LOUY)>ZSJ M()?2$]^3;G_;T,<#;T6Q8[G8;[JI$:3,='([M4+V#JLH8[%&YD>4FSJT8_?. MC1>[&U*:9F5(.8Q8]V3,#D-JX8J3CT+C-4$RO+-.K+S[M#'P'QJ&I^=I),!":\(RWWWX@>U'H^R7U]@GY!'-5IT"LQ4]_L[R MJ-KU>V93'(C1,JDN[8HZCH]AKMIFT`)34*GII=9:%7=U5#"?`/H&M6YCA'A\TTQ.=J7CDZ8A[!0'@H7F"C5.)Y3X(;K.#V%>E7 MB#DOGG`$H>"63G_`>PT^05F@UC)7%`]_/M+`01#QI(Z\:5ZLJBO_V&?]N/=_ MT;%GPGCR%`Y^==&5.!QS[^!P[XV8H1;"__/\/XD^;F M:C`%Y%69U).%&%E@HM MIR@!N6U+K#5:$#ISW MKA2_?@`G\DX#ITCO7:PRJ^T']:$#_;8)V5L?]G=M+:B@">J,I$6*.*5_6U[" M!XZB9,:_VR,&)Y5,>*<*J<_$A[+LB(63<`IF"?<]"'\.\QWCOR[SGH+KKW'1J*CW.&AX9&9[XT9_UC^&C!E7 M*&NQ*#9NK'CS%)#3W2QSU6WY?&C6O-C;([N29G=1E7=7K]?*%D0JG'XW$+>IV=0OK=#&ZT@=!$2MONJ[1?'6T;_^#2P#=,-K%KJ! M8VZ"^]_I/:SB2H5;/\SF7K!@3",$60O6LWQ5(O;*1VW0O6/XK7A`S$V_X^=F M!\#`QSY8]A25JN_PAO^DT/*!QPE^&7T%?LB?9M:OL#@QR`< M,VQO=^7SF?6X\0L`@+Z:T_T$=9T4.A\A<,C8T.@\?6H!R/ M^1I[#[2@`Z'QH^6&>#\R[6Z4"H?4-U!RVQ9_&?1US27TS9.0O?CY$'C;=`6/ MCK#5=W$684C*E!VT6\=&6O999P`WK8AM48YWGI/!6^H MCJ(V*I71_3E:JQ1K\/*1T%:TBD='VC:DUEZ!M.[Y(>VS]<.=);,O"8JB0A&- MX':6JL=&TG1&-,XH+==):$]ASE1,+A50F@6HE0+*)LKE`19[()QFQQ\F\30( MW;]95GYS#X_`3K]@H+!>2VX/>43"87^)C M(;)=-YMU;"E1JD!T2W'3;.4+8C\QY*S5KCKES&M@GA7A?)7R#:5GX02R'HXH M@2.KWE"AFXU0=?7E8P97)2TGZG,6UK.XPWBG`V!NNS4=%I'">)#@EOD.B(UN M2",<2*WOE)M'FOW#T-VF"WE@O&U,EAO@-$^A)5T2"B@4TQ0>$,'M#VU MRZ\.LV4.#DJF1S$Q%8[]2QA$!3VU6O5&7R"&/K;,G+D9WAX'X0S#P3DKW]7" M_'T>^+>)C27GQXF'2_(8P@E7!"BG[MBUWZ<-ZC^['KP2^'*Z7D4MV*CR MRZ#9*6FR5'`9]"\.8CC9#0\GM@G+1I6]-J&DFU+Q)AQ09GS43=#J;G+A?Q>U MK5>NF70;![(*E,'[X.A8+R]WRM'1&[3/%!W;J6@%-),3@%O]C8\;UC@\"LH. M*.I&FRF&[$%TBY(0E0+48LV(+5![T%4>&,,KV>@AT=LN:1Y9@%XJR7-`_&Z^ MQDV0RP<%+3!S44:\W?06.4U-LV\.ND?+:ZI&K$:L1JQ&K$:L1JQ&/.*(]`S_ MV?A&[W^!]V_P_1K_HF;<@N0Q?FO,K'#B^F\,?+3!_WW1[+C^YH!F$D\W?XU^ MA.]B"X24MVG%KSI)-X8NWN@A\:L^'P`#V=C]/Y(H=L<+\:7K.PP';5PH_&03 M#(X"BIRUV1-[/?0\@\32^H@P->?2)8SB^K:7H#K$ZZ1&1C`VHH(J:J`S&>&* M,LLU`T:')^Q@XE,P@NL;\931GEC^(JU@.'@;P9<^90];.-1M#/\A:'!N?#YD M4]A&D$B-3VA.Y2`'-)X;&F,+_G6'QI#HPO@&4Z1?E`'O1@;:26PLTD+48QC:_BUL,0E/L%P+@N&""T\5'4\+P@$/!Z`;D#3 MA.ROQ(U<@")BX1W./^=N%P$&07]A7,%`CN/BE#7CGAE3"_8@2%5F?$O:J068 M.KHC(-O0N)^Z]M3P@^P*)*S91208LFZDQ&&_U69(OW;>`BBP'-O&GD[.Q::' MN_J.=VE?*>6O<1RIY[51J%#@=`Z3"8@K*`?6>#\U)V2N0UMEN9,7/3.9$=7 MA7Y_8^%LHW2SC/D74[PZ_S7[S?<'P,!:\!X/#45!U1H:^N>(AK5Q9#=L9KD^ MD"-(T"#OV7%B>1N3R>%NT1M<"/WZ&:"9);/E5,.V21MP`.3OCI3GNRL\$+U@ M5YJP*V;CI+8%M&:\`D!/&MIV@!J!/R'ITV71#D76HGZC_2#NB.5B/QE5?!]C MR)<`-#53TXO:;PT-3T:**$-BJDS\-XQ=P"ZT46P[U"-;AKYIUH<-]*2]5[?L3ZMZ6 M,7*!N.RI'WC!9$$Z.CQGQ%,K!D$K`B*#,5&=GP&(W.SC<.$,SD<`'XP(9#'/ MF`4>LQ./&4Z83"+^_HA.ZI]L83#_[P6>*->_"[R[U!HTM^)I,&$@W+ED[8'- M9,!8A"%'``THLI,(+3+\I3AD5HQ\AZPO:&:2K^&PW-P0::=,LOY*['"F(5D$@*\J'>2<&K-:L:7(`0(+JT0 MSJ]O9>=R@=5-<):(U@^KM=TY$COA##80MZYFV$@0L!T9!C-,^PI MF\&"PP6!A)N<`"S?3:Q\$*#'8FFQM@+ M[B-C#-P8B)&)(&7892QQC/^BR^?B&"?MR.=8&@>)]GB'O3O0(-1]M67ICFH]5K= M&M(`7JJNGS!Z%>?V$;@4WT"(`=:0[F7H,VO+55#PDU;CAXR.U`+GL!PG1#J! M@Q\Q^MX4H%;TU7C6U:8,$[;XV65BI`%%$BP-&!B)8 M#H<1`K2,SYH!NG.4(`.%5SE7U>GP/D@\1*[-U"&=*54=P&EIX(06\$]E2D9^ M9,WQ:E8,A%$A!P3$82/``C`M'ZWN!!L_]5C9P8B"!!1N'+ZMKW9$R]+&7UJ. M3@76''Z^H\N2+XLO!:^AD#\*9`(D0*Q2,A^8LJ.OB,'X0)4@(?/]`JSZM+6S M@/P><"&%]E1GIK1A]#$*&B^4W@7:L@O$8$/V M]L@"3DUK_$$>#B"\EV:G46LT&N0/02*DZTTG*MWO`#L?,A@ME.;\&BQA'D2P M8X`]'LU4$X;^N4AV3"D1D&J%Y#KB1Q\-,H)S$T,".&WBZ]&4>6/CMM["O<'+ MB3L&(NG^D;OC(CUX``LQ-5SVK5H"S?#A!X``V@FB"&ZYR*7-,#[3!K1XT?L+ MC8VK3T-%,-XBRV1W0_(CX/AQ4?P%&!>JE"E*NX3N5DY60OZH."O@D>Y[[9I; M<^USKY`XEN@OLO!D&1XC\3.]`&'D*)F#0`97J#$Z%RFI^BDA(-34HS>64+Z MOD:VY<<;^\M/6T7Z1NY4S;$L;A6X'J+4Q0&'G1ED8FC7%#R?X3J+W;\M[OM%EF>!Y*(NY1'C/D&:"(@\>%.G=91W9C8"L7A]1288@"NA+D5 M\MU'6@P=:N'"=S\U\SA_('PCCZ&V9X%67&H@>4DDG&0MKQ\.(\92&\-!<"M(.N4S<&=T3 MTI3`+P/;"L,%0JIB6965>&G=FJTCT@-@':[1DXEV"ORZCH9;P[>X#8LD/XSR MA,L@+W3@/_C-_Z[7C8_8G>&-<0WBV%M01_Y*&)SX-T;WK4%A%F^,EE&OR]=R M.S^'E^HCN/G_K(\8G'!XVO+NK44D][L>!W,8*R6`M'M24[AR<51%9WR&+*5I M0+Y&*!4X9W60T]`[.LKG?WRU!7'2I9.PW/-2Z@,1F4(S&K*KZ1]`R!BC0-<. MBO<^5XBP%<,(1"@RXJ5'63O)9'IB(5P]5L2;I\7(2H3>K+R$A@VSN&B6#AUI M"JX9+WL-G"T4FK!Q MUQL7U*2NATL3)H/KJ77S>4B&`%`8'38F]XOK"]/`3\077IJU=J.Y$0*+,`&Z M'/H=D=-P3,`%'0#7C'7;HT>>$?8#%!>E+(X2UW/J01)+YP7&9KQST4+N?/`K*.L[`#%3>`F`/-&:S2_88/2'L,1G+8I9W6=I M3IP,YF!^A)L;?QO/=.*3NQ6$`X96CT@=13*Q*[=L MUF`^0Z%:V1;D21;V%1VW0%IHK^-.97+%TEN$N2)DI[H@RBUNG`A;ABXIT=#D M)<&535(W*-RP/D8QX38IWRS:![DXPY4`R0K$Q.P'[(-TZ!;MK=S0'/.B1IFD MQ2,BN5T(Y3'ZG@2OU)W#[4N"$O$FZ`(,X8T+9K:)U;ETC&C#O7010( MF7:12K1HO)#Y9F)"N)@M'E1HH(U@#/`$F3?]@/MAR1!F]H54?&'`8 MW(2+VZI(F=M(%9(!HV,/?<'P.DR:83EXY0(L65*.1'N?*,?(EI4%`ML.$`1' MG`\F&Z:EK$"$9L33!!!^%[B.3),3D0ZP'0YC,RXEI;01N@&=5@1";8E#BQC2 MH81A\NY6)\!HRP"E+,\%\4<&MUBI=56>;GY2-=02)@P0SBB93CE!M?7#X92: MW0K;K(XP:7!+Y1?,3LOR0X0/GP'%P^,)>+@'6MB9<&H60G12HLG6UZRRJT32 MOI^G.-P[62^V#J)?'?WE%\9W7V%K0OYU/-4"3X&_M`79[%$[DPF*;]6,Q.=: MK@^?U-#X$S)VJ<5S:@6M73..@WZ`G#3D=GQ^Q=N6.)U%8TTQ.(D&*@O,X!F4 M&!CGD1#OLOOEHXABYK;B=F_-#'NM:?LA[DIW15()?BYY"0CSQVY.4B'\49 MC03#4IP[AS7RZTB?2<$Z@5',N"F;FZS3TYLYW6)A%\9-*>5P4B']CE.*&@$? MXMC&4,T92TW0V^0;TTT:9H+2TISA2&0L&=@#)%;V5[@@XFD@E1K=^XEX#1WN MD+7@$HICC\=R49@2;3)*,#GN'83NA"(Y-39NB7'$8PS/&]"9)$D[%B&QX@_7GR\Z:\DP$52CCZOA0`R MF&>%-6.4Q-S33><>N'XM8Z`E_9)4/RX\$I?.CD9&&/DV_BS&SH\C!Y"^:YJ6 M#R[7J]5`H"=X1*3TUR&]8*"BD,\H8$3D_4>",R384P9H(\4]8N(Q:%^:8^$O MKC;8H,V*MO?_?-%X07]'<\N6?PMH1&=Z$MGF$8`D/[TU5%_XQOS'6VGO30W0 MZWJ]:F_0XSMT'EW_>UYHL.TPR2%!-C!Z5HB@"MD9-*1J5^;K7U"0KE!3A)I/I%D\*]Q\D!)= M!A&8Z9["2L[80_#UHO;IX63TJMEHUYJM?JW9Z?Q4ROO%==[J_&,I+W>Y;79. M**GSI^2VX!/:#?)U!"\*N;'$L(MJA+1.KZ$/`:>Y#.9VUU7Y."5=PE]N.&!C MW8AI[_)FJV::@T,#>@`4G!\JV\T*C8>@R'Z%Q@.@\=7!J?&G9X0]9(O]WL,1 MXJ'NVO],W9AMJER50'FIG)$Y)^EV8M.>JMM^)WG3;>[5FNUUM]]Q03L'-)EM ML\+1.E+J5BA:=R69[8/`M>XB.D/4`"-J-];=V*=RR6RLT"T!7*8U7Q;'46^+ MC]V5\JRMN52A/KC$N>>$&@$U:H/&NIOLP9=7[=`6>DVU.X^X.V;CU)96[8XF M.:P5T@^UMBUEBV>]*W#G]`>/S]4>17=^\L+ZB8!W2K!4J*I05:'J.:/J\37H M93=H7@!I7C0[8MN^!3&EZ62SPO80;K2Q=Q4WJ!>/&,AP@F3DL4/9^?>>*:6H MGEEK]M;9_P^WLL,I!<]FAYKF.IMTM3V/N#W==:;>:G<><7=>=9>B.(^VK+TU MZF>S*W#IM-!4L7@6+;^CP:34>,"KR*:.R"A8_!!K37.3V MP<%]E@A]U6P=&LIG%3>.'')=)&@5-WY$+>ZAPC7-SK'#-<\?36:GBAM?AZ-U MAM@*0Z_:ZT3.HQBBSP$UF+_2/?89>W#5;N,8NRIL?.^P5[/6;SU^"%^U0Z4[ MM$Z8K#;G$3=G"_6SVJ?'C!_OKM-JJ_CQ1[E\>OTMHWBJ^/$S$4U/!+Q3@J5" M586J"E7/&56/KTI7\>,/$LK7&=2:@U,(Y:MVJ$SX[&V94EIMSX,>H&IS3G=S M7IFM+?7I*G[\82Z=5GM+8^Y)Q(_+)U9TC.P]@8Z1F1BT+6K\IR7^>6\.V1#( M29LQR*[0ZSO@:+T6TG6J=HH8W%;>-OHLRL83F?[S!0][K/("3B*LM*AL_%-? M\$%2'PX1(MO=*$261OE,_(2:G!F!SUNTR98R:_;OY*.XVEM5_P1N<&A`MT5! M\RF@T@0:;3U@K.NA#MDA`N+4:;+&U!Q7'JAX"E--ID9\'_`FB$_/HH8!&QV:NW.L>O/GH/14=[DN2.SXPEYUE[59J/6;6R9?5]%(SSD#IF=6K>S MI7&X\GN?"4L_$?!."99'1]4YW("5V^TI5="H=NBIV:C7&CLSEDW^;X#8]3'EV9GFJL3`U>4:#.^^S'1E.0MWK]7[%(?.HB2Y\ M'3)W-DK"B(S7V#8;&]V2H=W!GJS!G++*>3MCU4*9DL[?L[D5T@V`R0V_,LN+ M^8N_)C/+-VY%I]>:$08+^`UGS:W@=@J0!Q.W1J_-P\!);)`?+7P`0/LE9,PW M+K$>@B&S][#']:O4?V"_U1Y*OW;>_D1#WK*_W#")C.__,CZY,Q>7G'GY]ONG MS$NRKZT.*>*5\<:^'&.J'[?A8@MS:B0.:V5HB;30,R*Z2P>)YV!'<[@F820W MFF*;X=A@%N`W9',LB`*:)/:?+NDQO<;=D6U!/;4T15PDWT@EXB799T3O7\WAYEG6K MJ5!^()1_]T?;(OVD$+J#*6DCE.^\(E)P5RWFP15V<<]U-G>5;B.AK2&6DW>= M%G@BJX(L#X303JW=7F?-KS!Y@IA\%/-Z"90EBM[3,RF;S:J;YP%9=(6LXQ/4 M@\LZ>[CG\U:-K`%MV1B4L5KL:R-_3A[BVF!M@<#*A5\5?JCVZ2P.THF(@ALX MG363]KY4]FQG$+"9YY/;QL3\!A] M3\[KUU,9L5)D\0DR=K>)!W@0Q0Y#47\/_&97!A?(J=B\K*M865J]%[ M_#J:U095YN(SWZ?3.$@/+GE6EN-'JD&W/;E5ALF'->VO%]>J#7K$#6K5^NU3 MJ..XK^6X>/X]TT/V'/TSO#7U%IB(&J`%@1)UHF0T M7_U[^&X=]@67O&BUV"S#%OMHY:#V2D#M;_@4[AV\L22/PAFCL5*#H3^,U=1^$?^*U`<<4KC:XI!02\8H"8HPY(>+D0*U8`&Q,ET(M)6V' M7S@\K]0-(UQ<37P*DCB;2_OQZN/7;`;NC,73P*GAB0`T_,FR=Y7!?LR9'\'9 MXI>?QA5P/L%>,-^7+DH.O(M',2J_D-68XL*%D"..,.;^$``L,C[ MJ0N#3N#9$(X_(1E6Y%H`5#+'*QV9R9QN?>`W>"W33LUAGNY\&]/J?3\3==VQ$5H8VWQ"+2`U*5S_BO]RZ(1/C&;PFP-,H^OOW^*9MC MG@4E@F.-G$Y*%M:=Y7HD+JVE3P`.!X<]LFR\,HA5<@B`\(H$'V`%L*]4>6L2 M,E8@BCPZP]QH]/>\?!@_]V[Q#GP$;/'4[S"9&$-GAFB,BW+?/[X?YG+>!=%H M7"*[:2,V`8%7$1`7))%NK"@*;)=0K@#)$H_<53N8S5@(SWH9>LKO!L?8BI+) M_>=4,GD;]I[-XM^K(O*;1Q`I),J]LZA)55%Y,9[#EY_C]*V?47E%TK'V7E2SZ-)1QLG]KFX[=N?FQ/ M\E[4LR?I/:T2IA6JSO_JT[RR7UBL*_?[LM5GX^_=_?*K_/(/N4_=MM$RT`L+,SP/[37 MNV@6\"XZ(^)T*.2^#;VG:8`%(_"%P_+=)._6MDW$,;.M">C(5)D.RD?RB2C@PW=.H8_[,P M0*!Q@A#)+T`2OW.=\MB>&D#B)V,<-22ZQM^#>,I`5)/Q0L(Y!5>%ZUMDQL?@ M'J3>41+!+J';]3:8,6'5AY\DI$M!-S/78U$<^*S.@X!X5!,Y`&!>-2.^90,N M/$;.`C@R\#L<$SB@&'@AW)TXG3MC6786011C"":XZ[I*86>E"U`UU#/Z85.MB633HT`!Y^A;[T[BL.ZQ>?QD`PA51?TR1@^V&=C*#YV"H7"@>/PVH37GD8AN[Z%RF#;%A`RQ[ M(7W7*DI$NXO/$=XT9> M.U_#B>6[?XLHS8Q[__+F:ZZF?4'$P!SXNAR4^$WPPT4+P0286YPXKI#HU#-Q M"./W)A?Y'F\5@B3")/7KR80\8NC M,'HE&S0"`I$16O?8"9H1'FN&@U$M&+=$+)N+7?B5U#DTG,!OSPKM@((QW"2` M.Z`[W(-\EFF1[5"W%SRZ)K2U0(^W>L3O8'DY:B%LN4,HA;&,B*%=UI$(V16B M%QN#E")')O$8Q/,$(_(TJA97_BSQ8G>NQ_J[/LP2)Z*Y"@R'[)C+B?`NA3YS MB<#'D*$"2$O#.KDLR6655-3AH6]*4]#TF)RJX+,)B'LB(N\.]0[1#D8<4_W( M<@@I.!D6B&!0'76E#`Y-@+[D%LNN9_2HT@*E%:'(:8Q,4A'T!5BM1T M2S1^3VP4A,:)!]I9"+*!3'.8`[#*YH)/"A5&,(DL[E)5B`,6UD"=(#S;X3`2\*H2AQ990Q-9B*2_"O9[I``0S;%8'*0_C\% MT1,X>/HJN872SJS2P[KZ;L2_=2-N)DK\D%$.@6-,+%>(./@D(^%%1?/7X4C6 M,4U+[_A)#\.(L!$VO,-M^!;P_+F%E$XSP07.;W^XR^T_I["70*OZP3?87PEP M"KBW1*H8:K)PS+@EBRY$:Y.595+/K(C[-P!2S6(K6(H2RGP*8*%A;U,+$\"Z M3!X7AHC9QS=]S/,>W8E:9I@=!I^1-^[&1_2'F;9O-*Z1Y4!RH(Q6>R89*.9X4^ MVJ$E\BGM:LW3?%"1NI3-MK!#EPP5XDX'Q+QR?THQC$Z$Q*(SQ=`J+&1\R]=7 M!%>T&\716WA5?]=A'KP7"./S'ER%7E:B7OPW#ZI MU\MFL<)``=_@L['V-ZZ_E+.0Y5)*!#PWD\<7\`F56(V<``Z\YGR,E&-5V0.R M7CACG(3B<+ MTB,U)4,SJ(G<5GUVKBD)C8KC5F%..9B5*TO85735:B%L8(3_C)>N>`D*O=+B M*RF`LW$W(D0(]08W#9")EE$WU@P])&\*JQ::D*9X/I1'/H57CB'@SE$&#!NA M.@6H]!:GI49M-#I7CD5,C$1TH8XM#UE*'UD#DR"H:.G\B1VE'&8WW2N6%>5] M%J>U'"B4A^E11&52A&H,+:0)&6M@6S[/GL;[1VZFL#4*98&<6MM?6^>PJQ^Q MA(3.\>DDB^@(;A20L@1@>P9W)CZ!\5U`^=SF5A/V2KX#-64[!:R]1K$(95X\ M8DG$I&4#T]N+"US`KG`M*C;^2N`6&[OR`"J%+P%Y5V@BPI0C8CN4Y$'&7E=S MX\M1M?60G(:\4O>"HI_(J5L>KHY,CKI+5(H\=@):YHR%G-0HG19.!I^48Z]$ M&L(?8B$.!K9<.R%OQ>*R;$X6&Y$Q<$(:DW$.VN(X>"EW6ON"H:$P8UQ*1=:I M"X_"54C$0`B*2&H5T4YU9'"H,L(U\P=G=1G9-37EUDA@S01,Z0]F8]E M\15WO$1F]R058+F%T!/%#$3)(\FHT`IBZ-0'F^YRG\0,HWAL,@UF_!!DFXOD MP0*T(+D1_&-1%D9$*>4H-"BAE.QCRR1:0)ENE!-]%(6J0@RZSL%O?YH6`[<\ MWAA-':O"@X0!25P&FC!9WD((%MH*,'C4M[S%WY)D=15)C\'2WP%(_TK<4.`U MX<%T?R3.A#,UKL/EC@CZMT8L%Y1&#(R>46NMH<1`C"\(U7TH>:#/V2`5*[%\ MKKX6RV@/>J$;5C-\L@*MF M_`NN-(O&^&:Y]_@-;2=)^7I<)A-2@"Q(@1511)D*?GXRX,I0+A[,AGZW(`$Z M6\RYU)(J&#PZBZ1IH'6_#KP'Q&RBM60.*@M7,VJIHS*GG(BSH,P:XB``\Y`B M6A8N<1)<4@W@R\R)X+Q`ERNN,B MK[4CX=)4BPPO]$,?BH;## MU(L)_/YETZSU>CVY'WF0$9H,MTUKT,@]R*M*FI(IE)`(*P@Y*#*%,4HF.0@X M1K8!@&+AT1&.UGBMG(\H^&1E.+]FX*4;7<)12W5@K2`/G-UHC*YR75%=`MFL M-9LM"7*HZ_#+1"UW)*]-DGHF?5AIO+*0;OEY\$7@00$Q6RC!D.OM+.O_?%YB M&07&BE2;ES@FZN=^_RE6JI+G2LAV\%H:-('"SBN2XYC&H;#F%X^Y(@D04`PB MN>2@!2-GW[X78->3JWB'%(<1;9W>=?R^V$&5.7_::YP%`A$:@ M)$3A2[-)7!<#O!V',&9Y.LXS1<2TN)X@ MP9?F+7!HG,,%LEG$V7!.?>^<&,T;I'<;0N4,MS5GA04F` MB"@+!M\7*P')5ZTAVKA*]"N=&;P;WKP?OO[UU]ME`PC.\,42O/5*1).2X#9$ M!]Z$BVU7_IA"J$$5>>\"\!'+90%\N1I>O5^:H9;N2E[ASY2N%C1!^EBVV#3N MLDQ$.BTCZ;)CJJF*2.S(`C\\U=[X7ER5JZ2LA#SL08Y3R&4#)BR MH=#Y34*\&_TI59E["],#,6C_WF=A-'7GW",ME8-0LPL)<^MRV5-R;*OP9T<: M_6`P[IY#90%->"2YDO'?P?Q@=Y1@.''-2$!MCE5&9EO4K M$P]?;7,GQ6K8T;N232B3!:8QG\*-Z%:$C_SED(%@[V-BY!2(B&'E$+G%(V1T M9,%<8G^YXJZ8`Z9("87NDOW"5%KDIC!CC=["A^?31>3::&@(QF-N>IL&$=4< MY9",&1H5O1K/[\M9<8PI9[TV8B'0TZ.T**3_R%L@&THN)>'4V"2U=KTB*CTA MH\!#P&GH4G7^:(X""[+-HA-5$U$M=)7EZN+S(+>YZTG]7)B"5MQG:KDBT$7` M@PGS,\LKB+98&V]A-IY`P,5&5PNQ<3AK0I*(9`%5'FX(BBVI)(+>B7R)SCZ3 MN.#"Z>6?0CU8:9)N)@#LVS(>B6^/.F6@7BCM!CBCP[2?B`'(XX$4J::=GK52T)`IQ6F'*MR'AP(A\,G\Y%:$2FU127Y8#H(7M^QN+XQ+4F(#<@<45/# MG)8H`X2+3[>2[F&Z*KFZP)J?I"ZY3&4;CL9I;-$DJN0V$7)@O/,:A# M)SFA\4:R4D#$)#]*.45!&75+:#O<+3U)7/X;59A?%J)(-,JZ^H!<)B[FB8T` M!N%)IMXPJ:?]1"."MT8QQ6;!P9L`POY64EQD`]FC716C*\8)GJZLVSUR`7T8 MB>W'2UM2D\&E7#J6D1M:]!+,(;V:D12B=?E+[D8D+2FPF3S%._7TJN%D2!QY M3I'S"*?FTL'*"&F`4CE3R?@\`RAOUPLY62DF%7A"ED:OI+)2 M*L3`0+(93T9BS816:)0SC&3$5FS]*0W,>DX!MO^@4T2Y72E)JAX:W(*%`0X\ MGS*)4&+45%G@<.FJ"@0VM%V'P22T9E'>\NWZ,25A2!$DTYMH;BVX5UIA';"1YR&FO^%&?#R"R&RZRX; MG$Q3!$1*QA_<8:NK#ES.2G#'#H%X!K=B[4 MHADMW(KQQN2#Z6M?%6HK@92"[SP9>5H;(;BM?,TZ((3F#+=3C9KD\=-42H38 M9U[6PT1'$*.F,HO(Z'E*93FH=)V!(ID[1);9$@V4(1M%R6S.=UA+I%O4 M#.;2):B$3![K*+1NLNIC.`E'LZ1(Y?)^1F+?^XQUAAN.KGSL#8+A[NB!.7J''GVFB"(8)A+@^(1YR(X.L!ZCS4,Z7Y`!:EU/@;UAU8TJ5 MYGS8"=?AQ?*$=S'+T/`[..,@7[.M!2"+DE2L)=/8@V5 M&E!WB4B`(H4;F+(,;\F@.E22?I(&]TNA]!F=:>DLN>&>CO,\Q#JA.0&3`59X M&2*E*Y:-2]0ZBEJD;JD7`KI^*.!*4!M9:>DE$>U-;QDCN'/&Z!!1OCA5MQ-H M%A.^'6[L*3RFSXJ\A@[5Z,((O/,G+>9/+"'A4L:0M`!GA$KNN,#@@+KP@J'9 M7V&!6PB!)&K"C)4-(# M\&RZ_67KZU?M_;+=[GH/T^WN&U':9R*P9[7P+WBPBM?-_]ZN+\M9TUK52O+A M6DD^]057.[P+^SA$L]!V?^-VC)D8LQI&E:W9M9/O%]K8O+UEI]8=#`X-YP$P M<'Z8W*+)5870C;I1P6%?UXRQPN3IDN:A6/^>'?UXE$.VI,IVU_*>8NJ#]&DT MF^N.RG'A.@<<;2V-/3L,8?9W14?KL33HF$>&[,'EYK4`YPQC]28]);43?.)- MFO6S7,IO3>E+:?5[\_3(Y43`.R58*E15J'J"J#H1B3?/JT<96QOF M^#X]TFC7.OUF=8#68*E9&[1Z%9;6JF"U7K]?H6FMQ;'57-=F_%08\2&EYQ)) M^9<08TTN,1?.N`S">OINMBM$>T%!7(:LBJ),BJ),1?DL8[>T4V&HP M<8U75$[SIZ>WV9+=UTR_YR MPR0ROO_+^,1#;VF],G1R6]SN'B0C1EP7X')P__*>$VIB4&>=&/3@:ZNV9R<) MK-JG1]RGIEGKM]9YB*L=JD[2B6H[F2MYO?U?R5G?@I@R_7;TUU;TNT6HI=FM MKNH3WJ`6R,CK+-/5!CWF!G5JW7:U0R>\0]U:TUP7&G4^E_.NJO.3MWZ<"'BG M!$N%J@I53Q!5)ZOG-"^:G8P*@ZWLL/)4\]FAU`A6>=FJ#;H$3>HW:IU.UL:#:L=>L@=ZF]O M=#G*!N7O4?D-%@?A7]+?CUU'9__"09E<\LU?HQ_SE8E+FA9]$-V1]+65?7XT M3&9,L!N4PTFMVU@4;H-65+S<(F]ZS!$B^L3+YD79KD_Z(*KYE2B&3W6YBUHB M+<^=,D639]'"ARI86M2,!781L'>+Q>1D2>3E;I09 MG"\WD\XTD#9$)2/5B$)O,RW:*6^U834$S)\((SU(UE0%EH51@$50^5;IQ6LC MR[-"6?-:5%R-]);!O/DVO67#J429OJ:U,11U68,?KDU-A=(5*.BQ2MKES5<: ME9K=B98'HI:J*.V*Q8FGS')4TV^M2PG"0+W:>0=BR\&>+U&L^20`5BSFYFIM MVPCH"^-S$*TFP.Q2:;/%.D4I7Z;^CF)`6GYS>-GFM$0L+O4"IHH$J@N-6H_!#X_+;8>JR*RWR-;7G*KV MLJR@<">V"<9=)RJF&I/P^-`;@?)K?'!]P#UVN,1^5KP`)Q5EQXI*\/F_+)JZ M=Q8VE<(2M5B),%--=/CA\NOG]`MJ87?%RPAC$R3)$6K&IQ@81+80Z+(V&;75LT;6S,*6M.]<;,(UF5JS[%#?]:KV-!2OGBN;)U`)3HWU1U2[.8\N MK&B/E>693ZQ\3'51,T7W)!O3WD\;_D;JZC(2WV.1Z/_"6:_6I%&4AZ.K@#JQ M4;5&RL,C\Q[B2S- M01SX>O=,T3<4M[2>W],:+U0O9(5"#F39EL-FKDT'#/OK<8Y%[0_FQ-*S'5BH MHK2\(K1N8?+UFN:\SKXI0<$V>\NSCJD=@T.M2V0;!NIRA]QQF=;3IE4"/PHC MO.`TUB!-:5/1-3*4((GUY?&:M9):RCV0 MQ755-Z4LJ?-WTD.1)?01R#/L3AX]X(N1WG;CW5PZE%M]A2K_Z.;G?<&4!JFC%TUMK0$,3Z"+0:5L\V M+]8EV4EHB?+VU%K0"'A-?XMWZ>0L'>].:LO`'TF`=XL':GE!WETA'&W7T%?O M#.*"&F+!O[#!M;P#TR_*@'%R[>'G'E+P\+,$@Z*E-IVP7`'(*XWP6N"KV<24:$3(J MWL,"3!W=G-=S"<$/LBN0L&87@0S.,W1Y29M!EYM(CJ2F"B=WVY\2![O"FH)` MG]*0(PP\XB;]Z*($A?M(VM7YLS6U7$E=V<+&6]Q;'JQISA\^\LCZ:[G3*6BGFIU8U+2-8,Y:B_N4;BYO=7,31L MSU,(>,K=V7C,D9H.@^T,1`?G"V/(9U+M=93`.5;'A`.GKW8)(DXQ9H,H@GHS M"*AV),&:H(SF8&G$W6IT[U`SO?D$:J:?$E>^I,-A+XQ?F0-K4-U/'I,!;\J" MA1\&[6#N>)'CRXT+F";?.OZ*6GOZS.:M/I?8S6AAR)J!M\FHZ!!G+4A4)Y=. M'[4#+4-F$1_DS7'Q,9N%V)9/MI_/L<-<6V$EZN$?E-**G&K!?-%8Y4[US*42 M+PXJ\*%0Z,J@4_TS>+>X!9UN#EN1IO>6=X['"CD`Q0O>X,6OV*,">X5?=5J9N_'"^/S:FPX M#.\&(@3J+I(:&1=9V9[KV@GJS7\E0=JD#8'B8PMU'$?%G;,$"+P+MZ/D`"[P MZNU977^>"'""$4KY^1W_0P!68D;7-S4-AK7.-FGR#9KW4[;<+@AGV9W0[CJ,JTU MQV(K"P0*]@,-)A&='(N#]9Z.QNO,&5(`<*5AZ7XZ`E]ZA":_:,'QHB#ML08< M8XY:')G[8FP=B7M>> M8R^X*:D%4=XUQA&(?`<$=Y3?_(2(C(S/W/*!;T89(X/&@*13X+WK)3C,\H1X MO(`_XA6+#0NMR+6QSGS^26K"ZWG*#2@X+@R)URPJD2+*/YE34]RX<3;W@@4H#GQTV6J.>G@"-M$G"?=$ MW4%\P&7$A0[;\FRZJX4B(Y#%K!!8]R2/AGWT8R7%R/`&4&:;7%=N@];JXSCNVU>RK]V@WGH@HM\4`Z7"PR'$AVR[.L_- M](\5`FYI*W>4I>7-J"*A%D)X_B,(17B&WILUDI=>KK%T6;-XKI.+R+<)JN5T M;<,M/&C\@S08X:$BHZSGK0RLTF4BX M9C-5&/XUN,=&T5FMDZ()>4]PMAH,\F#)1I'<=Q4EH#FC23*6QI;;[Y]RP1(` M/7RI!R:`#&#-W#LWS#V9!C'($$?1=M)%S1SW1G/X\VTDF.Z#T'/NL8LI0953 ML4L4N"5`:U+V%+#Q"5ZY%^RB)G'(/PPOOPWY>JX_W`P_7WW\]/TG!?+,-P/`5N"T3Y3BDV"Q43C MA4Z,A^3MQ[MT5T<$<[ZS,*(`>(IP\?*@#1$(1G*[-F MJ(=P+ZL[&R5AQ&30KN0/B,IWE_]?N]UJ%`>?H@RKE`/T.M3G7A+5Q^X/YM2Q MHW0:I4A4]FYX\W[X^M=?;VGH+U?#J_?X5]Y45L!D8>=+7N8A8&(%Y:QJ.7`9 M3X\+_RU:+;"I"5`]20W8DQ30QTU>.4QQ:EP.?D+VI%O6LBVLRT)W=JRX(=0, M&--C-,LK2XNI^0V4/VDS:6M(3(]U%C5\PWZB"&6R2%HZY"G:"5UJ-(FX=,-7 M,>7"]8LX[>V"+!"*2Z3KCT#7>3ZGLQ)AU1(F9]BJ;/^?-*P*M7#!2<>*MR'[ MDN4BWQI3_=8H/&!R-"`..9&*Z)J@FJ:,JB@36)PW2B>="MODTBR<N/$ MKIWX#>A=ZT,NSBXC?K1BD:>O:N,4^^7XD*>+R.0;[=8U[=;GI6C]]WI?[DML MWN['X84!7H*KT25Z M\BE8P(VFV-X(+I<+S3-CV8##;2<1.E?@N3M66[+HE,H`2_:1C/XM(@-TZ93; M4#&>S,=EUS1//D5>H$[G!]QJBM&XG)O@D=@AH*KU!`*J"J^34V+X-PS9%^F9 M(IKF.@0](X$M(,(^I/5T.SP<.0;6&(*"X9$/BY^8C\/;=]+?.+S];GP)+O#' M>J-5RT^ZA8$:)&M8J_3,7G/]7%T6[]DH-JYDC-=2?#%R6S3JH3W3`F'4@BUQ MHC0/"'DLO1FKD`FALV6G<7`:%4HFXS/IT9&X?B*\?KAA$_A^8J?)363&M,)P M(0)-DU23D^DZ-+[G2I6"4A`MAT>TJ`!1GA\."@_%Y*=QIB0T^CYWCI"E@H?, MD\=YQ&#C?)IYC+9D%7"!NX;;L.`.?013@82M%)P!_J3<&6J9! MZ^W.1^%&MW1<9@USRG>C+U/F?`I9A-NT4/>HD<*:6F**\B)YK)J,7\C9`:7E M7IFN0I:W-@C*<*77SR=K`]!V-"5=6YERU.R\UD&,86Y^-$9M"`"?4;)HNI"-/6;'D7`AZ%F#\*:Z;R5,G)XC$3)!7WK<':FBU;AO'QV, M2\`()H/+U6.O(F7)LCP2,3PN0H%XD'`IV$<1AZ?^)R@+Q.Y,:L=X?5#H*!=` M)(YX30-AI4+QPJ6X=A97W-Z,?*V1T9DF`7F&"6"`4( M@1,$-0=.+3=#[T*P212Q`_$HO7/__,ZB>H3RYJ_T1S* MJ41T#:/:@)=OP%3?>8']Y\__Z_\QC/]1[V#,T15QS?=DN;BFNXO"U:(/(C*) M'KH6WM=KN'()7F33-VP,7/1W+FJ8\#_Q<5!O-7[')[_`K3^$&[]>.M9GNA)? M`/G9H&1XT3]?U%LO#-?YYPN[:?9ZS>[@!:7;T50_1J'GUGF,S8N?VV:CT=#6 MO]M:MD`(_?B51U1\4%%A&^"B='F-=OGR3+/1W'R!A;`5K`TC2(%Q?P`^"?Q- MA]TM`;B1PMOM#3H:O&X4M.';>A(Y+W[NMAOMSC*\F?FVAZ==-YOUEED.3[<, MGEZGV]H7'DPJ>*^N#W6&-MMR!#+J-]J]SHN?-Q(\QM;,]>!+Y((1L2S@^9:_ M5"^K2&=:8[O:1SNCS(J.)DBUWQHZJG2UW.!X.Y3)[0$$R:\H2**+L%73KDG) MU.%&I5ORI=EIU("84-7P4":8B&(ZE,DKF#0R\X_HY[BMM[30@`^74A5:]2Y& MH\[T6Y0B:F%^*99@D9_[I;"O""W+$;.%A4D7._1$XQJJ54*7$5\(JUB`;G`1 MM)B+0-6$F7O0H2PIG.!Y@^^X@H4W-EZR='/',J&"7+`^>4&E:*=E:5A@@GS%I*.[7&AIEZBH549%SB>$D5LSZ(R&EHZI`*5P'L. M!)41SJ:4L\F/<,C0*(H+DH+@&JQN(GMM>G5D;YSO$?LZ5A&NFU\K_6*H1JQ&K$:L1JQ&K$:L1CZ*V\9^-;_3^%WC_!M^O\2]JQBUH^>/3`RY;K_'GU_C@"_%\O)C#\Q08YS#G MQ6L^.H'\ADH"XJ(R1FA\0#TR8Q;:`GX63[SY?OO^?UYG?Z(!7ZICJ_'[-S@67\=#-.A-2)(@C]\O(6/^91A$T640SD58GO#V94'D MD0!YC+LH5:'S-30B>PKC9DYJQ.R+27#W^O+J7R]^!@[1Z/>;O4%7+B-].3]L MQ,C-GM]`!\#X,4=?:+7`KB,S@ M8*.D39&L7\>_,LN+<<1?$Y#>;T64R'E3W4'P)*ATW^1"NIZ2A$.T!YFW/:@8C$J8BV(MHKFT_G36NK9,FE13X&B<@]V8:OB;T["HD0SZPN MXXJOK21:024G-/@>5'@#Y5I_\FS6I[M_C$)I;W M@1#Q=7Q)585"RL!7M/O;]8VHK'R;C#Y]NN0H_AU3WA`Q]=*V/-:I:6U_:I"?#S4[0U8O+2#:I.4L.$@?OB)-%'D*N'V/A''87KM/D.=YZ(LY!) MWKBB,@'NG9:P\?N_&:5QTN_X^?L\\&\3&]/BQXEWJ2HJ?1W?\OZ;MB9Z?':! MOF+8L7._BW1"'U_Q$$HV*5#SJAMN)AP[VU_E!,JCL0V)U0< MG6.=T$%Z0@]HKOEB\?S'*U%=`[5-SV/A9(&:I4^AX4$2O7=ALNC<#^(A-9R= M$/=8I+RE$4?2V)%(&>^RKO;Q$C(J.3P4PDQXAZ>/8CDK>ERV^:`N'ZK)QWGS[;-41@ZGS&\W:SEMB/E7 M43V,7T*9TH03S"6:06)G%@HT[D2C2QZ M##?:9?`I=IXLO10OM"*5S4GEZ;L@5Y#/B7L43Y^D5FH-'X.0N1/_@RBF)>T@ M0N%`21$$[?<,:U01G^>VH\!WQ%?LS/G6:K%9/K422X>4XHL1G@)2@/F*Z@NI M?JOR4F=*O`56_C4KK8AE/;$4.$J>$('LX`9Z=D1!-<4J3^@A#7F5)_3L/*$[ MG5`Z.L<4T*J9Q!DQ#\81,``MO6+8I5[C!V"SZ];/UPYTELR=POI=/ M6RF"SON\JKP/-CAP?;RU>$Y]\.C[V)U>(Y[>+YA5^*OXRN?BC(G MEB?#I.68[]V0V7$0/@61\]FV.FO'/6MYW:_9`?T#'_M@V=/_ M,BO\#F]X'Q//6^#/YYZ@\+R.7+'6M>$65R=O@Y.G-X(>^LX-X"]T;6R.@3\\ MJ;/"/?(;K+J84?!D0JO[_]LZVMVT;B..?*,#<="ZV=['K#0&2V;"3#7M5,#(3 M"Y4ECY*]I9]^I!XLQ99D*98C'OD'BC:5946\^QUY).^.20REVIP?O8ZX[ZS6 M3"0Q'`OF\7#.=]S?\ID(EELGNG-]GB)=\O6].8RW812L50G0@WLR-A5I M$%52NO5F=OOGS8BV09P2:CYCJ)5NET92HZC\;4YHK%.C+5%^5ARVB`#,ML)L MD18`($X!@;0`#/ZMH4%:`%!IB`K2`O1-"]`?*<27(U3;=,)1Y.N=R*'(%UGJ M4>1+FR)?Q&`Q:$T5' MZKNCG9YLC'W"6N1P('O/![*3160QFX]NYE]OWJZX&`E*>5.!2_SL:_FG\"/) M8C[JQ5N*M/B5KD4ZS"UP>#J8X]M7_LR%X,LT3*@`\=XGF/.7K<>B0+PNMIM- M(*+T7CEPCIG/EB[S94\X>;QGXCN/HT`W&Q'LF!?.Y,TJR(<[P8OO_I"_A47L MR7N=[KB8_+?A3A+#)UNJ(V#2-J;T2#8?'' M*B.Z<]A-XT\3^\!@,6^.1?Z5K/+YJ._= M;LJ-H'%33!^IG0`"J9W:IW92A`:IG4"E(2I([=0ZM5,3I%S%T2".EOA%FSD+ M52`MGWET92JN?!LFOY^3N5=;^@DYZN/@UW&P7KMQEQ0FJ]3)C?>!SR/WAP'^ M'TG^RU23+6A7*GU`FFAV%)>Y0>!%OR[`GYYS:3M(^9J!.-Y2S) M^IVA<&L+8!^*>UY<:/? M30Z8UJ%IF;]E8K6YZ;$@EQE`N%U#4AB)X2?J2"C\)Y@5/R2:3 M@Z^D22P,XO=)1!$@?M]0T[76D81S=FFTX$3!,6F/()P&C+^Z$WJR1%1V2R'D M8 MU[90'G+)2.>2:8\2"_3"SW#,VX>`Z$;+O#%RLFR`-3;%P^-ZMHI14:7D2!\SV-+9>@S[GLC5U' M.N+Q!T:I.RG5TJ"]ABH^&U`3QXYMF/\W]^'0U0!4E%CFD+V1&QPQ,TVED3F8 M>518/S@2.*#L8[A#V1BB96,TPP-E8_HM&_,Q.%CFC\%9*<,`96/T*AO3E\Y1 M-J;?0B$]Z1UE8[0L&_,1-,P\YO_!U@D'D_7&"UXYCQ>R9EOAK%C(U1VTU5]L M8SK&GVBIH!4U/::C*?W4DJW\SO: M--26\CILI'$J'OQT=3V@5]0I?NTS1))=47_+__X/4$L#!!0````(`*B!9D"TR,#$U,#DS,%]C86PN>&UL550)``/L%SU6 M[!<]5G5X"P`!!"4.```$.0$``.U=W7/B.!)_OZK['SCVV0$F-WN;J;MWTFVW@,4\H>S^O'UW$_5O!L-A^^1KU>U/TQBCZ\3RG[ M_D[_,R826GA+)K.OY^VI4O-WG<[#P\/)XUBD)US<=]YTNZ>=-76[(->_)NII MP";QVT[^XQ/IJZD?3C/:WMG962?[]8E4TFV$.&FO\]O7RYMX"C,242858;'F M1=)W,KMXR6.B,J&50F@9*?2W:$T6Z4M1[TUTVCMYE$G[P]__UFKEHA,\A6N8 MM/3GW?7P3_<<4QZ+E50G,9]UM-B[9Z?=CJ;L(-<*9L!4%',F>4H3O7K1F*0: M322G`$I&\4((33,'07D2+1A9)!3I$&UV\ZF`R7E['(O':#V]YN^'_A+B5RL;X8_0YK/4V%4SF*J-9*+0H@F%C?WSX3( M<::,"QG=$S+/Y->!5,GUE0Q,U.T5.OE#V_^B+N4&^"ZT\OJ#QP.J24.0LA<]K@,\0ED"6P!%5`8 MZ)N'<$G)F*:9+O=9DFG'E*?H-\I/_UU0M3(@<1WF%9#=9)D)FVIY@51]P[CB M>>,5SZY.H2O*4[\HS:Z\*X!_>@7@<$"Z`FG")%A,&*]OK4.R$&X([?%)2!;" M#4^INQ.2.7"#M%,Z*"3CX0C7)4T4DBEQCLJXNP<5DB&I@Z\LS`O)L-3!YYX9 M"[(;4FCUYAOF^\Q+E)7X_6-7FZ;*,^"2*B9Q&DY0_R)T+-NX3-U^KJHAX3WC0M$_,I9'D\^4$18C MDP,NS>4$AR$>DMBH.2A4_:$MP!+#*]2IJZSDAYZ%`"+A`O)/4X*[QA0^@O/#E&_1A-7!X_X`*O%=X@.L(&N/N9 M-!AA:`LBU9Z%47'28(3Q'`KL41@5)_4BC.<,GQG;:QH/M5VRRB+26]Z/,1`0 M8"_JO,Q0"(_"SX;2KG0[:"CR4:%P%RB=QOG M%Y+6'G1-OA*E%6@UFIA5RP%HC=D\P]9_X9;2K*T9V@6C=<*07G9B*..%6!=VE?VO5$TI0P73 M0C=I['XG#;.NZ;"(?/]Z'9)K<@`)5+->(?DC;L(XQ,;PX'W0H@RRJNU7&&=H MTF,H8<+-%]A7-V_!"CKF5*(C\X7S)'^`]QHDB*6E/=EYI(\FY8(Y6^/_:Q*/ MC/[*Q7==Y,%`6E:3?_G(,`^RK0O`=P`8TAGE#,YU]X3R5.OF$_]HR'1Q-DJY MW/M#KN[W\?[,:U56=XKU-CJNED_57ZTRJ"`Z,7$!2TAY]I:=;:%.C>%>7FCX M\K42)>\I=1CA`X9$%K*-?<-34X.K@/==\ATPJLN+D`BE=["??D+)/<8\FP0&/`>Z"X>Q)6] M'#S5?8?)3)\Z*K<"Q4*:X+N-\N$YY2V#:R.6[WJCLV0C]L>\7?8&JO\_^V-A M]:GP4LJPA=+3"T"WG&)W3`!)Z1^0_(*'`S+[;(Z>8_>^H!)_NLB2.'DIHN2\ M//3M?+P&];B;PQ:W\?PG8B#P^]D!1DP<4ZX#*P M;"/UR[@;SX[L>GSMH8%9OFND$E(:P`+27=%"2C<[`+)M]J`Z/TR!#*_I_8:D M>"[@;$=(2#KG@L4:18?4KNBT,.Y^24@;RN90&PQ>;5O72`NR(R![1B2T%G,[ M%FO(&9*!`L``00E#@``!#D! M``#M?5N3VSB2[ON)./_!Q_NLMMV7W>F)Z=E0W=PU6W;5496[MY\F6"0D<4T1 M&EYDJW_]`B0EL20"2)`@D)3YTJZN`L#\$D`BD3?\[3^_KJ)7&Y*D(8U_>?WN MN[>O7Y'8IT$8+WYY_>EQ,GV\O+U]_9]__]O_FTS>DY@D7D:"5\_;5T_+/`Y( MO?W+7]_]\/#AU:>GRU??OWWWT^3=N\G;?Y],_OZW*(P_ M_Y7_Y]E+R2OVR3@M_O>7U\LL6__US9LO7[Y\]_4YB;ZCR>+-]V_?_O!FU_IU MU9S_-J-?WI3_G'?]&3H+S\4;=_]_///;XJ_[INF85-#-NB[-__]X>[1 M7Y*5-PGC-/-BG].2AG]-BU_>4=_+"J8I(;P2MN#_-]DUF_!?3=Y]/_GAW7=? MT^#UW__O_WGUJF2=E_@)CE.U>>-%$2.Y&&&9 MD+F0U!T#.04_\6__6ZUGMEV37UZGX6H=D==ONA,5T)47QI,563V3I"5YC6,8 M)S1Z2C9?X^3.9[+_8DF+)2#WRF,R]/,JZ,_GE.$*" M=]0>D\J_]1Q2/]FFV7<^7;WADNSMSS^\?5,0S`1!1MBW,C:;?E[\X,7!A/T; M9ELF*.8T615RX2609S_Y.MF-5%"L/9`0"4,L?^MVK-B>T-4TD*^9H1 M=@14@FI'343]IBDLIB\E_G<+NGD3D)"3\"/_@7/EQ\G;=Y74^S?VJW].&0T! MI^,F\A:[CT;>,XE^>2W\>TE4Q,4R32H&F23J,D\2_LDP];WH#^(EUW%PQ1C7 M0)^J:=^D7E736!+P0)*0!C?L=VD#KM+2%J$EC\2S+VUGB\@G M]AT);?4_]TW2=2%'+ME7$R^Z91+CZW^1;0-MTG:6B*2K%8T?,^I_?EQZ"4GO M\XRK?EP=%E,,Z&2)_%+NS,B:)AG[^B,3[(T["=+<#LDW84222[9!%C01+XK& M5G8(G)%%F+(5&6HV/9+&\D(_9PH9HF M_BN:!"3YY?5;UK.X=/[5CVA*@E]>9TF^'ZZZSW:ZI<\3NE*23;4F@WW5(C;A M)5R`K)%NVGJG`\&^,P[VA;0RC=7LA%:_I''&;N_744':+Z]3LN`_:/.@9B44 MP#Z5;TT+N&%G6I[,)GNB#B28(@@$]3TZ4-)+&1#5#XA02;0W()H?$:&!F9N` MP'Y"!$QY^0-B^G=TF"!7;R"X_T`'3GK/!*+Z"SI4H`LI$-W/Z-#!C5C0D]F4 M4FD"H]CL"46#2=$`&)BAL#"I&B#S/A08)FT#Z&*!0L.D>D@\<0Q&/U9BD2T*R=.*7)^UD7;!]DL=>'H2\W=KCOU^2 M+&23L@>F=M<:_)@-EZYQ5%.V#8J#BJ!U4>C MIWV[UL`ZNM"&X$+KHI`.S+'61DT=F)>ME=HW,-^;KI(^,`]<:U/*P+QRVC:6@3GF MM`PP`W//Z1MF+)JE8YJ1R;M)&BYBIHWX'L^K\7V:Q]SC.UG3*/1#HF%YUAO/ MAG&Y#44P^_$I'_AO_CE=)*3X](<72Z:ZK\B:Z%RM!!^_?+P3?_;DCR8^2*.( ML3KQHAN:7+(#)I3@5C8V0E`QLXRYG]8TOLX_>,EGPG\S7:\3NO$B&7E:74T0 M6W@W_.VO)%@0P,*!M#=`UC\>9C.Z]:)L^Y@_W]U=B@F2MS1`RFSZT'HQ=,XN/YTLDC2!QXO0^,9\2F3 M.>QHGGD9N_IL[S&OB1>G3'&]3=GIR0Z)C,BXU,\W3,`OMPBC@80; M?@N6H)`WM9,(TVB9%?T9$4FF;,-0TN[(PHM*`AK,J9(6]HVHTX0M\T6QNU,F M+#[2V#O\IM@"GL]%1=JX-#N.\HW`=>^:N"1,WG,M-V/7B_D56=-4H(]I]'#A M]H[](IR[.+S"]/,%4WJ6*W:\27U&T&YG`PC!@CNA<+NG4>)A@G9#`8A'9.IA M.>Z!``8G26^MG?88.`P,NR6/V?5W[279EJ?>2%>5N*D#PO,THRN2G'!7?K;` M>MF'$=LH*2;1J?KV0%S+Q:NV`U\PS;'AG`+5,)T2@`P M=9?!`\$T,[=QFB5%B#P78%(1H>[B`$B80J`^]J%P$VX8+ZX(]TP4)Z-D4NLE5 MS0<+P+V$^N!]#5?Y2KH#&MLX(#6,U:0VM;%/ZD<:!]5'$^^W!@P32RC!4'<9W82R7UJ`^`TZN.@,( M"!;6(=1PNH\T?*@"#??&%!$NKL[)+^"QM>P9Y M>W`[L.7T/74\.\BY0+5#4E&F*8*FJ7%:H?X*NSEN!E:P,FX-S8(5AB12C?!D M5,M2QGL*#7BTFVIH4&::NF"B6:!&KXSU7")HU!ZJQ6UPFCLO&MDM%%U6LJGE M`X\P1Y>M;)0%P#PDN_G,)N5HLX$>GUALL-'78$C\ECCEV@G;C^=D6%)',3MB M5ZW=)'F#&T<==8EO#VG[7*@\'13EUI).#&W!C4Y[T%#Y`X,+%V!-0;=RVR83 M44@6-S.C8%W5I6!Z10=;XRRC4KG8S328/&L]@M M4'+6]=@`!4J4_C[:I00"RG7KN/ZHS1AT2>KDKZ%:Q5I8*M5(5`.7*UYAH M\/+`X^#H;Z$@*+*!D)4P5^"NO4:R!1"KH7=H#`I22#(&.N&I3,&H`53&M*,4 M>XIID4Z@"?&&+P0!G)F.;K5"DM'K0'42C5$N7LA4R6;6U!F-)PI!PAE)J0C\ M*UE4DZ1^(X%'F0YE,3=/F72:(:5.+.M+TF+@FJ$;>(&8NT'CQ]A=:<"/$>J6 MQ(^DLRT2/T3CCJXA0#9_7.!'W93E+_/\,S4JF#"6J_91BZD MRXXLX`L(RG%*>!9>/@!2TNW%@WR1IQG[_0^2)P\$;722U`2?OR)^,20OT"PF M0-S*``G7;![IEI#R!9I*,7^(O%A,#["+`>)NBU.2J4]R@B3-#!#!U-8=XJLP M(3X;J#FY'-C:`$D%Y^_7A>[,=*:#:E7\04R<3C\#9'Z*-^P+A0MQ3I,5?QR[ M?#]&3"&PBP'B?F/?^?XG]AV^=JX]?_D'\9)/;!E%-WD4;7\KR!`3VJ*[(:)_ M>MN):,WNAHCF,3F/N>^3-)WG4168P);A_?RQ-+SY5TPOC.BZ\"^'$>M"8]E" M,3:H_5SCZ1QL=$@B'5_QHZ5(;_1RI!C MA3%4%<;V6EQ=SZL["B^V)YI>H?L>%.`X`$F@/C\U,D[S4PA6WEC^;2S_)BS_ M%F9EADT0;L(@]R)9^3=96P2D_QYFR^+BS*V\RW#]1)N"]U2@8*-\(W#=2R]N M[N29.^)EV=#"&9E2WC>V&0"I.HM@()4>)49%=#[[7M4YVL;]A#*"O7E*J0OM MSFY8B\DJ#D*;$+I=H5C/2L\XRC7QOFI]!Z7]!W9`W\Z. M7LAY4=%`U,A`LN_T\6%V,9U=39L+*+\@0][4!#%!4$RQ%]6L[Y4'64(7N)5[-*W,H`"9>/=W?A*I1FCHO:&/C\^X20^#*A:7I)DS4M:R*)*0$T-U'T MP2M7`*_S%69YQ@N>11%)%EN^;^(YX87+\I2)"&_8M/,?R5>E/&Z7K_F*R_>E3244*3=VT&Z=KNR=L<)W5V* MXYT]7/<1UY?UX[Q&?8.R)X#<8@07,,55.T_PJ)X8'%/OM6%H5T,]SK5L5TWU M+"&Z%QJS2M=G$JZF.];V_KX.**U"]&YHEIP<@3-A@<>U"L.2T0:8XU MHN*3(VMJ8[O?6&,6-ZHL[C&7=LRE%69H;B7EP8_S,&5MSR#!KHKH"-7MG[:[S,7Y]C%_7PHH?XS?X4&%? M5RW\R'&;7LQ*OS%">8Q0;L:G&:'<.G+%=C3RCY.$;KTHVTY6-"99^&>;)\_D M@UB+((:0T2DV^#)/$A+[S94Q)2U,A)AJ?KJ+BU-!`G\-^W"@2R)>`>T-D/6/ MA]FLG/;'_/GN[E),D+RE"5*\M1?_022QM\TM#'SZ8>G-/DP_LFT@B0T5-C)` M0,79#[6=)R9$V;@?@D3QAN#V;7W!*?&_6]#-FX"$7(3]R'_@)/]8\_ZR7_VS M*3.NHE'T9T0DF0JK@))V1Q9>5!+0X"&7M'`0`ER^>IH6>^^.>D7]O9LP]F(_ MC!!"NF8!T]0XK5"SS>`"[90^ M`S0+5N@.&JRJ(.,]A3J;[`;R&I29:B,(FJ4'-'Y0/5\OJK4(FA7)[)UEV7FQ MWPW-TI3%X%!`"`;*1=C(]V,=Q,"*&^NUC_'N\/!@S>,:+Y!O*G`?+DKP@T%@ M4\+/)).7O"&@[6*&P8^OFSYJ]N0<&T*K3T0"A5R3UDW!=:H;_PX^4C1=QRZA\NEKUQ0)MQI98$OK\040)^5J(]89TP`@F M!1*RY*HS=WBPHXV4)`&G6;.["X"U8X0?'Y=,:H3%02+$I.SA!$;*6!H41$'G M1MW%/I!K+XF9E$L?2%(\.`K#`NQE'TZYYI^\KS`O`C9A6^:IB1+ M;[@F3.[8=@ZDX@[-/YWQI.XQ]P$>$*-0]16L'Y"$<9PN2KL,=(J`_0;L M.#P#"`A\G_NG[OD%ABWYTLA4B*3B\0)^`6"JS$/DQ?);7X>11I?OZ/)%Y/+] ME)+[^76:A2M&CXC!S8U&Y^WHO!V=MZ/SUK#S%G1)0N>X55%]6KM#:?1'AQ%` M.&WK%U#A*J+4+"/,_D,*$V?Z!(/^"%J26JP:(]F=D:+4CFZ"* M!C:U2L^7"$6)5Y]J$V$`18U5N=*T9$/A8E6GM+T14,!8M:G.9F,H`[!I4>;" M^:`+%JFIIA?!`P6)5N61VT(ZY9<1$=SMA MJ;AGTLW4MOL8$#0&!"$*"`*MH;/W.$T M\6L>IW8&,NAPU@QC>@39+-TX7NAQ7NB;';!3/PLWO'JUWO6^S6`XP#]XVZ+N M\QTL2`-P?B(HC6D%'8+VVA^6_5% M&(;L^=5.T0C3#4F\!5F5]KWM#4T>:)+-&6IZ2)XYUDM;]#1/:IG.=C__-5PL M_S^;$?:K,L*-;ZR#]1)`NN9()HJ7/MZ))_ODCT:*NT816_")%[%Y*@/B)`2H M&INI-LOW%ULBG]8TOLY+AK/?3-?KA&Z\2$:>5M?>:LU**`0_G=R)+/DCN'6" M(,_E=B+ECL8+MF)6AYU?>0RV'YB<7N6K)JK`G0P0^`&RUU.IU&@YA$'BU]67 M'Y=,TCZ]X)R,8$`W$T2&#'U&8U)I01^\KZ*)5S0U0,QL^G#[V_1"O",:&YCX M,%GD$>_.=MIZS?A=.1VX)/5B+P@]GC-R_>E$:*7\].01RV4:T9\DF'E\16WO MV6'%DR]XXNYNZ;$)I-%&(84;\O2?RT)(>_ M)EZ!"3D=Y$?^0^$]BE(5T<`&', M#,(HYTF/AVUR_=6/560?)Y,Q4/F)PM++V`Y8D[!C85$FX3#9 M^I'&WN$WQ9'A^87YIU'^=1SE&X'KWC5]2=BN+`KH\-/ABJQI*KA/:_1P4:=^ M=\^?1@GQ@NT#DRLDF"[8C77!_K`/]1*!TNV/X$6!"W8O7ZZ8QBL-BX!V.QM` M"/;4"87;/8T2USBT&PI`3]N7[[&KL1SW0`"#';7\%]Z"O(/B:.B"``CGK=ZF M.>TQ]N'LBGI4 M1H!I$!1F`M%G;`W,NU*Y*$&X_?8KF[BI=P M``!3=QD\$$PS\Y[1TV37SG] MI4*RL8T#4LMP%#FI36WLD_J1QD$E#D@@)5C2TC[9#PGU"0F*U,R[T.?2X(:0 MM'0"GSAH-7LY@1/D?G:?/))DPPB3G*&RILX(Y\*MHB>5GD#*]@.&X/X4G7'- M4+)V3O[NB$2IG&EH@9Q,!!-_]$@'%W!3W\]7/*"+!/?9DIL03XIM5]G[96C6 M!9FS*\:3]U4$N(]ON.D_8'2H]!-H>&XJEVU^[_QE#Q+#PY6^4"!'"NN$# M-,TNO239LEN$^A63IVJW8:E)FF+HEH%JC1:U_];1QH&@*JQ6UPFCLO&ME-$ET5 M&U/+!YZ7B:[PKU$6``MCV"T%;%*.-ON3\(G%!I=2#88D:@"G7#MA^_&<#$OJ M*&9''"AAM[2TP8VC3DW`MX>T_5Y[*=A$7GXDNE6LE0E) MK90%0[GR-28:O#SP.#CZ6R@(JNPA9"7,%;AKKY$-!\3Z,SI!"LF60R<\E3ER M]0?I51DE*,6>8EJD$VA"O.$+00#7H4&W6B$56^I`=:IQH%R\D*F2S:RI,QI/ M%(*$,Y+"4/A7LJ@"6?U&`@_$',IB;IXRZ31#"IM9UI>DSP!IAF[@!6+N!HT? M8W>E`3]&J%L2/Y+.MDC\$(T[NH8`V?QQ@1]U7[X@_,A-AMSB1XLGV`T_K\S= M@O!C[<]*:_:&\#R^(MGK*Y(MBV\#T=H+T(2A!54O`F(S%'=I#%N/A1B`'#$4 M4&>,(_!G+X``#05>&0.H*B,&A&4H!*D-0\O.`#.(3;SU"@6.16MJ]_HC%"46_:G- M&Z)0C-@T(JU*AU"0V+2BYO(G4#18E"'1E;OYB00H.E1Z$>C]5B@R;)J/M"@Q M%!0VU09:-1UJ'L"BU)SBD]?HA^+#HL+L;\3FGT6$L@*+4B.TW@I?EX(B1*70 M'.FK-S3A<:)S&H448/CZVYLCG.Q#G\N_%'_@A,[(_!7_]]/L=@_JRY<:"!`57K%]/8,^*2,O8[$K,-^EI:1$GP M3/$T7^1IQG[_@_BQ9%$;G1I.@L]?,=V2#\D?W143(&YE@(1K-J]T2TCEC"]$ MV06?@LO:#'RDQ;8@P?2+EP1I_4_<8+B+I'X9ML^VU8SP[D[+9:_BI]%-+>\JHZ_BIY%3^S;#I;1B\_B9](7ZH!%AX^: M9!`_2A^J,*2'R(O%QPNPBP'B;@NMDDD6.4&29@:(8!.U0WP5)FQ2:-)<#A?8 MV@1).1_P?KZ_\Z?>U%^&Y/15#FAS@T0][I6R^IKF4W-2^SG[ MSHK&Q7>++9I>D$48\SM:$YUZ/?LF]3H.VM#YLIMA(A^]R..IF#N14/OZD3%* M1"]\!`.D-XOE6A3.Q98W*99D95,K1'5%R7[=%HQE*';;_N6]O@[5SA?ML:9L M4J?T)DS2[#L8W;%+F\=N-+^8Z88IT=@./2CTM[27GRQC8.296^%R!H-1!RW3]J4!!T'';=1'1S^K1-4MO8 M"9YHYD7'QH*/-/N#9*?1;D>P>_^>0Q8>-`WINRC*]O8AC&^N]O+B)$@'!+9V M0'[DQ<=G!#2T-R MSYP3?6Y`#*SLNP7YZ6U:Q\?UC.,\7P>G=-5F0>"R+;[ M!S];^E+-\"/7LJRV%[[*._W'4H1["IM[VGN4(9@U(95M8BAJ+#H@5;J.$) M90DJU==2>5-5/>H4S#H@AW9AJLX`>4+5AT7]-L MD5?S@'('B];;N3P[U%B'19=M7>?`JK MI2<)H`S"HKX:36X_@+?S'.`/$Y]&[#"B2?'BYL2+@PG-EB29,*()HV99_"HX M!"E/_$I/3#N^&-C'ITLF6GA4L#_BN[T[>'UY_V$:![>S.\G#@Z)&!HKJ3Q\? M9A?3V=5T=YN0D"%O:H*8ZMUF+ZH%V5=ZO80N<"\C)&YX,M9'FH4^*04&TPKY M_2N,JP=AIXN$D+HO^26Q^OU-D!W';.$>7C.7/-RC:-H',2]?CY<2T_30?"=B M+@J%5[7VQ:T,D'#Y>'<7KD+IDQNB-B8^7Q>,^\5WV%4[W$V%ZMH/T"/A_Y-S M:UMKLB7=>R.Z);%VB2S%U?U\=S#"Z13U-$)J.207H+*J1Y>A6R]9/*GD+J-)`!(!6'^&+_0`.>:EDI1-7Q+]6KM#N;(+B2:G+" M1(U,$)!0GQ`F'CJ*GB[C&(`Q(S'YP@4>B*'JUB9(HELORK:B0Z7ASP8^*C!( M%(=[JTUA9$`#P#Y-+R1/]1W_T<0''Z_(VDNRXB8X_Y6PR>+K^-=\Y<55+(SL M\4#MWO:KGM4#_1EM'YG@/OSFB?V4>K[XWMQQE&\$KOMJ@9?# M9$WM$_Z>;D@2UP^,@UHK``#I8A](_6@\F"'2DC3A`PS`7O;AS,BZLF77[I`O M%XZTD*)V_S.&Z%X\-*MH-2FWO_S2JI`4._7ON=4[O=@>)Y>=L,'@V(-B#2=> ML4(,CCVRYF1L]QMK?*(+U1-=8\'[L>"]L(XX^^+]O"9A9!7?96W/H`QT#V=V MUV1;/5Y`ZH48/7QIQRN_9?8`*\08709FUI?J=+>;ZVRRNI=:IJ#;0VW-/KO= MHO*&H]P5\HFBAJU$=M>SA3G7C;*!1@4.AP&0\"=TT][/<6G`56AW?1@4^&I# M*SIYKV^UVTVT/.P(I9R7S@\U9N<#8K<7%=Y5OH'C.(#([85[=Y;L\OA:="=9 M3U>@9C^LW74^5EDR`DJ*AR+!H-AT3TJ%P4>DY!E-BH/A1:3PM\^2@6%%I-XH$ M,2@F+)J,5O;;`9R=NC0_3I+RD)ZLV,F6A7\6RZICQ1F]0:W5DFE#5JV,+$^GUFI_N$BVL(.%7$BP.\DE2*@/0W@!9M]PTSY\N9Y?$ MY%`(NTZ)H(F!C__C858IQ8_Y\]W=I9@;\I8F2/'67OP'D50(:&YA(@^_U,+* MHF2\VAV[S3*.>]&,_"L/$UZS_(&FC:FQFEW-9(L?ZO)Y2;+EK_D4G[^-K[_R M!X?OY_NRI.^::&XW@@G2E][LPY2IB+*L66$C(XGNX89-ST/D^:0,T7TD<4B3 M1^+G;*Z*CS;2I-'/2")[N7:8A/QBXB2,CO.)@Y0(D>#1(T+4G M%]L:S?P@/X1,*#)<^_B$BQ(!.\UE&B7$"[9<;2'!=,$4WT53I?.3N@&:_1U` MK(Y#6?6#AB;V";TBSQD/B4YR12*:N*%KHG=7EAF;^L("*:98=<0[@)G=\HE#R_C6_GX0JK7 MR268PS:8A>EGJ5!6=[$/Y.A*6%.TW[-5\*E4R%O/$CBW2^=FM>V'L=4V`=OB]?EN"F8"?5- MF(4GIM".HPRX=LT90'"_^,;R.V=1?F<@-6SZL\I9SO93AWOH*&-4PYV+,JVQ MEWFE!E1`N]E!!G>*RHB(;KTKK6H4YDI&N;XELR&<,T,U!O#5R(";4A`N4H"Q MD6J'&B%=LX!I:IQ6J/W2;AZ?@16L=(*B6;!"__9@5049[RG4>VXWE=*@S%3; M?-`L/:"MA^H%J:!:BZ!9D@25J*$W$9.DKH9<=S=*414-30#PJRD78R/=C M'<3`BC.4J3,6\?DFBOAH'M=X@9B;-/P8-40)?C`(;$KXF63RDC<$M%W,,/CQ M==-'S9Z<8P&H?DM6M`S-M6LU-):JVSJUR:Z-R50:;_T,S@TB:W@H$A*LX@G:Z(!`EEK((74/V@7"Q5$QH$Z0,U16PE'XR M$MP%!8U%0VJ;-`O%B44WLA*Y#&4*%@6J:V`[%"\JQ:E5O8(#4CM%8'Z:I+R\ MTI)&C(/IA%.6;3O6@-$:TUH)F!94=:H`LYO^W=7O?CXG1?6J)/0;2X^`.AA) MO.>KFQ\M8-*`708O8C7AIVD2T*R=.(7-ZULLBY*3T[RV,L#_C0< M7*/O,KH-W;X[?=WJ/![*L=.XYKZ6U#H$]3"@YU\1MCH3_JY#[8.\?#ZO&9NF MI+DL%+Q7/R1N=KX$,0?AO0R2^)#0(/>S1T\ZN>K6>.LR76P//QNJPR0;TATC M'KPM)ZBT0AW7QX,U=D?\@:$?20:#(.OB!`@[PX.[T'L.H\*PK40A;^\$0K[* MN34OV`5MK!.RY/HPM^JRXXIP6R;C]OW\R?LJ!M9F%`=P]^\A/7AANLP M.]C*CF')6SL@O^FL:_ZC*^*FS^F+9UL:B3QNY(I8Q79M:N.`U(T71L7K0#3A MIW#A#RZD!W>D'OY/`:;=*'CA?J2Q;P3QZ4`.B@QZ*7_GB?]S_:^/E"7@FRN9F+XET[G3Q520A94W>$SQ@5E^S?,%/N M$4@7ET"*BU#MG5&%,@_OB`V4HG(?O.O9`7/O"SJB$B82FAL[)UY#(@C:VX>P MBQ`#77;EC5T0S_C(/K8]K5\O:^*@_MWA5LJTB<=:@,%U$5\@(![:#1\@Q4U% MM[M3@/(]@QCX,:6^4+7J.G"UAT39)L^Q!Y<<9HX^*D>-I7?$)`NM@'\M(@ M+E7T9$T'1[A[C73&\QY"_G9T%\-!RU%]LN1J/E2_6<&.AV MKY:[@K:,A$.YHS6F#CSA@]K'G:9>%6EH-])Z3.\8TSNTL.+':$/AP,^%_H2T MV2T])OCTF\$O"T5$IU,)B*W7Z]*WX:*;.#7*3C9K=*E::KR=PC:!>.V5U@#@ M!0?Z`\'9JZ.A!B<.]`""L5=23`U&V\<*Q&BOR)@:HSJ^$PC*7J$QP!;K/$7V M"HJ9$Y"B.`P@9'M%Q2`[#QH-`#W@,>@QK5(VH0`QJ3"`X"`H+%2:2OOIP9(; MWRWT#]V=01M&@QXF"Z-%=WWH"!B2FXEN17?!#(F51G>'Z`(8$IR/[E[1!;`Z MA!;=S:,37#.[U]X5Q.!B[JA+V+NAF,&LRE=#)[>@=M:!*AMZ\ZB,,T>G6^CA MDV>SHE,B-%4E2%D$A/M/4QUL7]$"G0JAAUTW:AJ="J$'5Q6TB4YI:*T3`1+T M#F#M%GO;_SJ=T/G$]]+E9![1+VGG.F_P@:V7>-,EK5-U-YEE[;)XCB"]C>_7 MA/\A7E3FGKA^']X1`RVQIC>JBUI`_Y.GY?M43Y0_]Q+[8>%N.HCW)\K=BP\) MW82,[Q?;3VQ?U_'L'S105;WI\5,.&+>BR>XIW?OY/G[DQ;LRQPP`=!FKKO0. M[:&H'LD674*\E%R1\E\MA/(A7-0W8'J9'Q8KB_T)8CH/ZBA,`U.GJHG#` M2Q;?QD19%6:X-WQ`#JR%(LJV4![XH#6!F2 M<:K?:/7!`&6O*U3W<85.HC\`!I!5U,EN_S=&GX`!ZPR&`7PMR0F,L:$/#BCU M.#X--$W=[`/B06D-ZOI>L07?#-H/A!DT?[LYC'/VNTJFL&MO9P;(!D7#C(;' M[MJM`,!`F$%W7P&:@Z)A1L.5O3LS-`=UPHR#+4.,[;2-8U*G&3M/GO.L2&*A M,[+F5[]X<,F!8A;CH(`;I5;J+J5@?LY M*1NU?U?U-DUS_CH(?XIQ[V@408+V7\06TO9^+EQ8`:(O1',/G M,W&_+J3X]5>2^&%Z,/_+@,KZ(8#$8Y1!$W;2>,#EC,X``H**3$LO(1?LUA=P MWSN[F,M,N?+&8SFIL9R4(H=UT)6`QOH"3H/',-<7&+/+-2?35"!GU\LAN@#/ M#H!$;$$?%0DJ(]![;`>ZI=`KY!?1WKH.>G3"PA:K(`HPN@UFBSGPZ"-T4F/#!HY.89GAC,LX- MG;K5Z5`!1[L.Y5"!`!+L&D"(SE`.E0Y<`(2U#.54ZFM!-AH(/ MY0S19%'[G$QT)T:?#`%6@>Z]Q$%,,S)Y-TG])0GRB`235:4,3>8TF61+,F&] MUUZ\32=AH0:4U0`"7H`CVJ]H=<4#,]^Q40#!)*6=ZB'(E?5*:>6+;YZ1Y#XF M3\N$YHOETQ?Z!_&2],8+DZ;T\%[&UHFGZ@BW_(GM/D[:CJ`N&*4#.JA=H!M5 MC#%P&,K[W\-L&<9L@7&FBU:LV4$''/)Z!A`01.V.@:]CX.L8^#H&OHZ!K]]H MX*M)/0*=C4?.@AZ5?W0F'X.<`%P1T)ESNNX%UR:)[JHW'+Z9)6(?L>EG2HJ?J?) M9Q[;1GV2ZO%?W7/`5\,S@##>;L?;[7B['6^WX^UVO-VZTNBUE86!76%;*Z4# MNZ"JE5?;=[+O)RD/]V!W&B8I>#SI9!UY\<3;N\%;WM2TQ[5V?VM)62>W;W.> M9.TU]XOMH4D5X3G]XB5!%8STGC7,4K;QBY"+XB_I_I;?Y">U\D$##N*"B&\\90$!P=6N[#\M74F[CE!U413!*D1WWM/3B MEVN0!R^5*U#$'/L4G!.;7PI"ZSQN_OR`&/PQY[K2_;SX:UJW3!?03#,4^+D! M,?!E.#('\SL)%TNV[:8;DG@+L@M4?DA"7VBLL/OUX;&W=J+SI\V_KL,JOK>O MG:_[W3-DJ8-U;(2FX4U%OX?8N1Q5%8[[/&,WQC@(XT5YFO3$+^%W!LTR!YM: M\^L(V9O"CE_2J^CLA8@!,ONE''/!:7T*1I_DZ)-LY9/LBUCJ?^8II22X*F*L MRI5<7LIT:HZW'VATQ(Z.V-$1.SIB#3ON[!BF!NJ][?E&-%!?KY/KS4`CE]T8 MTM$EJ;MFEL*S`^27O:)S@*P`BPYQ('OL5:6S(Z<,[+"_#(TE?=WD@?SZ&1N_ M.E[7H$JAO4I+EM9)!]L:E&=8-&DG`3A0)IV;1JWI7H2RZ=Q4;(-N02@+ST;S M[A(A8#_8]4M%V\0KB9MX[+1:E1"*6D!E;"@M?C/Q"IDR6?!3G/7)Z(2LUA'= M$I).V(UL$H0)\3.:I),\9M-:%!(Z"BMM&SWKFE"+X;@XH-K,VAQC-,\B1G.? M-#\]+%A>RI_7([X*>7VY.)BQQ6[:[ZW[W3-AZ6\T8L-$8;:US=3F+P^_ MN%7S@853[5OSC+?52K\U7WF[*]&WYB5OIXY;M-(Q`9W2*`P\;MK9_SJ=T'E1 MH#LA2W[V;`J+#EV1"9L.;N?Q\H![J^%&-C/?L6$C,TEIIQ3VVH.%F_UKC;PH M`UL>O!;^%=F0B*[KYVD]Y;I%=_MZ]66=H^53MT7MB2?OJT#)!O1P`2-E)!2E M,QYI)(JM%;1R0V[E=^&O8(KN8*)F[@D^?BE"07CS(T,V`5Q[21S&"_Z"Q^Z@ M"'V^"<,HSX3!V,!>]N&\9\)"3VMX?'I&O!3A]I=D52 MUHJ+U&GZ*PD6#%6M@0!^3U]QP"X2D\2+^(OVP8K7V"UK9)_?%"_`"8AO;V"=U_VJJDF!)2P=D\U79H%5\ MBA/B1>&?)/B5'=:,V(,X.I3WG29AROY4C[U2Z"]]?\X^`YMU2OG^`O5Q`:5X M\UBE7XB:.2"8;KTHVRJ8W=C(&;%'#TLW$]OX^K15B[\7D;2B8E<33V3WES1U M2SB,9K?DCI$9F"(S1K_B.?@5^R'V*,QPEV!7W4;+F/-:[I0`3NREO>CFI00G*ICCJ*;JX@L&07`W1.:AF@;MX9='YFW279=C5B MBS"`.1G021`EV4<0A0XK=$)$!YF&_0G=\M3!J>5#0"=:M&948N1"%W6BNPG% M7E@@-'N5%'2@*?T`0'3VZA[HH(-XOH``[54N:`.PRYZS5X!`2VSVZ7D& MJ0$=SDA\C5"%`*>NHQ5K`86*4_GI9(�L>I#]GQOD)YA%.3`D?860Q3K=Z! MG7MA,MGP>%H>CLD3C7E(IA=OT^*)V#0K0S6?MQ-.8>LG;[M]QN*[N"8([12C M*G[X>.K[;"T'.QWAR!G0KK-]EX?Z8><;WE?<*DW4$, M9,^Q&'LA@;=Q@LX<=!'RQI'!<52U8TR3BE_!31!][4VT$(,6%4S$/V M0:;?8;K=7*/H7N;`$4^FYI M5$<7^]-Y6MN8H-$%"O7'!8G5&5U,45V> MA`UGT0VI0U"WDCB/=W?ABM?9:30$2-OHF#,$GW^?$!)?\GVTNZ"(#*30Y@:( M>ERR4>DBG,;L!+O+))R1MS1`RJ='=G'QDD)MNI__RB1-QB-L?\U77OQ(DDWH M"RPX+7L[<)+Y/LW+D"^2WE$OYD$5-V'LQ7X8+V:'Q7^QO0@C]OD%EUUYJO!P MF!H6-4/NR,*+KN,LS+;W\TO>BR1\OK?FF`/^A'U&\7DCP2Y90FK'E#6U3WB- MIYR++_DJ=4-H]#PS6.[]+/5M49<84F2P3FXXB%O?`;N4K-Z-CKG*O#\ICJJ)DJ?C+%YI-WTA<$Z MX_J[4Z';%#JW$-K1%#'TS0*?:VK@/H3.E:0O/R$G)CJ8;78$V):)SF?6!BW$ M4HK.8]8&J-Q8;G`L``00E#@``!#D!``#E?6MSY+B1 MX/>+N/^`&]_Y9B*DZ>YYK#T>>S>J]1AK5]W22>KQ.B8N'!2)*G&'191)EKIK M?OWAP5=5$220>%%]'^S62"#R@40BDG/^$<%U&%$_2X0P]/VSS!Q3E98_2? M;^^NT2EZ_<<_O?GF]AWZ\'"&OGG]YOO3-V].7__+Z>F__CE+\U__Q/[O,2HQ MHB#SDO_G7[YXJJK-GUZ]^OCQX]>?'HOL:U*L7GWS^O6WKYK17]3#V5^3JOV@ M/_C[5^*/[="CJ3]^R\>^^>&''U[QO[9#RW1H()WTS:O_?'=]'S_A=72:YF45 MY3'#I4S_5/)?7I,XJCC3)DE`TA'LOTZ;8:?L5Z=OOCG]]LW7G\KDBW_][_\- M(<&Z@F3X#B\1^_?#W944Y@^OV(A7.5ZQ9;J.'G%&<>93/!5X.?Q=5A1[GS$\ M?F!XO/D7AL?OAF:K=AO\ER_*=+W)\!>OC#&]Q45*DHO<,LK#TSK!_;Z*BLH% M]L<36\;_@5119A?SXREMXTP5%K:,\]&4EG%^CRW+Q^&$]O`%(%H=(ZF(7<9& M7=.?ZH%LPA&ERN'5*KPW,?Y487H>U5JSG9O$>T0\QL6G4W8TO?[AV]<<3?:; M?RQ6!<9KG%?O\/H1%\W,'#/QD6R(`)ZQLX`4-5E[A$U/=9KUV:1$_3%?"UR2 M;1&+TY)"8ZXB-,H2W_#Z&YQ>_7SXNWO?_?F#]_]^/4X@Q9%(U11 M$4]07X]X%1-J/FRJ?$"^BL@*"D134H0"J2?]YO3B+G!Z555KMKO(E M*=9[:]67!I7QD'TQ-J_K3=+`1A0X$M!1#[Q_@5!B,M'FG*JH]*WL950^<@*V MY>DJBC:OF`B]PEE5-K_A0G7Z^DUMN?ZN_O4_SK9E1>\'Q1DC-J\*CM!=6OXZ MJ&K-A MB(W*W.1XH+1)YW4M9PU@Q"$C`3JLA$WSF&@SSO#H>T\J_$`NTYS>[JDE0.]: M%3]ESW$5I5GY0*W*;90-'8)Z7T*.0S4(KN6(88$>"&KQ0"TBJ,8$U:CX/R0U M%X$8<#:0^L+%,[5[[Y^B`K^-2IRJ?JTC9?K;>.<`)T[W`RY64F\+4HGFD`? M MJ=*.'C-\28K[**/$Q=LBK5)@N'M`9\(J-WT`?I26_J8 M0?21#_J?*TS>3^%1L/RJ+-VA26S*N!=R;H#.LWHQ*NT!H'K(.6\`Q@3=8%5=2 M_PW]!8EY"$-R&OD;X)UA=&[7R&L<) MB(WNC(5EE!:GSU&VQ:=D>5H]82[\4;XK3]/N!G+ZN#ME.)PFPCVI:3R8`;%L M3,"0\6M<,!PYBF1)$6SPZZ'WN&,SUKC-2"$;K[6"W6%C`1U:W_$33K89/476 M4<5NM[O3)2GD:,)VE"$4V_8Y#!O/!GN#9(,C17%X<\UQ6YDNN(H];V,5#3?6 MNQKRAL>=WBSOG^@B/>!BW;G#AG:*QF<0T5>8WK4LJ^*A'5?GA#;`TTJ#!Q(A MQX@L$4<%,5S0W`B$!1.V-&Y:&DM.8\5H[/96@.`_G1U$H)QU>.INU^NHV#&# MH,`Q3I_%I0UXN"I-9OL,'07J^:@4N)!E#Y-9'HIJ"Z5R]FEPWYT4,PV04VG: M`057^KUE63V"XU<\6_!SE$GY&BB(X01C#27OFN2K:D\]-QK\79JGZ^UZ2-R4 M/X+(V.3D7LRJ22RT;0X'=`%,*H;%:;5O/J$&D1,T(^*,>KJX\:<0*[>VX9E<7MGV M(0:[KPDTYF@8JZR/[DUMC.F.0PVHK=PF&&:>7_GZF=Z#TGQU3M91>I@,/CH&*$-[<[F6FAH8^D6`"R,GP]PC M2BQQ=\Q^Q*R"`DY.HV=<1"M\&I7T\.=IF"5_F12ZD?#?G$8\4^24EU^@WU3D M%->9)N5IE">G25K@F,I!>15I"6.TM:2QBFCA.T9*G,T3X)+JH*],P_Q\WO`W18DQC@I+^DJ M\ESS6XJ8S'8:'PP\\H8G]58?@*\IVM!A3ZQ4'5L75$:^0XT5.4STV&9X/M[A MU39CB[F[WVXVI*CJ@-%+4IS1ZU"21CFKN/+A753\BMD9O=AL"O(<9>4M'\CM>+61+C M-ZD$+W%14`X6S=I0-8&V&_H/9>`FVG%&1AD7:3JL(HA5$RNZQ2WKQ66+ROYT MN+#K=F&C;F$W]<+2Z1[9;.WR%O7R$K:\;#K<+'$7CI1V?`OP6A9:PY`YR6AH M)T[S&C!Z[U;]S)H[9W_ZL"\^(:_LRHP?]>^,<3.(DV?$:3@PPLS!X\,IV+IW MPCD!A_AV[-JQ_N;'"AR50Q6.!OTKTZ.AY:N&9_51LJJ4U*P*X!108"_1Y)GG M`BN-E31<+X8=K3FOTSZTW_4^AA9240+BK7B*$C:@@BF.Z`3$M[6H2,LP(25" M7550T1,[8L9CSRXKNA#OHS4>-0Z'!T%=5'N3N=Y'#!IBX,):>1(.$C6V.#O! M%X\EM2+CP50L]:_LGNC-[$%/=FKGU6CXE1==SD\?]L/L]*MDKO*XP%3YG6/Q M[U5^7KM4ZONX1.\H?P=419/S^SKE)Q&!'/`.J`,50#L_<)\%4<#JHD3`'`SL MZ&$A'GH^GN,O;+EWNIF#1>O,RJDSP.DQ?XZ,?6%LPQ%?SM`00[O0AS>G9Q6& M\^<,\F[`(K3NT6F'\X0EW?RVBO*3Z[ZID MEY@,5\.5BYS"@#T>VL7%_:M@[YF)85R_V0FLZO>@WG,?PYN_`W5C&M3158D: MY$V>^D(ST-$;'F-:63,X/6!P[\'M8\/@WIB&P6G)NO]PXH(\M#G:9L3+TOL] MS^J\N]%R:X-C@"?:WERNE48-+&SIM&'N$266&!YJ9_?7\M/HZ(^08Z2=Q+E) M>W\-U]4&6!HK68;X=;I.F2?WR]__[H_??//Z1_H[_M.;'[_BT0XI:\"V7*99 M&E6X#*`RCV6!C+/.LY**/DTKJ:$Q4"75G\NYDA+``BNI0>X1)99XOH#A@K=> MR^OV"N6H5$R,AE[+AF=U?D/KP(I'H3*LT$PQEVARS*\@W5'6CEWCC_X.%)9V M'N=7)`8HY.7]F&-DD@T!UGQ480R,,%EW3Y=CL?(AO7M#?#M<_?![GNN>Q\,G MYT51,/28F?=VUPVY%4&LO$L/_[\ZFNB.][ZE&HWY)Z.5[*'&*2R@3#K!R=># MD!/D(8](,^$B(*A$&DK20QX][O9"3FH"1*>O$_$/:D+_!!4G2)6AKLJ3.]UK MQ.O2NRQZU/0QODS+.,K^CJ/BDO[FT`)2&`DHA"29T;7V:!M/"[B(`48^\DE/F;!L<`!6IO M+N=!H[A"&84#.38,$:U8[UP]O:^&K2/)'EYCHL0/P[?`KAWIS7*)BZ-.Y>.# M(&^#1Y-YJ7=\!%7[M=`"WA![I(6*`B)N_-Q9=F00@01/\&8!)0'>->7R3-1X MYN\R+LPCM>OXP%CC"WEO3M]7\KH(PQPNY4.<';R62]D5N+K.C:@F=/$)%W%: M'FEY[>]LU=PYG-]Y^9T:$&]#PROPB*I*,ZFZ(V7W6`&><1[Z4%5"ZB_RY#RJ M#M\])L<9J*B]^;RIIUHO4;"(P0VFFH:Y2919%#JQZ2JG]A`NJ]MHQSK/4!M7 MHI5T/K66WG0,(ER&TS$N=I*<;-`(RG-J`+.*0`SR3/*<1L1J--5IBH^>ZP8\ M1VG&\+@D!?/@=+;L.7ZLNO\ZVQ8%/NHM:#@+M)*`'C376[%K1!+&,(`RGUCB MJ*%382'J6#:]:)KB3W]-5T__9QMEK*\+KR+%T.LP&?(\F,T$<4_`('KQ8E887Z^,&FT^,%_^L>;'N>-%Y M80(X70RW,K&X*"[O1+4^[5[IY=>BJ:&`FY%L2N=Y&`+N7C1%L`O2)%^)#K.\ M>VZ2;5R5BSRYQ\5S&M/S>K3>S-1XN*=F>%[GT>PU8)X!TX`.7)%FDL=$FW$O M)%#G_9;%YK(VQRPZ?[&MGDC!F`@> M@;]HQ\[S:53Y.+=`GLEM92.:1VVU[11BJ#/->?$/LHNR:D?U[+LTH[=UDN-Z M4)=J/72E-)O)H*B")D0O5TH8:M"J",XY`%`7306)NPXW5"/'39`6/70P@TS? M.2_.;MY1(%=W(P65I(-`KY.'D[E><`Z0FUT4)%QU6<`;^$K6QS_`HY=T\8D: M9SR'CC!_#JNH.G*E&!P##?OHS^5GJAX&^[F,,P^HL03T[IO)*/3$693 M/N/%JL#,Q7K%O#8"J,RG!`0,78M,Z-;0X;-;$5+70D MP'N/JU!B,='EFWL9^IED6ZH(BMUEFE%-*!4>R3BPU!S,YTE<6JA(@`TD)C)F M$F4.F7J-[L_Q)BIX%._-\J\XRJHG:F?_=;N.\L:%/.)6TOX:Y'=2AN+<,76/ M.E1X/"5'AM^<.#H]MSO8?^606J"#*^<%>'D+(%;XO,^`IXX!3YP!98UB@`,> M((W$D.GNU3+?\V>4\RM2[*1*>7`46"7OS>9)(7.8J`$:2!T/LY$H\L90%;]3 M"=8M1Q,!@%-`E+(F*"_73TVNG?!2`ORA6Y386`D? M:<[,*3=P3@W]V2"IF4WC+9>9`0N6P+S',#+%!4?.S__:EA4+>02Z/D<^M^GX M'``3U.TY@(\U!Z`56JVZ/`5&KAR>5N@U/F5BJ>>SIG[?[SDC+^?8%ISR<4[R MWE#K](MU$>=\I(4=Y3E=$9V#3O'SS@C&X9,@\2@^6LR#T0/0>!Y44@0Q+1W MJA_J`2JJ04RT9(LX:KR05H,<=U?TT$-S9X*QWMK(6%+T69+T6-(HLA`VLM$^ M)M96)D!4`4NLG(HJ.!QC$E70S.4GJH!!"QY5<,2^PZB"89[,+!6Q'*T:S`,C M\J1I^#J:&^L2E*N$1`!*SMV8_]PR-X,0]*")N$X75"<5SGB5/"O@-7M^_8U3 M<;.\3/,HC]-\Q6,D9?I8X1.H>AZ9VKFV[L%FCK0$/U8HK>M"4\N@U#.4W)`$ M*8QR0%>+`CJ;ILG5F:0B0@3"Q$#FR^AA(QEE:L+X4?%](R:D@I"(LOL%G.C MP&ZIGEZ2+"6],GE#3BN]+RT4:Y-`"%&<38**:0TR:Q3:*+[&O"PM-FB.5%JJ MK,8(W;2$]K3$+*)_-;>9I)":$L_]I]K=+'\B)"GO22:K.20999!8UYO->=TT M"H[9ZYLFP;VD0(,EUPVQD2CRQK2^BZBY<(=CG#ZS0TT>FCDQ%%2A97A*UZO? MU!GIX,*#*ZV18.R1;TJ&%"TJ(8J#3`@)T6&;J6PO;J]^'LMA'QP`DN/^1,ZE MMP],7U[-4`5+:2VD-?A&\8:0T,%%)]/LL1$(0\V_**-'_EF!D[222^;D8'"0 MR]"D[D_;!C`WZ01HN,JU2`=4G,NJ2&,>G1&5XJ63_X#_N:7:+!/JF/T':[A4 M$<0$A7]'XKJ@(^.&1'*<%6)JGHN!$]WOLU6,_3,LY(N2U$B\'V MY>`.,UP3[LD\>C$]R]>H\UAL(#?C)4 M[[%$OS!$$<PB MKM)G[N*:*+L"GPBX3?0!^NEAP;P340L[5'=+Z%H0>PQVG\_T-YQE_Y&3C_D] MCDJ24^S*;UE.W$H)_^RL"C!CX2"`3*?)IB,]'FW4L)F#EH M#%=>Y2*UXF\X73W1DZ#V`#9_OZ6FY&'L>U@DO`?90)!UO:_N>VT*F_A&W/3Z M0U]28SYAMG!1,@\T*AE=7[VPZ!PC&;$2MV.^\+Y+P.)-E#;5S19Y9'4X`V;!Y,D$7?&8Z8(+*2U(L<5IM61\) M7KLS+?@,3K6"#YQ[P`)ZPO>57 MHAZ**,''R`U&P6A]`Y2IT;E="Q4'CAKH^J&(CF1-C=\$Q$3/=V)67)*7-&+X MR"ZI@X.@M\:]R=Q?XVIHZ!<.+U!J\#`#B1I77I:7Y&9;E564)_08#^`/T80> MR/.AB*7KS>&9'*]=?EUS6B34T&U;5-=:3&_00$TB3X,(XIA\3JXEW_BK8S`]A%9M0_-#84J,*&IO1W10CKZAEE)]'AT3R=.6]W^YA;<-Z,3>G8 M63,$VJ.DOA1/S.@*`3POTVSW*_QO4_;R4KRM MVMK`D1B.\I3H,,ISFFY4LJIS[)^++N]D49U%1;&C`C]44Q?T+32E5P6&\]0C M67X.J">Q&XK`!K>4.!15Z!&OTCQG<>@LSYF#F!W-%WEBD6*<)ZJTNDKFUMI6 MQ(C+?I7-A_Q1_90:'PQ4)\.3.N_/4T.=R5DUP5FBQZY0M\*2':5M6S+%^^'8 M1\8WQ:')/3XKH1I\W6%N+G?(498/WB:G^6B817V.E[@HF.^D+2Q.\B8TEX?D M'@B2YE>0O.KIV;U40II&0SO3V@5ES[AX)+HUD!I$^N7R2=[$F<^"+N/Z'IO+M;D^/V0L3&IW6?6C0('@?E_WN;'M1`4#CRP4+^E%8 M`]]V65/-PL2C`)P%;+EI07-ORNT5!('T5O>F2AQ]U0T1O1R.$$U=2=($$?2O.ZT>8).@J@X$-$?7#5,L\S#9B` M;GJ+@1-&\N3=)!MH*E3?H^0&V/0W<'-+/K<'XVJPH50H@T.!RP3$.L^787X= MGZCG-#P(>E'=F\QY;X5PA08D7"-JK)C#*[+0D5=Y7&"J3<^Q^%?K,7E\"JMO MRL.@?)EB.CC9>X&U13.@:<.7#;2O4`.?63'24I@S>HJ=$,K)%UD5KOO=OQ07 MLL9MD/V$/I\8#=R5DEG=5]IC8%$O$:*!',:Q.,5IS7.H[;&N<,L[HGWT!1MP+=1]H"+ M]9LQXR<,)B:&D%^,O1I%?DD#&TAS7X'`+RP]&@<>5UHZ48]0Q"@-9WL%4@*' M=EA(N?)[")Q3<_Z9DOB,KW)Z!^<1?'=I^>M(N)?*)T"U.C:U\XX>+6S4`0\9 MIZ7$9P)AGF$,3>@"]++GFU98 M8*\NS;-H:0H136*Z!GX5OJ2?21NKV?4S8<=4FF_I[V[H@HA"G9(CP+SX$5SBGDOY`7__9:]2-XL^5_+Q7.4 M9LQ_$9SO-_H)M&;_*#^!O]=7>.N\!-=(68@&%RT*_+F=/[&7 M$V_L+X,EMB,1/@O6A'EW$&2P$C2"D)[0L4[?"KMP;F$=JIK:1AR'EA#XMMU$ M5GM=2V61).G8M6YJ.-AF&Y[6U\$D@P]1%?9H`6SUMIA$#?T$*=+BS/ZB MR[A9^$;J>Y==WXCFI'9](XK``_M&%+&TZ!MQQA=;+M7.3T(:5&?J&]&5[VG? M"&AQ7LC%]5WT*5UOU_NFPRTN+M:;C.RP]6!S57B^KZY3>,W^[CI%@-?KB'UN MAKF/U'0"$J4[45I6W5J0LW4(;.)'ZS5Z6J MA(3(RK')79,H_^D6N$INL+EI1^T]YK.W[4O6EKV>*^(T<*0=I7#"=W,2^+P4 M[7>$>.`.35#N@9\]:A10#X=@[GW;[`CRY#%372_7&&Y:3@VMG&==SL[N)Y(E M]$[%*C-4.YDRE@Z$:M.C";VIPR/(H`UL`7^`1^Z!?8+*'O#?_^Z/W[SYPX^\ M1L@4*:[VG5PXB#K'3!,)>.7,>#<8!30R`I0.L#>3\XC_&EJ8P)XQUA$%?H1] M7>S4\D3=:?4/+;TX'@-P'RNV_U2WY_T*74A:@_\C+WA33)V3,$Z$*ZI_ZD0@ M?84O'HADX-A%#:8K2V%XIYV)58"Q+ M_M3^&&+K*0/QTI=&&1OMM$^'=`)V18,-#_;KX\->WFJ,T"R)-6Y=L^F3ONYA M5S+:LYKVJ,$P0&:K_KXC9GQ_(0[NMMSUHBRW:^'N84GSEY2HIE;/7519CZ30 MA>O;`:Z*G_/BUQ3F*0.*V@I/#.S+\E5J+[8-WR5L!?UNV]NB-L.YHTD$&%Q1 M=+'L^7WZ`^!&D4_L6L);R,)%>%*[XU'*H0=WT"MPG.BS,.0Y^!Q&\;0 MN:U40T4=V)?O;YM8;%<>-Y45#&F8W4;%3<'[\"0<]<:25#+0ICZV8JC)@'@V MV-`F*M`S0V!.#4LTUT-JNJDQV="$XY"$-_"<%WL51S,'"'I,MC(AQ$@T`NS% MJC3"4-NN\\P/2#HIW\,"121P;-L.V:-\5.V4';UXT-=DUFD'=3: M[_")>RXOW':4`;&_;"^DJ\N8]>*D>8LR0-\]6B81\V:`7Z=+WEKT[YC:&B^K M*X?ZZMIHOJ&Y9(:&S!W915FUD[FB!OX,,3)ZTW@Q&7KPM$\Y(UP!QWD-#^:% M,D+6NA.*^Y[8'YYZ9L8\G%%#@DRFF.CWN&.5CW.ZIW;OL;SG[_$0X)'2G\KU MGFQAP5KPF2`*+#N5UD!#E90:7&BBPA3#\V"1/+/\VO>DHH:@V.K41F1;(\UK M$W'T'@OY'G*BZ,#QFW7>DRRU\O#/P/.RF<97-E$##W)DPG&% MV*]*B#HZ)X\6ETQQ(7SH2*\$@T;LR,!7%H-'>K.'BAXAD/(F'L-'AA9@(GY$ MRE7?"G*HK]IN(W-,%[1`^ MQX_5NZBJ_^MO:?64YCB:D*Q$S7E:QO1XWQ:3A82TO[=605("Q_7>ZB/R MOY%`A?GE,>J00;^$OK/J+\MH[48E7GLN`LT$)9>M#<>V(ZR*@B2,`.6Y4-NB#$$I<_@W284"M/'SUL<7@,4_3W%V43GB)>4##.XV*Y38>0KZ#MTB-WOZ15= M+3U^:C@XI&AX6O?A10PNHH!GYZJ?Y#3195]@HV:DAO'H6%L&BH]*Q1PHN[1U M8$/6)A[GZYB=$;H",5CG"B/_*J=W9GYC+[E+\^$IRO=;U+"FB&YZ7,$Q\&UA MZ&/JX4&U*E)N;8@4G&V>5I]1;R8#V;!AD)@NN*&OLFF9=X^+YS3&PV2\)_R] M!2<U2'))!\ MS/N82I\/75F>H<[PF*+8?0['%"5C;LH3Q-GY'U.?"Z=?P#%%Z?K\CJF^.O1T M3!W)A_=0[OIJ?1:5+)*7_<,NA,]1QJZ"P[\=<=J93P@/_`8"]NB^8-!Y6#C_ MH8='2'^@A24C]M?A<_$L_D2GJ([::WMSU@V#GYU/<1]-7SEQONCQVE+9':]_ M$+S.\8H50].S!$=]N"N&T6?MP95L0R_NV['U-BU;!WX$3XNR^IG*1!L4OEC2 M^P5']?PXK,,/,%"Y.U=(^2F%YPI[_5IP\^$CI(2>Y%J[UY/V<;=W_:V)$-?= M$\3I0#4A30$$3@KBM*"7SE;8I?9>=H>-]CG;O^O6+>?$Z4*OJHRQSS5CZ[H* M$6+ZXH\_.*WJYOJ3B5HTG)!C-9M:-' M(3J/^I8ZY@1:_-;:(H8X9G,+CC)9R$E+3&-U7H(+9S`OR.:47MTXGK*.Y-Z; MD!'E5E;+V(-CDND3Y,GM@<(.\.:V!W9^CVXOXO;Q4C[+-[>MO7BG[>W@9$9+8'UB4I[C`S,1)?ULE':40MD2RY0Y")/MNEF/71R.KR%/W5 M6(K58$?F9W583JI@]V>GFD@%[T0]43Q+X0M[_:9]E;!20`'R%FV5(D`%]3WX MB)7EFDMO[+&R6G**'`J'G7Y0[TB.J_0WCH"LFH3R>(..48/S.@\` MKCLR]8%K5-!R3@VPCEU-U;J'1+A&3.,"0[3YYOL--\;I,ZL=65(3\6Q;%,?M M<)3&@E]=!^;TUYEB`#BL3845*D`]*UK(@9Z`QV2":+'()$G9-HRRVRA- MKO*S:)/2^Z%$]B=&0ROG#L_J6OX[L&A#X9ZFU,X1D,,4Q)W@+=%DF%\YNDZC M1]9#GE6F6)*UD&W?X?H2J-3^+K!!?0($G&1'4+7O4A;P!EB,7=?;H)@;ES#? MM'2$[$LH%V2BQBM3+P?.\4=F52MMN^G1(`^'=%8_+;*EX/6]&Q8I`5WF:O#( MQB:U28SQ;BU:TN:Q;Q5V`M'D8^CN`A,7#6=7BW"7B:'+`^88_&DFK0'&[@OS MO"'.V")O\9(46!X!X00&W`%I M#Q>/CDM[2`,=GB&Y!G.4[F&,V-9%/9P11QKM1WP(M$]0C7A]+I^@1XX[FN2> M.Z^K@PU$O*ROY[;%(JFT?""+F.K8`M\6)-G&+(MNU!>B_!VT=?'4_+Y4R20B M$/5@DSJ3VA\<>LD]QKQWU7);Y&G%V@@QWR,S%3;3IK6C/:PN803,6,A>*W'\ M]8H\OTIPRK;9=^P'MKN^Z^TN^JM_7-,%R2YXMY>!JEPC(S1WS,!,SIW4#%S; ML\=_?:PQYA$%COB.@"TVI*";DS4;[%H/CN;Y*GT#CH(=F=M]Q^,:.&+040>^ MZ188)E-7C=\$Q$1##]:[-,-E17)X%-[_$VM:J&N-HL MMLSR<6C!C/1QM*R8[-8H-S'@;^GOGZ(2<^L]=.=SJ"B.V>\Z7/:\?0NRP46U M8\5FJD7.J_WQV])[+-VK"I]`-^;(U*YWX>7PK?$$Y3C0U5&%SP3"/)<71G%; MN<.KE'FY*?!H?5@%96H8X.HX-)WS%I7BYM@!10RJ]ROD*">)*GL\/S^(..D[ M_(SS[:%XC`^"/@#L3>8K(K\0X$"^=T.$("N+=``%W+4(,4:K'B@4X"K[K<9X,9:E!3])^&XX&QVPG$E@`N M*3,A)O96Q7/HO/2F/M6D7.-+:-#]-`3G.44-"J=+4IR6%(F]QX\''OL7NDZO MSDH0`_9Z#@6D*)6UU2MWSDA&08/^]F?SUC=E'RRHO8DIYN`,D/KV%,9Y*5M^ MHL@9VZ]\::[\RK<_U,HKGY@RS"N?@&W^/@:EPD^I'"T@,#H6>!`-SNEZ8XM0T8`9?>.<)%KL\>`:(^LU MR7F\.R\:4]YLJ[*B-YHT7\G]9`H?P9UF(Y/[\J!Q%$0"](FH!%6B'AK!>I)I M+@&!\=6OEGJ@T.@%LVL\,])(='0L4$L-SNE:T!A0[D+H-2QB;@2J"$[[38P> MZ(]E%(LHV8#M0,<93[2X:5K9L"Y3U54MX1'PO*05KT):8CHW:T9Q3NWEC/#7 MU#.2\_2=0\&R.".H)J$19#\%!XU0U*]RYYDCD%*!3V=0_FD8#RH&S0/VM>M"<^UY[Z"B<\"%;1D'7B5ABOJ%=L,CS M;91=IS'.2WR)\4BP^L10R$DNF=++$2V!K7W"6*,!<*@*V*@&CBAT<+2Z-3*, M3\!($%6'J*.L)FX9I%?/E-`3'?:Y=$Q0/<'NI/>[]2/)#K:O].\`=\/>/,XO M?`(8$M"\.PV&>48F&>&[<$94\:/BG@I?5*1DQ!4P.A9<+F-@3N>5,FI8(:_W MX\PD6ASR+#(U'A_RDEK9Z3+%R6!,E_)XJ.C(YO4E/B>H!SJL(3G-8Z+-.-^5 M5L:[G4J$2_4S<#V4\>G]E3@9QP-6M<0V;:!")`T22-K6=Y;=?(ZO M][@254FN25DN*HKGX[9BGI$'0LUG4K#>\G4&_7CE+/A$P#VH#]#Y@^<&%Q$# MB]C=^IG'/@414H.U(/88[#T3+\8X*9E'C\7HT&WV+JI8!-KN9BF/39-(L^%L M\/P]"%3GA@T+>>(J>"VP26>2:FJX2,0RYT-4J1YO1C$XQJAFM:?F$R(6L([$ M"%\5>J1EPPA;;+M1Y=&`$T.MN%$]1@-*8)O['SU&`PZY44.38>A&;6+_&F_J MS+RHDG!`)>[Y5=WG:1EGI-P6N`V-G["N%;X`JO61F7W=8D=0@%Q@K5($V/GO M247MHXJ@RS2/\CBE.Z5UUH4YQ%2DAP`8Z'G7X,>*)4(57(>Q'/Q1_^+4<.A^ MD4SK>K/P2FD=X!->+2&L=W&2PT27;2$%:N2%0S[0BA#Y>-LX$)^03QPCW)0* MC/78Q?LG:@*152Z2N3IR.,C(:;U\(S.;_$U5.%+)5\C"AF>+VR+!IA) MVM+R^VB]^;&A)H`1.B$<1(-;?G5?KP_7N`M!/A"H^XXG].M,R#KXH;NGC;@5 MIKCD^6UWL(MQ+\;L[:X;4J==\;#*FPT/,ON)54TJKW)1\USV(.P$"/05V2HR M7GI\(,)!-T&]*X8!3H)ER#A>5N)GK5[R/ONI(*4T:,<=I%GL.(Z1MX1[^ZB# MDO;GP$&`PX0C=?K(L$)]S/=RLAYWJ#^N2;'F^)^@FH(3)&A`5.59>@H*]L#E!RGEG1XO[[]&YW@3%5S>6>S(7W&452*N[Z_; M=92C>UP\I_%\\3L2FYB]PYM'@7#A;CG7PMS@`/6A)@S MVK?@TLU#!6AW2[(TWDT55YP:#A;*X6E=BV`+]P0)R.B7^M_0M1,G&4UTN>?Y M68#DJP= M!\:X2G189?I`&C_A9)OAFV5S4+/8V-[Y3O*2URN5Z1[#64`/J]K0W.>$"8R8 MR=O@)$IO[&.E7?LU$/4P.YA"W691@9(VL(CQH^SQIMCC3;R'G'BG",>Y%=R#.H-0+'W^$V.F M^@[6HG?I..4;A_Z<8>[DSI/%FF4B_;:GD`Z$1N=3<$#7-`CW(5X=#OPF%O6` M!XKTTF`\,>&F7UD\W!TCH8-C0X&R-C1E`'47+H!PE*=$AU'!8JZH,/.8C2>2 M);@H63)P==@-2?E]/:)/X0%Y$;=/&[BN?<\MQI5SV4/F][_[XS=O M_O`C[YHX1:C[J+1Q(1N.45/@KM^]=DD*G*YR$3L7[WH5SWZBA@Q[7+O#49;^ MAF71:/H3`/>?.B!?.U$=(\B>=$DOX&VJ1@>YY\B/.-ZNMQEK@,S?C5@X2X&?<%ZFS[A[%7^/JYOE0_1)%M0!FP4: MKZ$'S7DH1H=._<`8]Q'BT1AAHBJ`JT(LL=KW9;5(G_D;*,/H)N_^6WI%G?H` M?#&53>PMNU.*`2BYTR(]@-.B`W>"&`*('A*J!#F[9$^*#M'GGV_W8T7/(9Q< M1$6>YJNRM]7/\3*-4]G[N_J'8(?C%`"?*CT1(`.Y&)593>#\"Z6GF1VDI:=E M'QCKZ<.)_>OI0PS,]+0Y/89ZFAOQ<]+34M$9U-/C_#.M,2,M;40W:K%EX::4 M^[@\U+^PCT%U:%2!>-###!QJX.F7<7%'B7E][`8WW@N"-R8MN\:D44UZ6B,8 MHMJ+MJP1,[;[/HB6F-[-D_JM>#PE=WPP^``:FM3]FY6`V@0`!-+,H_PD>DSR M7:B;Q+]>E265XW,JUOE*9/&(OF(7ZTU&=ACS0;?U&^\M70!Y*6^CV<#%OD%0 MO67WP=`#9?#YX@0D2X_G&`ODD,"NS;$3")Z@!D71L`\U2"(%AKC*P3.4:&)Y M<3QKAUZSXB;!XCVN)H+:%;^"[O;QV=V_9.LE8K2A:6&"V5770M*A>I+!@=I* MW"S;XFBWI$QY?,>$4&I\:MIT8@2$^TH.-0XL*K(K(->@@7YI$`GWR"OY.I[YX\)*Q"V;NV M(/9EE!8_1]D63P?%6YK2KC=%";1S'TOKAJ#X(88@ZC!$O(9=AR-B2"*.I8WP M>>^LL1E+/^Z_21CC>K7;EXQQSXR&67ER]*1_VK\#6+<97=[Y'^L2'1>?E_P=!?XY7[)D,"K)=/3U\)'^G-\Q.#YF8!JISN[01IG!PO>,%)BSY MG"&"2([1CB*`*H$/JCX2_@O]DA+A..#X(>?0$.@X=\2TEV$D*.\#76M!;VDM MYMHVGC2U5QAX'L=J4JD1IJC':4J M4Y(^?9/L-+3*;I^BNW<+7F!%WAU".@AB31U-YEKP!4`D.A9!6T%8P-KXVE,3 MPNOW!+!9Y%)`U)CD.=%*'A(G,NS9>\I1S"?P:VABE1H4YR\2#3#$H(5)G=+D M-S%DHJ':_/?;NSNRB[)J=[]]O+X^D^O.\9$0!3H\HVL9H5!1#191N(@"AC?6 ML46"L4H=H"J`9IV0$:+!M=GHV"X%AA=;_Y`7=?(M2\EZBY>DP"/IK;;FM:^7 MU>"[WHT<-NJ`\SR]0+U^["V6FE*'K,#\MP7+@'&Q+0;G];@M]N![WQ8,^LO9 M%<-K9;@K1A;`=_I'O]EADY!R1U'F7J3D%M-%I6?Y2IZ7J#L!.$U$%9"_O$55 MC&!YC.[H!>4U'G2!;3!"#*43T6@X0:HT.TNHT99&:>=/=9;[3ED?*FK?Z[IS M1G+NZWT@%&&J8]94,?&Z%>4#172BFJ;%N<&)[Q9P<*T#[OI!^STT^YVC3E"# M*6M#4^/*7\<%MB>(X1NZ?*?-!2=.5_'%;+.W.T;"2&U&JW/[WV8=#B]IFX4K M&VEWN>UL,MD:&OK@]MNP-$5]19CE]"?'1J4$(T)-)AHIA1R)[ M%`+LQ?ULMQ:7.G&3/[#/C4K;K99:FCZOX;Y*:LP.EVKZ$R$) M2SF4Q:V,#+605-I,Z?SQM"#)EAYW+,B2'F\YUMI#=C&'105HH>\AP?5(&"19 MK<-\"E4ZBA[F+,[^XE/,.V.QB^H;J9M&Y2/C$E)#D_LO(S6$A5DI*3MT&9:3 MJI%`#1;<\Q*XHM2H-`U6E9IFI=_M=$4/_'R5/F9XP5O)7:9Y6N%K%M0CVF-) M=I3R=\!--3F_^UYG#0)(8'""!`ZG'(D9=D!371`"YK*]VQ')>^'!\D@%M2\, M;T,#,WLLAD'RO5AY[<15'@=/VX+4J>"R"M!!*3L@H17:8H M?0-WA(2P.SK8]HO1-#@VF04M=@RYT*#+_.Q MB,)8)TB%6:X>VZWN"^)T&?UJH[_A=/54X63QC(MHA=]OF7J\69XSFG"=37RS MK4IJFB04`<0Q>(6.*Z]WL4?RZO M6\*.%Q(='PR_,0U,ZN&:).(@0C;OG>`GT6.2:?H*O^JS&H1QG89VC_.4%%Q7 MXX2G(@S==72^`R6Y*,SOY?5'!1']9!@GU(' MMZD)WO0)+@7!94UPL/P@G3U%P'PVU!A-=>.]QZ;:Y2[WC:A_!=$6T[-[*U&] M_Y9:XP!WE+B@S(*S1%"5-$1O\X0WD=I[4NTB&T)L)@V!(T!>^[;9X@)')3[' MXM^K_"JGJ-%-DAX=T5K?@"VXD;E]N2=&D8"X'6Q195*=JX$8IL>GFLP0$,LL M'3WUHS1_[)T^X2K19 MY5>.#EVR;Z,RC5D0J_!K2:1)\2N@3$W,[EJR.#CQ\"<`LK@HWC65A0^R$MEK M4KLSN6,S809E(?[(?QO&QZFZ)@3(:._ZC;T-E$H^S/'!<,TV,*D'M<:A!O5A M3O"3Z#')T"RLKVAW.":KG#<+J+/\J:"^2^EA7)$<[P_Z#2?'D:=V)H,8E6"@ M7ER@8.RT35*/?``X2QMG3@^]MO8%11"U&**#D;^Q"*R9\\.:4ZCH<:>HN<.. MRG7+G8.1G#OT``U@Y)MO=F)WI?P>H10\*SI([RW/:8*3M[L/)6MT6/=>R5>+ MN$J?17;\>(U)^$3`HU#YOZ]G* M"B(;S``470U(?KN<]7!!'3+HE]"QPI"E(1;X'=J]?T3TWQ>1HXJZ7G:TWH7NZ!YFC:>/YV MQQF37=P^9>SE#:@UR`M-MZT;8#+*@WG$`$!W]4B,@-'"."GAT&3K2QL(:7QF MKWC#WO0!*S?LX6&IH($A;19K-K3U569$GK-B#4U)@V`=B'0VTGB5AA$6&^J( M=]&G=+U=BU2*FR4'3P4NRN[P/['&F65%JK$+6-=U12W?#V6$(.X/A]1"S1FQ M&6MTD,#G!+48]5HYAW-$:LGAH1M2G]U^=^IMM./QVI>DZ/?0^2M.5I@%=9;5 MGNM?LE^!LP!WK28T;UVB]-`"=8UR33DDH:C&B1=,^'*OI]17B&/&JA'7N"%5 M^AUM:*B@$DMKX+M(ZN$3M:B:,O4TIOP=N+CIQ/SN"Y<>Q77,KF".^B(0,&?# MY"`O\H17.;W*8[*6F8#C@PUSD/?/-CX@"/'G]^O6/S9"T+%DX/!>[7N6%9O@?OCWY]ML_L'=( MQFX^[`]O3G[X_OOZ5]\%LKDEBT=45\3W(=M64E(]7:<^`!^KLHG=GZ MHY/L)OH\]'UR,KN2F9T3I>OE`\$GYN&$[D_+!F+PRO`CW"3J+/)<;[EI+WV6 M165YL^1*C)XO*@%@QA2?*99.]06?)Q?H?0.>](>#4J3 M#336.\V$_@+/#B'#0LW,\0? MIR\90Z/-[QK]6?U>.?:O#Z$+M4TQ>OA>(.>>Y_,X7>7I,HVCO*H3X^@5C)N6 M*2ZGK@IZ'T-/:B4@KB6PAP7JT$`-'N&#TC77@I@Q.$AF;0^MB?2?Z0_,,FP' M)O:49;LO=`WP,"*GP.7CO-M)U@4^5!>MWTKU8#W^PM;AVLTZ-]/9Q3<2*==1@V/=28&R3F9NH")1MF M%E'C[;+4P`L9&3-Z&1IGB%^1^"E*\VM2EC?Y)2EPNLI%2:1XU[5=Z_K:E^]) M=8Y+.HJ)]:)D<67T2M<;()$H1U"``FD9&]?R_"7#]2NTHE@CJC:7`F<4UTBC MI,4:\A@0G!F`EP2&,ZK90CE2(XX:S%&'.NJAQDK'HPY[%)6HQK\_*HC6<+4_ MB*=U#E^J6WK4'T_85/X%5H!R=VE.=R5$<`-43+=,$JAE9 MX]!+8VNP0#,ARSBWMGIBQ1P;0J.64-(0NF&(B9S;/4=$T50,J7^1X`TI4];Z MH'[^.!%_01N*Q!/5[FW&/_W+1]YAI`YMV>9ID#8CJEN20!;/M!3K8 M5D%A)+2>X_&,KE6.RMU$L;F"JTJ.(VPF&KP+&9U\1I%:L:=`KEQ&I4K]0RO1 MRT,`_$4SEV&M(0U>2V.;IQGH.;8J?L+)-J,*M6V@4U<;?V"7@+!3N<7DI/;H4,7'L0G^OJ6]*,24TY:*[2C;]$H?F!36"6?/CV(` M+BT3SI9O2^?8LN0MDV3%CF_KY/S_9,6K;<+#DCNSL^!OFY68S(D=&0DMPW$\ MHVLE"PYMI\=^^-(=NSW(CS:`O5 MR1ONJ8P'E9,.B8D^`15K^ M2K=369(XY=?FCVGUA&)1^)0EBK/I1&P)/2?8?_Q[M(ER"@OM<"[Z^[%'0CHQ M^^.'K^^_K@-00A1O5)%7HKUL?G7^AY*>/Q=EE:ZCXU;MXX.`FGY_,M<;D$)C MHM3"FUT(GH2W1(UA_GTS_"+T-U+\>I7SBD5E^1Y7-\L[ND>+YY'77.4O#;PS M$Q!?Y30-_["5"%22G/\:B)[TX/M2R0:#30%]#-,$Y?RK! M'_>R,/:C!3X&!]L+_CYJ7G7K8`J) MJ$^,!LJR9%9?8><2\)"`.V MP)LH39I^976+LJ9XKVA,)G6YF$QF+:5#!6BX7`\5[.PD@5CF@TEV2(U*T]*O M[-6PCA0H]I8SHB6OH\DD^LP/O?&[[#+-32[[T-J&/@00;O,>8F)GHQK09Z>! M\)+UQVE?7\%IJ]ZVJ53B1K?D.)N-LW)$UZR#E$W^ZGN+BW/^5CT4_*#U(2Q# M1P&`ISP=!4P`:2U.Z`/E[-3=X([2G$5\!,4&S8M(6!3(`PO]H->]*-^AM-QK M@L!+Y;?P[]&[.*3",!I6HB.9EDH?0,\\D?G=OZ&6LMI`[WKA!LT MB4>-WP3$1,.SKNGH4HB'VJ%333($VN^P/=A4+: M.*8P;4BH44#TY^@Q$R$.4NV7D=@\BE]!BUN-S^[\$0MG=.#J!*T$ M'MPG%^UA$J;"DB+3"9"3ILD-A,?VT+WZ84/RB^V[J/@5\V:=FTU!GJ-L),]! M[U-0RH,:"/=U(QLTT);B@2X^H!83U*!BD`KABDJ8]K[*Z5UW+;1T]$BV%5?B M<<>#C>CPBCX^I?$3NS(W3%FW3(EJS$.D,VB*)3%9!<\!$$T[I.LTQU?TQ\G^ M54<#H8$+1Q,ZU^<-1/0+@XDXT,`MJXZY.=2K2L(B0T7]4X%Q?E:0LCPCQ884 M$_:QPG"(0AZ9UK5`<-"(PT8]X'"U:Y468T-90EX`!:HB.D27AX;2_]#=%LY( M>?2:-SH&(N>'4!0*;?-K:H^(F.%PE-PY$P>-5,B) M$C,-MR$+C1MUKT^,@FS%X]E<;T8&4==M[@AQ^(O68[_`!/,R+NYO[UZ]7=R= M+]C+5KG=4'5=H;=G__G==]^^1DFQ75'[/=\NZ?`M*^,00+A'!(KJYP2V`:$])#='A MHZFP)TG*N!MEY_@99V3#^%UGJ8S(O?)7H"TP.;OSW=!B@'HH-*E.!CO#`67P M31)U5"8]*DE-9?4452B.8Z9]G?$NY+M]'(\-@,0]'T[DO,5J#1`PF?&=80=W8[MFG)DA<@%P@B"JK M/+^1MIJ@.::ZC@BR!U*%3Z"OHR-3^PH`'\,!U,''*DV0=CPM`IUUJ$J2J^=> M%1$B$!X::OX//$,+)[>XX,][E!+1I%9^"BA^`CD1)J9V7DVK!H]Z\$7JJX$1 M99TFXV-CVY"YZ9$IZCP&.$-4Q8E`^&FX.R[6FXSL,!8=%.OZK.,VDN(GD-TQ M,;7KW=&`KPLI-`@86E+6B8)MCY:X@UJ\FXRYQ[Z\N+^]_2K`YE"5)@+AIN'F M.,=E7*3\3G*SK#,EQ@M&Z7X&V20*T[O>*#T4F">G22+1K@#EBSKXE3S9IS2N M*=UPC`)L%QW9(E"6&FZ;?F&519YTW:/Y'^0'B\YWD(VC,K_[Z)Y>B1X>JMFA M41\[X(/W&QI@X;TB/Y*(CF?\QP#[2DC4"9K#?FS^]295T7R=\J=0J&ZI\ M`KSYCTWM(7"U@SV["H5*3"<03AIJ[I^I1+,@T/MMS,K'+K<9.RXR+(Z.^PV. MTV4:]QRV[]*,?D+RL=NTM4DA.M\8N&M)90@BAB'J4$0=CKPT58WEWM-'AR?\ MP`C`'./3A%V-6:`U#[TN.Y;%>RPK&Y;UWU'6+?8!#AQ[NX"X63WCNU+,)Z5_ M^4ZN"^2C8#>AP]G<7WP$1,1`PC>>#<2-=U+$BB"B1+3X07N4!;G82"6#*'+- M].5]N]J6%?W]MR/O[)(QH%?U@[F&Q]OS5X,#=&VK+<]J@*\?`MDP>B MQ"\+YMHWW]_B@KT_7D3QT]]Q5'S(JS2[W&;9[F?N11XWS#0_AYI@BF"\&%O? M?/^_$$,#,3P01P1Q3)!`Q<>/'F$,@RTA5# M8LIQ"SOO^]=&.T_S<^C.4P3C9>=]_]KESG-&J9V=QXB?X<[3%4-BRG&_+C%> MII'>B]:I*-(ZTAIA;"C0!38TI>N=QF&B'M"031%&>4IT&.79DXJ+BMV>6<.N MF^6Y:&@Z6E=+X0NH'U4^LW,W:@^TN"1RX&$K:JEPF@#8%U8QB6[PBJII?[`E MY20F#:">!.!Y**@#SHZHJ"%VF=I2":^68I"#'=I^:M"T('NM\"J)$HP M/+SN='@PO20P00P5*T$([@@UMB7C0]I%[1'>F35<6(*V]!$C3ELJ?-A5\V[J M>U^F>93':;[B*<0*V\YP*I-"BIH@W2<>U$7_:KSX2W^#&6I1$ZGR5G:I-T;8 M*XB(>[Q)&MXL6][P#/R`U0^A4GQ8)=%H14RCCUBH[.-1*YNB8-54V2J^W75# M^OV@ZL".2U(L<5IM*1U7.;W?IB3A?RX7SU&:#211>(8*BGQRCIV?N"D11"1> M`$J6"A?C+*,[Z,LTK\.[O]*/FIHA;V`*AZ.)1`NKN$<+BCIB6+I@V1NWJ3O( MB4>5)DAKV='$^R%SJAJV1PU=(<*V_&TS$D@^3.\0@WWJ52X0.A^";@\J`)Q? M'?9+^;=HV+DVN*'0_,ZP7[J_K=(?\+Z@)6P$SE^_3IVZ9NYX-=KA04`GSOYD MGLHU!_'42-A&U'AA&AO2Z&JJS5GCMWM,]U1:I;@\QX_5NZBJ_TO\E*\62VH( M/WPD[%%DL&:;E0E!4213EB``XZ=?*N:5WF$+<9.YPG$5E*=[7V+4H^:^M:(?:2SJ3V$'0 M:8"6DBXXY[;4`1*SRU(!KP^QQ72_8OWAOJM)L5C1>T9].G5GU6@`@.[G0#%6 M!>.\DL1]K^04:C!!#!74X1(V4D![28@IGPV-D_)RYIB:OK(-9YY0&L$@4A(IK\M/&` M\W;:X?I6XG#]B0ZLM-]N7`,$/]NX0LQ+97>G%,">>F;`3Y-NST,/82N&EXUG ML!GPQEK5`6N/89R[$@ M$TH^K1>M.P)?WXBR20N@U*&`SX/\NHSW>5!CI:I[WM+7I:>CJ,8IA#VHL"6( M+C?]A/0[:))+VCQTN^Q>\I;WDX2"7QQTZ.!SI@I?/Z MJF8M10!2RMHB-0#MUX:'QR2C\)K.AH5`)HC/>%ILB#;W/.KMG!0FD6`>\MJRUP$M4'3U!Q8\$'4*5T+/`-8@\#M22RL@]\#ZN*?V[3:,8N4Y.SY?RSS>70L M\,@:G--Y;7D.%+50PZ8]C[.5:/'*K_"TW<8/,!NK[*'T#5"81N?V+51!:WVH M<7FH.GR]4N:Q]V+^764,5A'CK,!)RFMCR+PZTU_`2_G+9O9;ZX5!/$$" M>OT?,SN?5!:!`#@;6/BZV^4;5>D;^,26^/6F]N5U'\,!XGBW2Q/@[!K:6*I/ MA[[VSI`(C6T>*0\M^E[/HJ+8L12U-=GFU55^\8E5W[]97D9I\3/K;7ZX00QF M,/6]3D/R[GN=1LG(`^F"8F/?:X,4$EBQ4$*!%_LCPPQQU&9'N(/'^+AA1=2R M`K>L6#)6/#-D`[M?-7;HD/M5=RT\I^_M7X47CR5OORLYUB=&0Y/QAF?U=9A+ MP$/.<6N4`+3,(HZ9@+'MQ-%(\<1-TU6FX(2,$$UV>:[$2C54Q)AXE=.K++XF MI;1"M'PDM`;K\8R^]L``:(C\6Z&@(E64Z1KN!1"GM[\`N[XGY/51%X.!8,@B#QTLU'A81 M".3Y5F4]`?/3YCVI>W,6W)A=`6S19G[A MZ466(('+"9H3A9:#2O8B2$0&'L(Q@J/T4M_R4GSC*F:D#*]M792[V=$\T M)3.$,W#H2/,#T6$!"B!F](PX]"@]J"'H M!'TF'+93R>)4L9+%Z5`EBSJF73RM,.,#M96(Q#/,?"M8F"H]S1(65J3B\`#J M,_>:_D1_V?R*_A\#27_S_P!02P,$%`````@`J(%F1Y7X'W.V.P``A;`$`!4` M'`!B8W)X+3(P,34P.3,P7W!R92YX;6Q55`D``^P7/5;L%SU6=7@+``$$)0X` M``0Y`0``[7U;D]LXDN[[B3C_PG94-WLFI5==:1R]_;3!(J$ M)*XI0L.+7.I?OP!)22R)`!(D2)`HODQ[2@"9^3&12.0-?_O/IW7P:HNCV"?A MKZ_?_?3V]2LJ\?=JX=5 M&GHXNB)K_.J_+V;35\ZKMW_YZ[OW]U]>?7NX?/7^[;N/SKMWSMM_=YR__RWP MP^]_9?_SB&+\BKXRC+/_^^OK59)L_OKFS8\?/WYZ>HR"GTBT?//^[=N?W^Q' MORZ&LU^]Y#"A//CCF_S'P]"S1__X.1O[[I=??GF3_7H8&OM5`^E#W[WY[R_3 MN;O":^3X89R@T&6TQ/Y?X^R/4^*B)`--RL(K[@CV_YS],(?]R7GWWOGYW4]/ ML??Z[__W_[QZE4,7D0#/\.(5^^^WV>VS=S[ZQ(UVA/@UV]*G&PB'--IV>`I_4,QGI';&E_Z:`#WB('\":'Q.5L#DB$0%2#RRRE(?8_>G M)=F^\;#/D/G`_L%(_N"\?5?(SK_1/_US0@GP&!$W`5J>$,G]O6VB+M,H8J_T M8Q<%?V`478?>%?V>%?3)AK9-ZOX;Y@36?VR8I5R.7]*T1"FZI(GOZ+[RKH$TXKB,BR7I- MPGE"W._S%:(*_RY-V`;*C`H^Q8!)'9&?ZYT9WI`HH6^?T_VF.G'5"+#Y"M:5RTIT;!N2/R-!"DU3*(<)O[WYHSK MALC?<1#\5TA^A'.,8A)B[S:.4QQQB96,;YOHAPBQ]3O?K1])4$%DY>]UB5J@ M^#$SK=/862*TR2K`\H$&B=X#.GGRI717C35(^@-Z#$X5FGB0B-CR M\6@2N:](1,_8O[ZFIW+ZRP+3G<:;YN_@GBFS,U)&"'UA=B[^JQN0&'N_ODZB M]$`%BMRS0]?S!Q4CWFP0V]\<=^4'WG[V(B)KE:,.@8%"7SEH0"0\5J'`%V?K MP*ADE2BK53`N[P:"BUQ(.+K:.@DYYY-`S4/KI$*"A?"$!P;C_=#!$%B08!!^ M'CH(,$\9&(\/0\=#>MP%0_'1#B@@/@HP)O]N!R;"&[ON$&V."M44!L`H[&X.U14$`)CL?@35)@+!".R.#M4T&D M^8C"W]Z<@4`?^%UG%H1+PI@$OL=R6)Q'%+"<#B=>89S$CIN;2,XF^UY.&J+4 M\]FX'(`53GSZ-0^LR3,E-+ZLFVP*[03#,B[T^&-+>_4]BNZB3"B]WU"08KH" ML^V;XZ15F-F]F_G,!)FDR8I$_I_8D[/#F]$#-C+S$LS"\]$]()\?T%:9TCTC M]_MMI,Y"49MLFCG@+&#ZE9XE.S MFL1^9B<_LH"`F\C8`$P=X]]C_+OA"0@B96,HG(?"&`H?0^%C*%SD3&EBBELG M*PH(B>WZEQ$MKV5>OXP8NNH9ZF5$TFL[R%Y&=%W9X?8R`NQ*3KR7$697]PEV M&A4)28*==T[L+T-J:+J(U5.Z+DE#EBGB;$C@NSY6"'RH/:^;V$8=FAH5C$Z6 M$_06O'\\*-$1#5,[RG)=?SJ?\UY[]J..%)`@HU!$*;DAT2=>H+^!;.E@+ M0=F7I>!^VY#P.OV"HN^8_66RV41DBP(1>4I3=1";!=?-T>LDG2#Q2`RE?Z?*-'\C!N7+0MS''_Z8[NYS%.#L M9?0]E*,'_ M9')&E2-=CW'E]V_X%`/Q>TRU"S/[Z'YPM[C"&^:;%[(&F&$B#2%T,:OZR%2E M'W^_H%;`:DV5J3`,"9W6!X9V!]H$H3#HM%XPQ!)EU7@YG=$#-AA):C)V/L,$ M&_1\AR-Z?$]VK&!,^!GX0PT0GL8)6>/H#%6QSH+-ZIZ=J\)Q4Q@^I6U#LCC@ M$_O&E'"QJ$PUP5A$#;K$WV)V$F:G)`!#\BDF&;D-Z7$OR\EFRT$HZ\U>'>'`?B!=J*=GP[AGX@I[\=;H6"D[E&`.D^J&\8VQ)R18,-)$LBSQ4C>YB^8XVOJNR"X2#35&.',!%/3$PG4H'=\] M"S.FDP6`G_UNB$2A-%>,,$`FWJ01W>/B8V#B]&PE%`[E^298I":(SSS2ERA> M42EF_[G^5THMQX"YPJK_*I*NQ@\<"@AB^=7P2`.)T)2,N#C)%9IMZH?BE0J: M,]8WU&'A&."?'.+[]T5X_W"(X/&C-'DLWAAK'&K5.+1#+/.XW"U*OB0!SL*Q M]I1GJ"8!C)49)RC`W6&V8`+BF"CGX5B7>W\F,M+P]M`E1,0@4^'X"^'_4KS\`0#:4IL\`;J98-:HOP*/!- M.BDQLL6\KP5L#RK<[,$?YFROD4,)AF@H#=FY6A&2E&F+)I3P6D)%FMD'7T,] MQP1R1@>6&-DB)A"&R_BHU,W`Y:;GRK>6W`C*["P6GFJNRR<9>#[7T/=N21A4 M7'L]=.;!QSG%##E;<('OS[!:#&M"<*(X`C=MVQ:ID'G$%.L";(%%%E!HF!%O M#TSJ^[%:QP-;D)(&)/8#&_7ML$4GJSH?X#7.MJ0_Z,U7TE?=8MS%W5JKL1X:@:.H.I&MB<,V+A6^IP.&]8":6G6J#9=IG%"__ZS MH%,M9XR&CH-7V,T>R?KI\0G@C])`PC7]DF2'<=[AO#AKW0D&C-;OW,NY/S*01.T4#<;_0][S_2]S#QOD;NBETO_(U* M>G"3!L'NMXP,/J$UIFLB^N/;1D0K3M=$-$L[FJ>NB^-XD09%"@@5P[O%/'=? MNU?4J@[()LM,\`,ZA80B0='V4`,M4G^@*+O76U!'6SG&(*G":GW.*$/D2CK_ M58XQV;+L;G%9LK]FF-7!>)[;*]1-9G0--3!][!S1(V3#:B M>V:&YA:#L.^(=/S8`DU$ZG!:H,%L.>!H`^330XRD86_5$'.$BON=50X:FYP- MM\F9#8V2#O9%V0(I1P8O=FB@)1$R;1V!Z0_KN?K+(3"?-#K?S-`ZE*[),Q!7M*]^PRSP0KS^!_GXH1 MQL@48EXY9NSB-7;QDOM2;`&AFD52QUUM2W8)H":;>X2R12PJ.230D)DMDB!$ M02F2:0LB8G6A'G^S)>.*BXN2I\@6-.0:E&LBVJ)`JQ@D36.KMN3'2E<+T-UN MBU:5"4NMF+8MRD0&CL8HN2WK"WBRJ8Z_VZ*!JUDDH,0\6Q2+&`-9;B`8A<$W MXP-X%&U9%F)6B6(F(AB5P??G>]$-2S4T[.RYIFR]8>O@&Q&.3>=CI6ZZDG8MIAPBI6Z6@L+NB_A_=EQV04CCR3*^FPX*/07=%VK6W,ZF_)HO M[B`-16J3^?WL8C*[FE3W?GU&AGBH#F(\SV>?&`4EUWP1-Q;0!9ZE@42VSN50 M\4=I(.%R/IWZ:U]8\<@;H^'UGR*,P\N(Q/$EB38D[Y["IP0P7$?Q,LHE@'4> M\I,T86V;@@!'RQU;-^$"L_9+:4S5.::?1E1JW>1!+Z,*^]OI-0O/"IFK[V!H M]L+Y%6:=V;)UO?B,49"PQD:?TS4*]WWM!!0ISS90P%FO?]AIB6>3+F1=LGM9 MWGI+5%<89QQ6:SS!!)O\?H1G_,AN?1IL.:SMC7^.Q!07/>H$T?-+SF;V/9X%C] M-E:_:2HA$S6@/2T4$S:K'8N7QN*EUG9#6\#3"PUI>`"U)9PYWG&J?,>IS']H MBVC`T%!U\-H2UP6B`W'+VR(P[6AH#4Y?6V1NO*`FYXJ7?/%]:87]V'_.J>6SU]N=BJY\4Z4FVL)5!JB^;1 MKJY;C"G88B^,6:ICEFH+6:JULR&ZSTC]X$1DAX)DYZQ)B!/_SSHWRH@?TF$6 M*8201OFAERF5T-"M;A$H&*$CS;!X,+M8]FA/"%(.`>,UD/6/^]DLQWR>/DZG MEWR"Q"-UD((V*/P#"Y(?JT>\C#3!^Q6:?9EDK^0#Q!VD@8#BXW\IK4P^(=+! M[1#$RW,#CZ\;DXZQ^].2;-]XV&R1Q+DLO M4<6[3KW[O,[\=KQNR1#@#'1#D&8$L4G2\R4D?DT"5$Q&`K.\K@ M@_OR(^K090+$*5&+N=B2G@1(K>:ZN&V1BTH."2!:"@9@[*?;?QM>Z)`B8M"Y_18'-4Y?EC!L:8 M@=&"]W$H8(P.N/%P-Q[NVBY2K;DK=7K8B_UER&Z&1O3?*'?#^N'2V9#`=WT< M'_X!/_JI/K&;@V`]JIK==.*Z5`Z]ZR=VAPZ.[]D;=L+R-]@,'96N)&27J.?M MBNX67U#T'6>.80"1JG-;*\R%T*HR40.A5SAV(W^3(\-N3T+A#D"FPC0-1-ZR MT`>.DT+,LJ85N<:J+BE5]P4M$C^' M?(*!BD@4LPXJ[#]LM]RB@!U@Q%)8:VY?6)O1E1/Y+KM534"^$L=JCS0`!%5N M$5Y199'%).F.C7.2@)]9<;H)!DN[(]L5+ZDR]+/]D1]FMA3!>@+.Z9R>7^0?T!.-#-MP$`PD*ESX]9D_B&"MXG-5\3/<,E[+P8&M)/L$$$U6-&HO3JW#_49AI@BVZI:28(D[H215N MLH'GC1'O.BP<;LDNWZ.=W^*0==EG9C\U8-AE]>*S7H,GC8'^,=#?HT#_MQC? M+:[CQ%]3>G@`5P^R+&2OQ=$X!O-Y*(S!_#&8/P;SP<%\X`G+EK4C.P^?-VB1 M1DIL@0;`+ZD;MK1%Q<`P4G>,@_'I>5<1-7R:^4#`F/6\K8:B3*G'.VUI.J$# MJ#IA4EN:,JCA!_3UV]*L0`T#8YG572=5"`Z652:X8B`(CI)51K=R#!".DU4V=^-P%1PW M*VQM?:G4<."LL,/KYOC#8;+*(%?*:H1C9)5A+HH]PB&QQPRO5^T#=V1:99"# M4[GA^%AEDS=+K^RT+C)K'/-.&I%/,N?/GDY@7QS5QW;8*J<>:8S>-Z!D$QZSKVA>4%/_O!OG1;RA(<1;7%==1ZGFDAO*TN;O"7AK0 M/:7D*[RA2ZAT@2T)8SE+C1ZDF9'LK-B8"[6GM%0J6$OH9?6"#592IT6#W%4B MRQM5F#EFCM9B8;],#C[T_)23")=8W>ECCNB8(]JC'%&0C/=%DFL0"RM;&5;V MD.:]<,QKY:$PYK6.>:UC7BLXKU6L>6U9,IS-D#2PV&U9-7QH]'L*;$G?E&"F MP15A2]*F?.'5.XO9DJNI($EUW$'=>X3?YZW$'UEPVW%+T>UZGF#HXSKT`*N1 MU,CSRSTO0&D`.>+4&!H]534]5=5)'Q,W\;?LVATUOU6=A_6#^7NTRRZ2^8$B M+^O_F:>]Q,QXR)F(XW2]D?O+VWW)Z/(;77ZCRV]T^;7F\@/ONJ.K;W3UC:Z^ MT=4WNOJT>QSJ6]&V+*1Z:.DRK_N8L.;A!/E!["24Y!0%BOZ*VL_O50J;D,9F MN6S[]//G%WH_RTVK'J(AOVFRQ1%:XG7NM-[=D.B>1,F"`UG_N)\5-X+.T\?I]))/D'BD!E*F)%Q2B5D?5W\1"MM]\4-_G:ZKJ)). MTKKFOD#6>RS4'(J/:(7\3?'N^8IJW(=GZ(E(%DS32Z9/$4A(B`N;Z`MZXGU^ MSE"MY+#[DZJNN;O*=_2'YQMZF3JUF1I(G4WN;W^;7/`7<>4`'2_&RS1@TZER MV&RH>!2Q-:;\48@\'[$BS.MO9WHV9IL^*US)JX#_Q-X,L26PNZ,[+"M+9/U2 M]FN%RAL)MA+%:9@4+6#F!--3!4L/*$5Q'\@%/I+W^PJ'#RM\_#5"84R/1;+'OT,]V6._/B\RG)=F^\;#/CE$?V#\8>1]*CF[ZIW]>4Z,L MV56&(WD_MTW2%"]1D+^X(@PC&&&@M&+-]->?1='D\P)N3L!`-,5DH_L)A=/S M@Y05[!_E\?K)#5)Z2L[S-=:;-"D(/ZTQIFRE9Z:,UF<;!2>B.GA9W+0;>E]) MB(Y_R?0S[9;TAT.R'X\IZ'R3HGE6BWQ!C["K-;6TA#DFT&E]8&AWH$T0 MEH=.ZP5##Y0(-5Y.9_2`#:J>V1_0$K^#\E&:TJLUP]!56R[G,TRPD;)F,AL4 M);NO:"V6*/Y0`X2G]!BPQM$9JN(]!C:K>W;V#7R*8\W$\[*##^];\(:;7!&G M-)7L$K&J@D_L&U/"]:XRU01C$3VN,FN:.=59%PX`0_(I)AGY1.FX"X__7\K& MZ02SJV=/Q6T8)U'*Y(0I)N&ZD4\QR+5.0R2T289*()@0@U3.<8`J7F05DQJU9CN2?U* M0J]0!M@3$BP8V3W9]Q%Q,?:R(K>I[S*=<(-QG$<9SB(`P%EF+T$E7NHF=]$< M1UM*FF`+$@TU1CA3<04]L7`'DH[OGH49LT8$@)_];HA$X?*L&&&`S)-+9]A" MF[ANNF:Q:^S=)2OF6SCK)EZ4\>91Z`N\H';B`WKB,:KS'2:7_`QOTHB:PO$Q M$>K4AR1<2- M'S@4$,0*6\,C30"1=Q?@,I7_;%)@V:DE+@@IK(VI'XIW3]"9]+6![T#_"'OQA MSO;]>(7$=S!$/;\76:X5(9GTMFA"":_E>WUE6;;P-=1S3"!G=&"-KBUB`F&X MC(]*M29<;GJN?&O)C:!.W6+AJ>:Z?)*!IST-?>^6A$'%G7B&SCSX.*>82&8+ M+O#]&59`9TT(3A1'X%8MNAD5><#O"V%+>D/>O.5]-5IV+)>58^IT,9.]JQ0%?FIY6R[WL(C M[XD#!D4YY:QWH,`:DX,!4MK;MY>-U#O4-/44:"\?9["(U89(.3C? M.XATW.K38JBZGWCIN3^MQ4AM/V&K<1-3BT???F*D?",8'"%[C&_%_FYPB.PQ MP'D-6N!8#-_NYGG<>%W"X=A88H(#[Y^#XV*/D2UI1`N'Q!XK&MZ@&H[.\`WH ML2_^>5Z911?7#+-8-=4@+``2NRCX`Z-*%KNG0NLMJ.V1STB].;\2 MI*.W#@DDDG8L6?NW#@BD!_IN`Z*4O79(,/T@!D#Z0=J!B&VJ]T7^[7V`0OY& M`YRB@;C;S$:E&D9,D&"8!B+HI]IS?.5']+.0J+I1,W"T%I)4VGT^)T^I4:@& M4E/&^]WBX"**T80:Y_C\T@W9<*UBOW_/_&!+EI<@DZ/3MK+0:5K)/![*[A;T M36L29F_.=$I\@9=^R(ZW593"9G9'['7HU:$TG]8:F7,4(-8J8*_%2N\O?)@R MBN5/T$I\]6Y2ROV\V+$AF6@6SMALAREH."Y M2&A\AUX`V$J\VV1QFDGH'3,X\B7*W<=5YFD@LX3"@D1KNCOGAJ/`T@!.T4`< M$];W'XL/=(W<%3-$OU&+*[A)@V#W6T8&G]`:TS41_?%M(Z(5IVLBFK5$FJ>N MB^-XD09%>YK,FSW/2VO=*VH.!6231=H.=I*8%2T/[;[?_R3(WD977:6V%=\! M"9ML\N:13`,RG2^XQJ!RC$%2A?>)<$89(O>T>J:*V.H&(5V26L=?\$`2%)PZ M#>C9[@^<'-T%'+9;>Y_)E?3,)Y%OV\+[>Z3CNV=AO*^TE>LF0085<+0!\@,4 MGM;,G])<,<0*[/"L'&;B4;+S`4Q.9-EPX5O<@G_W/LX/\.Q[7&E]A]*:\ MNGS(G$&Z<9.];Y`@/N=FDB8K$@GL/.WOL0&T+?(#5DUQ0W*'6\O8G;YND!`6 M7K",@?@VS/70IXC$W!L.];_)'N!^Q_YRQ0Y6>8[9P>U[*+_O!%0I%;T&/!;N ME]F1/O1`%FF;KS($G-P3CZM=\86=,6.2$7-=_JV^R[C4U6&H6IY0-/V;J M_F1UY9EE655_WE`I10$K5Q.:B]U28A3X\<;?\<9?/K'$_7X;QRD]**;1X1A4 M9`?P,I'X7Z+6TTRNC@<_R;O0>/[6]^AZ%5UY+!K;`])_]Y/5#`>9.HM7_N:! M7%>TT)4Q!7M*]^P6>YK@^U2,,$:F$//*,2)2A]4">[PS6T.+-4'XS!80JEDD M=1(P;.GE"+@!C1N/L$4L*CG<2X4T&=D621"BH)0C;@LB8G6AGE%F2W]3+BY* M85=;T)!K4*Z9:(L"K6*0-,T6;*]Y9,]6"S!WQ1:M*A.66EF:MB@3&3@:\SYM M65_`DTUURJ4M&KB:Q4/_`V$MNRV*18R!K)P>C()R+["^+0>`5]&692%FE1P\ M1[`:3S`JRBW2^B8BG(0Y6\1">*V5(-'5%DTIYI^?DPSF7[D/7M\6P'C%>P4F MFN\$[+DIWO+==SWGGFM,G0UH)`,]-Z:D9_?V\XULV7.DIIB6^+`MAUJ.'P`0 MS[5%`?'"$9#:$S`&RGUI>VNG3,=[L?8ZNU:9<'MJMG=`U>U\TYYFZ1U$9Z[Y MMFMKV]NW>H=M3SH_MF>BOC3$.6WLVO.6O4B`JYHIMN>/>8D05W7U;,^2?)$( M-^EZ;\^%"9V4VH!QM>>JA3;+LN'G`WM.4AW4?<)AM>SN3AH/ MP@&UY)3564]+.++#/TWUJ*H3#OOPSU@]J9N'0S[\,Y?N[AG!96DC=7$PN=KO4YC$H94=*?TK6&,;S`6W)+#&=HN.7DN/HB+<%;XR.UY?5XT$$CVMKSW=5IT/U!VC]>+PW M_T_*O,2U":^8W@'9-P9-9)K>71Z(%:6?LVN1!<[7?ZHXX7SJ_P!D5)=JQ=?,;T M@S%Y_IRN45AD[XDN&U2>;>#.KU(5':7M*]UOCG]YH/^*DV>\$]DBZ.PK$&/QBF'`=$4D\UYR[O%T;40Y\1Q;^:0S#+) MT`QO"E]UZ4SX7'B$C6.5YYM@L6HS+RW[P^F.%'WIZ,YPQYR\\<5.]]$$J"^;!$Q,:M[D9$%)&T1#1@:JHD`[;4YZ"4Z MD/0-6P2F'0VM(19BB\S)E;7<=66+KA9RNI<=<>H&&(J>=[."J2)P@!@,2\^[ MRP$UM#C/SQ;5T9+U7!UYL65AC8U,^]#(M.=6CVPC:NCK!\/4\Z[84FVL):)H MB^;1KJY;C"O88B^,[2!5BZ9$B9WMJ?>^8J&<(=R>;3DDB(#)ZNUI]F&!!4B0 M;T\A]PZJ.ADO[5E4O8-'6XXF&+/AM^5HH0X`C-[P^V\TJ$$!HS3\3AHU4]O` M"%G2/`-80@(W-2VQNP4)Y'`L++&[@74]<%PL,;:!!;QP7"RQJX%UUG!:%2OXCM!TU2CH@Q/E MAIFSIO9(XO^9O:IA"R"UAW;8W*<.88W:]ERF5'9#=U=92"`8H:/#0?'@S]A; M'M63H&4(8+P&LFY9])!:O^S;1MO*QA4G0[069?[C?E:<1.;IXW1ZR<=#/%(' M*6B#PC^PH#]"]0@=/0AR`S)O],:Z%P8!72<1"F;X7ZD?L8L:[DE<65\+G*JW M1\&`2OO+32%1%.W8E7T95K?A]9.+X_AN<>@D_*Z*9+4GZ*VP7Z'9EPG#3%`G MS!VDI<3?W](O=!\@%^?9[7,<^B2:8S>EHI6]M)(FP#S-)?RYL%-S$/O+\)GN MI!_PBJV*2O1`$S63NL5ANK]VA>UWA5J;A-[!$?%\T)\4,LQI1E#S86VP%*E1 M(>!'\4EM-%[X4C)(^(M/.E@#0:5\%79W3^6".QW3O*`YQNY/2[)]XV&?V7`? MV#\8<1]*E6ST3_^\KKCHM:",]W/;)$WQ$@7YBRM*Z@0C##10<%VVD\291IP2 M^A&IH!?;8[@\1H[BBUV)9K;-'[.^)`72;;S"1.N%O5TS"2*,O!TS:K`W65+# M>%F^#8"#`GB^R58`^]U'U%>B8DCWA%[AQX354D2II&Z5/]`TT?M#S8Q^_,P, M+=U*`V)&]`"30O2<2FG["-EP$PQDUJ._/53(23L=0*:89(1:ERSL3X\+*Y8C MR43F]*P!FV16L/:4'>5EYL??A^UI^4N/*&WZJLP\^`*QW04TV23F!V`J'E0&L#!0O-;G-`@8B7[)T\U+]M` M0@6D,+-[MK+4:W8CAI_D&?'\!2L::IYPX2<0#S;0J.H8H2JGZ&2>A=OL(CSF M2*):8TO/N6=NE)I/,:EOQGX]AHD>^_4,LCAN;'JCH:RF/2^'+1BV@A!1",[9 M4JPI%T:9U\,6D1+P26#1J?;*E_HG$]"CL#W2`>"8*&<[V%*>RQ<9:81BZ!(B M8K"5'67P5"'A6R1BTH."2`QJ[VRP[X)@+0]"(E<`6K) M!K9@(C-E52)78$R4JY9Z:\5P0BOM[>*]JU9JG+S6WDKJ'58:-ZC5KSE/OVO%?]!$Z6H]Z>MZ:?>$C*ZMKS6_03CCHU0^U91;W#J'D2 M,ABLX9=YUTNF!0,T_-9(FM++X/;E\(WQ^N6"<)2&;X9WE18,QW3XQGKSM',X M6I88Z36KXH\X==7OXZ,3LSY`*Q)0_&.'49?L&K;[4'IFA]T^:M#5J-G'7@CV M;I*[!95KUF@I\MW*1A?""2^U@\(,,V\D,P/`.$JFC$GJ8Y+ZF*0^K-CSF*3> MLP2-H8`QYBB,\2\MICS(E'AI`2]%2ZO3\XU+PI@$OL?.],XC"EAK6"=>84R/ M\VYVADV<3=:!T4E#E'KLBD7X2:?)T[LY\S2GL%FKPV,#?1*6RZ!-:X-8YQ=8\C^2SG7;M$;O=Q/3Z&\%D:2;R/B)>ZR1P)/Z]\ M='_['UWLCO_6U.](]$AS0-RC'2,H]_&=MGR##39'_!'0KSB!L2":8H01NI=[ M4Q\]^D$6\9!R(1YOA(5TG3)OI[?/*Z.[VHHJR9E M>[L\END(T5!SA,\H%9?TOWXB7260*289R0Y#I>N")08]?&+?F)+T+(1/-A96ZI8IGRR!8,-=2$ M,3\W216I<*R!%HS["(_44!6,-$+V!OG>WK4=>B58Q0*O,-,$6V2#HV1W'Z`P MH;0Q=9+=>1H6O,I)MA-*-S8NT81 M"Y'&):)'7SBF,#VXA+8[A:'!*A[$F?N9(E%I3)US,PSGYG7%K'` MLT6_3A/*YX<^GA@>(N3A\Y!C9:Q<:8X]"9ZUE-68X7F"@K[D`ULPTX((J9&A M9$O&J"X`:^@U6R"$=.=5BS'8LCH5^"8U,]QL$:(&4,DR[MIK/-.W=3960%1@ MHKD"HN="HGL_D[O8;$%.30/5CS.WU]&IM^J(XV"R3A>=\UD^O`@2^6Q!@L-C MN=F>NE/;%A-'#DXCW[\M>E@.4Z/,3%O4+P`FW_0@QX2?%@/&H.>W M&<@Q4`YC@Z'I>8]_.33RY%0P%CWO%`Q0'QH$0KG7W19'CZ3K2F!].PX_,QX, MF7+WN[[)#3RK!&[8*9N]/9.CFA6V<(`&;_H"!"E(&8L&15K+;L?#"#\Z69F&I2 M(RWDL<6B5(-%7(AOSP)2LJLAS6!LL1:5CQSUV__88CBJ0:9:,]2>X6C`5:0& ME;S`H46+L>_@J%:6'Z'JNJ7GX<^Q0Q:.B^*5LPC(C[AQ-T_X@PTT\E0EKE$/ M3Y%#_C*[R"B^#>\VF/T0+@N';5AV%>V)"<0]*A6?ZH3_\9S+;EN^_4\:YS>E M/A!VPU[H^EGFP'%C>B`L+^4^(EN?0G^Q^T87>)FEPX5&LM9F+;[*`'!K$B7^ MG]GG/E3WA,LLE,P#`##%PL9:S@>;F?O8-^;NLR[(=$U%&,7X"N?_5>*Q^A$F M"R>O,-V$7#];.O3?`0[R;7@2R>%P!9[7!Y9.7'5@ MED[FF6P_6$7<_NXU8=]1^42C^_\Y>2=A'U'/*?G4?GVR?3K@N2D'FM.S#W4P MBPI?B\3\4G]`'Y@LLA?WFJ`RBQ',,.1A/?O(I;I<,)NE.;WCIISQKL!0>9I1 MGEA.=<41Y6#,@T]#]1_49Z8O24@52DK_5B@7>MIO#$#50TT:HQS**Z[XK2<# M@`?UF>GF,@!\:`]EH,)5T1P.X$,-PW'TXO"Y.Q]CF-1)0C>6QS3)*E[)#&_8 MF3!<7E-TI;UYZC_(0+O`XFKR!S)QLSM[Q2GN'(X5GV)THSZCM>@;(#NO2>>9 MY:ITK_QM'*?L&BQV(_,A(,WC"CK/+$M,AJ@Y_@4E3(QV=PN^@`$8K?$TP^RS M+W&WR;3Y]1..7#\^1D!$C(KF]8`E5AL"^F!G@\>6D'586*$(7]"3D\=2#>@1 M5^0>%0\>^UFJ]K-D!MP-BV'"^UARIXS]*\WWKQQJGA]`NL:&@SP4QH9*K354 MZGTFZ-CF1LHGT7<(M@6M!CCPT+1\@0G%JOU<(5L$KU6DGE60J*91V"*Q72$, M.8G94ES0%:;PE+L6:A-^R9$-\9(ENW;<;Z`C@&NDM]@BP["=K&[:10O[DTEY MK`&#$$11CD,+&X]-T(DRFEI8FS9!5RN!R+*=I1ZF;=5*V%(?IUM2A=G`[97+ M&6G$I5]!RM)8VRNILP)`2=YV>PT9#!0D-L-.;\://?750-=CH^PYRRSL!G"4 M6SXHI[]89FWK@5$YA]DRP[LE853,-[-%'VI"4T=J5'OVMH&]6P^N>I.8;3G0 M--K#P540MD1Q&N#`6>&`+$];`C3ZP0,D5-KBQ6X)O(HLSO9VX_YL'8JPZ:V! M>@E[LR+`3?H;M."F.AT%@H-!8*@2HZ M--HDULE0)7(M'L)L<5YK!!!PPK/*@=UTU1IMG5[8-?[^>N?:WB;N$SKU(TFH M:.0A$IB%W-<"?082LKMM-5B0/F5&C/ZO:*MH'TB>*9!MD1= M6(]#3#HR#G3\3J+O+%.>N#A6^P+RF:-+8G1)C"Z)(1P.ZN\=H[-A=#:,SH;1 MV=#DV*)L4E@G*#!XH#9O>_Z"WIY\179U]V?=]W0')>YWNFU2Q<>*,9Q-@$(' M'7),:IZ`E9_;X;FX)FV-3LO5/3@F4<2*4QEI%[OCD*(\8?(#15Z1+/J)#DQB MJG&RG*3LE_C@0ZDZ7K?ZPIJM:D78/,I)?>20>D.B!?:3-,+*`'7RUC;3.)1E M&>2"J;E"QO.S&@MUEVA^Q^1M&-.=+`NL9ET"'E8H?"Z;+&TPETP>*-U38!/, MSW5DYQ@_?[W1]N&UF?R:KA]Q=+?(?HW+48&,.]V82EYG\D9!6R`T>&]A4YNG MJ,AA[/R._>6*JJ_)%D=HB?>U.O>1[W(];]V\?<@`EVRF2>.T//#9;ZIM(37V7L&N<*M[3BM$#!#LYQN`":35*1C3$\;TA%KI"6T12]SO MK)4%]JZR],QH/`IXUAA5&U>U/'I,UQF2-,5EC.,D:QCI/P(+N M73F,VQ,U6P&&GM';RQ1Y.R9:R;QNI>5G,^8V'G%CHO]5>H M#:0!M=>+R2HQ!OCQP4@JMS(?)))M^:/`,/_%`H6@T64!QNV743R;.:;A)XJA MG.HEFU6'*9EP;(?18KZ;;4L]F0*.\Z#;`O0P=P*.O')K`4/=,0W[>[@-,V7X M*A_<[,07FET`![9FDUQ+@:V91&BB\.A'09^#<@(=1$W2=O-P'981P[5)`@5K]YX+#._/C[383Q_G++KD`5O=<0I'5<%R)Y><#1 M^IT(RU9?.&;LC1E[+[ZA4`]LL3$5CH?"F`HWIL+U+Q6NMR[I#JP%Z^2K'6== MW4-">TEP+P9>_L&VA8RWEP*N_"S6J8/9I221P/=8!/9HT,4.66374D1X1?EE M]A:UO,@:._2#,'L,I1Y+'8/[A_6\IQOWKDY:&WEG+TE`UP-A(&HB+`;ZZ[P%@=DPZBK\IK6F-[]P>JRC.AM!FC6!.\!/7%.68(9)ILO7Y*8 M$I%U\9N3H\(Y([YRE!ERBY@Y19+;&/ITF&F$R[2B' M2W;WZ7[#\%VV$/T@3;AE<\!9W;/SB9Z9IE3WW84W)*)'__`RI?M\Z.ZN<.1O M,ZU3RC_^2I(K'--13*U.XL_86U*N2@,X[+?T%@-PX1!'**!?;N*M6=//)-?, MA7SRV(?-,M%LGFG>@P4E68R2T2;(S^VO_;Z8$\BE7C38'/%BT3D99;1Q#]VA M<]#84N;0^VR,R8VFN-Z;Z0T)R14CC1+.A+/"/OH61A@%_I_8^TR-#DKN4:D> M;Y.91'Y,?RKG.4LLL;9?USV`U=:Q>)F!YIA@98O#5&HE\889()CL4)#L)&!7 M#C)&;(&>F-B300:"5RC`<4'%OLTX+X0E&&J62B,\>PQGCW&LR'1*[&!;PL6 M7"Z)BFUKRQJ!H"$ZG-@2/!?AT"Q$UEX$W,!M3*J+1W@=T[!7#DRGPD)+MNA6 M*;\:K:!*A-,J5CX](74K%Q0+%MP?")AAHE@F MVK"X%K["C\D19#$CD#DFLMWW"O^!OEN0V<4?:)KH2PKJDD3^GYE9(_P($EC M>N.8WBB@>TQO5";VV_P3V>(HS)+QECATJ?93T)^JT^U):&S9G!_S(,\\]N*= MSA8D!'R2INO.EFP$&$8*MITM>0A`8*#6NRWR,F99]R'+NN/BM6TYUA:B.%]D63=T>>`)_S(ZD7NPL_H*]?,H6=]'0[@DO8^/5#'6>3_&8,<8[!B#;24&&S["=;]X\,N)KP(-P#&.>GJR MUVI)VH*;-E2(BI5FG;]7A]0IFN@O4`+A")&&K@!;!+2-Y0W9B%\@?NK""7;K MV1+\:15-B%/2ED!0JT"*_=ZVR.*8&M.'U)B>"TD;VZ>*I\R6V&M;^JJV/]66 MC:#/V4D4_QAW6]D-;9,)\/,:#_#GQK6>Z'[UL\R%]D7T-(WK"P/ZVL.^"ETE M]^>E2M+4'U,O,#$F)(P)"9"U6"<;0;2JNZV'/6[^7]%:%$$7#341K-RD=+VC M&$^6=(4QH$$E`1A%>>;8+%2"9[^;#+J6N.^%Z-!XF8WOO2%]+T>I"1)KC$" MSAK#]6.X7D"WU>'Z87FA=!@98[C[!`6Y96,+%D).QT"@`D@O+B`%0N4E!99` M@'#\*+8LE3$RU(?(4,\C&K*%TO!(;HN"'>,3->(3D&-Z>\JVM["(72[6K1BP MB$A]('8M(2#G-:[]XCD?[5IK'-D550)``/L M%SU6[!<]5G5X"P`!!"4.```$.0$``.T=RW+C-O*^5?L/7%UV]L"1-8XGF:GQ MI.171BE[[)7L/$XIB(0D;"A``4C9RM=O`^!;I$12]`@NZV29Z$8_T6@`#?+3 MCT]SSUIB+@BCIYW>VZ..A:G#7$*GIYV'D=T?G0\&G1\_?_J7;?^$*>;(QZXU M7EGWLX"ZF%^P.;9^.QM>6[9U],/'WKN[&^OA_MQZ=]0[L7L]^^B];7_^]"3< MC\*9X3FR@!X5'\<.?SKMS'Q_\;';?7Q\?#LFS.$KX;]UV+PKD8\^'`,O&MIA M`?7Y*D9X&G/OK<#.VRE;=L-&B71L'_7LXUZ,%G`.PI3AA:T2\;LLHHM),0XT M%(#C)V=6#"];"A`(76+A%Z/HM@)I/$+_S*A,H3$^!=BCXZYL'B.!(W"*B".* M2:@F2:&7I4`9I<&\F(;K\ZZ_6N`N`-D`A3EQ8KSM2%D$09QBSJ"A@"_A+W@) M/+04(`3"GB*TB'$F2(P50V&#'B.J9\!2#7[B$^Q_Q7-L5@@ M!U<8])__^0_+4B&#S!>,^Q9=0]ZL9QUIKIF#?!75TIHN=(4N]GP1]V4G?;T% M+CK=F@RM>TMSAE1?31C:,@Y+.-J(!6P^\IL;(^XFW13B!C_9R?= M-.-G+3I7X25&4K^:\)`?QQ^ZTLI=BJ=R;JUF&X_S#%83VU2([_7R5%2>-$_=M)),V;RDU(51B(<^<-.D!O[2#K65S&*0I'_V1&>M,FQM$E3 M-10D)E4TD4(+?^]LD'P65H6-"$?^V#EPK*4=E5PB0E*_FCC%QC2F^1PCGS29 M8K;DE%5TDF#IGTVT4IQ`51PD$8(<'2=YDHA2YBM\]2QZNE@0.F'A(W@HTZJ/ M4?H]Q!-+)5H?$7=DA-ZAH/MBPS-8O6>8_XB#A.+Z055E97YYZ.C(\NV+D):Z9]] MZEJ7BJPU2,A^ZN9HK;$1".S>TL_J=VYDA,@AQ";$K/=5Q\M;N!@S?!J9M)JE M'48%\XBK/8"R>;'"IN$!:;0%.*+9C$)%O6FVO@"QSJ$*8VFQ2)F3WQV./S.T\1I;:\Y;L: MW@)\6%>2CX-S2)/!0A/;/5N0*243B+HR$W74!A:A4WL!6G0@5=_!)RH2:,L5 M3F1R2X0#<2G@&/[Y"O0ME>DD'%C]F`/K+N3@E;O`.QBOS%%J=%6DAWBZZ]IF M2\=MF?Q]HE7;NMCL(/GH3'C0`*F?[*GC,*^?O?K02/DE[;\H,?"OU`9A-#3=:Z29%]Y18^ MT8%\QCP7T=YVV_)_ZPWT:_#:F";L7PT]K[!HB"BTY9+])JN#:PW]XJ3U^X9I;E\ M2QZQM?^V/.%=[27#P06J#EH7^XAX,'CQDQ\@[_FC1)Y@6TYRW#Q<7&B6K'O- MTL%I)HAP>XF\`,O-0%A2J>&-Z$K8NC9';Q2.5ZH2,C+I[K[3D&Y;+I3?F(P] MZ`KXLGZ1?,E-2>!+!1O@Z]_"&B2,J7IWJ=3(HPZ>).MKW,"#"6*._(#+\_() MX^6F;W MZ#.;^V_+-=Z7NH:F+V/,,*%_<(#80'+`4I^!B5JS^7J7;9GY^S(S#R*2!\L6 M#SU03_!LXSK7>5O6_J'2H-;$#W;?NH)L>5E2G5!;_E"\F;EYS7I8AQ093=:N MR%++);87'J*PJ(3?Q"?M18CJA%KRCG='1=$B=@Y9%J,9L>Z`$5BT1HP<(D=L MLD=,IC-9N8*6F*,IMI&`.+^0!(5*];5-F7IBHT?$76%/.:(2QV[ M]ZUZ8O659-9/6C++9]9E))D^N(TDLY1D:HF4&QF'X;#[.7W;JE`RT[1+5B+3E$=_5JE-X51[Q MJ9N_^A@^R5Z15!=M,=R("Z)7X@23Y$V?!XK2CWI+QD8#?="Q]JTR_R.2C MR^:(T`$T2$DZE@;4ES'N%:`;<%W*U*W#_NAN>-8?7O2C"2,G1&GSWD1)6'<< M(.U>/LG%*1;JI&PEW??,`P>/)=@&M8,@?M1-^V9Q734HD)>:U'5&*G(6J@)I M@+'SF; MK3TVP$#0&?*N0=,P3*XPOD%/9![,8Y9+FYNK765&B*_RO(<7STX[#L?@W$4B MZ1=!^/4D@HEFDT1QLVD2E;M7,`V$+]]`D?.O]><&.-@2\@O)`XSA$?+P"#OR M8)%@$8;H`2RP859/AG\-A&.R'9ZM2H@F(AOUTGM_EZZRF)95!'5^KR_2]4F)%JH"+V_1*),,IW\W$Z^D.GLO_)U=/[J M!O$_L2IA3*Q9(FEU;`-3*'D$5;PV*6PQ;X5U/KJ^)G-Y)33+?L%S(YE?X]ID M=I-M4D93U2DY&;9![3]9RNSWQLN%9*T7^7TF.:B+M(^POI/T_X.L%KNU9"]& M>6&2UY#XA4L:35716UF?MBUZ M5&;40`4I5.-4L7EJ@K0:>9!XGJN^"V:E$@`3)B1UILW#?3>=/PZ)^+-DV[4& MO)$;L#*.PDH(8!X6C%X&6@"Y-EHL.%LB+V^\JN!&F%+)+#=2T_RGGAFX#C@/ M7Y1\H900\YU_:F!.&K+X!;M37+(AO`7&`)\I9+!L[%<$-G+@7\!Z0*I=OE8W M:Z3"EOV;Y@)/,.C;S:QJPN.NOA`XV0"I!&GJ7L\FYL]G"&*O&-#;A?RFAPR[ M2AQ(&ZX)&A,OLSO22D\O)_$H$'>)PQ0J[^`5(,T+L!';=YRY@>/+#4Y1+%@A MA`DC6#B<+'2F%%ZO*@FMU4#-#*SAZV%A*%VJE\,.TB^[#<7;#--\T`%/,)9W MME14^CG"?$DI.+^>WDB@@'>7+[/=+,7B@;NWGP?-J0DE]!V'M^O:*TBO5\_T,4O!OH^B(U&O5]"/[1GI6A$S3!=R9@2;DW8AL MGK8=;/_)6F23Y-SHBK.YMI^:2HMV+,^35QV&DN[:RXLQ_4\0$.@Y9P*\FR_" MU5;6[)M!S%MPQ-=[UCVXN&G_7AN52D6K?>E7>DUT12B8'9)C&7#*BFB;HQM1 M1!.Q+VO&>9+;K3]^,:/JY[MA>+%C%(ROK\^S7EC::MY8^AG!$O9WG!M&:T_W M/X*N&9V"N\R34J'HS2BYNM(J@`:<4MY4*0X2:Z5%]=$,DG41,CV:,:Z..A(; MY>7;#&J$3*H`NS^=<.#B19C.0:97.:]+-Y7O0Y$Y7=#8Z ME->FN$R)[YCP\W)N!S=78@+CQ@<:=VBE@T:F_KZ\V;0YJURB;)PL;S9-HM+) MZRO2A54#JAF$\=7W/,RG*WGOBTX@Q2'`ZKV&CE%M^& MS\FZ"<)$@7Q\S\+4%GGQ6P3".Y+WT7W02+B*T/O:OMXHIRAB7:1E*X5X0?+T M0Y3M>H<<;Z29^,JWQK0RR<'"W$[B>_2]&+1ZV(UF@Q@)EAH0IN,6R4+R_#+YJ!3 MY8UJ]U:48OJ5M5IAC4)(%&X.!\!1E^N&&UXF0A+T(2=1NH)$R;=R/VPYF[/[4$%/\*%DKG9,V0ABP M8QKM!8(_8C*EF2IE8/E";AJFG+D:SW#2RF&!!DYJ:0J,4-!MCDO25K.PC`^;/Z)L@MY/4G7DY'60N4HCBU[$T13:B?B3- MO+YZVD3LRIAFR!R?X:L4-0GO10W/FP55X[>PP++/N;S0(T'/5A)$[2N'&[)J MZ1IN]L2;SVJ?"S*\Z+Q*[U;&PC\WE;WEDW45J4'2,EX1+OQ?8'J7RQE%5+U' M2+TY^P*6.C5UV(B`"6&RJ7CA2QN5.&)`0PG5]DK\`J>==5B1R`Y'7\JUV]'B MVB'0]H&F17D(RZJ3#=^,XMKM=]^;Q!5%PFLRA;X`2]P)!H:EV2IXW7-3VI?K ME::5HQE@L"F!Y3E M7)15DH:>"M8]:%0UNK58/?O`VKW17XC1M\HB;?P"YZ;MAU1:JB' M_-;\@]';\@^C"[Q`W->G1%\PK.KD(#LH=SI6"\-`@9-94MW>I>'U MI[R46\',$TUFG^].PNG_$CDS>1GK@?K$NPH\;_6+$B@K9CT4,T4^.:HM6MFFG>\XO2WY8OV>L+.5745;6C%Z6= M+1]CWJZ5;1V\6&WDOU];3Q5KV"]'#S6^V+E%)W5Z>G'Z*?@,;<584J&#EZ2- M_7W#]\C:B[#@MCDM^K%)U37Z^&8ZT=\KDPG.',&__P=02P$"'@,4```` M"`"H@69'83AQ.;C[``".2@D`$0`8```````!````I($`````8F-R>"TR,#$U M,#DS,"YX;6Q55`4``^P7/59U>`L``00E#@``!#D!``!02P$"'@,4````"`"H M@69')V:0P?$(``!A<0``%0`8```````!````I($#_```8F-R>"TR,#$U,#DS M,%]C86PN>&UL550%``/L%SU6=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` MJ(%F1SK\V1Y-/```RI,$`!4`&````````0```*2!0P4!`&)C`Q0````( M`*B!9D`L``00E#@``!#D!``!02P$"'@,4```` M"`"H@69'E?@?<[8[``"%L`0`%0`8```````!````I($1E0$`8F-R>"TR,#$U M,#DS,%]P&UL550%``/L%SU6=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`J(%F1V9`G/,:$0``^;(``!$`&````````0```*2!%M$!`&)C'-D550%``/L%SU6=7@+``$$)0X```0Y`0``4$L%!@`````&``8` *&@(``'OB`0`````` ` end XML 49 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814

Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Operating activities

Net loss $ (24,884,000) $ (33,517,000)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

Depreciation and amortization 137,000 137,000

Stock-based compensation expense 7,773,000 6,550,000

Amortization of debt issuance costs 329,000 329,000

Change in fair value of foreign currency derivative 793,000 (732,000)

Changes in operating assets and liabilities:

Receivables 1,995,000 $ (1,123,000)

Inventory 683,000

Prepaid expenses and other assets 1,331,000 $ (29,000)

Deferred collaboration expense (117,000) 45,000

Accounts payable and accrued expenses 12,582,000 3,602,000

Interest payable (512,000) 957,000

Deferred revenue 1,602,000 (880,000)

Net cash provided by (used in) operating activities 1,712,000 (24,661,000)

Investing activities

Acquisitions of furniture and equipment (1,076,000) (41,000)

Change in restricted cash (1,472,000) 1,000

Purchases of investments (48,343,000) (15,852,000)

Sales and maturities of investments 35,874,000 29,000,000

Net cash (used in) provided by investing activities (15,017,000) 13,108,000

Financing activities

Sale of common stock, net 1,175,000 106,600,000

Exercise of stock options 3,861,000 4,636,000

Employee stock purchase plan sales 356,000 310,000

Net cash provided by financing activities 5,392,000 111,546,000

(Decrease) Increase in cash and cash equivalents (7,913,000) 99,993,000

Cash and cash equivalents at beginning of period 54,540,000 21,164,000

Cash and cash equivalents at end of period $ 46,627,000 $ 121,157,000

X

- Definition
Represents deferred collaboration expense.
+ References
No definition available.
+ Details

Name: bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 8

-Article 9

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the period in the carrying value of derivative instruments reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInDerivativeAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_IncreaseDecreaseInRestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetIncomeLossAttributableToReportingEntityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow to acquire debt securities classified as available-for-sale securities, because they are not classified as either held-to-maturity securities or trading securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireProductiveAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from the stock plan during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromStockPlans

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 50 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 5 - Stockholders' Equity
9 Months Ended

Sep. 30, 2015

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]
Note 5 — Stockholders’ Equity

On March 3, 2015, the Company filed a $150,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective upon filing and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale.

On November 6, 2013, the Company filed a $125,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. The Company has $10,000 remaining under this shelf registration statement.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 125 227 1 false 58 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.biocryst.com/20150930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.biocryst.com/20150930/role/statement-consolidated-balance-sheets-current-period-unaudited Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.biocryst.com/20150930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Sheet http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.biocryst.com/20150930/role/statement-consolidated-statements-of-cash-flows-unaudited Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Disclosure - Note 1 - Significant Accounting Policies Sheet http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies Note 1 - Significant Accounting Policies Notes 6 false false R7.htm 006 - Disclosure - Note 2 - Stock-Based Compensation Sheet http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation Note 2 - Stock-Based Compensation Notes 7 false false R8.htm 007 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts Sheet http://www.biocryst.com/20150930/role/statement-note-3-collaborative-and-other-research-and-development-contracts Note 3 - Collaborative and Other Research and Development Contracts Notes 8 false false R9.htm 008 - Disclosure - Note 4 - Royalty Monetization Sheet http://www.biocryst.com/20150930/role/statement-note-4-royalty-monetization Note 4 - Royalty Monetization Notes 9 false false R10.htm 009 - Disclosure - Note 5 - Stockholders' Equity Sheet http://www.biocryst.com/20150930/role/statement-note-5-stockholders-equity Note 5 - Stockholders' Equity Notes 10 false false R11.htm 010 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.biocryst.com/20150930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies 11 false false R12.htm 011 - Disclosure - Note 1 - Significant Accounting Policies (Tables) Sheet http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies-tables Note 1 - Significant Accounting Policies (Tables) Tables http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies 12 false false R13.htm 012 - Disclosure - Note 2 - Stock-Based Compensation (Tables) Sheet http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation-tables Note 2 - Stock-Based Compensation (Tables) Tables http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation 13 false false R14.htm 013 - Disclosure - Note 1 - Significant Accounting Policies (Details Textual) Sheet http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies-details-textual Note 1 - Significant Accounting Policies (Details Textual) Details http://www.biocryst.com/20150930/role/statement-note-1-significant-accounting-policies-tables 14 false false R15.htm 014 - Statement - Note 1 - Fair Value of the Company's Investments by Type (Details) Sheet http://www.biocryst.com/20150930/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details Note 1 - Fair Value of the Company's Investments by Type (Details) Details 15 false false R16.htm 015 - Statement - Note 1 - Scheduled Maturity for the Company's Investments (Details) Sheet http://www.biocryst.com/20150930/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details Note 1 - Scheduled Maturity for the Company's Investments (Details) Details 16 false false R17.htm 016 - Statement - Note 1 - Summary of Receivables (Details) Sheet http://www.biocryst.com/20150930/role/statement-note-1-summary-of-receivables-details Note 1 - Summary of Receivables (Details) Details 17 false false R18.htm 017 - Statement - Note 1 - Inventory (Details) Sheet http://www.biocryst.com/20150930/role/statement-note-1-inventory-details Note 1 - Inventory (Details) Details 18 false false R19.htm 018 - Statement - Note 1 - Summary of Revenues (Details) Sheet http://www.biocryst.com/20150930/role/statement-note-1-summary-of-revenues-details Note 1 - Summary of Revenues (Details) Details 19 false false R20.htm 019 - Disclosure - Note 2 - Stock-Based Compensation (Details Textual) Sheet http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation-details-textual Note 2 - Stock-Based Compensation (Details Textual) Details http://www.biocryst.com/20150930/role/statement-note-2-stockbased-compensation-tables 20 false false R21.htm 020 - Statement - Note 2 - Stock Incentive Plan Activities (Details) Sheet http://www.biocryst.com/20150930/role/statement-note-2-stock-incentive-plan-activities-details Note 2 - Stock Incentive Plan Activities (Details) Details 21 false false R22.htm 021 - Statement - Note 2 - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details) Sheet http://www.biocryst.com/20150930/role/statement-note-2-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-incentive-plan-details Note 2 - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details) Details 22 false false R23.htm 022 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts (Details Textual) Sheet http://www.biocryst.com/20150930/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual Note 3 - Collaborative and Other Research and Development Contracts (Details Textual) Details http://www.biocryst.com/20150930/role/statement-note-3-collaborative-and-other-research-and-development-contracts 23 false false R24.htm 023 - Disclosure - Note 4 - Royalty Monetization (Details Textual) Sheet http://www.biocryst.com/20150930/role/statement-note-4-royalty-monetization-details-textual Note 4 - Royalty Monetization (Details Textual) Details http://www.biocryst.com/20150930/role/statement-note-4-royalty-monetization 24 false false R25.htm 024 - Disclosure - Note 5 - Stockholders' Equity (Details Textual) Sheet http://www.biocryst.com/20150930/role/statement-note-5-stockholders-equity-details-textual Note 5 - Stockholders' Equity (Details Textual) Details http://www.biocryst.com/20150930/role/statement-note-5-stockholders-equity 25 false false All Reports Book All Reports In ''Consolidated Balance Sheets (Current Period Unaudited)'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Consolidated Statements of Cash Flows (Unaudited)'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. bcrx-20150930.xml bcrx-20150930_cal.xml bcrx-20150930_def.xml bcrx-20150930_lab.xml bcrx-20150930_pre.xml bcrx-20150930.xsd true true XML 52 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814

Note 2 - Stock-Based Compensation (Details Textual)
$ / shares in Units, shares in Thousands
1 Months Ended 9 Months Ended 12 Months Ended

Aug. 31, 2013

shares

Sep. 30, 2015

USD ($)

$ / shares

shares

Sep. 30, 2014

USD ($)

$ / shares

Dec. 31, 2014

shares

Unvested Performance Shares [Member] | Incentive Plan [Member]

Allocated Share-based Compensation Expense $ 0

Stock Options and Restricted Stock [Member] | Incentive Plan [Member] | Vest 50% Each Year Until Fully Vested [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 50.00%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 2 years

Stock Options and Restricted Stock [Member]

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized $ 14,839,000

Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year 1,782,000

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two 5,632,000

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three 4,627,000

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four 2,508,000

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Five $ 290,000

Performance Shares [Member] | Incentive Plan [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | August 2013 [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 75.00%

Number of Milestones Achieved 3

Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage 25.00%

Performance Shares [Member] | Incentive Plan [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | December 2014 [Member]

Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage 100.00%

Performance Shares [Member] | Incentive Plan [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares 1,032 1,250

Performance Shares [Member]

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized $ 11,982,000

Employee Stock Option [Member] | Incentive Plan [Member] | Vest 25% Each Year Until Fully Vested [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 25.00%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 4 years

Employee Stock Option [Member] | Incentive Plan [Member] | Non-employee Directors [Member]

Share-based Compensation Arrangement by Share-based Payment Award, First Vesting Period After Grant Date 1 year

Employee Stock Option [Member] | Incentive Plan [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term 5 years

Employee Stock Option [Member] | Incentive Plan [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term 10 years

Incentive Plan [Member]

Allocated Share-based Compensation Expense $ 7,553,000 $ 6,388,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares $ 8.15 $ 8.19

Employee Stock Purchase Plan [Member]

Allocated Share-based Compensation Expense $ 220,000 $ 162,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares 1,475

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares 497

Percentage of Salary to Purchase Common Stock, Maximum 15.00%

Percentage of Common Stock Shares, Beginning 85.00%

Percentage of Common Stock Shares, Ending 85.00%

Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee | shares 3

Shar-based Compensation Arrangement by Shar-based Payment Award, Maximum Number of Shares Per Employee, Amount $ 25,000

Stock Issued During Period, Shares, Employee Stock Purchase Plans | shares 41

Allocated Share-based Compensation Expense $ 7,773,000 $ 6,550,000

Number of Stock-based Compensation Plans 2

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares 917 2,362

X

- Definition
Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.
+ References
No definition available.
+ Details

Name: bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Employee service share based compensation nonvested awards compensation cost expected to be recognized year five.
+ References
No definition available.
+ Details

Name: bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.
+ References
No definition available.
+ Details

Name: bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.
+ References
No definition available.
+ Details

Name: bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.
+ References
No definition available.
+ Details

Name: bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the number of milestones achieved.
+ References
No definition available.
+ Details

Name: bcrx_NumberOfMilestonesaAchieved

Namespace Prefix: bcrx_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents number of stock based compensation plan.
+ References
No definition available.
+ Details

Name: bcrx_NumberOfStockbasedCompensationPlans

Namespace Prefix: bcrx_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents percentage of common stock shares beginning.
+ References
No definition available.
+ Details

Name: bcrx_PercentageOfCommonStockSharesBeginning

Namespace Prefix: bcrx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents percentage of common stock shares ending.
+ References
No definition available.
+ Details

Name: bcrx_PercentageOfCommonStockSharesEnding

Namespace Prefix: bcrx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents percentage of salary to purchase common stock maximum.
+ References
No definition available.
+ Details

Name: bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum

Namespace Prefix: bcrx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.
+ References
No definition available.
+ Details

Name: bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount

Namespace Prefix: bcrx_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Share based compensation arrangement by share based payment award first vesting period after grant date.
+ References
No definition available.
+ Details

Name: bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate

Namespace Prefix: bcrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the percentage of performance awards that remain unvested.
+ References
No definition available.
+ Details

Name: bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage

Namespace Prefix: bcrx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The highest quantity of shares an employee can purchase under the plan per period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of vesting of share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of an employee stock purchase plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=bcrx_UnvestedPerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=bcrx_IncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VestingAxis=bcrx_Vest50PercentEachYearUntilFullyVestedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardDateAxis=bcrx_August2013Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardDateAxis=bcrx_December2014Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

DELAWARE	62-1413174
(State of other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

4505 Emperor Blvd., Suite 200 Durham, North Carolina	27703
(Address of principal executive offices)	(Zip Code)

		Page No.
Part I. Financial Information
Item 1. Financial Statements:		3
	Consolidated Balance Sheets — September 30, 2015 and December 31, 2014	3
	Consolidated Statements of Comprehensive Loss — Three and Nine Months Ended September 30, 2015 and 2014	4
	Consolidated Statements of Cash Flows — Nine Months Ended September 30, 2015 and 2014	5
	Notes to Consolidated Financial Statements	6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		19
Item 3. Quantitative and Qualitative Disclosures About Market Risk		31
Item 4. Controls and Procedures		31
Part II. Other Information
Item 1A. Risk Factors		32
Item 6. Exhibits		47
Signatures		48
EX-10.1
EX-10.2
EX-10.3
EX-31.1
EX-31.2
EX-32.1
EX-32.2

	2015 (Unaudited)			2014 (Note 1)
Assets
Cash and cash equivalents	$	46,627		$	54,540
Restricted cash		1,622			150
Investments		23,700			18,232
Receivables from collaborations		7,495			3,849
Receivables from product sales		—			5,641
Inventory		—			683
Prepaid expenses and other current assets		4,970			6,172
Deferred collaboration expense		88			76

Total current assets		84,502			89,343
Investments		47,787			41,116
Furniture and equipment, net		1,146			207
Deferred collaboration expense		282			177
Other assets		5,239			6,031

Total assets	$	138,956		$	136,874

Liabilities and Stockholders’ Equity
Accounts payable	$	3,782		$	2,849
Accrued expenses		23,027			11,329
Interest payable		5,517			6,029
Deferred collaboration revenue		2,102			1,481
Deferred product sales revenue		16			5,605
Non-recourse notes payable		30,000			30,000

Total current liabilities		64,444			57,293
Deferred collaboration revenue		10,122			3,552
Deferred rent		345			394
Stockholders’ equity:
Preferred stock, $0.001 par value; shares authorized — 5,000; no shares issued and outstanding		—			—
Common stock, $0.01 par value: shares authorized — 200,000; shares issued and outstanding — 73,337 in 2015 and 71,955 in 2014		733			720
Additional paid-in capital		556,095			542,943
Accumulated other comprehensive loss		(1	)		(130	)
Accumulated deficit		(492,782	)		(467,898	)

Total stockholders’ equity		64,045			75,635

Total liabilities and stockholders’ equity	$	138,956		$	136,874

	Three Months						Nine Months
	2015			2014			2015			2014
Revenues
Product sales, net	$	5,699		$	—		$	6,236		$	—
Royalty revenue		126			5			1,776			1,951
Collaborative and other research and development		5,162			3,233			35,643			6,211
Total revenues		10,987			3,238			43,655			8,162
Expenses
Cost of products sold		1,346			—			1,361			—
Research and development		20,067			13,036			53,711			33,286
Selling, general and administrative		2,731			1,812			10,326			5,413
Royalty		5			—			507			78
Total operating expenses		24,149			14,848			65,905			38,777
Loss from operations		(13,162	)		(11,610	)		(22,250	)		(30,615	)
Interest and other income		134			14			367			50
Interest expense		(1,241	)		(1,217	)		(3,862	)		(3,684	)
(Loss) gain on foreign currency derivative		(352	)		4,082			861			732
Net loss	$	(14,621	)	$	(8,731	)	$	(24,884	)	$	(33,517	)
Basic and diluted net loss per common share	$	(0.20	)	$	(0.12	)	$	(0.34	)	$	(0.52	)
Weighted average shares outstanding		73,262			71,801			72,752			65,057
Unrealized gain (loss) on available for sale investments		91			(1	)		129			(2	)
Comprehensive loss	$	(14,530	)	$	(8,732	)	$	(24,755	)	$	(33,519	)

	2015			2014
Operating activities
Net loss	$	(24,884	)	$	(33,517	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization		137			137
Stock-based compensation expense		7,773			6,550
Amortization of debt issuance costs		329			329
Change in fair value of foreign currency derivative		793			(732	)
Changes in operating assets and liabilities:
Receivables		1,995			(1,123	)
Inventory		683			—
Prepaid expenses and other assets		1,331			(29	)
Deferred collaboration expense		(117	)		45
Accounts payable and accrued expenses		12,582			3,602
Interest payable		(512	)		957
Deferred revenue		1,602			(880	)

Net cash provided by (used in) operating activities		1,712			(24,661	)

Investing activities
Acquisitions of furniture and equipment		(1,076	)		(41	)
Change in restricted cash		(1,472	)		1
Purchases of investments		(48,343	)		(15,852	)
Sales and maturities of investments		35,874			29,000

Net cash (used in) provided by investing activities		(15,017	)		13,108
Financing activities
Sale of common stock, net		1,175			106,600
Exercise of stock options		3,861			4,636
Employee stock purchase plan sales		356			310

Net cash provided by financing activities		5,392			111,546
(Decrease) Increase in cash and cash equivalents		(7,913	)		99,993
Cash and cash equivalents at beginning of period		54,540			21,164

Cash and cash equivalents at end of period	$	46,627		$	121,157

	September 30, 2015
	Amortized Cost		Accrued Interest		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
Obligations of U.S. Government and its agencies	$	23,119	$	42	$	28	$	(2	)	$	23,187
Corporate debt securities		27,249		141		26		(14	)		27,402
Certificates of deposit		20,909		28		10		(49	)		20,898

Total investments	$	71,277	$	211	$	64	$	(65	)	$	71,487

	December 31, 2014
	Amortized Cost		Accrued Interest		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
Obligations of U.S. Government and its agencies	$	20,307	$	22	$	—	$	(23	)	$	20,306
Corporate debt securities		27,152		151		5		(47	)		27,261
Certificates of deposit		11,838		6		—		(63	)		11,781

Total investments	$	59,297	$	179	$	5	$	(133	)	$	59,348

	2015		2014
Maturing in one year or less	$	23,700	$	18,232
Maturing after one year through two years		27,183		25,459
Maturing after two years		20,604		15,657

Total investments	$	71,487	$	59,348

	September 30, 2015
	Billed		Unbilled		Total
U.S. Department of Health and Human Services	$	—	$	5,444	$	5,444
Green Cross Corporation		129		—		129
Seqirus UK Limited		1,922		—		1,922
Total receivables	$	2,051	$	5,444	$	7,495

	2015		2014
Work in process	$	—	$	267
Finished Goods		—		416

Net inventories	$	—	$	683

	Awards Available			Options Outstanding			Weighted Average Exercise Price
Balance December 31, 2014		2,362			9,605		$	6.21
Restricted stock unit awards granted		(155	)		—			—
Restricted stock unit awards cancelled		1			—			—
Stock option awards granted		(1,319	)		1,319			11.99
Stock option awards exercised		—			(1,102	)		4.36
Stock option awards cancelled		28			(28	)		9.05

Balance September 30, 2015		917			9,794		$	7.19

	2015			2014
Expected Life in Years		5.5			5.5
Expected Volatility		83	%		87	%
Expected Dividend Yield		0.0	%		0.0	%
Risk-Free Interest Rate		1.5	%		1.6	%

Note 5 - Stockholders' Equity (Details Textual) - USD ($) $ in Millions	Mar. 03, 2015	Nov. 06, 2013
Maximum Aggregate Offering Price	$ 150	$ 125
Remaining Aggregate Offering Price		$ 10

Note 4 - Royalty Monetization	9 Months Ended
Note 4 - Royalty Monetization	Sep. 30, 2015
Notes to Financial Statements
Royalty Monetization [Text Block]	Note 4 — Royalty Monetization Overview On March 9, 2011, the Company completed a $30,000 financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of $22,691 from the transaction after transaction costs of $4,309 and the establishment of a $3,000 interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment. As part of the transaction, the Company entered into a purchase and sale agreement dated as of March 9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii) the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the “Currency Hedge Agreement”) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company’s collaboration with Shionogi was not impacted as a result of this transaction. Non-Recourse Notes Payable On March 9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the “PhaRMA Notes”). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March 9, 2011 (the “Indenture”), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14% per annum, payable annually in arrears on September 1st of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes. Royalty Sub’s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company’s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes. On September 1, 2014, Royalty Sub was unable to pay the full amount of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the Consolidated Balance Sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company’s future results of operations or cash flows. The Indenture does not contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type. The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed. Foreign Currency Hedge In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2016 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $1,950 will be required if, on May 18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company’s Consolidated Statement of Comprehensive Loss. Cumulative mark-to-market adjustments resulted in a loss of $460 and a gain of $4,082 for the three months ended September 30, 2015 and 2014, respectively and a loss of $793 and a gain of $732 for the nine months ended September 30, 2015 and 2014, respectively. During the nine months ended September 30, 2015, the Company realized a currency exchange gain of $1,654 associated with the exercise of a U.S. Dollar/Japanese yen currency option. The Company is also required to post collateral in connection with the mark-to-market adjustments based on defined thresholds. As of September 30, 2015 and December 31, 2014, no collateral was posted under the Currency Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of September 30, 2015, the maximum amount of hedge collateral the Company may be required to post is $9,750.

Note 3 - Collaborative and Other Research and Development Contracts	9 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	Note 3 — Collaborative and Other Research and Development Contracts U.S. Department of Health and Human Services (“BARDA/HHS”). In January 2007, BARDA/HHS awarded the Company a $102,661, four-year contract for the advanced development of peramivir for the treatment of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a September 2009 contract modification was awarded to extend the i.v. peramivir program and to increase funding by $77,191. On February 24, 2011, the Company announced that BARDA/HHS had awarded it a $55,000 contract modification, intended to fund completion of the Phase 3 development of i.v. peramivir for the treatment of patients hospitalized with influenza. That contract modification brought the total contract award from BARDA/HHS to $234,852 and provided funding to support the filing of an NDA to seek regulatory approval for i.v. peramivir in the U.S. In December 2013, BioCryst submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December 2014. The BARDA/HHS contract expired on June 30, 2014 according to its terms. On March 31, 2015, the Company announced that the Biomedical Research and Development Authority within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This BARDA/HHS contract includes a base contract of $13,314 to support BCX4430 drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $36,169. As of September 30, 2015, a total of $16,300 has been awarded under exercised options within this contract. National Institute of Allergy and Infectious Diseases (“NIAID/HHS”). In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The total funding under this contract as of September 30, 2015 could be up to $34,002, if all contract options are exercised by NIAID/HHS, over a five year period. The goals of this contract, including amendments, are to file IND applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase 1 human clinical trial. As of September 30, 2015, a total of $29,875 has been awarded under exercised options within this contract. BCX4430 is the lead compound in the Company’s BSAV research program. The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions that are related to the development of peramivir and BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company’s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause. Seqirus UK Limited (“SUL”). On June 16, 2015, the Company and Seqirus UK Limited ("SUL"), a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the "SUL Agreement") granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the "Territory"). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment in the world and was approved by the U.S. Food and Drug Administration in December 2014 for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. The Company retains all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S. Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion. The Company will exercise sole decision-making authority with regard to the development and commercialization of RAPIVAB outside of the Territory and is responsible for all associated costs. In December 2013, the Company submitted a New Drug Application ("NDA") for RAPIVAB to the FDA. Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory filings and interactions with the Health Canada and the European Medicines Agency ("EMA") until marketing approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development. Under the terms of the SUL Agreement, the Company received an upfront payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from the date of the SUL Agreement (the "Royalty Term"). The Company developed RAPIVAB under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL. The term of the SUL Agreement shall continue on a country-by-country basis until the expiration of the last-to-expire Royalty Term in any such country in the Territory. Either party may terminate the SUL Agreement in its entirety if the other party breaches a payment obligation, otherwise materially breaches the SUL Agreement, subject to applicable cure periods, or if the other party suffers an insolvency event. The Company may also terminate the SUL Agreement if SUL or any of its affiliates seek to challenge the validity of the Company's patents. Termination does not affect a party's rights which have accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations exercised by the Company, the SUL Agreement provides for the termination of any sublicenses granted by SUL to third parties, and in the case of termination by the Company for cause, the ceasing of SUL's activities with respect to RAPIVAB, the discontinued use of all Company intellectual property and the termination of licenses and rights previously granted to SUL. If requested by the Company, SUL shall also promptly sell to the Company all licensed product it then holds in stock, otherwise, SUL may continue to sell such licensed product for designated periods. Shionogi & Co., Ltd. (“Shionogi”). In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan and to provide rights for Shionogi to perform a Phase 3 clinical trial in Hong Kong. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan. Shionogi submitted an NDA to the Taiwan FDA in late 2013. Green Cross Corporation (“Green Cross”). In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea. Mundipharma International Holdings Limited (“Mundipharma”). In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (“PNP”) inhibitor, for use in oncology. Under the terms of the license agreement, as amended, Mundipharma obtained worldwide rights to forodesine. Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (“AECOM” and “IRL” respectively). In June 2000, the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the “Licensors”). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000 per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement may be terminated by the Company at any time by giving 60 days advance notice or in the event of material uncured breach by the Licensors. In May 2010, the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i) any milestone payments the Company may receive in the future under its license agreement dated February 1, 2006 with Mundipharma and (ii) royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged. In consideration for these modifications in 2010, the Company issued to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally, at the Company’s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination of cash and shares. On November 17, 2011, the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL. On June 19, 2012, the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of BCX4430 to BioCryst for any antiviral use. At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash, in shares of the Company’s common stock, or in a combination of cash and shares. On January 6, 2014, the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (“VUW”) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties, the terms and conditions of the contracts are substantially the same. The University of Alabama at Birmingham (“UAB”). The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company upon three months’ notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties’ proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Collaboration Receivables [Member]
Assets
Receivables	$ 7,495,000	$ 3,849,000
Trade Accounts Receivable [Member]
Assets
Receivables		5,641,000
Deferred Collaborative Revenue [Member]
Liabilities and Stockholders’ Equity
Deferred revenue	$ 2,102,000	1,481,000
Deferred Product Sales [Member]
Liabilities and Stockholders’ Equity
Deferred revenue	16,000	5,605,000
Cash and cash equivalents	46,627,000	54,540,000
Restricted cash	1,622,000	150,000
Investments	$ 23,700,000	18,232,000
Inventory		683,000
Prepaid expenses and other current assets	$ 4,970,000	6,172,000
Deferred collaboration expense	88,000	76,000
Total current assets	84,502,000	89,343,000
Investments	47,787,000	41,116,000
Furniture and equipment, net	1,146,000	207,000
Deferred collaboration expense	282,000	177,000
Other assets	5,239,000	6,031,000
Total assets	138,956,000	136,874,000
Accounts payable	3,782,000	2,849,000
Accrued expenses	23,027,000	11,329,000
Interest payable	5,517,000	6,029,000
Non-recourse notes payable	30,000,000	30,000,000
Total current liabilities	64,444,000	57,293,000
Deferred collaboration revenue	10,122,000	3,552,000
Deferred rent	345,000	394,000
Stockholders’ equity:
Preferred stock, $0.001 par value; shares authorized — 5,000; no shares issued and outstanding	0	0
Common stock, $0.01 par value: shares authorized — 200,000; shares issued and outstanding — 73,337 in 2015 and 71,955 in 2014	733,000	720,000
Additional paid-in capital	556,095,000	542,943,000
Accumulated other comprehensive loss	(1,000)	(130,000)
Accumulated deficit	(492,782,000)	(467,898,000)
Total stockholders’ equity	64,045,000	75,635,000
Total liabilities and stockholders’ equity	$ 138,956,000	$ 136,874,000

Note 2 - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan (Details)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Expected Life in Years	5 years 182 days	5 years 182 days
Expected Volatility	83.00%	87.00%
Expected Dividend Yield	0.00%	0.00%
Risk-Free Interest Rate	1.50%	1.60%

Note 4 - Royalty Monetization (Details Textual)		3 Months Ended		9 Months Ended
Note 4 - Royalty Monetization (Details Textual)	Mar. 09, 2011 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2014 JPY (¥)
JPR Royalty Sub LLC [Member] \| PhaRMA Notes Member] \| Currency Hedge Agreement [Member]
Collateral Already Posted, Aggregate Fair Value		$ 0		$ 0		$ 0
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments		(460,000)	$ 4,082,000	(793,000)	$ 732,000
Foreign Currency Transaction Gain (Loss), Realized				1,654,000
Maximum Amount of Collateral Required to Post		$ 9,750,000		$ 9,750,000
JPR Royalty Sub LLC [Member] \| PhaRMA Notes Member]
Private Placement of Senior Secured Notes	$ 30,000,000
Debt Instrument, Interest Rate, Stated Percentage	14.00%
JPR Royalty Sub LLC [Member] \| Royalty Monetization [Member]
Revenue Recognition Royalty and Milestone Revenue Recognized	$ 30,000,000
Revenue Recognition Royalty And Milestone Revenue Recognized, Net	22,691,000
Transaction Costs	4,309,000
Interest Reserve	3,000,000
PhaRMA Notes Member] \| Currency Hedge Agreement [Member] \| Japan, Yen [Member]
Derivative, Forward Exchange Rate		100		100
PhaRMA Notes Member] \| Currency Hedge Agreement [Member]
Payments for (Proceeds from) Hedge, Investing Activities				$ 1,950,000
Required Foreign Currency Hedge Per Dollar \| ¥							¥ 100
PhaRMA Notes Member] \| JPR Royalty Sub LLC [Member]
Percentage of Carrying Amount in Excess of Fair Value		50.00%		50.00%
Currency Hedge Agreement [Member]
Collateral Already Posted, Aggregate Fair Value		$ 0		$ 0		$ 0
JPR Royalty Sub LLC [Member]
Revenue Recognition Royalty and Milestone Revenue Recognized	$ 30,000,000
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments		$ (352,000)	$ 4,082,000	$ 861,000	$ 732,000

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Preferred stock par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares outstanding (in shares)	0	0
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	73,337,000	71,955,000
Common stock, shares outstanding (in shares)	73,337,000	71,955,000

Note 1 - Summary of Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Billed Revenues [Member] \| US Department of Health and Human Services [Member]
Receivables
Billed Revenues [Member] \| Green Cross Corporation [Member]
Receivables	$ 129
Billed Revenues [Member] \| Shionogi and Co. Ltd [Member]
Receivables		$ 1,071
Billed Revenues [Member] \| CSL Limited [Member
Receivables	1,922
Billed Revenues [Member]
Receivables	2,051	1,071
Unbilled Revenues [Member] \| US Department of Health and Human Services [Member]
Receivables	$ 5,444	$ 2,778
Unbilled Revenues [Member] \| Green Cross Corporation [Member]
Receivables
Unbilled Revenues [Member] \| Shionogi and Co. Ltd [Member]
Receivables
Unbilled Revenues [Member] \| CSL Limited [Member
Receivables
Unbilled Revenues [Member]
Receivables	$ 5,444	$ 2,778
US Department of Health and Human Services [Member]
Receivables	5,444	2,778
Green Cross Corporation [Member]
Receivables	129
Shionogi and Co. Ltd [Member]
Receivables		1,071
CSL Limited [Member
Receivables	1,922
Receivables	$ 7,495	$ 3,849

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2015	Oct. 31, 2015
Entity Registrant Name	BIOCRYST PHARMACEUTICALS INC
Entity Central Index Key	0000882796
Trading Symbol	bcrx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Common Stock, Shares Outstanding (in shares)		73,336,871
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Amendment Flag	false

Note 1 - Inventory (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Work in process		$ 267,000
Finished Goods		416,000
Net inventories		$ 683,000

Note 3 - Collaborative and Other Research and Development Contracts (Details Textual) - USD ($)		1 Months Ended						9 Months Ended	50 Months Ended
	Jun. 16, 2015	Sep. 30, 2013	Feb. 24, 2011	May. 31, 2010	Sep. 30, 2009	Jan. 31, 2007	Jun. 30, 2006	Sep. 30, 2015	Feb. 24, 2011	Mar. 31, 2015
US Department of Health and Human Services [Member]
Contract Term						4 years
Collaborative Agreement Contract Value						$ 102,661,000
Collaborative Agreement Additional Contract Value			$ 55,000,000		$ 77,191,000
Collaborative Agreement Adjusted Contract Value									$ 234,852,000
National Institute of Allergy and Infectious Diseases [Member]
Proceeds from awards for Research and Development Contracts		$ 5,000,000						$ 29,875
Expected Receivable From Awards for Research and Development Contracts								$ 34,002,000
Collaborative Agreement Period of Contract								5 years
UAB [Member]
Period of Agreement								25 years
Renewable Period of Agreement								5 years
Base Contract [Member]
Government Contract Receivable										$ 13,314,000
Additional Development Options [Member]
Government Contract Receivable										22,855,000
ASPRBARDA Contract [Member]
Government Contract Receivable										$ 36,169,000
Proceeds from awards for Research and Development Contracts								$ 16,300,000
Green Cross Corporation [Member]
Proceeds from License Fees Received							$ 250,000
AECOM and IRL [Member]
Milestone Payment Maximum								4,000,000
Milestone Payment Minimum								1,400,000
Annual License Fee Minimum								150,000
Annual License Fee Maximum								$ 500,000
Advance Notice Period for Termination of Agreement								60 days
Stock Issued During Period, Value, for Modification of License Agreement				$ 5,911,000
Payments for Modification of License Agreement				$ 90,000
CSL Limited [Member
Proceeds from License Fees Received	$ 33,740,000
Milestone Payment Maximum	$ 12,000,000
Royalty Term	10 years

Note 1 - Fair Value of the Company's Investments by Type (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
US Government Agencies Debt Securities [Member]
Amortized Cost	$ 23,119	$ 20,307
Accrued Interest	42	$ 22
Gross Unrealized Gains	28
Gross Unrealized Losses	(2)	$ (23)
Estimated Fair Value	23,187	20,306
Corporate Debt Securities [Member]
Amortized Cost	27,249	27,152
Accrued Interest	141	151
Gross Unrealized Gains	26	5
Gross Unrealized Losses	(14)	(47)
Estimated Fair Value	27,402	27,261
Certificates of Deposit [Member]
Amortized Cost	20,909	11,838
Accrued Interest	28	$ 6
Gross Unrealized Gains	10
Gross Unrealized Losses	(49)	$ (63)
Estimated Fair Value	20,898	11,781
Amortized Cost	71,277	59,297
Accrued Interest	211	179
Gross Unrealized Gains	64	5
Gross Unrealized Losses	(65)	(133)
Estimated Fair Value	$ 71,487	$ 59,348

Note 1 - Significant Accounting Policies (Details Textual) - USD ($) shares in Thousands			1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 03, 2015	Nov. 06, 2013	Jun. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Mar. 09, 2011
Currency Hedge Agreement [Member]
Collateral Already Posted, Aggregate Fair Value				$ 0		$ 0		$ 0
Foreign Exchange Contract [Member] \| Not Designated as Hedging Instrument [Member]
Derivative, Loss on Derivative						793,000
Derivative, Gain on Derivative						1,654,000	$ 732,000
JPR Royalty Sub LLC [Member]
Revenue Recognition Royalty and Milestone Revenue Recognized									$ 30,000,000
Certificates of Deposit [Member]
Restricted Cash and Cash Equivalents, Current				150,000		150,000
Royalty Receivable [Member]
Restricted Cash and Cash Equivalents, Current				70,000		70,000
Collateral for Credit [Member]
Restricted Cash and Cash Equivalents				1,402,000		$ 1,402,000
Maximum [Member]
Maturity Period of High Quality Marketable Securities						3 years
Average Maturity Period of High Quality Marketable Securities						18 years
Maturity Period of Short Term Investment						12 years
Average Maturity for Portfolio Investments						1 year 180 days
Minimum [Member]
Maturity Period of Short Term Investment						3 years
Long-term Investment Maturity, Minimum						12 years
CSL [Member] \| Agreement [Member] \| RAPIVABMember \| Contingent upon EU Marketing Approval [Member]
Proceeds from License Fees Received			$ 7,000,000
CSL [Member] \| Agreement [Member] \| RAPIVABMember \| Revenue from Sale of Inventory to be Recognized When the Inventory Transfer Is Complete [Member]
Deferred Revenue, Additions			3,740,000
CSL [Member] \| Agreement [Member] \| RAPIVABMember \| Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]
Deferred Revenue, Additions			1,223,000
CSL [Member] \| Agreement [Member] \| RAPIVABMember
Proceeds from License Fees Received			33,740,000
Revenues			21,777,000
Milestone Payment Maximum			$ 12,000,000
RAPIVABMember \| Customer Concentration Risk [Member] \| Sales Revenue, Product Line [Member]
Concentration Risk, Percentage						90.00%
Loss on Sale of Investments						$ 0
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax						13,000	0
Amortization of Financing Costs				110,000	$ 110,000	329,000	329,000
Investments and Cash				119,736,000		119,736,000
Securities Offered	$ 150,000,000	$ 10,000,000
Restricted Cash and Cash Equivalents, Current				1,622,000		1,622,000		$ 150,000
Revenues				10,987,000	3,238,000	43,655,000	8,162,000
Interest Expense				$ 1,241,000	$ 1,217,000	$ 3,862,000	$ 3,684,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount				3,821	4,240	3,673	3,986

Note 1 - Scheduled Maturity for the Company's Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Maturing in one year or less	$ 23,700	$ 18,232
Maturing after one year through two years	27,183	25,459
Maturing after two years	20,604	15,657
Total investments	$ 71,487	$ 59,348

Note 2 - Stock Incentive Plan Activities (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2015 $ / shares shares
Awards Available (in shares)	2,362
Options Outstanding (in shares)	9,605
Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 6.21
Restricted stock unit awards granted (in shares)	(155)
Restricted stock unit awards cancelled (in shares)	1
Stock option awards granted (in shares)	(1,319)
Stock option awards granted (in shares)	1,319
Stock option awards granted (in dollars per share) \| $ / shares	$ 11.99
Stock option awards exercised (in shares)	(1,102)
Stock option awards exercised (in dollars per share) \| $ / shares	$ 4.36
Stock option awards cancelled (in shares)	28
Stock option awards cancelled (in shares)	(28)
Stock option awards cancelled (in dollars per share) \| $ / shares	$ 9.05
Balance September 30, 2015 (in shares)	917
Balance September 30, 2015 (in shares)	9,794
Balance September 30, 2015 (in dollars per share) \| $ / shares	$ 7.19

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating activities
Net loss	$ (24,884,000)	$ (33,517,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	137,000	137,000
Stock-based compensation expense	7,773,000	6,550,000
Amortization of debt issuance costs	329,000	329,000
Change in fair value of foreign currency derivative	793,000	(732,000)
Changes in operating assets and liabilities:
Receivables	1,995,000	$ (1,123,000)
Inventory	683,000
Prepaid expenses and other assets	1,331,000	$ (29,000)
Deferred collaboration expense	(117,000)	45,000
Accounts payable and accrued expenses	12,582,000	3,602,000
Interest payable	(512,000)	957,000
Deferred revenue	1,602,000	(880,000)
Net cash provided by (used in) operating activities	1,712,000	(24,661,000)
Investing activities
Acquisitions of furniture and equipment	(1,076,000)	(41,000)
Change in restricted cash	(1,472,000)	1,000
Purchases of investments	(48,343,000)	(15,852,000)
Sales and maturities of investments	35,874,000	29,000,000
Net cash (used in) provided by investing activities	(15,017,000)	13,108,000
Financing activities
Sale of common stock, net	1,175,000	106,600,000
Exercise of stock options	3,861,000	4,636,000
Employee stock purchase plan sales	356,000	310,000
Net cash provided by financing activities	5,392,000	111,546,000
(Decrease) Increase in cash and cash equivalents	(7,913,000)	99,993,000
Cash and cash equivalents at beginning of period	54,540,000	21,164,000
Cash and cash equivalents at end of period	$ 46,627,000	$ 121,157,000

Note 5 - Stockholders' Equity	9 Months Ended
Note 5 - Stockholders' Equity	Sep. 30, 2015
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 5 — Stockholders’ Equity On March 3, 2015, the Company filed a $150,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective upon filing and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. On November 6, 2013, the Company filed a $125,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. The Company has $10,000 remaining under this shelf registration statement.

Note 2 - Stock-Based Compensation (Details Textual) $ / shares in Units, shares in Thousands	1 Months Ended	9 Months Ended		12 Months Ended
	Aug. 31, 2013 shares	Sep. 30, 2015 USD ($) $ / shares shares	Sep. 30, 2014 USD ($) $ / shares	Dec. 31, 2014 shares
Unvested Performance Shares [Member] \| Incentive Plan [Member]
Allocated Share-based Compensation Expense		$ 0
Stock Options and Restricted Stock [Member] \| Incentive Plan [Member] \| Vest 50% Each Year Until Fully Vested [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		2 years
Stock Options and Restricted Stock [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 14,839,000
Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year		1,782,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two		5,632,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three		4,627,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four		2,508,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Five		$ 290,000
Performance Shares [Member] \| Incentive Plan [Member] \| Vest Upon Successful Completion of Specific Development Milestones [Member] \| August 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		75.00%
Number of Milestones Achieved		3
Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage		25.00%
Performance Shares [Member] \| Incentive Plan [Member] \| Vest Upon Successful Completion of Specific Development Milestones [Member] \| December 2014 [Member]
Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage		100.00%
Performance Shares [Member] \| Incentive Plan [Member] \| Vest Upon Successful Completion of Specific Development Milestones [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross \| shares	1,032			1,250
Performance Shares [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 11,982,000
Employee Stock Option [Member] \| Incentive Plan [Member] \| Vest 25% Each Year Until Fully Vested [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Employee Stock Option [Member] \| Incentive Plan [Member] \| Non-employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, First Vesting Period After Grant Date		1 year
Employee Stock Option [Member] \| Incentive Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term		5 years
Employee Stock Option [Member] \| Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term		10 years
Incentive Plan [Member]
Allocated Share-based Compensation Expense		$ 7,553,000	$ 6,388,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares		$ 8.15	$ 8.19
Employee Stock Purchase Plan [Member]
Allocated Share-based Compensation Expense		$ 220,000	$ 162,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized \| shares		1,475
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant \| shares		497
Percentage of Salary to Purchase Common Stock, Maximum		15.00%
Percentage of Common Stock Shares, Beginning		85.00%
Percentage of Common Stock Shares, Ending		85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee \| shares		3
Shar-based Compensation Arrangement by Shar-based Payment Award, Maximum Number of Shares Per Employee, Amount		$ 25,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans \| shares		41
Allocated Share-based Compensation Expense		$ 7,773,000	$ 6,550,000
Number of Stock-based Compensation Plans		2
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant \| shares		917		2,362

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company